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Abstract 
A detailed understanding of correlations of drug levels with drug action is an important 
aspect of the pre-clinical, clinical development and routine use of anti-cancer drugs.   
In furtherance of this important aim, the research in this thesis sought to develop and 
apply novel, highly sensitive, analytical methods to examine and understand 
correlations of drug levels with drug resistance mechanisms, therapeutic efficacy and 
side effects. 
LC-MS/MS is a state of the art analytical technique used to characterise and quantify 
both bio-molecules and pharmaceutical agents.  Based on LC-MS/MS techniques, novel 
sensitive analytical methods were developed for the quantification of 1) tyrosine kinase 
inhibitor anti-cancer drugs  to examine the interaction of these agents with drug 
resistance mechanisms, and 2) the multiple myeloma drug thalidomide as a pilot study 
to identify potential correlations between serum drug levels and toxicity/efficacy. 
Acquired resistance to chemotherapeutics through the over-expression of ABC transport 
proteins has presented a significant clinical challenge.  The up-regulation of ABC 
transporters such as P-glycoprotein (P-gp), Breast Cancer Resistant Protein (BCRP) and 
Multidrug Resistance-associated Protein (MRP-1) is an important cellular mechanism of 
resistance in vivo and in vitro.  Using cell-line models and the developed LC-MS/MS 
quantification method it was established that dasatinib, an agent used in treatment of 
chronic myelogenous leukaemia, is a substrate of ABC transporters P-gp and BCRP but 
not of MRP-1, and that dasatinib does not inhibit these transporters at clinically relevant 
concentrations.  Another Tyrosine Kinase Inhibitor (TKI) being used in breast cancer, 
Lapatinib, was shown to be an inhibitor of P-gp but not a substrate of this resistance 
mechanism. Levels of other TKIs were also found to vary in their uptake in primary 
models of brain cancer. 
Using LC-MS/MS, the circulating serum levels of thalidomide in multiple myeloma 
patients were studied.  A clear correlation between dosing regime and serum level was 
seen; however, the research also unearthed evidence of a significant incidence of non-
compliance which could have far reaching consequences for patient treatment.  
Overall, LC-MS/MS methods for the quantification of chemotherapeutic agents in 
complex biological matrices produced sensitive and accurate data which we 
successfully exploited to characterise resistance to new drugs and examine correlations 
between serum levels and treatment variables.  
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1. Introduction 
Cancer as a disease affects millions of people through the world either directly or 
indirectly.  Three main approaches are used to treat cancer; surgery, radiotherapy and 
chemotherapy.  Different approaches or combinations of modes of treatment are 
indicated depending on the type of cancer, its location, degree of progression and/or 
level of invasion and metastasis.  
In brief, surgery is used to excise tumours or the affected organ if the tumour is small 
and localised.  Surgery is also used to determine the extent of the disease and whether it 
has metastasised to other locations.  Radiation therapy or radio-therapy, administered 
internally or externally, works by destroying both cancerous and normal cells in a 
targeted area.  Most normal cells can recover while the cancerous cells may be more 
sensitive and die.  Chemotherapy is the administration of drugs to treat cancer.  These 
can be classic chemotherapy drugs such as anthracyclines and taxanes, or targeted 
therapies, such as monoclonal antibodies and small molecule tyrosine kinase inhibitors.  
One of the challenges of cancer chemotherapy is resistance, be that acquired or inherent 
resistance.  The goal of this research was to develop analytical methods that could be 
used to examine treatment efficacy and model processes important in resistance. 
 
1.1. Treatment of cancer 
The conventional chemotherapy drugs, used in the treatment of many forms of 
advanced cancer, attack proliferating healthy and cancerous cells leading to potentially 
serious side effects including myelosuppression, hair loss and gastrointestinal problems.  
The emerging goal of cancer pharmacology research is the development and optimal 
application of targeted therapies.  Advances in molecular targeted therapies have 
yielded various anticancer agents[1].  These targeted therapies are specifically active in 
cancer cells, thereby giving increased activity while having reduced incidence and 
severity of toxicity and side effects.  Optimal targets for such individualised treatment 
schemes are targets that are only present in the cancer cell and are involved in 
carcinogenesis and tumour survival.  Characterised examples of targets of  such include; 
the BCR-ABL protein which is considered causative in many cases of CML; the human 
epidermal growth factor receptor (EGFR) family, associated with tumourigenesis and 
disease progression; mammalian target of rapamycin (mTOR) which regulates protein 
synthesis; the Raf/MEK/ERK pathway is which is implicated in a variety of cellular 
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functions including proliferation, cell-cycle arrest, terminal differentiation and 
apoptosis; the ubiquitin proteasome pathway which plays a role in cell cycle control and 
tumour growth; the overexpression of cyclin-dependent kinases (cdk) or absence of cdk 
inhibitors which provides tumour cells with a selective growth advantage and vascular 
endothelial growth factor (VEGF) and its receptors (VEGFR) which are a target of 
antiangiogenic treatments[2].  Therapies which target such mechanisms include 
monoclonal antibodies such as Herceptin and cetuximab and tyrosine kinase inhibitors 
such as dasatinib, imatinib and lapatinib.  
 
1.2. Resistance to treatments 
Resistance to chemotherapeutic agents in cancer can be an acquired phenomenon or 
intrinsic to the patient.  Inherent or intrinsic resistance simply means that the cells 
already possess mechanisms which make the drug ineffective, while acquired resistance 
occurs after exposure to treatment and the cells respond/develop/enhance specific 
characteristics to overcome the toxicity of the agent.  Multi drug resistance is the 
development of resistance simultaneously to many structural and mechanically diverse 
antineoplastic agents.  Overcoming multi drug resistance (MDR) is one of the greatest 
challenges of cancer care and cancer treatment[3].   
A tumour is defined as clinically resistant to the maximum tolerated dose (MTD) of a 
chemotherapeutic agent if the dosage of the drug in the tumour does not achieve 
complete response (CR) or partial response (PR).  This may be due to different 
physiological mechanisms, including[4]:   
• inappropriate application of the drug, for example inadequate infusion 
• low metabolic activation in the case of the use of a prodrug 
• pharmacokinetic alterations in the plasma for example the metabolism, excretion 
or drug clearance rates of the drug may change 
• tumour microenvironment; this would take into account the vasculature of a 
tumour and the delivery of the agent to the tumour 
• tumour availability – i.e. the architecture of the barriers, for example the blood 
brain barrier 
 
However, it is the cellular mechanisms of resistance that are more commonly focussed 
on in the laboratory and translational research setting. 
 6
 
The cellular mechanism of resistance can be attributed to many factors including:  
• ATP-binding cassette (ABC) transporters 
• modulations of the cell death pathways 
• alterations in DNA repair pathways 
• decreased DNA topoisomerase II activity 
 
However, perhaps the most commonly studied mechanism of resistance is the active 
efflux of chemotherapeutic agents by ABC transporters.  It is the ABC transporters, 
which will be examined in more detail, to expand on the breadth of information already 
gathered within this research group[5-8].  
 
1.3. ABC transporters  
The ATP-binding cassette (ABC) transporters are a large family of transmembrane 
pump proteins which are responsible for the classic MDR profile of resistance to many 
substrates. Using the energy of adenosine triphosphate (ATP) hydrolysis these proteins 
transport a variety of substrates across membranes, as well as being involved in various 
other biological processes. ATP hydrolysis involves the cleavage of the 
phosphoanhydridic bonds to yield high energy inorganic phosphate (Pi) and Adenosine 
diphosphate (ADP). The exact mechanism of this energy dependent transportation is not 
fully understood, as reviewed by Seeger and Van Veen[9] and Ambudkar et al[10].  
This protein super-family is known to include 48 ABC proteins [11]. The family has 
been organised into seven groups with the nomenclature A-G.  
All designated ABC transporters have a common structural element[12], principally an 
ATP-binding domain of 200-250 amino acids.  This amino acid sequence is the 
nucleotide-binding domain (NBD).  The NBD unit includes two short conserved peptide 
motifs known as Walker A and Walker B[13].  Glycine rich Walker A and hydrophobic 
Walker B are involved in ATP binding.  A third conserved sequence called the ABC 
signature [14], located between Walker A and Walker B, is unique to the NBD unit.  
ABC transporters are NBD containing proteins associated with hydrophobic, membrane 
embedded, transmembrane domain (TMD).  The TMD usually comprises six 
transmembrane α helices and it is the TMD that is believed to convey substrate 
specificity for transportation.  To be functionally/biologically active, ABC transporters 
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require a minimum of two TMDs and two NBDs.  In “full transporters” the two TMD-
NBD units are part of the same polypeptide chains where as “half transporters” 
comprise of only one TMD-NBD module.  The activity of half transporters requires the 
aggregation of multi-protein complexes.  Full transporters are usually in the plasma 
membrane and half transporters in the intracellular membrane with the Breast Cancer 
Resistant Protein (BCRP, ABCG2) being the exception[15]. Figure 1-1 outlines the 
structures of these three ABC transport proteins.  
 
 
Figure 1-1: Schematic representation of MDR proteins[16]. 
Illustration taken from Litman et al[16]. 
Models for the predicted structures of MRP-1, 
MDR1 and BCRP. The transmembrane helixes, the 
ATP-binding fold (filled bars) and glycosylation sites 
(ξ) are indicated. Note that the orientation of MXR is 
‘reverse’ to that of P-gp and MRP-1. The latter 
proteins are oriented in the order TMD-NBD-TMD-
NBD, whereas the orientation of MXR is NBD-TMB. 
It should be noted that these figures are highly 
schematic, and that the transmembrane segments 
probably form some kind of a pore in the membrane 
[17] 
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1.3.1. ABC transporter evolution  
The expression and action of ABC transporters is not solely a response to cancer 
therapy.  ABC transporters are more likely an evolutionary response to the need to 
remove toxins, both naturally occurring physiological toxins as well as xenotoxins from 
the body.  However, as a large number of current/traditional chemotherapeutics are 
based on naturally occurring compounds[18], ABC transporters play a significant role 
in resistance to these therapies.  
 
In the taxane family of compounds, paclitaxel (taxol) is isolated from the pacific yew 
tree (Taxus brevifolia), while docetaxel (taxotere) is a semi-synthetic product of the 
needle of the European yew tree (Taxus baccata).  
 
Vinca alkaloids, used in the treatment of leukaemia, were the first plant based 
chemotherapeutic agent.  These were isolated from the Madagascan periwinkle plant.  
 
Anthracycline chemotherapy agents are also naturally derived products, though not 
plant based, with doxorubicin being isolated from the fermentation broth of 
Streptomyces peucetius.  Epirubicin is a semi synthetic derivative of doxorubicin. It is 
largely unsurprising then that these naturally occurring compounds and their analogues 
suffer reduced efficacy due to transport by ABC proteins.  
 
Table 1-1, adapted from Lage et al.[4], lists the ABC transporters known to be involved 
in multi drug resistance, including some of their chemotherapeutic substrates as well as 
their physiological substrates.  The classical MDR spectrum of drugs referred to in 
Table 1-1 is expanded upon in Table 1-2.  
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Table 1-1: ABC-Transporters associated with drug resistance[4] 
ABC Transporter 
Drugs 
Physiological 
Substrates Ref 
HUGO1 
Name 
Common 
Name 
ABCA2 ABC2 Estramustine, mitoxantrone Steroids [19-22] 
ABCA3 ABC3 Doxorubicin Surfactant productions [23] 
ABCB1 
MDR-1, P-gp, P-
170, PGY1 “Classical” MDR spectrum2 
Phospholipids, neutral 
& cationic organic 
compounds [24-28] 
ABCB2 TAP1 Mitoxantrone, Peptides 
[24, 29, 
30] 
ABCB3 TAP2 Mitoxantrone, Peptides 
[24, 29, 
30] 
ABCB4 
MDR3-P-gp, 
MDR3, PGY3 Paclitaxel, vinca alkaloids Phosphatidylcholine 
[31, 
32] 
ABCB5  
Doxorubicin, camptothecin, 5- 
fluorouracil Pigment transport? [33-35] 
ABCB6 MTABC3 Cisplatin, camptothecin 
Mitochondrial 
porphyrin uptake 
[36, 
37] 
ABCB11 
BSEP, SPGP, 
ABC16, PGY4 Paclitaxel Bile salts 
[25, 38, 
39] 
ABCC1 MRP, MRP-1 
Anthracyclines, vinca 
alkaloids, methotrexate 
Glutathione-, and 
other conjugates 
organic anions, 
leukotriene [40-42] 
ABCC2 MRP2, cMOAT3 
Platin-drugs, Anthracyclines, 
vinca alkaloids, camptothecins, 
methotrexate 
Glutathione-, and 
other conjugates 
organic anions, 
leukotriene C4 
[41, 
43-46] 
ABCC3 
MRP3, MOAT-
D, MLP2 
vinca alkaloids, methotrexate, 
cisplatin 
Glucuronides, bile 
salts, peptides [47-50] 
ABCC4 
MRP4, MOAT-
B 
Nucleotide analogues, 
methotrexate, Organic anions 
[47, 
51-53] 
ABCC5 
MRP5, MOAT-
C Nucleotide analogues 
Organic anions, cyclic 
nucleotides 
[47, 54, 
55] 
ABCC6 MRP6 Anthracyclines, cisplatin Glutathione conjugates
[25, 
56] 
ABCC10 MRP7 Taxanes, vinca alkaloids 
Organic anions, cyclic 
nucleotides, bile salts,  
leukotriene C4 
[57, 
58] 
ABCC11 MRP8 5-Fluorouracil 
Organic anions, cyclic 
nucleotides, 
leukotriene C4 
[57, 
59] 
ABCG2 
BCRP, MXR, 
ABCP 
Mitoxantrone, anthracyclines, 
camptothecins, topotecan Prazosin [60-64] 
Table 1-1: list of ABC transporters associated with drug resistance and their 
substrates, physiologically and chemotherapeutic[24]. Yellow denotes transporters of 
further interest.  
 
                                                 
1 Human Genome Organisation  
2 See Table 1-2 
3 Canalicular multispecfic organic anion transporter 
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1.3.2. P-glycoprotein 
The mechanism of multi-drug resistance was originally described in the 1970s when 
cells selected with just one agent, showed resistance to the cytotoxic effects of multiple 
unrelated agents.  The cells were treated with actinomycin D and showed resistance to 
mithramycin, vinblastine, vincristine, puromycin, daunomycin, demecolcine and 
mitomycin C[65].  The protein responsible was identified as P-glycoprotein or P-gp, a 
170kDa plasma membrane glycoprotein[66].  In addition to the cross-resistance of 
agents, a decreased intracellular concentration of the target drugs was also noted[65].  
This was attributed to the active efflux of the agent from the cells[67-69]. Gottesman et 
al.[70], showed that P-gp is an ATP-dependent drug pump involved in the transport of a 
broad range of structurally unrelated compounds.  Bellamy[71] identified that P-gp also 
confers taxane resistance and can cause intracellular redistribution of the drug.  
 
The precise molecular mechanism of drug transport by P-gp is not entirely understood.  
However, it is known that P-gp possesses a central pore which appears conical in resting 
phase with the apex of the cone, at the cytoplasmic end, appearing practically closed. 
The P-gp substrate binding site is located within the pore.  Using QSAR (quantitative 
structure-activity relationship) studies, Garrigues et al.[72], identified two 
pharmacophores (distinct P-gp regions that bind certain types of substrates).  However, 
more recently, Pleban et al.[73], identified the drug binding pocket at the interface of 
TMD1 and TMD2.  Interaction with the binding site in the presence of ATP induces 
ATP hydrolysis.  This hydrolysis is essential for drug transport[10].  It appears as 
though ATP binding and substrate binding causes the closure of the drug binding pocket 
while ATP hydrolysis causes the TM rearrangement.  Results from Omote & Al 
Shawi[74] suggest that the substrate is actively transported out of the lipid bi-layer 
whereas, alternative researchers propose that P-gp acts as an outwardly directional 
flippase[75, 76].  Ultimately the substrate is either pushed or flipped out. Figure 1-2 
shows a schematic depiction of the structure of P-pg.  
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Figure 1-2: Schematic models of P-gp 
Illustration and figure legend taken from Loo & Clarke[77].  
A): White cylinders represent the TM segment in TMD1, 
while the grey cylinders represent TM segments with TMD2. 
The branched lines represent the glycosylation sites and the 
rounded rectangles represent the NBDs. The residues 
shown in the TM segments are predicted to be part of the 
drug binding pocket because cysteines introduced at these 
positions in TMD1 can be cross-linked to cysteines 
introduced at the indicated positions in TMD2 with MXM 
cross-linkers that are substrates of P-gp[78]. 
 
B): Model of the organisation of the TM segments base on 
cross-linking and cysteine-scanning mutagenesis studies. 
The common drug binding pocket is at the interface between 
the TMDs.  
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1.3.3. MRP-1 
The ABCC1 gene encodes for the ABCC1 transporter protein which was the 2nd ABC 
cancer resistance transporter to be discovered.  This gene was identified in 1992 by Cole 
et al.[40], in small cell lung carcinoma cell line NCI-H69.  MRP-1 or ABCC1, is 
considered the founding member of the C subfamily of ABC transporters.  The ABCC 
family of proteins have 12 members labelled ABCC1 to ABCC12.  Members MRP-1 to 
MRP8 (ABCC1-ABCC6, ABCC10 and ABCC11) have been shown to be able to 
transport anticancer agents.  MRP-1 has a broad range of substrates, including 
therapeutic agents such as anthracyclines, vinca-alkaloids and methotrexate a substrate 
profile similar to P-gp.  However, MRP-1 also transports glucuronate, sulphate and 
glutathione conjugates [79, 80]. 
 
MRP-1 overexpression is found in various cancers including breast[81], ovarian[82], 
renal cell carcinoma[83] and melanoma[84].  However, studies carried out have both 
confirmed and rejected a correlation between clinical outcome and MRP-1 expression, 
suggesting that the clinical role of MRP-1 in relation to multi-drug resistance may 
benefit from further investigation [4].   
 
Structurally MRP-1 is similar to P-gp with the [TMD-NBD]2 core, however, MRP-1 has 
an additional N-terminal transmembrane domain (TMD0) which is linked to the core 
region by an intracellular linker region (L0), see Figure 1-3. 
 
Figure 1-3: Schematic of MRP-1[85] 
 
Illustration from Borst et al., showing schematic model of MRP1 indicating the trans-
membrane segments adenosine triphosphate binding sequences, and the location of 
carbohydrate (CHO) chains. 
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1.3.4. BCRP 
The third most investigated member of the ABC transport family is Breast Cancer 
Resistant Protein (BCRP), also called ABCG2, MXR (mitoxantrone resistance protein) 
or ABCP (placental ABC protein). The BCRP protein is a half transporter identified 
simultaneously by three separate studies[60-62]. 
This 72kDa protein, arranged in the format of [NBD-TMD] with ABC domains located 
towards the N terminus of the polypeptide chain, has been thought to function as a 
homodimer though recent studies have suggested a tetramer bridge[86]. It is interesting 
that the conserved ABC domain is in a reverse arrangement in BCRP as compared to 
ABCB or ABCC groups and the membrane insertion pattern and topology indicates 6 
transmembrane helices[87].  
 
The expression of BCRP in various normal tissues (including the placenta, colon, large 
and small intestine, sebaceous glands, islets and acinar cells of the pancreas) suggests a 
physiologically protective role. Jonker et al.[88, 89], have suggested that the protein 
may be responsible for either the transport of compounds in the foetal blood supply or 
the removal of toxic metabolites.  
 
However, BCRP has been detected in various in vitro cancer models, particularly 
following exposure to mitoxantrone. While the P-gp substrates vinblastine, paclitaxel 
and verapamil are not substrates of BCRP, BCRP does transport a variety of dyes (e.g. 
Hoechst 33462), chemotherapeutics such as flavopiridol topotecan, irinotecan and its 
active metabolite SN-38 as well tyrosine kinase inhibitors erlotinib, imatinib and 
gefitinib[90].  The BCRP variants R482T and R482G have been found to be expressed 
in drug selected cell-lines MCF7/AdVp3000 and S1-M1-80[91]. These functional 
variants are associated with an amino acid substitution. In the wild type BCRP position 
482 is the amino acid arginine (R), whereas in variant R482T position 482 is occupied 
by threonine (T) and in the variant R482G position 482 is occupied by the amino acid 
glycine (G). This  results in a loss of methotrexate transport activity but increased 
methotrexate resistance[92].  Figure 1-3 illustrates the substrate specificity of BCRP 
and the R482G variant[93].  
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Methotrexate
Hoechst,
Flavopiridol,
Phenophorbide,
Mitoxantrone,
Topotecan,
TKIs,
Doxorubicin,
Daunorubicin,
Epirubicin,
Rhodamine 123
Wild-type BCRP R482G variant
Figure 1-4: Differences in substrate of BCRP and R482G Variant[93]  
 
 
Illustration adapted from Sarkadi et 
al., 2004[93] 
 
 
 
 
 
 
 
Table 1-2: A summary table of the substrates of P-gp, BCPR and MRP-1[4, 94] 
P-gp Substrates BCRP Substrates MRP-1 Substrates 
Anticancer 
Anthracyclines – 
doxorubicin, daunorubicin 
Anthracyclines – 
doxorubicin, daunorubicin 
(R482T) 
Anthracyclines – 
doxorubicin, daunorubicin 
Epipodophyllotoxins- 
etoposide, teniposide 
Epipodophyllotoxins- 
etoposide, teniposide 
Epipodophyllotoxins- 
etoposide, teniposide 
Vinca Alkaloids – 
vinblastine, vincristine  
Vinca Alkaloids – 
vinblastine, vincristine 
Taxanes – 
paclitaxel, docetaxel  
Taxanes – 
paclitaxel, docetaxel 
Campothecans - 
Topotecan 
Campothecans - 
topotecan, irinotecan 
Campothecans - 
topotecan, irinotecan 
 Methotrexate Methotrexate 
Anathracenes – 
bisantrene Bisantrene (R482T form)  
 Mitoxantrone  
Fluorescent Compounds 
Hoescht 33342 Hoescht 33342 Calcein 
Calcein-AM BODIPY-prazosin Fluor-3 
Rhodamine 123 Rhodamine 123 (R482T/G) BCECF 
Selected substrates of P-gp, BCRP and MRP-1 
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1.4. MDR Inhibitors 
Given that multi drug resistance is mediated through the over-expression of cell efflux 
proteins and has such an impact on treatment and the efficacy of therapy, it is hardly 
surprising that inhibiting or reversing this activity to restore sensitivity is of key 
importance. Some work has been carried out at a transcriptional level to control the 
activity of ABC transporter but with limited success[95]. The majority of research in 
this area involves the use of small molecule agents to inhibit the function of the MDR 
protein, see Table 1-3. 
 
With the focus primarily on the inhibition of P-gp, the first inhibitor was discovered in 
the 1980’s.  The calcium channel blocker, verapamil, restored vincristine sensitivity to 
resistant leukaemia cells[96].  Cyclosporin A (CsA) was also shown to restore 
sensitivity of vincristine and daunorubicin in leukaemia cells and as well as showing 
efficacy in solid tumours[97].  However, clinical trials of combination of these agents 
with chemotherapy drugs proved unsuccessful[98]. For verapamil the tolerable drug 
levels were less than those which inhibited vinblastine in vitro[99]. CsA when 
administered with doxorubicin did increase the area under the curve (AUC) of 
doxorubicin by 55% and was shown to inhibit the clearance of doxorubicin and its 
metabolite (doxorubicinol)[100]. However, such doses of CsA had high levels of 
serious side effects.  
 
Second generation inhibitors of P-gp include SDZ PSC833 (Valspodar) and S9788. 
SDZ PSC833 is a derivative of CsA, and S9788, a triazine, was based on the chemical 
structure of verapamil[101, 102]. However, combinations of these with P-pg substrates 
also failed to improve treatment. 
 
GF120918 (Elacridar), OC144-093 (Ontogen), XR9576 (Tariquidar) and LY335979 
(Zosuquidar) are 3rd generation P-gp inhibitors.  These agents are more selective than 
the second generation molecules and effective at nanomolar concentrations.  Elacridar 
and tariquidar also inhibits BCRP. Phase I/II trials of these inhibitors are underway in 
combination with a range of chemotherapeutics[103-106]. Investigation into the 
inhibition of P-gp is not limited to these molecules. In a comprehensive review, 
Baumert & Hilgeroth[107] describes, in detail, the variety of compound classes that 
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effect the action of P-gp.  These include isoquinoline and quinoline derivatives, 
quinazolin and indole derivative (such as gefitinib, lapatinib and erlotinib), pyridine 
derivative (nifedipine), oxygen heterocycles (such a coumarin compound 
furanocoumarin cnidian), cannaboids, terpenes (such as non-cytotoxic taxane 
derivatives) and others. 
 
Less information is reported on specific MRP-1 inhibitors.  Gekeler et al., reported MK-
571 to inhibit MRP-1 without any effects on P-gp[108]. Sulindac sulphide, the active 
metabolite of Non-Steroidal Anti-Inflammatory Drug (NSAID) sulindac has been 
shown to inhibit MRP-1 efflux[109].  
 
A fungal toxin Fumitremorgin C (FTC), was shown to inhibit ABCG2-mediated 
transport[110]. Ko143 is a more potent, specific and less toxic an analogue of 
FTC[111]. 
 
However, despite the array of compounds and other methods (antibodies, siRNA, 
plasma membrane alterations) of ABC inhibition available, the modulation of ABC 
proteins is not simple. Translation of effective combination in vitro to in vivo is 
complicated by non uniform MDR expression levels in patients but more critically by 
the unpredictable drug interactions.  Also, it is important to bear in mind that MDR 
proteins are expressed naturally in the body and not only in the tumour cells.  Table 1-3 
outlines some the classic MDR inhibitors. 
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Table 1-3: Classic MDR Inhibitors[94, 109, 110] 
P-gp MRP-1 BCRP 
First Generation VX-710 (biricodar) GF120918 (elacridar) 
Verapamil Sulindac Sulphide Ko143 
Cyclosporin A  Pantoprazole 
Tamoxifen  XR9576 (tariquidar) 
Second Generation  VX-710 (biricodar) 
PSC833 (valspodar)  Fumitremorgin C (FTC) 
VX-710 (biricodar)   
Third Generation   
LY335979 (zosuquidar)   
XR9576 (tariquidar)   
GF120918 (elacridar)   
OC144-093 (ontogen)   
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1.5. Tyrosine kinase inhibitors 
Tyrosine kinases are enzymes that catalyze the transfer of the γ phosphate of ATP to the 
tyrosine hydroxyl groups on target proteins [112].  Strict control of the tyrosine kinase 
activity in the cell regulates important processes such as cell cycle, proliferation and cell 
death.  In many cases, the abnormal proliferation characteristics of cancer are driven by 
growth factor receptor-mediated signalling.  In tumour cells, it is often the failure of the 
control mechanism that leads to excessive phosphorylation, and pathways sustained in 
an activated state [113, 114].  The characterisation of the role of these enzymes has led 
to the development of pharmaceutical inhibitors of such kinases.  Such inhibitors are 
now emerging with some success from oncology clinical trials into mainstream cancer 
treatment [115, 116].  Table 1-4 details some of the current tyrosine kinase inhibitors 
approved for use in patients.  These small molecule inhibitors compete with ATP 
binding at the tyrosine kinase domain. This negates the catalytic activity of the 
receptor[117].  
 
The focus of this thesis is the tyrosine kinase inhibitors lapatinib and dasatinib. 
Dasatinib is administered in response to imatinib-intolerance and imatinib resistance in 
patients. These TKIs will be expanded upon in greater detail.  
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Table 1-4: Overview of Approved Tyrosine Kinase Inhibitors[118, 119] 
Name 
Trade 
Name 
Research 
Name Target 
Approval 
Date 
Imatinib 
Gleevec4 / 
Glivec5 STI571 Bcr-Abl, PDGFRα, - β, c-KIT 2001 
Gefitinib Iressa ZD1839 EGFR 2003 
Erlotinib Tarceva OSI774 EGFR 2004 
Sorafenib Nexavar BAY 43-9006 
C-RAF, B-RAF, c-KIT, FLT3, 
VEGFR2, -3, PDGFR-β 2005 
Dasatinib Sprycel BMS354825 
Bcr-Abl, SRC-family kinases, 
PDGRFβ, c-KIT, ephrin (EPH) 
receptor kinases 2006 
Sunitinib Sutent SU11248 
PDGFRα, - β, VEGFR1, -2, -3, c-
KIT, RET, CSF-1R, FLT3 2006 
Lapatinib Tykerb GW572016 EGFR(HER-1), HER-2 2007 
Nilotinib Tasigna AMN107 Bcr-Abl, c-KIT, PDGFRα, - β, 2007 
Pazopanib Votrient GW786034 
VEGFR-1, VEGFR-2, VEGFR-3, 
PDGFR-a/β, and c-kit 2009 
 
 
                                                 
4 USA 
5 Europe/ Australia 
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1.5.1. Imatinib 
Imatinib (STI-571, Gleevec (US) Glivec (Europe)) was the first commercially available 
small molecule tyrosine kinase inhibitor, rationally designed against the BCR-ABL 
oncogene.  The BCR-ABL gene encodes for the 210kDa Bcr-Abl protein which is 
involved in the main signal transduction pathways including Raf/Ras, MAPK, P13-K, 
Src kinase family.  Imatinib was approved for the treatment of chronic myeloid 
leukaemia (CML) in 2001[120] and at the time was the first treatment of its type.  Bcr-
Abl made an excellent target as it is present in 95% of CML patients and the Bcr-Abl 
tyrosine kinase is, by itself, sufficient for the development of leukaemia[121].  Imatinib 
also inhibits the tyrosine kinase activity of the c-kit receptor in c-kit positive 
gastrointestinal stromal tumours (GIST)[122].  The main mechanisms of imatinib 
resistance include alterations of Bcr-Abl, c-kit mutations, P-glycoprotein up-regulation 
and alpha acid glycoprotein binding.   
 
Resistance to imatinib has been seen to have been attributed to mutations at 17 amino 
acid positions within the Bcr-Abl kinase domain[115, 123].  Imatinib resistance in vivo 
and in patients has also been identified as being due to both Bcr-Abl under-
expression[124] and Bcr-Abl over-expression and gene amplification[125, 126]. 
 
Mahon et al.[127], showed that cells cross resistant to imatinib, from treatment with 
doxorubicin, could have imatinib sensitivity restored in the presence of a P-gp inhibiting 
compound.  Additional studies have confirmed that imatinib is a substrate for P-gp[128] 
and BCRP[129].  However, Gardner et al.[130], suggest that, though P-gp and BCRP 
affects the distribution and excretion of imatinib, inhibition does not improve clinical 
outcome.   
 
The resistance mechanism associated with alpha1 acid glycoprotein (AGP) is attributed 
to AGP binding to imatinib and blocking imatinib inhibition of Bcr-Abl[131].  The role 
of AGP has been investigated in Ph+ cells and K562 leukaemia cell-line and shown that 
a combination of AGP and imatinib does not influence the growth[132].  A study by le 
Coutre et al.[133], showed that elevated levels of AGP in patients corresponded with 
slower response rates to imatinib treatment, though no correlation was shown between 
resistance and AGP levels.  
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1.5.2. Dasatinib 
Dasatinib (BMS-354825, Sprycel™), is a thiazole-based ATP-competitive, dual Src/Abl 
kinase inhibitor[134], approved for the treatment of imatinib resistant and imatinib-
intolerant patients across all phases of chronic myelogenous leukaemia (CML)[135].  
Dasatinib is effective in treating imatinib-resistant CML as dasatinib is insensitive to the 
activation state of Bcr-Abl.  Imatinib is effective in sustaining the Bcr-Abl protein in its 
inactive conformation, however, mutations at 17 amino acid positions render imatinib 
ineffective by “locking” Bcr-Abl in its active conformation.  Dasatinib is less selective 
in its binding requirements and binds to the active form of the Abl kinase thus 
overcoming 14 imatinib resistant mutations[136].  
 
Dasatinib also targets the Src kinase pathway.  Dasatinib inhibits the action of Src 
family kinases (SFKs) Lyn and Src at nanomolar concentrations in prostate cancer as 
well as inhibiting FAK and CAS kinases[137].  The Src-family kinases are non-receptor 
signalling tyrosine kinases that are involved in cell differentiation, proliferation and 
survival, see Figure 1-5.  Originally identified as the viral (v-Src) cancer causing protein 
in Rous sarcoma virus, a chicken tumour, discovered in 1911[138], there has since been 
11 members of the Src family kinases identified in humans[139].  As a proto-oncogene, 
it is the disruption or alteration in the levels of Src activity which modulates signal 
transduction through several oncogenic pathways.  Elevated levels of Src activity has 
been identified in colon cancer and breast and other epithelial cancers including 
pancreatic, ovarian, lung and head and neck cancers, as reviewed by Frame[140].  
 
 22
Figure 1-5: Src mediated pathways in tumour progression[141] 
 
Illustration taken from Fizazi[141], based on work by Summy & Gallick[142].  
Figure 1-5 shows Src-mediated pathways that may contribute to tumour progression. 
Abbreviations used: CAS, Crk-associated substrate; ERK, extracellular signal-regulated 
kinase; FAK, focal adhesion kinase; IKK, IkB kinase; IL-8, interleukin 8; JNK, Jun N-
terminal kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein 
kinase MAPK/ERK kinase; MLCK, myosin light chain kinase; NFKB, nuclear factor kB; 
PI3K, phosphatidylinositol 3-kinase; RhoGAP Rho GTPase-activating protein; RTK, 
receptor tyrosine kinase; SOS, son of sevenless; STAT3, signal transducer and activator 
of transcription 3; VEGF, vascular endothelial growth factor.  
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1.5.3. Lapatinib 
Lapatinib (GW572016, Tykerb™), a 4-anilinoquinazoline compound, is a small 
molecule dual inhibitor of the tyrosine kinase functionality of the epidermal growth 
factor receptor (EGFR or ErbB1) and HER-2/neu (erbB2) receptors of the epidermal 
growth factor (EGF) family[143] approved for use in breast cancer treatment[144].  
 
There are four Erb proteins, ErbB-1 also called EGFR (epidermal growth factor 
receptor) or HER1 (human epidermal receptor), ErbB-2, also called HER2, ErbB-3, also 
called HER3 and ErbB-4, also called HER4.  All four have a typical extracellular ligand 
binding region, a membrane spanning region and a cytoplasmic region containing the 
tyrosine kinase domain[145].  Typically the binding of the ligand causes the 
phosphorylation of the tyrosine kinase in the tail region, which then initiates 
downstream signalling.  Ligand binding stimulates dimerisation of the receptors, which 
can form homo or hetero-dimers.  HER2 has no known ligand and preferentially 
combines with HER3 or HER4 forming a heterodimer[146].  
 
HER2 and EGFR has been the focus of targeted treatments in the form of both small 
molecules and antibodies.  These two members of the ErbB family have been focussed 
on for a number of reasons including being commonly over-expressed in several 
common cancer types. Also, erbB3 has an inactive kinase domain and needs to dimerise 
with HER2 to promote downstream signalling.  There is no clear link between erbB4 
and cancer progression.  However, signalling of the erbB family in cancer cells has been 
linked to proliferation, adhesion, migration and decreased apoptosis[147], as illustrated 
in Figure 1-5.  Overexpression of erbB1 and erbB2 correlates with poor clinical 
outcome in breast[148], lung, pancreatic, head and neck, prostate and renal cancers, as 
summarized by Carter et al.[149].  Lapatinib reversibly inhibits erbB1 and Her2 by 
binding to the kinase domain thus inhibiting substrate phosphorylation.  This prevents 
downstream signalling pathways, preventing proliferation and survival 
mechanisms[150, 151].  
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Figure 1-6: Ligand binding on erbB receptors and the downstream signalling[149] 
 
The signalling pathway for erbB receptors 
 
Abbreviations used:; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated 
protein kinase; PI3K, phosphatidylinositol 3-kinase; TKD, tyrosine kinase domain NGR, 
neuregulin, JNK, Jun N-terminal kinase; mTOR, mammalian target of rapamycin; PTEN, 
phosphatase and tensin homolog;  
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1.5.4. Erlotinib 
Erlotinib (TarcevaTM, OSI-774), a quinazolinamine derivative is an EGFR targeting 
small molecule anti-cancer drug, approved for the treatment of non small cell lung 
cancer (NCSLC) and in combination with gemcitabine for the treatment of pancreatic 
cancer.  Erlotinib was initially approved, in 2004, for the treatment of locally advanced 
or metastatic NSCLC after failures of other regimes and in 2005, approval was given for 
the treatment of pancreatic cancer in combination with gemcitabine in patients with 
locally advanced, unresectable or metastatic pancreatic carcinoma[120]. Erlotinib is a 
selective and reversible inhibitor of EGFR.   
 
The primary causation of resistance to erlotinib is the mutation of the EGFR target, 
specifically a secondary mutation of the target called T790M.[152] 
 
1.5.5. Gefitinib 
Gefitinib (IressaTM) is also a small molecule reversible EGFR inhibitor. Similar in 
structure to erlotinib, gefitinib is also a quinazolinamine derivative. Gefitinib was 
approved by the FDA in 2003 for the treatment of patients with NSCLC who had failed 
a platinium based and docetaxel based treatment [120].  Gefitinib was re-examined 
following the results of a large study (ISEL) of which showed that there was no survival 
benefit in a randomised trial of gefitinib vs a placebo[153]. Though the results of the 
trial were negative, analyses showed improvement in the gefitinib arm of the study in 
patients who had never smoked and in patients of Asian origins[154].  Evidence 
suggests that gefitinib may have a role in the treatment of patients with specific EGFR 
mutations[155].  Lynch et al., identified somatic mutations in 8 out 9 lung cancer 
responders to gefitinib based therapy[156]. 
 
Gefitinib is also susceptible to T790M mutation of the EGFR target as a mechanism of 
acquired resistance[157].  Further information of the mechanism of resistance of 
erlotinib and gefitinib are detailed in Bianco et al.[158] 
1.5.6. Sorafenib 
Sorafenib (BAY 43-9006, Nexavar) is a dual Raf kinase/VEGFR inhibitor that effects 
tumour cell proliferation and angiogenesis.  Sorafenib has shown increased activity in 
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five tumour types – renal, colon, pancreatic, lung and ovarian[159] and was approved 
for the treatment of advanced renal cell carcinoma in 2005 and the treatment of 
inoperable hepatocellular carcinoma in 2007[120].   
 
1.6. Interaction of TKIs and ABC transporters 
Though targeted therapies such as tyrosine kinase inhibitors were heralded as the magic 
bullet to cancer, they are not without their limitations.  Acquired resistance to lapatinib 
as a monotherapy or in combination with chemotherapy usually occurs within 12 
months[160].  Acquired resistance to imatinib is seen in 45% of cases of CML, 
according to a study of the usage of imatinib in the clinic[161].  Acquired resistance to 
tyrosine kinases inhibitors can be through mutations in the targets or changes in 
signalling pathways.  However, ABC transporters have been shown to have an 
important relationship with tyrosine kinase inhibitors[87].  Table 1-5 summarises the 
interaction of P-gp, BCRP and MRP-1 with tyrosine kinase inhibitors.  
 
1.6.1. Imatinib and ABC transporters 
A variety of mechanisms are responsible for patient relapse on imatinib including drug 
efflux, Bcr-Abl amplification and kinase mutations.  Gorre et al.[162], identified an 
amino acid substitution at position 315 (threonine – isoleucine) which led to resistance 
in 6 out of 9 patients.  This amino acid substitution prevents the formation of a 
hydrogen bond with the drug. Druker et al.[163], focussed on ascertaining why Bcr-Abl 
remains inhibited and, using x-ray crystallographic analysis of mutated proteins, 
established the effect of point mutations, by x-ray crystallography, on imatinib 
activity[164].  
 
However, molecular aberrations of the target alone are not solely responsible for 
resistance.  Mahon et al.[165], showed an interaction, in Bcr-Abl expressing cell-lines, 
between imatinib and P-glycoprotein and that inhibition of P-gp led to an increased 
uptake of imatinib in the LAMA84-r cell-line.  Using 5mM glutathione-conjugate 
stimulated MRP-1, Hegedús et al.[166], demonstrated that imatinib inhibited MRP-1 
but only marginally and at high concentration, 50% inhibition at higher than 100 μM.  
Mukai et al.[167], has also shown that imatinib does not inhibit MRP-1 at up to 200μM.   
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The relationship between BCRP and imatinib is more convoluted.  The role of imatinib 
as a BCRP inhibitor has been shown in CML cells as imatinib reduces the efflux of 
200nM BODIPY-Prazosin in a dose dependant manner[168].  This study also stated that 
imatinib was not a substrate of BCRP as inhibition of BCRP did not alter response of 
the CML CD34+ cells to imatinib. This was in agreement with a previous study which 
showed that imatinib increased the accumulation of BCRP substrate, topotecan, but that 
imatinib itself was not transported by BCRP[169].  
 
However, other groups have found imatinib to be a BCRP substrate by comparing the 
level of imatinib accumulated in BCRP over expressing cells when compared to 
parental cell-lines[170]. Brendel et al.[171], also showed that a CML cell model, K562, 
which was transduced with the BCRP gene was 2-3 fold resistant to imatinib and that 
BCRP inhibition reversed the resistance.  This group also showed that less imatinib was 
accumulated in the BCRP-transduced cells and that imatinib interacts directly with 
BCRP at the substrate binding pocket.  This implies that imatinib is both a substrate and 
inhibitor of BCRP. 
 
1.6.2. Dasatinib and ABC transporters 
As dasatinib is used as a treatment for imatinib resistant and imatinib intolerant patients 
it is clear that dasatinib overcomes some of the molecular causes of imatinib resistance 
in CML.  Specifically, dasatinib’s lack of specificity for the activation state of Bcr/Abl 
overcomes mutations of Bcr/Abl that lock the kinase in the active conformation[136]. 
However, given that imatinib is a substrate of BCRP and an inhibitor of P-gp, it is 
important, if dasatinib is to truly treat imatinib resistant patients, to establish the effect 
of ABC transporters on dasatinib. 
Caco-2, an intestinal epithelial cell line model, is routinely cultivated as monolayers on 
permeable filters for studies of the transepithelial transport of drugs[172].  In 2008 
Kamath et al.[173], showed using Caco-2 cell model, that dasatinib had a 2-fold efflux 
ratio indicating that dasatinib maybe a substrate for P-gp, however, when assessed in P-
gp knock-out mice, there was no difference in the amount of unabsorbed dasatinib, 
suggesting that dasatinib may not be cleared by P-gp.  
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Further work published in 2008 by Hiwase et al.[174], showed, through the use of 14C 
labelled dasatinib, that the intracellular uptake and retention (IUR) of dasatinib was 
significantly lower in P-gp over-expressing cells (K562-DOX) compared to parental 
cell-line(K562). Similarly the IUR of dasatinib in BCRP over expressing cells was 
lower compared to the parental cell-lines, and the use of a BCRP inhibitor (Ko143) 
significantly increased the IUR of dasatinib in BCRP resistant cells.  Also Lagas et 
al.[175], identified that dasatinib was a substrate for P-gp and BCRP. Looking at 
polarized canine cells, transformed to express P-gp (ACBCB1), MRP2 (ABCC2) and 
murine BCRP (ABCG2), dasatinib was seen to be transported in the P-gp and BCRP 
models but not the MRP2 model.  This group also examined the oral uptake of dasatinib 
in vivo with wild type and P-gp and BCRP knock-out mice, and concluded that P-gp but 
not BCRP, restricts oral absorption of dasatinib. 
 
As an interesting side note, one mechanism of cellular uptake that dasatinib has 
overcome is transport with OCT-1.  OCT-1, an organic cation transport, is an influx 
transporter.  OCT-1 has been shown to increase the intracellular level of imatinib[176].  
Differential expression or function of OCT-1 appears to be a significant determinant of 
patient response to imatinib mesylate.  Dasatinib is not a substrate for OCT1 and thus is 
not susceptible to alteration intracellular concentrations of this transporter protein[174].  
 
1.6.3. Lapatinib and ABC transporters 
Lapatinib has been found both in-house and in the literature to interact with P-gp.  Polli 
et al., showed that lapatinib is a substrate of P-gp and BCRP while also inhibiting the P-
gp transport of digoxin by 74%, and the BCRP transport of cimetidine by 82% [177]. 
Lapatinib increased the accumulation of P-gp and BCRP substrates in P-gp and BCRP 
over-expressing cell-lines[178]. Collins et al.[179], showed lapatinib to have an 
inhibitory affect on the action of P-gp and suggests that lapatinib has a high affinity for 
the binding site of P-gp, affecting P-gp’s ability to transport substrates. Lapatinib has 
also been shown to increase the expression of P-gp[7, 180] and to inhibit the action of 
MRP7 (ACBC10)[181]. 
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1.6.4. Gefitinib and ABC transporters 
In-vitro studies by Ozvegy-Laczka et al., found gefitinib to be a transport substrate of P-
gp and an inhibitor of MRP-1[123].  Similarly Kitazaki et al.[182], and Nakamura et 
al.[183], have shown gefitinib to be an inhibitor of P-gp and BCRP respectively.  
However, a more recent study suggests that gefitinib may act as a transport substrate for 
BCRP as gefitinib competed with 3H mitoxantrone transport and depleted cellular levels 
of ATP[184]. 
 
Table 1-5: Tyrosine Kinase Inhibitors and their interactions with ABC transport proteins 
Agent P-gp BCRP MRP-1 
Imatinib Substrate [165] Substrate[170]/inhibitor[169] 
Marginally 
inhibitory [166] 
Dasatinib Substrate Substrate Unknown 
Lapatinib Inhibitor[178] Inhibitor[178] Unknown 
Erlotinib 
Substrate[185] 
Inhibitor at high 
concentrations[186] 
Inhibitor at high concentrations 
[187] 
Substrate at low concentrations[186]  
Gefitinib Substrate [123] Possible substrate[184] Inhibitor[123] 
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1.7. Therapeutic drug monitoring of cancer drug levels 
Therapeutic drug monitoring (TDM) involves the quantification and interpretation of 
drug concentrations in biological fluid with the view to adjusting the drug dosage or 
scheduling of a patient to maximise benefit.  Therapeutic monitoring of drug levels is 
carried out in a range of disease classes, and agents monitored include cardiovascular 
agents, antiepileptic medication, antibiotics and anti-inflammatory agents, 
immunosuppressant, anti depressants and some anti-cancer medication[188].  
Therapeutic drug monitoring is most suited to drugs that [189]: 
1) have a large degree of inter-patient variability at a given dosage 
2) can be measured in biological fluids 
3) have a narrow therapeutic index (TI) 
4) show a correlation between exposure and response 
5) have a sensitive robust method of analysis and quantification 
6) have a specific target 
 
Cancer, as a disease type, does not lend itself well to the therapeutic monitoring of an 
agent as frequently the drug plasma concentration is not representative of the drug 
concentration at the site of action.  The target site may be distant from intravascular 
spaces and solid tumours frequently have their own blood supply.  Patients who have 
been heavily pre-treated with other chemotherapy regimes may have a differing 
response.  Similarly, many agents are given in combinations, complicating the 
evaluation of therapeutic effect by altering dose or scheduling of one agent.  
 
However, some of the characteristics of chemotherapy agents that do align with the 
requirements for TDM are that they (a) have a narrow therapeutic index (TI) (b) can be 
measured in biological fluids, and (c) display a large degree of inter-patient variability.  
 
Also, there are a vast number of quantification methods for anti-cancer agents available, 
some of which have been developed to quantify drug pharmacokinetics in animal 
studies[190]. Part of the difficulty of therapeutically monitoring cancer agents in 
patients is determining an appropriate outcome.  If the desired outcome is 
“improvement in cure rate” this requires a minimum of five years follow-up.  
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It is clear, however, that there are many potential benefits to TDM for cancer 
chemotherapy.  Personalising patient care has become a focus in cancer research in 
recent years[191].  However, the individualisation of patient care should maximise 
chemotherapy intensities by administering concentrations, within the TI, that are at the 
upper end of the nontoxic range.  Clinical trials have shown the benefits of avoiding 
sub-optimal drug concentration or drug concentration in the toxic range by achieving 
maximum chemotherapy intensity[192].  Alnaim[188], and Rosseau & Marquet[193] 
comprehensively reviewed systems for evaluating response in cancer TDM including 
methods for dose individualisation such as  
1) a priori method - where the dose is calculated based on several factors including 
age, gender, body weight, and where the formula designed, must have  a close 
relationship between the estimated parameter and pre-treatment factors. 
However, no concentration data is used to influence the concentration profile.  
2) test-dose methods – a two stage process where a large dose of a moderate 
concentration of the agent is given and multiple blood samples are taken to 
evaluate pharmacokinetic parameters. These parameters are used to calculate the 
full dose necessary.  
3) posteriori methods – are adaptive methods, convenient for repetitive 
administration or long continuous infusion. Nomograms, multi-linear regression 
or Bayesian estimation are frequently used for these methods. 
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1.8. Quantification techniques 
The accurate quantification of agents in biological matrices such as blood, serum, urine 
and tissue samples is the cornerstone of TDM.  Clinical decisions and further treatment 
options for patients can only be based on accurate validated analytical methods.  
Likewise when determining the efficacy, dose limiting toxicity or pharmacokinetics of 
new agents or new combinations of agents, accurate and precise quantification methods 
are required.  The predominant quantification techniques used are spectrometric based 
instruments such as ultraviolet radiation (UV) or mass spectrometry (MS).  
The use of UV is prolific in analytical laboratories as instrument costs have decreased 
significantly in recent years.  UV is suitable for quantification purposes as, in UV, 
analyte concentration is related to detected absorbance by the Beer-Lambert Law 
( clA λλ ε= ).  Aλ =absorbance at defined wavelength, ελ =excitation coefficient at a 
defined wavelength, c=concentration and l=pathlength.  In reality this means that when 
the pathlength (l) and the excitation coefficient (ελ) remain constant, as they do during 
most experiments, the absorbance detected is proportional to the concentration[194].   
 
Mass spectrometry is based on the generation of ions in a gaseous state and separating 
them according to their mass to charge ratio (m/z) detection is based on their m/z.  
Though the instrumentation is significantly more expensive than UV instruments, MS 
instruments are attractive to an analyst as (a) they provide chemical and structural 
information about the molecules from their molecular weights and fragmentation pattern 
and (b) they are extremely sensitive with detection limits typically in 10-12 to 10-15 
molar range[194].   
 
The separation of molecules and introduction into an MS system is usually through on-
line coupling to a chromatography system. The most common front-end separation 
techniques for MS are Gas Chromatography (GC) or High Pressure Liquid 
Chromatography (HPLC/ LC) system.  Chromatography is the process of separating the 
components of mixtures between a stationary phase and a flowing mobile phase. The 
concept of chromatography was originally conceived by a Russian botanist, Mikhail 
Tswett, for the separation of plant pigments. On a glass tube packed by chalk powder, 
Tswett loaded plant leaf extract and petroleum ether as saw a separation of brightly 
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coloured bands[195]. The term chromatography comes from the Greek terms from 
“colour” and “writing”, though interestingly, Tswett is also the Russian word for colour.  
 
1.8.1. GC-MS 
Gas chromatography is a technique for the separation of volatile components of 
mixtures by differential migration through a column containing a liquid or solid 
stationary phase.  In GC, the mobile phase is an inert carrier gas and does not contribute 
to the separation.  There are two types of GC columns, capillary columns and packed 
columns.  The stationary phase can be thin layers of high boiling point liquids, oils or 
waxes (GLC), or solid sorbents and polymers (GSC)[195].  
 
The advent of coupling separation methods to high-end detection methods began with 
the union of gas chromatography (GC) with mass spectrometry (MS).  This link in 
techniques was, in part, a natural analytical evolution as the requirements of compounds 
for GC separation are the same as the requirements to produce a mass spectra i.e. both 
volatile and thermally stable at the temperatures used to achieve separation [188, 196]. 
However, GC-MS is limited to a range of analytes which are volatile and vaporise 
easily, most anticancer agents display neither of these properties. 
 
1.8.2. LC-MS 
HPLC is the separation of components of mixtures by differential migration through a 
column containing microparticulate solid stationary phase. Solutes are transported 
through the column by pressurised flow of liquid mobile phase[195]. HPLC is a 
complementary technique to GC, as HPLC is recommended for a wide range of sample 
types which are unsuitable to GC.  
 
The coupling of the LC to MS allows for the identification of analytes across a broad 
mass range, enabling the detection of low mass drugs and metabolites up to large 
biomolecules.  However, coupling HPLC with mass spectrometry is less straight 
forward as it is not possible to simply connect one to the other without the use of an 
interface.  The role of the interface is primarily the removal of chromatographic mobile 
phase.   
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In HPLC the component being analysed are frequently in complex mixtures.  
Identification and quantification by HPLC relies on the retention characteristics of the 
analyte.  Even with accurate reference compounds it is not always possible to either 
achieve complete separation or to confidently identify and quantify the analytes of 
interest in complex mixtures.  However, MS detection primarily identifies the molecular 
mass of the analyte, with more sophisticated instruments providing further information 
such as the product ions, providing increased specificity and selectivity.   
 
It is the diverse utility of HPLC and the specificity of MS that make LC-MS one of the 
most used hyphenated techniques in an analytical lab.   
 
LC-MS/MS or tandem MS in its simplest form, is the combination of two mass 
analyzers. The first MS isolates the ion(s) of interest from the other ions. The ions(s) 
then get fragmented and travel on to the 2nd MS where the mass of each fragment is 
detected. There are two main types of MS/MS instruments used for analysis and 
quantification of small molecules, the ion trap and the triple quad. The instrument used 
throughout this project was an Agilent 6410 triple quadrupole mass analyser, and will 
be discussed in more detail here.  
 
1.8.3. LC-MS – Triple Quad 
A triple quad MS is a tandem MS system consisting of three sections with distinct 
applications. Despite being called a triple quadrupole, the instrument actually consists 
of 2 quadrupoles and a hexapole. A quadrupole consists of four charged rods which run 
parallel to the flight path of the ion. The quadrupole determines the selectivity of the 
ions trajectory to the detector by creating oscillating electric fields.  As seen in Figure 
1-12, the quadrupoles are the first (MS1) and last sections (MS2) of the instrument, the 
middle section, the collision cell, is a hexapole. In the collision cell, ions collide with 
nitrogen gas atoms to give rise to product ions. This process is known as collision 
induced dissociation (CID).  The resulting fragment ions travel to the last quadrupole 
(MS2) where the mass to charge ratio (m/z) is detected. Additionally, there is an 
octopole ion guide before the first quadrupole to focus ions. 
In each scan mode, the instrument operates is a subtly different manner. The difference 
in the MS modes used are outlined below.  
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1.8.3.1. MS2Scan 
MS2Scan detects all ions in their precursor form (barring in-source fragmentation). As 
the ions enter the MS, they pass through MS1 and through the collision cell unchanged 
and without fragmentation to the detector in the final quadrupole, as shown in Figure 1-
7.  
 
Figure 1-7: Schematic of MS2Scan 
MS1 Collision Cell MS2
MS2Scan
Monitor all ions  
Schematic diagram of mode of action for each quad in MS2Scan mode. 
 
1.8.3.2. SIM 
SIM is an acronym for selected ion monitoring.  SIM is the scan mode discussed in the 
optimisation of the fragmentor voltage (Section 3.3.2).  In selected ion monitoring the 
precursor ion is detected without collision in MS2.  MS1 filters the ions so that only the 
ions of a particular m/z ratio are permitted into the system.  The detector continues to 
monitor the same single m/z value over the entire scan period, as shown in Figure 1-8. 
 
Figure 1-8: Schematic of SIM 
 
SIM
MS1 Collision Cell MS2
Select m/z Monitor 
Single Ion  
Schematic diagram of mode of action for each quad in SIM Scan mode. 
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1.8.3.3. Product Ion Scan 
Product ion scan is used to determine the product ions. The ions enter MS1 where only 
the ions of interested are filtered in and sent to the collision cell. Through collision with 
nitrogen gas, at operator controlled voltages, the precursor ion is broken into the product 
ion(s). In this way it is possible to identify the product ions, as shown in Figure 1-9. 
 
Figure 1-9: Schematic of Product Ion Scan 
Product 
Ion 
Scan
MS1 Collision Cell MS2
Select m/z Product Ion ScanGenerate 
fragment ions  
Schematic diagram of mode of action for each quad in Product Ion Scan mode. 
 
1.8.3.4. MRM 
It is this process for monitoring for a known precursor ion, fragmenting the precursor 
ion in the collision cell and monitoring the known product ions that is called multiple 
reaction monitoring (MRM). Outlined in Figure 1-10 is a schematic of the three quads 
and there operation during MRM analysis. 
 
Figure 1-10: Schematic of MRM 
MRM
MS1 MS2Collision Cell
Select m/z Monitor Selected 
Fragment Ion(s)  
Schematic diagram of mode of action for each quad in MRM Scan mode. 
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1.8.3.5. Ionisation 
One of the other key components of any MS is the ion source.  The ion source is where 
the sample is ionised (with either a positive or negative charge) and converted into a gas 
phase.  The main ion sources interfacing with LC are electrospray ionisation (ESI) and 
Atmospheric Pressure Chemical Ionisation (APCI).  ESI is a soft ionisation technique, 
meaning that normally the analyte ions remain intact and do not undergo a large degree 
of in source fragmentation.  The inlet of sample, either from an LC or infusion pump 
system enters the source chamber as a mist, where it is mixed with high temperature 
drying gas (N2)6.  This rapid solvent evaporation causes the droplet to shrink to the 
point that surface tension can no longer sustain the charge.  This is the Rayleigh limit. 
At this point the surface tension is pulled apart and the droplet, or analyte molecule 
receives the charge.  This is called Coulombic explosion[197].  
The analyte spray can be in an “in-line” or “orthogonal” position.  The Agilent Triple 
Quad instrument used in this thesis employs an orthogonal spray position system.  This 
allows for uncharged molecules and unionised mobile phase to flow straight to waste.  
Figure 1-11 shows a schematic of the source orientation in the Agilent Triple Quad. 
 
Figure 1-11: Schematic of Agilent 6410 Triple Quad Ionisation Source [198] 
 
 
Schematic diagram of the ESI ion source, demonstrating the orthogonal positioning of 
the nebuliser to the MS  
                                                 
6 In the case of the Agilent 6410 Triple Quad the dry gas is nitrogen, though other systems may use other 
gases.  
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Figure 1-12: Schematic of Agilent 6410 Triple Quad [198] 
  
 
Schematic diagram of 6410 triple quad, taken from the Agilent Technologies website[198] 
MS1          Collision Cell         MS2 
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1.9. Extraction procedures 
Sample preparation in bio-analytical analysis is necessary to remove the analyte of 
interest from the biological matrix.  In general bio-analytical chemistry, the biological 
matrix can be blood[199] or plasma[200], the most common in pharmacokinetic studies, 
but biological matrices may also comprise of saliva[201], hair[202], urine[203] and 
others.  Blood, serum and plasma contain approximately 10,000 different proteins with 
a total concentration of 6–8 g/dL, and urine contains 50–100mg of protein/dL.  Plasma 
also contains approximately 3mg/mL of sodium, 0.2mg/mL of potassium, 15–38.5 
mg/dL of urea, and many other organic and inorganic compounds[204].  With such 
complex mixtures and the dynamic ranges of proteins, fatty acids, lipids and salts, it is 
clear that it is important to remove these components from the analysis, as these factors 
could confound the analysis and flood the detector with irrelevant ions.  
 
1.9.1. Solid phase extraction 
Solid phase extraction (SPE) is one of the most common bio-analytical extraction 
methods in publication literature, a search of journal articles using the sciencedirect 
search engine for the term “SPE” yielded 151,017 hits, with 4,657 hits for the year 2010 
alone.  SPE involves a solid-liquid phase separation of the analytes from the biological 
sample, by the selective transfer between a liquid and solid state[195].  The analyte is 
physically separated from the biological matrix by the differential interacting with a 
solid phase sorbent material. These sorbents, packed primarily into either disposable 
cartridges or discs, can be polar, non-polar or ionic depending on the experimental 
requirements. Solid phase extraction is based on four distinct protocol steps (1) sorbent 
conditioning, (2) sample loading, (3) washing and (4) analyte elution, as illustrated in 
Figure 1-12.  
 
The availability of commercially available solid phase extraction material, cartridges or 
sorbents, has led to uniformity in analysis and makes method replication and transfer 
from one lab to another more straightforward.  SPE is also frequently used in on-line 
extraction.  Automation of sample clean-up is advantageous as it decreases the high 
level of manual handling and error associated with manual extraction procedures. 
Though on-line SPE is faster and allows for increased through-put injections and offers 
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high recoveries, extensive method development is required to optimise many 
experimental variables[205].  
The commercialisation of solid phase extraction cartridge material has led to a lack of 
specificity, though some groups overcome this through the evolution of molecularly 
imprinted polymers (MIPs) as a SPE material[206, 207].  For example Anderson et 
al.[208], details the application of MIPs as SPE material for the detection of low levels 
of benzodiazepines in hair samples.   
 
 Figure 1-13: Schematic of solid phase extraction procedure 
 
Schematic diagram of the basic experimental protocol for SPE 
 
Sorbent 
Conditioning 
Sample 
Loading 
Washing Target 
Elution 
Solid phase 
sorbent is pre-
conditioned prior 
to sample is 
loaded 
Sample is loaded Analyte of interest is 
adsorbed to the solid 
phase packing material 
and the interfering 
components of the 
sample are eluted 
Analyte of interest is 
eluted and collected 
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1.9.2. Protein precipitation  
Protein precipitation is based on the interaction between the precipitation reagent and 
protein groups. Soluble proteins generally have a hydrophobic core surrounded by a 
hydrophilic surface including ionic groups that are not involved in intra-molecular 
binding.  Organic solvents interfere with the intra-molecular hydrophobic interactions of 
proteins[204]. 
 
The addition of a volume of solvent (frequently acetonitrile) to the serum causes the 
proteins of the serum to precipitate and leaves the analyte of interest in the solvent, 
which can either be injected directly or dried down and reconstituted in a smaller 
volume to concentration before injection. While this is the fastest and simplest method 
for sample preparation, it is the most likely to cause ion suppression issues, especially in 
ESI, where the co-elution of endogenous compounds such as lipids, phospholipids and 
fatty acids affect the ESI droplet desolvation process[209].  
 
1.9.3. Liquid-liquid extraction 
Liquid-liquid extraction (LLE), also know as solvent extraction, is based on the 
partition of an uncharged analyte between an aqueous phase and a theoretically water-
immiscible organic phase until equilibrium is reached[204], illustrated in Figure 1-13.  
LLE is a popular alternative to SPE as it is robust and sensitive, and requires no 
additional equipment. LLE is considered a time-consuming extraction procedure but 
provides extracts that are generally less prone to ion suppression[210, 211].  The most 
frequent criticism of liquid-liquid extraction is the lack of automation in analysis.  
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Figure 1-14: Schematic of liquid-liquid extraction procedure 
 
 
Schematic diagram of the basic experimental protocol for liquid-liquid extraction 
 
Aqueous biological 
sample containing 
analyte (black dots) 
and biological 
matrix (yellow 
dots) 
Immiscible 
organic phase 
Shake to allow 
phases to mix 
and molecules 
to partition 
Phase separation 
with gravity/ 
centrifugation 
Organic phase with 
analyte of interest 
Aqueous phase with 
biological matrix and 
confounding analytes 
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1.10. Analytical methods for the quantification of TKIs 
The development of analytical methods for the determination and quantification of 
tyrosine kinase inhibitors by LC-MS has predominantly been driven by 
pharmacokinetic studies in the drug development stage. Table 1-6 outlines recent 
methods published for the analysis of TKIs by HPLC-UV and LC-MS/MS. 
 
Given the current advances in cancer research towards targeted therapies, especially  
TKIs, the development of analytical methods to quantify these agents is in creasing in 
the literature.  Some methods have analysed multiple TKIs simultaneously, though, for 
some, this has involved complex gradient LC methods and long run times[212, 213]. 
TKIs are rarely administered in combination with each other and combinations of TKI 
and chemotherapy agents are more commonly administered. However, some clinical 
trials detail the use of one TKI followed by another[214], or the use of two TKIs 
simultaneously[215].  This would suggest that some of the methods published are 
unnecessarily complex, and are more focussed on analytical novelty than application 
practicality.  
 
The method developed in this thesis is the only validated method for the quantification 
of TKIs from  in vitro samples[216]and hence, represents   a valuable laboratory 
research tool.  Also, this method has been shown to be applicable for the analysis of 
multiple TKIs in a short run time, with a simple, stable isocratic elution.  With minor 
alterations this method would also be applicable for the analysis of clinical samples 
(blood and tissue) samples.  
 
As discussed in further detailed in Section 3.9.6 and Section 3.9.7, the method 
developed in this thesis has equivalent, if not greater, sensitivity than reported in 
comparative assays.  The use of an LLE extraction method is also simply 
straightforward and easily transferable to any lab setting.  
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Table 1-6: Comparison of Analytical Methods for Tyrosine Kinase Inhibitors Biological Matrices. 
Analytes 
Determined 
Biological 
Matrix 
Sample Clean 
up Analytical Method
Run 
Time 
Sensitivity 
(LOQ) % Recovery 
Author, 
Date Ref 
Dasatinib 
Lapatinib 
Erlotinib 
Imatinib 
Gefitinib 
Sorafenib 
Cancer cell-line 
models 
 
 
 
 
LLE 
 
 
 
 
 
Isocratic Elution, 
LC-MS/MS 
 
 
 
 
8 mins 
 
 
 
 
 
200pg/million cells
400pg/million cells
 
 
 
 
86-112% 
 
 
 
 
 
Roche 
2009 
 
 
 
 
[216] 
 
 
 
 
 
Dasatinib, 
Imatinib, 
Nilotinib Human Plasma 
Protein 
Precipitation 
Gradient Elution, 
LC-MS/MS 
20 
mins 
78.1ng/ml 
62.5ng/ml 
61.5ng/ml 95-114% 
De 
Francia 
2009 [212] 
Dasatinib, 
Imatinib, 
Nilotinib Mouse Plasma 
Protein 
Precipitation 
Hydrophilic 
Interaction LC-
MS/MS - 
ng/ml range – data 
not shown - 
Hseih 
2009 [217] 
Dasatinib, 
Imatinib, 
Nilotinib 
Sunitinib, 
Sorafenib, 
Lapatinib Human Plasma 
Protein 
Precipitation 
Step-wise gradient 
elution, LC-MS/MS 
20 
mins 
1ng/mL 
1ng/mL 
1ng/mL 
1ng/mL 
10ng/mL 
5ng/mL 93.3% 
Haouala 
2009 [213] 
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Analytes 
Determined 
Biological 
Matrix 
Sample Clean 
up Analytical Method
Run 
Time 
Sensitivity 
(LOQ) % Recovery 
Author, 
Date Ref 
Erlotinib 
Gefitinib 
Sunitinib 
Sorafenib 
Cell Culture 
Media 
Blood 
Protein 
Precipitation LC-MS/MS 5 mins 
12.7nM 
11.2nM 
12.6nM 
10.8nM 
96-109% 
86-107% 
74-84% 
90-105% 
Honeywell 
2010 [218] 
Erlotinib 
(OSI-774) Human plasma LLE LC-MS/MS 5 mins. 10ng/mL 79-87% 
Masters 
2007 [219] 
Erlotinib 
(OSI-774) Human plasma LLE LC-UV 3 mins. 100ng/mL approx. 100%7 
Lepper 
2003 [220] 
Gefitinib 
Human plasma, 
mouse plasma and 
tissues 
Protein 
Precipitation LC-MS/MS 3 mins. 
1ng/mL (human) 
5ng/mL (mouse) 81-103% 
Zhao 
2005 [221] 
Gefitinib Plasma LLE 
on-column focusing 
gradient capillary 
LC-MS/MS - 0.1ng/mL - 
Gueten 
2005 [222] 
Gefitinib Human plasma LLE LC-MS/MS, isocratic 5 mins 0.5 ng/ml 111-124% 
Jones 
2002 [223] 
Imatinib Human Plasma SPE 
Gradient elution - 
LC-UV 
45 
mins 0.05μg/mL 96% 
Widmer 
2004 [224] 
                                                 
7 Actually recovery not specified 
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Analytes 
Determined 
Biological 
Matrix 
Sample Clean 
up Analytical Method
Run 
Time 
Sensitivity 
(LOQ) % Recovery 
Author, 
Date Ref 
Imatinib Human Plasma 
Protein 
Precipitation 
Flow injection 
analysis 
LC-MS/MS 
3.2 
mins 30ng/mL 97-99% 8 
Mičová 
2010 [225] 
Imatinib Human Plasma LLE LC-UV/DAD 
12 
mins 80ng/mL 98% 
Roth 
2010 [226] 
Imatinib Plasma LLE LC-MS/MS - 10ng/mL 90% 
Titier 
2005 [227] 
Lapatinib Human Plasma 
Turbulent flow 
on-line extraction 
Isocratic Elution, 
LC-MS/MS 
<0.4 
mins - - 
Hsieh 
2004 [205] 
Lapatinib Human Plasma 
On-line 
Extraction LC-MS/MS 3 mins 15ng/ml 75% 
Bai 
2006 [200] 
Nilotinib 
Dasatinib Human Plasma SPE HPLC-UV 
40 
mins 
10ng/mL 
(nilotinib) 72-78% 
Masatomo 
2009 [228] 
Nilotinib 
Imatinib 
CGP-745889 Human Plasma SPE LC-UV 
35 
mins 50ng/mL 
80.1% 
91.8% 
89.0% 
Davies 
2010 [229] 
                                                 
8 Though ion suppression of 78-87%  was reported 
9 Imatinib metabolite 
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Analytes 
Determined 
Biological 
Matrix 
Sample Clean 
up Analytical Method
Run 
Time 
Sensitivity 
(LOQ) % Recovery 
Author, 
Date Ref 
Sorafenib Human plasma 
Protein 
Precipitation LC-MS/MS 6 mins 7.3ng/mL 95.8-97% 
Zhao 
2007 [230] 
Sunitinib Human plasma LLE: LC-MS/MS, isocratic 3 mins 0.2ng/mL - 
Minkin 
2008 [231] 
Sunitinib Human plasma LLE LC-UV 
10 
mins 10ng/mL 
20ng/mL-50%, 
60ng/mL-56.4% 
200ng/mL-70.5% 
Blanchet 
2009 [232] 
Sunitinib 
SU1124 Monkey tissue LLE LC-MS/MS 5 mins (2.10 ng/g) - 
Barattè 
2004 [233] 
ZD6474 
(Vandetanib) 
Mouse plasma and 
tissue LLE LC-MS/MS 5 mins 
20ng/mL (plasma) 
10 ng/mg (tissue) 88-90% 
Zirrolli 
2005 [234] 
Table 1-6 details the validated analytical methods of the quantification of TKIs. The method highlighted in yellow has been developed within this 
thesis.  
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1.11. Multiple myeloma 
Multiple myeloma (MM) is a disorder which is characterised pathologically, by 
malignant plasma cell accumulation, which is generally derived from one clone of the 
bone marrow[235, 236].  As illustrated in Figure 1-15, plasma cells are derived from 
the B cells (B-lymphocytes), a type of white blood cell, made in the bone marrow, 
whose normal function is the production of antibodies as a response to an a infection 
or disease[237].  The clinical manifestations of this malignancy are heterogeneous and 
include destructive bone lesions, anaemia hypercalcaemia and renal insufficiency.  
The median survival time after diagnosis is 3 years with alkylating agent therapies, 
with improvements in treatment increasing survival times[238].   
 
Figure 1-15: Hematopoietic Tree Plasma Cell[239] 
 
Figure 1-15 shows the generation of plasma cells.  © 2008 Terese Winslow, U.S. 
Govt. has certain rights. Image reproduced with permission.  
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1.11.1. Treatments in Multiple Myeloma 
The treatment of patients with MM is generally stratified into two options, as 
illustrated in Figure 1-15, depending on eligibility for transplantation[240].  
Transplant eligibility is based primarily on age and patient fitness.  While the outcome 
of patients randomized on early or late stage autologous peripheral blood stem cell 
transplantation has been equivalent, early treatment decisions after diagnosis are 
required as alkylating agents may hamper subsequent stem cell collection[241].  
 
Traditionally patients who were eligible for transplantation were given a combination 
of vincristine, doxorubicin and dexamethasone (VAD) to reduce tumour mass prior to 
transplantation.  The introduction of novel agent-based therapies has replaced long 
established cytotoxic protocols such as VAD. The most commonly used new therapies 
include thalidomide, lenalidomide and bortezomib.  There are three main treatment 
regimes - melphalan, prednisone, thalidomide (MPT), melphalan, prednisone, 
bortezomib (MPV) and melphalan, prednisone, lenalidomide (MPR)[238].  
 
• Palumbo et al.[242], demonstrated the benefit of the addition of thalidomide to 
the melphalan, prednisone (MP) standard therapy. Patients showed a higher 
response rate and longer event-free survival with MPT when compared to MP 
which was confirmed in subsequent studies[243, 244].   
• The combination of MPV was studied by Mateos et al.[245], where V 
indicates Velcade, the trade name for bortezomib.  This study showed that in 
newly diagnosed elderly patients, 85% were alive after three years compared 
to 26 months with MP alone. 
• A phase I/II study by Palumbo et al.[246], examined that the combination of 
MPR, where R indicates Revlimid (lenalidomide). The maximum tolerated 
dose was defined and 81% of patients achieved partial response.  
 
 
Of the novel agents discussed here, thalidomide will be discussed in greater detail, as 
the remit of the project was to examine thalidomide in patient serum.  
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Figure 1-16: Treatment strategy for multiple myeloma 
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The treatment strategy of multiple myeloma, adapted from Kyle[235].  
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1.11.2. Thalidomide 
Thalidomide (α-phthalimidoglutarime) is a synthetic glutamic acid derivative 
currently produced by Celgene Corp, Warren, NJ.  Thalidomide is reported to have 
been first synthesised in 1954 by Chemie Grunenthal in West Germany[247, 248].  It 
was sold as an over-the-counter medication for the effects of morning sickness due to 
its perceived safety, though was never approved by the FDA in the US due concerns 
about neuropathy[249].  In the early 1960’s it received notoriety and was withdrawn 
from the market due to two independent clinical reports detailing birth defects in 
babies whose mothers had taken thalidomide[250, 251].  The use of thalidomide 
during the first trimester of pregnancy led to phocomelia, defects of the long bones, 
absence of auricles, cleft lip and cardiac and gastrointestinal anomalies[252].  
Thalidomide re-emerged in the clinic when Dr Sheskin discovered a benefit of 
thalidomide in a patient suffering erythema nodosum leprosum (ENL), a potential 
complication of lepromatous leprosy[253].  This led to a WHO investigation which 
showed complete remission of symptoms within weeks of treatment[254].  This 
finding led to renewed clinical interest in thalidomide in areas of rheumatoid arthritis, 
systemic lupus erythematosus and other autoimmune disorders.  
 
1.11.3. Thalidomide in multiple myeloma 
A study of thalidomide in a variety of cancer types was prompted by the inhibition of 
growth seen in foetal tissue. However, no significant results were seen in this study, 
possibly due to the numbers of malignancies examined and the lack of focus of the 
studies[240, 255, 256].  The benefit of thalidomide in multiple myeloma was first 
noticed following a study by Singhal et al.[257], on 84 patients with refractory 
myeloma. This result, though carried out in an uncontrolled patient group, was 
remarkable as most of the patient enrolled, who had already relapsed following high-
dose chemotherapy, showed reduced tumour burden following thalidomide treatment. 
A randomized trial by the Eastern Cooperative Oncology Group (ECOG) showed that 
a thalidomide-dexamethasone combination was more effective than dexamethasone 
alone. Based on this study thalidomide was granted accelerated approval by the 
FDA[258].  
 
 52
1.11.3.1. Mechanism of action and pharmacokinetics of thalidomide  
Thalidomide has a chiral centre and as such, the two different enantiomers of 
thalidomide should have different pharmacokinetic properties, however, at 
physiological pH and temperature, thalidomide will rapidly interconvert to a racemic 
mixture[259].  A sedation effect appears to be primarily due to the (R) isomer while 
the teratogenic effect has been linked to the (S) isomer[260, 261]. The precise 
mechanism of action of thalidomide is unknown though there are numerous 
immunomodulatory and non-immunomodulatory properties.   
 
Thalidomide’s effect on TNFα 
Thalidomide inhibits the synthesis of tumour necrosis factor alpha (TNF-α). TNF-α is 
pro-inflammatory cytokine that regulates the inflammatory cascade.  The action of 
thalidomide on TNFα is felt to be largely responsible for the clinical benefit seen in 
patients with ENL[249]. 
 
Thalidomide’s effect on angiogenesis 
Tumour development was first associated with angiogenesis in the 1970s but it was 
not until 1994 that it was shown that thalidomide inhibited basic fibroblast growth 
factor (bFGF)-induced angiogenesis[262]. Vascular endothethial growth factor 
(VEGF) and bFGF are produced in excess in a variety of malignancies[263].  
Thalidomide has been shown to inhibit VEGF action in co-culture models of bone of 
multiple myeloma cell lines and marrow stromal cells[264].  It has been proven that 
the anti-angiogenic properties of thalidomide are linked with its teratogenicity. 
 
Thalidomide’s effect on T Cells 
Thalidomide has also been shown to co-stimulate primary human T-lymphocytes, 
inducing their proliferation cytokine production and cytotoxic activity[265].  Through 
this stimulation of the autoimmune system, thalidomide enhances an immune 
anticancer response.  
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1.11.3.2. Adverse effects of thalidomide 
The major concern in terms of adverse effects of thalidomide is teratogenicity.  These 
concerns are addressed by a system called System for Thalidomide Education and 
Prescribing Safety (STEPS), whereby the physicians, nurse practitioners and 
pharmacists must be registered with the educational program.  Furthermore education 
is given and sexually active patients are required to use two forms of 
contraception[266, 267].   
 
The most common adverse effect associated with thalidomide are, constipation, 
neuropathy, somnolence, depression and venous thromboembolism.  In a recent 
review, Mateos discusses the incidences of grade 3 and grade 4 adverse effects in 
multiple myeloma trials[268].  The addition of other agents to thalidomide generally 
increases the incidence of adverse effects.   
 
1.11.4. Thalidomide metabolism 
In 2000, Teo et al.[269], completed the first comprehensive study on the role of 
various human cytochrome P450 (CYP) isozymes on thalidomide metabolism.  A 
previous study showed that metabolite formation was reduced with CYP inhibition 
but failed to identify the metabolite or the CYPs involved.  This study showed that 
human CYP isozymes showed little or no effect on thalidomide metabolite formation.  
The author concluded that the interactions between thalidomide and other drugs are 
unlikely due to thalidomide’s minimally metabolism by hepatic CYPs.  
 
In 2003, Lu et al.[270], published work based on thalidomide metabolites in mice and 
multiple myeloma patients. Having developed methods for the analysis of the 
hydroxylated and hydrolysis products of thalidomide by LC-MS, they used this 
method to detect the metabolite products in the urine of mice and MM patients. From 
the analysis of patient serum, the authors determined that the “lack of detectable 
hydroxylated metabolites” in MM patients who were responding to treatment 
suggested that the metabolites are not responsible for the therapeutic effect.  
 
 54
Chung et al.[271], analysed the thalidomide levels in the plasma of mice, rabbits and 
five MM patients over 24 hours after the first dose. The authors noted that 
hydroxylation products were not detected in any of the 5 patient samples, though they 
were detected in mice plasma and moderately in rabbit samples.  Table 1-7 gives the 
structures of the main metabolites of thalidomide mouse urine.  
 
Table 1-7: Thalidomide metabolites found in mouse urine[271] 
Mol. 
Weight Metabolite Structure 
276* 
N-(o-carboxybenzoyl) glutamic acid 
imide 
292†,‡ 
cis-5′-Hydroxy-N-(o-carboxybenzoyl) 
glutamic acid imide 
294* N-(o-carboxybenzoyl) isoglutamine 
292†,‡ 
trans-5′-Hydroxy-N-(o-carboxybenzoyl) 
glutamic acid imide 
276* Phthaloylisoglutamine 
450† Thalidomide-5-O-glucuronide 
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276* Phthaloylglutamine 
274† cis-5′-Hydroxythalidomide 
274† trans-5′-Hydroxythalidomide 
274† 5-Hydroxythalidomide 
* Hydrolysis product.  
† Hydroxylation product.  
‡ Not yet confirmed by comparison with authentic standard.  
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1.11.5. Thalidomide quantification methods  
Several analytical methods have been published for the quantification of thalidomide. 
Given that the agent is approximately 50 years old, it is not surprising that there is a 
body of work on thalidomide.  Table 1-8 details the validated analytical methods 
available in the literature for the quantification of thalidomide by HPLC-UV or LC-
MS. Every effort has been made to ensure that this table is as comprehensive as 
possible.   
 
Some of the original analytical methods developed for thalidomide focussed on the 
separation and analysis the stereoisomers of the agent[272]. Early on in the analytical 
history of the drug stability was also recognised as a problem but the majority of 
authors have addressed the issue of thalidomide hydrolysis in serum through the 
acidification of the sample prior to storage.  A variety of sample clean-up methods 
have also been applied including SPE[273] and PPT[274] and LLE[275], though it 
should be noted that, for the three most recent published methods, the LLE method 
described are adaptations of each other[276-278].   
 
The method developed in this thesis, Section 5, is highlighted in yellow in Table 1-8.  
This method employs a simple isocratic separation, and a straightforward LLE 
extraction.  When compared to the other methods published, this method is more 
sensitive, and only a small volume of patient serum is required for the accurate 
quantification of thalidomide.  This is also the only validated method for the 
quantification of thalidomide in cell-line models, though the application of this is 
discussed further in Section 5.5.2.  Overall a sensitive straight-forward method has 
been developed which compares very well against published literature.  
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Table 1-8: Thalidomide analytical methods 
Analyte, 
ISTD 
Biological 
Matrix 
Sample Storage & 
Clean up Analytical Method 
Run 
Time Sensitivity
% 
Recovery
Author 
Date Ref 
Thalidomide 
Umbelliferone 
Human serum 
(0.1mL)  
Cell-line models 
-80°C, 1:1(v/v) 25mM 
citrate buffer pH1.5,  
LLE 
LC-MS/MS, Prodigy C18 
(150mm x2.0mm, 5μm) 
ACN/Water/FA, (30/70/0.1) 
13 
mins >3ng/mL 
91.8% – 
115.1% 
Roche, 
unpublished  
Thalidomide 
Phthalimide 
Plasma of 
Hepatocellular 
carcinoma 
patients 
(1mL) 
-80°C, 2/1 (v/v) in 
stability solution. 
Modified LLE10 
HPLC-UV BDS Hypersil 
column (250 × 4.6mm, 
5μm) ACN/10mM 
ammonium acetate buffer 
(pH 5.5) (25/75, v/v) 
10 
mins 
LOQ: 
100ng/mL 
>90% 
within 
0.05–
50μg/mL 
Saccomanni 
2008 [276] 
Thalidomide 
Phenacetin 
Human serum 
from 
mesothelioma 
patients. Rat 
serum and tissue 
(0.2mL) 
Serum 1/1 (v/v) tissue 
1/4 w/v) citrate-
phosphate buffer (pH 2, 
0.2M), stored at −80°C. 
LLE 
HPLC-UV vancomycin 
column (Chirobiotic V™, 
250×4mm) 14% acetonitrile 
in 20mM ammonium 
formate, pH 5.4 
>18 
mins 
LOQ 
~25ng/mL in 
serum 
54%-100% 
for 
enantiomers 
in different 
matrices 
Murphy-
Poulton 
2006 [275] 
                                                 
10 Adpated from Yang et al., 2005 
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Analyte, 
ISTD 
Biological 
Matrix 
Sample Storage & 
Clean up Analytical Method 
Run 
Time Sensitivity
% 
Recovery
Author 
Date Ref 
Thalidomide 
Phenacetin 
Rat plasma 
(0.1mL) 
-20°C 
200μL ice-cold 
acetonitrile/methanol 
(1:1, v/v) containing 2% 
(v/v) acetic acid 
HPLC-UV Hypersil C18, 
(200mm×4.6mm, 5μm) 
ACN/10mM ammonium 
acetate buffer (pH 5.50) 
(28:72, v/v) 
11 
mins 
LOQ: 
51.6ng/mL11 >90% 
Yang 
200512 [277] 
Thalidomide 
Phenacetin 
HBSS13 buffer 
for transport 
assays in Caco-2 
cells 
(0.4mL) 
1/2 (v/v) ice-cold 
acetonitrile/methanol 
mixture containing 2% 
acetic acid (v/v) 
HPLC-UV Spherex C18 
column (150×4.6 mm; 5 
μm) ACN:10mM 
ammonium acetate (24:76, 
v/v, pH 5.5) 
10 
mins 
LOQ: 
6.4ng/mL14 90-110% 
Zhou 
2003 [278] 
Thalidomide 
Plasma and 
semen from HIV-
seropositive 
patients 
(0.5mL) 
0.025M Sörensen’s 
citrate buffer pH 1.5, -
70°C 
SPE 
LC-MS-MS Summit, ODS 
C18 (35x3.2mm, 3μm) 
H2O: ACN: Acetic Acid 
75/25/0.1 4 mins 5ng/mL 
Plasma> 
69% 
Semen 78% 
Teo 
2002 [279] 
                                                 
11 Reported as 0.02μM 
12 Adapted from Zhou et al., 2003 
13 Hanks Balanced Salt Solution 
14 Reported as 0.32ng/50μL aliquot of thalidomide in HBSS 
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Analyte, 
ISTD 
Biological 
Matrix 
Sample Storage & 
Clean up Analytical Method 
Run 
Time Sensitivity
% 
Recovery
Author 
Date Ref 
Thalidomide 
Phenacetin 
Human serum 
(0.5mL) 
Protein precipitation, 
using trichloroacetic acid 
HPLC-UV Discovery C18 
(125 x 4.6mm, 5uM), 75% 
MeOH/0.1M potassium 
dihydrogenphate15 pH3 
> 16 
mins 
LOQ: 0.222 
mg/L 79%-84% 
Toraño 
1999 [274] 
Thalidomide 
enantiomers 
Labetalol Plasma (1mL) 
1:1(v/v) 0.025M 
phosphate buffer, pH2.5 
SPE 
HPLC-UV Bioptic16 (150 x 
4.5mm) 2-propanol: 0.1M 
phosphate buffer, pH4, 
(2:98, v/v) 
13 
mins Not specified 
Not 
specified 
Haque 
1998 [272] 
Thalidomide 
Phenacetin 
Human serum 
(0.5mL) 
10% H2SO4 (7.4μL) in 
500μL serum, -35°C 
HPLC-UV Nova-Pak C18 
(300 x 3.9, 4μm), Gradient 
elution consisting of water, 
ACN, and NaH2PO4 buffer, 
0.5 M, pH 3.0. 
20 
mins 
LOQ: 
50ng/mL 
Not 
specified 
Simmons 
1997 [280] 
                                                 
15 pH adjusted with 43% phosphoric acid solution 
16 Racemic analysis 
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Analyte, 
ISTD 
Biological 
Matrix 
Sample Storage & 
Clean up Analytical Method 
Run 
Time Sensitivity
% 
Recovery
Author 
Date Ref 
Thalidomide 
Ciprofloxin 
Plasma of ENL17 
patients 
(1mL) SPE18 
HPLC-UV Nucleosil C8 
(150x4.6mm, 5μm) 0.01M 
potassium dihydrogen 
phosphate 21% ACN (v/v) 
4.5mM Heptane sulfonic 
acid pH2.319 
~20 
mins 
LOQ: 0.0625 
mg/L 79.5% 
Delon 
1995 [281] 
Thalidomide 
Phenacetin 
Rat plasma and 
blood 
(0.2-2mL) 
1:1 (v/v) 0.025M 
Sörensen’s citrate buffer, 
pH 1.5, -25°C 
LLE (Diethyl –ether) 
HPLC-UV  LiChromart 
RP-C18 (250x4mm 7μm) 
ACN :water (35:65) 
> 6 
mins Not specified 
Plasma 
93% Blood-
87% 
Eriksson 
1992 [282] 
Table 1-8 details the validated analytical methods of the quantification of thalidomide. The method highlighted in yellow has been developed 
within this thesis.  
 
 
                                                 
17 Erythema nodusum leprosum 
18 No reference is made to stabilising the samples to avoid hydrolytic degradation 
19 Adjusted with concentrated orthophosphoric acid 
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1.11.6. Aims of thesis 
The aims of this thesis were 
 
• To develop an analytical method for the quantification of pharmacokinetically 
relevant concentrations of dasatinib and lapatinib in cells. 
 
• To explore to the applicability of LC-MS/MS for the quantification of multiple 
tyrosine kinase inhibitors. 
 
• To use this analytical method to explore the interaction of dasatinib with ABC 
transport proteins P-gp, BCRP and MRP-1. 
 
• To explore the interaction of lapatinib with P-gp and to determine if lapatinib 
inhibition of P-gp is as a competitive substrate. 
 
• To examine the interaction of lapatinib with BCRP and MRP-1. 
 
• To develop an analytical method for the quantification of thalidomide levels in 
serum. 
 
• To assess the thalidomide levels in a multiple myeloma patients. 
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SECTION 2.0 Materials and methods 
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2. Materials and methods 
2.1. Cell culture methodology 
The following materials and equipment were used for all cell culture based experiments 
in this thesis.  
2.1.1. Cell culture reagents 
? Cell culture media, DMEM: HamsF12 50:50 (D8437), MEM (M5656), RPMI 
1640 (R8758), DMEM (D5671), EDTA (E9884), DMSO (D5879),  p-
nitrophenol phosphate, (1040), Triton-X-100 (CAS #9002-93-1), NaOH (S5881) 
were purchased from Sigma, Dublin, Ireland. 
? L-Glutamine, 200mM 100X, (25030), Trypsin 10X, (043-05090) Na-Pyruvate, 
100mM (11360) and Non Essential Amino Acids (NEAA) 100X (11140) were 
purchased from Gibco 
? PBS, Oxoid, BR0014  
? Foetal Calf Serum (FCS), (DE14-801F) was purchased from Biowhittaker, The 
same batch of serum was used for all cell culture experiments (Lot #7SB0015).  
 
2.1.2. Cell culture solutions 
? PBS: PBS solution was prepared as 1 tablet in 100mL of UHP water and 
autoclaved 
? Sodium Acetate Buffer: 0.1M sodium acetate, 0.1% (v/v) triton-X-100 pH 5.5 
? Phosphatase Substrate: 10mM p-nitrophenol phosphate solution in 0.1M sodium 
acetate 
? 1N NaOH: 40g/L NaOH in UHP 
? EDTA, 1%(w/v) solution in UHP, autoclaved 
? 1X trypsin: 50mL of 10X trypsin and 10mL of 1% EDTA solution was added by 
filtration to 440mL of sterile PBS. 
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2.1.3. Cell culture equipment 
? Cytoguard laminar airflow cabinet, Holten LaminAir Maxisafe, 
? Sterile universal container, Sterilin, 128a 
? 96-well plates, Costar, 3599 
? Cell-culture flasks: T75cm2, T25cm2 vented and non vented flasks were 
purchased from Corning 
? Cryovials, Greiner 
? Disposable Haemocytometer Fast Read 102, Immune Systems Limited, BVS100  
 
2.1.4. Cells, cell culture and aseptic technique 
Cell culture procedures were strictly adhered to as outlined in NICB Cell Culture SOPs, 
[#001-01, #002-01 and #003-01] 
All cell culture work was carried out in a class II laminar airflow cabinet. All 
experiments involving cytotoxic compounds were conducted in a cytoguard laminar 
airflow cabinet. Before and after use, the laminar airflow cabinet was cleaned with 70% 
industrial methylated spirits (IMS).  Any items brought into the cabinet were also 
swabbed with IMS.  Only one cell line was used in the laminar airflow cabinet at a time 
and upon completion of work with any given cell line, the laminar airflow cabinet was 
allowed to clear for at least 15 minutes before use.  This was to eliminate any 
possibilities of cross-contamination between cell lines.  The cabinets were cleaned 
weekly with industrial disinfectants (Virkon, Antech International, P0550).  Details 
pertaining to the cell lines used for the experiments detailed in this thesis are provided 
in Table 2-2.  All cells were incubated at 37°C with an atmosphere of 5% CO2. Cell 
lines such as DLKP and DLKP-A did not have any CO2 requirement. Cells were fed 
with fresh media or sub-cultured every 2-3 days in order to maintain active cell growth.  
2.1.4.1. Cell-lines 
Table 2-1 outlines the details and sources of all cell-lines used in this thesis. Table 2-2 
outlines the media and growth requirements for all cell-lines  
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Table 2-1: Details of cell-lines used 
Cell Line Details Source 
DLKP Non-small lung cell carcinoma[283] NICB 
DLKP-A 
Lung, adriamycin resistant variant of DLKP, selected by 
Alice Redmond.[284] NICB 
DLKP-Sq 
Poorly differentiated. squamous cell lung carcinoma, 
established by Shirley McBride[285] NICB 
DLKP-Sq/Mitox-
BCRP 
Squamous cell lung carcinoma resistant variant of DLKP-
Sq, selected with mitoxantrone, selected by Helena Joyce NICB 
DLKP-Sq/Mitox-
MDR 
Squamous cell lung carcinoma resistant variant of DLKP-
Sq, selected with mitoxantrone, selected by Helena Joyce NICB 
A549 Lung adenocarcinoma ECACC 
A549-tax 
Lung, a taxol resistant variant of A549, selected by Laura 
Breen. [286] NICB 
HL60/S Acute myeloid leukaemia cells[287, 288] ECACC 
HL60/Adr Acute myeloid leukaemia cells, adriamycin selected.[288] 
Melvin Centre, 
Kansas State 
University 
HL60/Mdr1 Acute myeloid leukaemia cells; Mdr1 transfected 
Balazs Sarkadi, 
Hungary 
HL60/Mxr Acute myeloid leukaemia cells; MXR transfected 
Balazs Sarkadi, 
Hungary 
RPMI-2650/Tax 
nasal septum carcinoma, variant selected at NICB (Yizheng 
Liang) by exposure to increasing conc. of taxol (final conc. 
200ng/ml) over 6 months[289] NICB 
NCI –Adr/Res Ovarian; Adriamycin-selected NCI 
2008/MRP-1 
human ovarian carcinoma transfected to over-express MRP-
1 which is predominantly localized in the plasma membrane 
[290] NCI 
KB-3-1 
Cervical; KB-3-1 is a subclone from KB cells, which is a 
HeLa derivative[291]. Prof Gottesman, NCI 
KB-8-5-11 Resistant variant of KB-3-1 developed with Colchicine[291] Prof Gottesman, NCI 
IGROV-1CDDP20 
Resistant variant of IGROV-1, epithelial ovarian carcinoma, 
cisplatin selected[292] 
Dr Britta Stordal/ 
Prof Jan Schellens 
NICB: National Institute for Cellular Biotechnology, DCU, Dublin, Ireland 
NCI: National Cancer Institute, Bethesda USA 
ECACC, European Collection of Animal Cell Cultures, Salisbury, Wiltshire, UK. 
                                                 
20 IGROV-1CDDP cell-line was used in collaboration with Dr Britta Stordal 
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Table 2-2: Cell-lines used and their growth requirements 
Cell Line Basel media 
(%) 
FCS CO2 Additives 
DLKP DMEM*: Hams F12 50:50 5 
Non- 
CO2 - 
DLKP-A DMEM: Hams F12 50:50 5 
Non- 
CO2 - 
DLKP-Sq DMEM: Hams F12 50:50 5 
Non- 
CO2 - 
DLKP-
Sq/Mitox/ 
MDR DMEM: Hams F12 50:50 5 
Non- 
CO2 - 
DLKP-
Sq/Mitox/ 
BCRP DMEM: Hams F12 50:50 5 
Non- 
CO2 - 
A549 DMEM: Hams F12 50:50 5 CO2 - 
A549-tax DMEM: Hams F12 50:50 5 CO2 - 
HL-60/S RPMI 10 CO2 - 
HL-60/Adr RPMI 10 CO2 - 
HL-60/Mdr1 RPMI 10 CO2 - 
HL-60/Mxr RPMI 10 CO2 - 
RPMI-
2650/Tax MEM 10 CO2 
1% L-glutamine 
1% Na Pyruvate 
1% NEAA 
NCI –Adr/Res RPMI 10 CO2  
KB-3-1 DMEM 10 CO2 
2% L-glutamine 
1% Na Pyruvate 
KB-8-5-11 DMEM 10 CO2 
2% L-glutamine 
1% Na Pyruvate 
2008/MRP-1 RPMI 10 CO2  
IGROV-
1CDDP RPMI 10 CO2  
DMEM: Dulbecco’s Modified Eagle’s Medium 
NEAA: Non Essential Amino Acids 
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2.1.5. Basic culture techniques 
2.1.5.1. Sub-culturing of cell lines 
The waste cell culture medium was removed from the tissue culture flask to a sterile 
bottle. For anchorage-dependent cell lines, the flask was rinsed with 1mL of 1X trypsin 
solution to ensure the removal of any residual media.  A volume of 2mL of trypsin was 
then added to the flask and was incubated at 37°C for the required period of time until 
all cells were detached from the inside surface of the culture flask. The trypsin was 
deactivated with an equal volume of complete media. The cell suspension was removed 
from the flask and placed in a sterile universal container and centrifuged at 200g for 5 
minutes. The supernatant was then discarded from the universal and the pellet was 
suspended in complete medium. A cell count was performed. An aliquot of cells was 
then used to re-seed a flask at the required density with fresh media. 
 
For the sub culturing of suspension cell-lines the use of trypsin was not required.  
 
2.1.5.2. Cryopreservation of cells 
Cells for cryopreservation were harvested in the log phase of growth. Cell pellets were 
resuspended in a suitable volume of FCS. An equal volume of a 10-20% DMSO/FCS 
solution was added drop-wise to the cell suspension. A total volume of 1mL of this 
suspension was then placed in a cryovial. These vials were then placed in the vapour 
phase of a liquid nitrogen container, which was equivalent to a temperature of -80°C.  
After a period of three hours, vials were removed from the vapour phase and transferred 
to the liquid phase for storage (-196°C). 
 
2.1.5.3. Thawing of cryopreserved cells 
A volume of 5mL of fresh warmed growth media was added to a sterile universal. The 
cryopreserved cells were removed from the liquid nitrogen tank and thawed rapidly at 
37°C. The cells were removed from the vials and transferred to the media aliquot. The 
resulting cell suspension was centrifuged at 200g for 5 minutes. The supernatant was 
removed and the pellet resuspended in fresh culture medium. Thawed cells were then 
added to an appropriately sized tissue culture flask with a suitable volume of fresh 
growth media. 
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2.1.5.4. Sterility monitoring of cell culture solutions 
Sterility testing was performed on all cell culture media and related culturing solutions. 
Samples of prepared basal media were incubated at 37°C for a period of seven days. 
This ensured that no bacterial or fungal contaminated media was used. 
 
2.1.5.5. Mycoplasma analysis of cell lines 
Cell lines were tested for possible mycoplasma contamination in house by Mr. Michael 
Henry, according to the SOP 007-01.  
 
2.1.6. Safe handling of cytotoxic drugs 
Cytotoxic drugs were handled with extreme caution at all times in the laboratory, due to 
the potential risks in handling them. Disposable nitride gloves were worn at all times 
and all work was carried out in cytotoxic cabinets. All drugs were stored in a safety 
cabinet at room temperature or in designated areas at 4°C. All agents were disposed of 
by incineration. 
 
2.1.7. In vitro proliferation assays 
2.1.7.1. In-vitro toxicity assay for anchorage-dependant cell lines 
Cells in the exponential phase of growth were harvested by trypsinisation (Section 
2.1.5.1.). Cell suspensions contain 1 x 104 cells/mL in the appropriate culture medium 
were aliquoted at 100μL/well in 96-well plates using a multichannel pipette. Plates were 
gently agitated in order to ensure an even dispersion of cells over the well surface area. 
Cells were incubated overnight at 37°C and 5% CO2. Test drug dilutions were prepared 
a 2X their final concentration in cell culture medium. Volumes of the drug dilutions 
(100μL) were then added to each well using a multichannel pipette. Plates were then 
mixed gently as above. Cells were incubated for a further 6-7 days at 37°C and 5% CO2 
until the control wells reached approximately 80-90% confluency. Assessment of cell 
survival in the presence of drug was determined by the acid phosphate assay (Section 
2.1.7.3.). The concentration of drug which caused 50% cell kill (IC50 of the drug) was 
determined from a plot of the % survival (relative to the control cells) versus cytotoxic 
drug concentration.  
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2.1.7.2. Combination toxicity assays 
As described in Section 2.1.7.1, plates were seeded at 1 x 104 cells/mL and incubated 
overnight at 370C and 5% CO2. Cytotoxic drug dilutions, tyrosine kinase inhibitor (TKI) 
drug dilutions, and inhibitor drug dilutions were prepared at 4X of their final 
concentration in media. Volumes of 50μL of the drug dilution and 50μL of the TKI 
dilution were added to each relevant well. The final volume of each well was brought up 
to 200μL where necessary with drug-free media. Plates were then mixed gently as 
above. Cells were incubated for a further 6-7days at 37°C and 5%CO2 until the control 
wells reached approximately 80-90% confluency. Assessment of cell survival in the 
presence of drug was determined by the acid phosphate assay (Section 2.1.7.3) 
 
2.1.7.3. Assessment of cell number – Acid Phosphatase Assay 
Following the incubation period of 6-7 days, media was removed from the plates and 
disposed of. Each plate was washed with PBS and this was then removed. Efforts were 
made to ensure that no residual PBS remained in the wells as this would interfere with 
the final reading. To each well, 100μL of freshly prepared phosphatase substrate was 
added. Phosphatase substrate was prepared as described in Section 2.1.2. The plates 
were incubated in the dark at 37°C for up to 2 hours, monitoring colour development. 
The enzymatic reaction was stopped by the addition of 50μL of 1N NaOH. The plate 
was read in a dual beam plate reader at 405nm with a reference wavelength of 620nm 
(BIO-TEK®, Synergy HT).  
 
2.1.8. Accumulation and efflux studies 
2.1.8.1. Accumulation assay in adherent cell-lines 
The triplicate T25cm2 flasks were seeded with 5 mL of 5 x 104 cells/mL and allowed to 
attach overnight. The cells were exposed to the desired concentration of agent, prepared 
in complete media and incubated at 37°C with 5% CO2 for the desired time. After this 
period, the media was removed and the flasks were rinsed with 5mL of cold PBS and 
2mL of trypsin was added. The cells were allowed to detach over a period of 5 minutes.  
Once the cells detached the trypsin was deactivated with 2mL of complete media and 
the cells suspension was placed in a non-sterile extraction tube. The samples were 
centrifuges at 200g for 5 minutes. The supernatant was carefully removed and the cell 
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pellet was resuspended in 1mL of PBS. At this stage 50µL of the cell suspension was 
removed for cell count analysis by Guava flow cytometry. Alternatively 9μL of cell 
suspension was removed and counted in a haemocytometer Fast Read 102 (Immune 
Systems Limited). 
The samples were centrifuged again and the supernatant was carefully removed again 
and the cell pellets in the extraction tubes were frozen at -20°C until required. 
In the case of thalidomide accumulation studies, cell pellets were stored in 50μL of 
25mM citrate buffer, pH 1.5, (as detailed in Section 2.2.3.2).  
 
2.1.8.2. Efflux in adherent cell-lines 
The triplicate T25cm2 flasks were seeded with 5 mL of 5 x 104 cells/mL and allowed to 
attach overnight. Following the overnight period, the cells were exposed to a 
concentration of tyrosine kinase inhibitor for 2 hours. After 2 hours, the drug was 
removed and the cells were rinsed with 5mL PBS. The control flasks were trypsinised at 
this point. Dependant on experimental requirements, 5mL of warmed media or 5mL of 
warmed media with MDR inhibitor was then added to the remaining flasks and these 
were returned to the incubator for the required time periods. Cell pellets were prepared 
from the remaining flasks as described. 
In the case of thalidomide efflux studies, cell pellets were stored in 50μL of 25mM 
citrate buffer, pH 1.5, (as detailed in Section 2.2.3.2).  
 
2.1.8.3. Accumulation in suspension cell-lines 
As in Section 2.1.8.1, triplicate T25cm2 flasks seeded with 5mL of 5x104 cells/mL. The 
TKI was prepared in cell culture medium to 2X the final required concentration and 
5mL of the drugged media was added to each flask and incubated for 2 hours. 
Following incubation the cell suspension was pipetted to a non-sterile extraction tube. 
The samples were centrifuged at 200g for 5 minutes, the supernatant was removed and 
the cell pellet was washed with 5mL of cold PBS. The samples were centrifuged at 
200g for 5 minutes. The supernatant was carefully removed and the cell pellet was 
resuspended in 1mL of PBS. At this stage, 9µL of the cell suspension was removed for 
cell count.  
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2.1.8.4. Efflux in suspension cell-lines 
Triplicate T25cm2 flasks were seeded with 5mL of 5 x 104 cells/mL.  Following the 
overnight period the cells were exposed to a concentration of tyrosine kinase inhibitor 
for 2 hours.  After 2 hours samples were pipetted into extraction tubes and centrifuged 
at 200g for 5mins.  The supernatant media was removed; the cell pellet was 
reconstituted in 4mL of PBS and centrifuged again at 4000rpm for 5 minutes. At this 
stage, the control samples were taken and counted.  Drug-free media or media 
containing the appropriate MDR inhibitor was added to the cell pellets at this stage and 
the samples returned to the incubator for a further 30, 60, 90 or 120 minutes.  After this 
further incubation period had elapsed, samples were centrifuged and the supernatant 
media removed.  The cell pellet was reconstituted in 1mL of PBS and an aliquot 
removed for counting. 
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2.2. Analytical methodology 
The following materials and methods were used in relation to analytical methodologies.  
 
2.2.1. Extraction and LC-MS reagents 
? Lapatinib ditosylate (SRP01211l), dasatinib (SRP00930d), gefitinib 
(SRP01240g), erlotinib HCl (SRP01331e), imatinib mesylate (SRP00530i), 
sorafenib tosylate, (SRP01590s) lenalidomide (SRP016751l), and bortezomib 
(SRP02310b), were purchased from Sequoia Chemicals, Pangbourne, UK. 
? Water MS grade (39253), acetonitrile MS grade (34967), propan-2-ol MS grade 
(34965), formic acid ammonium salt (ammonium formate) (F2004), formic acid 
(33015), tert-butyl methyl ether (tBME) (34875), 1-chlorobutane (34958), 
human serum (S7023), thalidomide (T144) were purchased from Sigma-Aldrich, 
Dublin. 
? Chloroform (C05C11X), dichloromethane (C10A11X), and ethyl acetate 
(C13C11X) were purchased from Fischer Scientific Ireland.  
 
Details of all the drugs used during the course of this project including storage and 
disposal conditions are given in Appendix I 
 
2.2.2. Extraction and LC-MS equipment 
? LC system: 1200 Series Rapid Resolution LC  
? MS system: 6410 Series Triple Quadrupole LC/MS   
? Genevac EZ-2 evaporator, Ipswich, UK 
? Blood-tube mixer: Stuart Scientific, UK 
? Glass pastuer pipette: 2mL 150mm glass pastuer pipettes (612-1701), VWR, 
Ireland 
? Extraction tubes: 10mL PPE tubes, VWR, Ireland 
? LC vials: 1.1 mL, conical bottomed, Chromacol vials purchased from Fisher 
Scientific, Ireland.  
? pH meter: Jenway 3320, instrument was calibrated before each use. 
? LC-columns were purchased from Phenomenex UK, Agilent UK and Apex 
Scientific, Maynooth, Ireland.  
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Table 2-3: Chromatography columns used is this thesis 
Column 
Name Dimensions 
Packing 
Material 
Particle 
Size Application Source 
SynergSi 
Hydro 150mm x 2.0mm C18 4μm TKI optimisation Phenomenex, UK 
Hyperclone 150mm x 2.0mm C18 3μm TKI separation - validated Phenomenex, UK 
Hyperclone 150mm x 4.6mm C18 3μm TKI optimisation Phenomenex, UK 
Prodigy 150mm x 2.0mm C18 5μm 
Anthracycline separation - validated 
also 
Thalidomide-Umbelliferone optimisation Phenomenex, UK 
Prodigy 150mm x 4.6mm C18 5μm Thalidomide-Umbelliferone - validated Phenomenex, UK 
Agilent 
XBD 50mm x 4.6mm C18 1.8μm Thalidomide-Umbelliferone optimisation Agilent, UK 
Agilent 
Eclipse 150mm x 4.6mm C18 5μm Thalidomide-Umbelliferone optimisation Agilent, UK 
ZORBAX 
SB 150mm x 2.1mm Phenyl 5μm Thalidomide-Umbelliferone optimisation Agilent, UK 
YMC-
UltraHT 50mm x 2.0mm C18 2μm Thalidomide/ Lenalidomide optimisation 
Apex Scientific, 
Ireland 
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2.2.3. Extraction and LC-MS solutions 
2.2.3.1. Dasatinib - lapatinib quantification 
? Stock solutions: All TKIs (lapatinib, dasatinib, erlotinib, gefitinib, imatinib, 
sorafenib) were prepared at 50μg/mL in ACN and stored at -20oC. Day stocks 
were prepared at 10μg/mL in ACN. 
? 10mM Ammonium formate, pH 4: Ammonium formate was accurately weighed 
(630.6mg) and added to 800mL of LC-MS grade water. Formic acid was added 
drop-wise to adjust the pH4.  The volume was then adjusted to 1L. 
? Lapatinib and dasatinib mobile phase: 540mL of ACN and 460mL of 10mM 
ammonium formate measured separately and mixed.  
? 1M ammonium formate pH 3.5 extraction buffer: 31.5g of ammonium formate 
was dissolved in 400mL water. The pH was adjusted to pH3.5 using formic acid. 
The volume was then adjusted to 500mL.  
? Lapatinib/dasatinib extraction solvent: tBME/ACN, 3/1 v/v 
? Lapatinib internal standard: 500ng/mL lapatinib in ACN, prepared fresh from 
the day stock 
? Dasatinib internal standard: 500ng/mL dasatinib in ACN, prepared fresh from 
the day stock 
 
2.2.3.2. Thalidomide quantification 
? Primary stock solutions of thalidomide, lenalidomide and umbelliferone were 
prepared at 1mg/mL in ACN and stored at -20oC 
? Working stock solutions were prepared fresh daily to a concentration of 
100μg/mL in acetonitrile of thalidomide and 10μg/mL of umbelliferone 
? Umbelliferone internal standard: 600ng/mL prepared fresh from 10μg/mL 
working stock in ACN 
? Citrate buffer, pH1.5: 25mM (7.35g/L) sodium citrate in water (MS grade), pH 
adjusted with HCl to 1.5 
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2.2.3.3. Anthracycline quantification  
? Mobile Phase: To 720 ml of MS grade water, 720μL of formic acid was added. 
The pH was very carefully adjusted to pH 3.2 using concentrated ammonium 
formate (300 mg/ml, in MS grade water). Finally, 280 mL of MS grade 
acetonitrile was added and the bottle was gently shaken to mix. 
? Extraction buffer: 1MAmmonium formate, pH8.5, aliquoted and stored at -20oC 
? Internal standard: Daunorubicin 200ng/mL in water 
? Silver nitrate: Prepared as 33% (w/v) in water and stored at -20oC, wrapped in 
tinfoil. 
 
2.2.4. Flow injection analysis 
Flow injection analysis was used to identify the precursor ion and products ions as well 
to optimise the fragmentor voltage and collision energy for each transition.  Pure drug 
was prepared at 250ng/mL in ACN.  For the determination of the precursor ion, 10μL 
were injected six times using an injector program.  For the determination of the 
optimum fragmentor voltage, product ion and optimum collision energy for each 
transition, the injection volume was changed to 5μL.  The sample was injected twice at 
each condition.  
 
2.2.5. Dasatinib and lapatinib quantification 
2.2.5.1. Liquid-liquid extraction procedure 
To the cell pellet, 100μL of 500ng/ml internal standard was added.  Dasatinib 
500ng/mL was used as the internal standard for lapatinib and conversely, 500ng/mL 
lapatinib was used as the internal standard for the quantification of dasatinib.  Also 
200μL of 1M ammonium formate pH 3.5 buffer and 1.6mL of extraction solvent 
tBME/ACN (3:1) was added to the cell pellet.  The extraction tubes were vortexed and 
mixed on a blood tube mixer for 15 minutes.  The samples were centrifuged at 3200g 
for 5 minutes; the organic layer was removed with a glass pasteur pipette and 1.1mL of 
solvent was transferred to conical bottomed glass LC autosampler vials.  The vials were 
evaporated to dryness using a Genevac EZ-2 evaporator at ambient temperature, without 
light.  The samples were reconstituted in 40μL of acetonitrile with 20μL injected 
automatically by the autosampler 
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2.2.5.2. Preparation of standard curve 
To an extraction tube, 50μL of cell suspension in water was added, as well as 100μL of 
500ng/mL internal standard and 100μL of analyte varying in concentration from 
1ng/mL to 2000ng/mL. Samples were extracted as outline in Section 2.2.5.1. Each 
concentration point was extracted in triplicate. Samples were analysed by LC-MS at 
intervals during the sample run time.  
 
2.2.5.3. Preparation of recovery samples 
Recovery samples were used to determine the extraction efficiency of an extraction 
system. Two types of recovery samples are used in this thesis.  
“Calculated” recovery samples were prepared by calculating the mass of analyte 
injected and preparing this concentration of analyte in a 2X concentration and adding to 
a 2X concentration of the internal standard. As an example, 100μL of 100ng/mL of 
dasatinib was added to an extraction tube. This was a mass of 10ng in the tube. A 
volume of 1.6mL of extraction solvent and 100μL of internal standard was added to the 
tube. A volume of 1.1mL of solvent was removed and dried down. Assuming 100% 
recovery of the analyte in the solvent the mass of the analyte in the vial was 6ng 
(1.1/1.8*10). The sample was reconstituted in 40μL and 20μL was injected. This 
equated to 3ng on column. This was 3ng in 20μL equates to 150ng/mL. A 2X of this is 
prepared and mixed with a 2X of the internal standard. Samples are dried down and 
reconstituted and injected.  
“No matrix” recovery samples were prepared in a manner similar to the standard curve. 
Extraction tubes were spiked with analyte and internal standard, however, no cell pellet 
was added to the extraction tube. Samples were extracted as outlined in Section 2.2.5.1. 
 
2.2.5.4. System standard preparation 
A 10mL solution of lapatinib 100ng/mL and 100ng/mL dasatinib was prepared in 
acetonitrile and divided into 200μL aliquots. Aliquots were stored at -20°C. A system 
suitability standard was analysed before each run to verify the instrument was operating 
as normal. During the analysis of a batch of samples, system standards and mobile 
phase blanks were run at intervals to identify any potential instrumentation errors.  
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2.2.5.5. Chromatographic and mass spectrometric conditions 
Chromatographic separation was achieved using a Hyperclone BDS C18 column 
(150mm×2.0mm i.d., 3μm particle size) with a SecurityGuard C18 guard column 
(4mm×3.0mm i.d.) both from Phenomenex, UK, though if available a small diameter 
guard column should be used. An optimised mixture of acetonitrile–10mM ammonium 
formate pH 4 (54:46, v/v) was used as mobile phase, at a flow rate of 0.2mL/min. The 
column temperature was maintained at 20°C and the temperature of the autosampler 
was maintained 4°C. The complete chromatographic run time of each sample was 10 
minutes, which separated dasatinib and lapatinib from each other with retention times 
2.3 and 5.1 minutes respectively. Peaks were quantified using Agilent Masshunter 
Software (Version B.01.04). 
 
The mass spectrometer was operated using an ESI source in the positive ion detection 
mode. The ionisation temperature was 350°C, gas flow rate was 11L/min and nebulizer 
pressure was 345kPa. Nitrogen was used as the ionisation source gas and ultrapure 
nitrogen, the collision cell gas. 
 
Analysis was performed using MRM mode with the following transitions: m/z 
581→m/z 365 for lapatinib, and m/z 488→m/z (231 and 401) for dasatinib, with a 
dwell time of 200ms.   
 
Quantification was based on the integrated peak area as determined by the Masshunter 
Quantification Analysis software which quantitates the peak areas of the MRM 
transitions of each analyte.  Table 2-4 details the transitions optimised for all TKIs used 
in this thesis, * indicates quantifier ion. 
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Table 2-4: Summary of MRM transition conditions for TKIs 
Name 
Precursor 
Ion 
Optimum 
Fragmentor 
Voltage Product Ion 
Optimum 
Collision 
Energy 
Dasatinib 488 120 
401* 
231 
30 
50 
Lapatinib 581 200 365* 40 
Gefitinib 447.2 160 128* 30 
Erlotinib 393.9 160 
278* 
336 
35 
25 
Imatinib 494.2 120 
394* 
217 
99 
25 
25 
30 
Sorafenib 399.1 100 
252* 
326 
35 
20 
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2.2.6. Thalidomide quantification 
2.2.6.1. Sample handling 
A blood sample of 10 mL of was collected in additive free blood tubes and the blood 
was allowed to clot for 30 minutes to 1 hour.  The clinical specimens were then 
transported from the Mater Hospital to NICB.  All blood samples were collected under 
the full ethical approval of the hospital Ethics committee.  In the lab, the non-clotted 
serum was transferred into a 15mL Falcon tube and spun down @400g, 30min at 4°C.  
An aliquot of serum supernatant was mixed 1/1 (v/v) with 25mM citrate buffer pH1.5 in 
extraction tubes. Samples were frozen at -80°C until extracted. 
 
2.2.6.2. Liquid-liquid extraction procedure 
A 200μL aliquot of sample (serum: citrate 1:1, v/v) was added to a polypropylene 
extraction tube.  To this, 50μL of internal standard (600ng/mL umbelliferone) was 
added, along with 50μL of acetonitrile and 2mL of extraction solvent (ethyl 
acetate/ACN, 3:1, v/v).  The extraction tubes were vortexed and mixed on a blood tube 
mixer for 5 minutes.  The samples were centrifuged at 3200g for 5 minutes.  The 1.1mL 
of the organic layer was removed with a glass pasteur pipette and transferred to a 
conical bottomed glass LC autosampler vial (Chromacol).  The vials were evaporated to 
dryness using a Genevac EZ-2 (Ipswich, UK) evaporator at ambient temperature, 
without light.  The samples were reconstituted in 50μL of mobile phase.  Two injections 
of 20μL were injected automatically by the autosampler. 
 
2.2.6.3. Standard curve preparation 
Human serum was mixed with citrate buffer, pH1.5, (1/1, v/v) as a biological matrix.  
This was to mimic the collected patient samples as thalidomide is unstable at 
physiological pH[282].  Thalidomide standards were prepared fresh at drug 
concentration of 40, 20, 10, 2, 1 0.2 and 0.1μg/mL in ACN.  This equated to a serum 
concentration of 20, 10, 5, 1, 0.5, 0.1and 0.05μg/mL respectively.  
A 200μL aliquot of serum/citrate was added to an extraction tube.  To this, 50μL of 
internal standard, 50μL of thalidomide standard and 2mL of extraction solvent (ethyl 
acetate/ACN 3:1, v/v) was added.  This was extracted as described in Section 2.2.6.2. 
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2.2.6.4. Chromatographic and mass spectrometric conditions 
Chromatographic separation was achieved using a Prodigy C18 column 
(150mm×4.0mm i.d., 5μm particle size) with a SecurityGuard C18 guard column 
(4mm×3.0mm i.d.) both from Phenomenex, UK. A mixture of acetonitrile: water 
(30:70, v/v) 0.1% formic acid was used as mobile phase, at a flow rate of 0.5mL/min. 
The column temperature was maintained at 20°C and the temperature of the 
autosampler was maintained at 4°C. The complete chromatographic run time of each 
sample was 13 minutes, which separated umbelliferone and thalidomide from each other 
with retention times of 7.9 and 9.3 minutes respectively. Peaks were quantified using 
Agilent Masshunter Software (Version B.01.04). 
The mass spectrometer was operated using an ESI source in the positive ion detection 
mode. The ionisation temperature was 300°C, gas flow rate was 11L/min and nebulizer 
pressure was 345kPa. Nitrogen was used as the ionisation source gas and ultrapure 
nitrogen as the collision cell gas. 
 
Analysis was performed in MRM mode with the following transitions: m/z 259.1→m/z 
(186 and 84) for thalidomide, and m/z 163.1→m/z 107 for umbelliferone, with a dwell 
time of 200ms. Both product ions of thalidomide were monitored, 84 m/z was the 
quantifier ion and 186 m/z was the qualifier ion.  Table 2-5 details the transitions 
optimised for all multiple myeloma agents used in this thesis, * indicates quantifier ion. 
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Table 2-5: Summary of MRM transition conditions for multiple myeloma agents 
Name 
Precursor 
Ion 
Optimum 
Fragmentor 
Voltage 
Product 
Ion 
Optimum 
Collision 
Energy 
Thalidomide 259.1 120 
84* 
186 
10 
25 
Umbelliferone 163.3 130 107.1 20 
Lenalidomide 260.1 90 
187.2 
148.8* 
106 
25 
15 
40 
Bortezomib 367.2 130 
226.3* 
208.1 
321.1 
15 
30 
20 
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2.2.7. Anthracycline quantification 
Epirubicin, was quantified according to the method published by Wall et al.[293] 
2.2.7.1. Extraction procedure 
Frozen cell pellets were thawed in the dark, 200μL of water and 20 μL of 33% silver 
nitrate was added. The sample was vortexed. 100μL of the internal standard, 
daunorubicin, was added, followed by 700 μL ice cold isopropanol, 100μL ammonium 
formate buffer pH8.5. This mixture was mixed well before 1400μL chloroform was 
added using a glass pipette. The extraction tubes were mixed using a blood mixer for 5 
minutes, and then they were centrifuged for 5 minutes at 3200g. A volume of 1.1mL of 
the organic layer was removed and placed in a glass vial. The vials were evaporated to 
dryness using a Genevac EZ-2 evaporator at ambient temperature, without light. The 
samples were reconstituted in 30μL of mobile phase with 20μL injected automatically 
by the autosampler. 
 
2.2.7.2. Standard curve preparation 
A broad range of standards were prepared, ranging from 5000ng/mL to 1ng/mL. A cell 
pellet was spiked with 100μL of water, 100μL of epirubicin, 20μL of silver nitrate and 
100μL of internal standard. Samples were extracted as described in Section 2.2.7.1. 
 
2.2.7.3. Chromatographic and mass spectrometric conditions 
Chromatographic separation was achieved using a Prodigy C18 column 
(150mm×2.0mm i.d., 5μm particle size) with a SecurityGuard C18 guard column 
(4mm×3.0mm i.d.) both from Phenomenex, UK. Mobile phase (as described in Section 
2.2.3.3) was run at a flow rate 0.25mL/min. The column temperature was maintained at 
45°C and the temperature of the autosampler was maintained 4°C. The autosampler was 
operated with the light off. The complete chromatographic run time of each sample was 
9 minutes, which separated epirubicin and daunorubicin from each other with retention 
times 4.2 and 7.4 minutes respectively. Peaks were quantified using Agilent Masshunter 
Software (Version B.01.04). 
The mass spectrometer was operated using an ESI source in the positive ion detection 
mode. The ionisation temperature was 300°C, gas flow rate was 10L/min and nebulizer 
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pressure was 345kPa. Nitrogen was used as the ionisation source gas and ultrapure 
nitrogen as the collision cell gas. 
 
Analysis was performed in MRM mode with the following transitions: m/z 544→m/z 
(397 and 86) for epirubicin, and m/z 528→m/z (321 and 363) for daunorubicin, with a 
dwell time of 200ms. All product ions were monitored; however, transition 544m/z 
→397m/z was for the quantification of epirubicin and the transition 528m/z →321m/z 
was used for the quantification of daunorubicin. Table 2-6 details the transitions for 
anthracyclines used in this thesis, * indicates quantifier ion. 
 
Table 2-6: Summary of MRM transition conditions for anthracyclines 
Name 
Precursor 
Ion 
Optimum 
Fragmentor 
Voltage 
Product 
Ion 
Optimum 
Collision 
Energy 
Epirubicin 544 100 
397* 
86 
10 
30 
Daunorubicin 528 100 
363 
321* 
10 
30 
 
 
2.3. Statistical Analysis 
Analysis of the difference of comparisons such as percentage survival calculated, mass 
of accumulated agents etc, were performed using a paired two-tailed student t-test 
(Excel® Microsoft).  
 
* - p value of ≤ 0.05 was deemed significant 
** - p value ≤ 0.01 was deemed more significant 
*** - p value ≤ 0.005 was deemed highly significant 
 84
 
 
 
 
 
SECTION 3.0 Results and discussion 
 
 
 
 
The development and validation of a quantification 
assay for dasatinib and lapatinib  
 
 85
3. The development and validation of a quantification 
assay for dasatinib and lapatinib 
Introduction 
Previous work carried out in our group has shown that lapatinib modulates the uptake of 
chemotherapeutics by inhibiting the action of the P-glycoprotein efflux protein (P-
gp)[179].  To investigate if this inhibition was due to the action of lapatinib as a 
competitive substrate or through other mechanisms, it was necessary to develop a 
quantitative method.  This method would be used for evaluating of the drug kinetic 
profiles within the cell and therefore to determine the role of MDR transport proteins on 
the uptake of lapatinib.  To avoid the use of radio-labelled drugs our studies focus on 
mass spectrometry as quantification tool.  Radio-labelled agents are frequently used in 
assays to determine the transport characteristics of the agent[58, 294].  However, the 
hazards associated with the use of radio-labelled material including exposure hazards, 
waste disposal issues and additional legislative requirements, make other methodologies 
preferable.  
At the commencement of this body of work only one analytical LC-MS method for the 
quantification of lapatinib was published[200].  This method detailed a solid phase 
extraction (SPE) method, with a 75% recovery, to remove the analyte from the 
biological matrix.  
Our aim was to develop a straightforward LC-MS method for the detection and 
quantification of lapatinib with an optimised and simplified extraction procedure, 
possibly using liquid-liquid extraction (LLE) as a sample clean-up step due to its 
compatibility with complex biological matrices.  
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3.1. LC separation 
The optimisation of an LC separation is a process involving the adjustment of an array 
of parameters in a logical, sequential yet interwoven manner. The stationary phase (the 
column) the mobile phase and the internal standard are all under investigation.   
The selection/identification of an appropriate internal standard is of crucial importance 
to the development of the method.  The “gold standard” of internal standards is to use 
the deuterated form of the analyte of interest; however, this is frequently a prohibitively 
expensive approach.  Alternative tyrosine kinase inhibitors were examined as potential 
internal standards.   
With lapatinib as the primary focus dasatinib, gefitinib and erlotinib were evaluated as 
potential internal standards. Initial experiments focused on gefitinib as an internal 
standard, examining its separation from lapatinib on various columns.  
 
3.1.1. Column optimisation 
Preliminary investigation into the separation of lapatinib and a possible internal 
standard, gefitinib was performed on three columns, as outlined in Table 3-1. A buffer 
of 10mM ammonium formate pH4 was selected as mobile phase A (MPA) due to its 
compatibility with mass spectrometry, acetonitrile was used as mobile phase B (MPB).  
Initial separation was performed using gradient elution from 10%B to 100%B over 10 
minutes.  Using this as a starting point, an optimum mobile phase for isocratic 
separation was improved.  This process was applied to all of the columns investigated.  
Figure 3-1 is a representative chromatogram taken from the Beckman HPLC-UV 
system.  These chromatograms show the effect of minor alterations of the percentage of 
mobile phase on the analyte retention.  By increasing the ratio of organic to aqueous 
phase the peaks moved closer to each other and eluted faster, while the lower 
percentage acetonitrile causes both peaks to elute slightly later and give better baseline 
separation.  The red trace shows elution of lapatinib and gefitinib with isocratic flow 
and a mobile phase composition of 78% (v/v) acetonitrile/10mM ammonium formate.  
The blue trace shows a lapatinib and gefitinib separation at 76% (v/v) 
acetonitrile/10mM ammonium formate.  
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Figure 3-1: Preliminary evaluation of separation of lapatinib and gefitinib 
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A representative chromatogram showing the separation of lapatinib and gefitinib on a SynergSi Hydro RP C18 column  
 
Minutes 
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At the higher ratio of acetonitrile, gefitinib eluted at 1.6mins while lapatinib had a 
retention time of 2.8 minutes. At the lower ratio of organic solvent in the mobile phase, 
76% acetonitrile, gefitinib had a retention time of 1.8 minutes and lapatinib was eluted 
at 3.2 minutes.  
 
Reverse phase chromatography is based on the partition of the analytes between a polar 
mobile phase and a non-polar stationary phase, normally C8 or C18. Octadecyl (C18 or 
ODS) columns are generally the first choice in the development of a new method and 
are used for the separation of moderately polar to polar solutes in the pharmaceutical 
industry, food analysis industry, pesticides and bio-analytics.  
 
Table 3-1 shows the columns assessed and the separation conditions found to give the 
optimum separation of lapatinib and gefitinib. Each column was assessed by multiple 
injections of lapatinib and gefitinib in acetonitrile. Each column was equilibrated for a 
minimum of 10 column volumes with each alteration in mobile phase composition. 
Column #1 initially performed acceptably, however, on subsequent multiple injection a 
shift in retention times of both analytes was seen.  Column #2 proved to have excellent 
separation of both gefitinib and lapatinib at 60% acetonitrile; however, column #3 was 
the most applicable column for the separation required as it gave equivalent separation 
to column #2 but due to a lower flow rate, lower volumes of solvents were required.  
 
Column #1 initially performed acceptably, however, on subsequent multiple injection a 
shift in retention times of both analytes was seen.  Column #2 proved to have excellent 
separation of both gefitinib and lapatinib at 60% (v/v) acetonitrile/10mM ammonium 
formate pH4 at 0.4mL/min.  However, column #3 was the most applicable column for 
the separation required as it gave equivalent separation to column #2 but due to a lower 
flow rate, lower volumes of solvents were required 
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Table 3-1 Investigation of suitability of HPLC-C18 columns 
# Column Name 
Stationary 
Phase 
Particle 
Size Column Size Optimum Separation Flow Rate Comment 
1 SynergSi Hydro RP C18 4μm 150mm x 2.0mm 
ACN:10mM Ammonium Formate pH4 
(76:24) 0.4 mL/min unsuitable 
2 Hyperclone C18 3μm 100mm x 4.6mm 
ACN:10mM Ammonium Formate pH4 
(60:40) 0.4 mL/min suitable 
3 Hyperclone C18 3μm 150mm x 2.0mm 
ACN:10mM Ammonium Formate pH4 
(60:40) 0.2 mL/min suitable 
Table 3-1 gives the details of the of the columns used in the optimisation of the separation of gefitinib and lapatinib 
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3.1.2. Internal standard selection 
Having determined the Hyperclone C18 150mm x 2.0mm 3μm particle size, to be the 
most applicable column for the separation it was then necessary to determine which 
tyrosine kinase inhibitor would potentially be the most applicable internal standard.  
 
Table 3-2 compares dasatinib, erlotinib and gefitinib in terms of peak shape, separation, 
resolution and limit of detection by LC-MS.  The asymmetry factor (AsF) of a peak is a 
measure of the peak shape and a means of measuring peak tailing.  The perfect 
chromatographic peak has an asymmetry factor of 1 indicating that the peak is perfectly 
symmetrical; however, values up to 1.5 are generally acceptable.  Peak asymmetry 
factor is calculated by bisecting the peak at the apex and measuring the peak width at 
10% of the peak height, Figure 3-3.  The peak width from the peak tail to the median is 
divided by the peak width from the peak front to the median.  Tailing factor (TF), 
similar to asymmetry factor is a measure of peak shape.  It is determined in a similar 
way but the peak width is measured at 5% of the peak height as opposed to 10% for 
peak asymmetry, Figure 3-2. Capacity factor (k’), also called the retention factor, is the 
fraction of sample compound distributed into the stationary phase divided by fraction in 
mobile phase.  This is calculated by subtracting the column dead time (t0) from the 
compound retention time (tR), divided by the column dead time, Figure 3-4.  Resolution 
(Rs) is a parameter which measures how well two adjacent peaks are separated, Figure 
3-5.  
 
The asymmetry of the gefitinib peak at 2.6 was greater than the maximum of 2.  The 
resolution of all three combinations was good as there was clear baseline separation of 
the analytes.  
 
Based on the AsF and TF, gefitinib was excluded from limit of detection (LOD) studies 
by LC-MS. Based on the separation, peak shape and LC-MS, LOD studies, dasatinib 
was selected as the appropriate internal standard for lapatinib. Table 3-2 details the AsF, 
TF k’ and Rs for each separation.  
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Table 3-2 Assessment of internal standard 
Drug 
Asymmetry 
Factor 
Tailing 
Factor 
Capacity 
Factor Resolution 
 CA
BCAsF =  
AC
ABTF
2
=  
0
0'
t
ttk R −=  
( )
( )21
12
2
1 WW
ttRs
+⎟⎠
⎞⎜⎝
⎛
−=
Dasatinib 1.3 1.2 0.37 11.18 
Erlotinib 1.0 1.2 0.86 7.63 
Gefitinib 2.6 2.0 0.50 10.89 
Asymmetry Factor, tailing factor, capacity factor and resolution were measured from 
HPLC-UV chromatograms.  
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Figure 3-2: Tailing Factor[295] 
 
Tailing factor, a measure of peak tailing, is defined as the distance from the front slope 
of the peak to the back slope divided by twice the distance from the centre line of the 
peak to the front slope, with all measurements made at 5% of the maximum peak 
height.  
 
 
 
Figure 3-3: Asymmetry Factor[295] 
 
The asymmetry factor, a measure of peak tailing, is defined as the distance from the 
centre line of the peak to the back slope divided by the distance from the centre line of 
the peak to the front slope, with all measurements made at 10% of the maximum peak 
height.  
 
 
Diagrams reproduced with the permission of the authors [295]. 
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Figure 3-4: Capacity Factor (k’)[295] 
 
Capacity factor is a measure of the retention of a peak that is independent of column 
geometry or mobile phase flow rate. The capacity factor for a gradient elution cannot 
be calculated in this way. 
 
 
 
 
Figure 3-5: Resolution (Rs)[295] 
 
The resolution between two chromatographic peaks is a measure of how well they are 
separated 
 
 
 
 
 
 
 
Diagrams reproduced with the permission of the authors [295]. 
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3.2. Optimisation of extraction procedure 
The method by Bai et al.[200], described a solid phase extraction step to remove 
lapatinib from the biological matrix.  This method, however, was aimed at the 
extraction of lapatinib from plasma where our focus was on the extraction of lapatinib 
from cells.  Due to the high binding affinity of TKI agents to intracellular targets, and 
the complex nature of cell culture samples, liquid-liquid extraction (LLE) was chosen in 
preference to other forms of drug extraction methods[210].  
 
3.2.1. Solvent optimisation 
A range of extraction solvents were examined.  Figure 3-6 shows the recovery of 50ng 
of lapatinib and dasatinib using various solvents, ethyl acetate (EA), dichloromethane 
(DCM) and t-butyl methyl ether (tBME) alone and in combination with acetonitrile 
(ACN).  Alone, tBME was the most efficient solvent for the extraction of lapatinib.  
DCM alone was the most efficient solvent for the extraction of dasatinib.  However, the 
addition of ACN to the tBME extraction solvent improved the recovery across the 
solvent range, and the mixture of tBME: acetonitrile (3:1, v/v) gave the optimum 
recovery for both lapatinib and dasatinib.  
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Figure 3-6: Recovery of lapatinib and dasatinib with different extraction solvents 
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50ng of each analyte was extracted using a range of solvents and solvent mixtures. Results 
are presented as the average of triplicate estimates as a percentage of non-extracted 
samples calculated to equal 100% recovery. 
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3.2.2. Optimisation of extraction buffer pH 
Liquid-liquid extraction is based on a partitioning of solutes between organic and 
aqueous solvents which are immiscible.  Frequently the aqueous phase is a buffered 
solution.  The extraction buffer controlled the pH of the extraction system and stabilised 
the system.  The stability of a pH controlled environment allowed for reproducible 
extractions.  Alterations in the extraction buffer pH may also increase or decrease the 
amount of confounding biological substances recovered[296].  
 
Figure 3-7 shows the peak area of lapatinib and dasatinib for 50ng recovery across a 
range of pH buffered solutions.  
 
Extraction buffer pH3.5 was selected as the most appropriate.  While the pH3 buffer 
gave a better peak area, it also had greater standard deviations and thus greater 
inaccuracy, imprecision and irreproducibility.  
At pH4 and above the recovery of lapatinib was dramatically reduced.  Similarly but not 
to such an exaggerated extent, the recovery of dasatinib improved at lower pH buffer. 
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Figure 3-7: Effect of pH on lapatinib and dasatinib extraction 
Effect of extraction buffer pH on lapatinib and dasatinib peak area
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Representation of the peak areas of lapatinib and dasatinib when extracted with 
varying pH extraction buffer, the average and standard deviations of triplicate 
determinations 
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3.3. Optimisation of mass spectrometry detection conditions 
Using flow injection analysis (FIA) the optimum multi-reaction monitoring (MRM) 
settings were determined for dasatinib and lapatinib, as well as for the additional 
tyrosine kinase inhibitors of interest.  Table 3-4 gives the transitions from precursor to 
product ion as well as the optimum fragmentor voltage and optimum collision energy 
identified for each analyte.  The quantifier ions are indicated in the table (asterisked), 
though all transitions were monitored with the qualifier ion which adds specificity. 
 
Given in the sections below (3.3.1 – 3.3.4) is the development and optimisation of 
dasatinib for analysis by MRM.  Optimisation was carried out by FIA of dasatinib at 
250ng/mL, varying each condition sequentially.  The use of an injector program 
allowed for the multiple injection of the same compound, from the same vial, a defined 
number of times.  This permits multiple injections to be viewed and analysed in one 
data file, which eliminates the majority of error associated with inter-injection 
variability. 
 
The determination of the MRM transition of each TKI was carried out in a similar 
manner; dasatinib was selected as a representative sample.  
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3.3.1. Precursor ion determination 
The precursor ion, also called the parent ion, is “an electrically charged molecular 
moiety which may dissociate to form fragments”[297]. These fragments may be charged 
or neutral moieties.  Charged fragments can be detected, forming the basis of tandem 
mass spectrometry, and used to further identify the analyte. The precursor ion was 
determined by FIA of dasatinib, at 250ng/mL (10μL injected). 
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Figure 3-8: TIC of MS2Scan of dasatinib 
 
 
Figure 3-8 shows the total ion chromatogram (TIC) as detected in MS2Scan mode for four injections of dasatinib by Flow Injection Analysis 
(FIA) 
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Figure 3-9: Extracted MS Spectrum  
 The MS spectrum of dasatinib extracted from the greyed out section of the TIC in Figure 3-8. The predominant ion, a protonated dasatinib ion, 
determined to be 488.1 m/z, is annotated (*). This is the precursor ion. 
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3.3.2. Fragmentor voltage optimisation 
The ironically named fragmentor voltage (FV) is not involved in the fragmentation of 
the precursor ion to the product ion as one would assume, rather it acts as a filter for the 
MS.  While it is possible to fragment the precursor ion by increasing the fragmentor 
voltage, this is not the purpose of the fragmentor voltage.  The purpose of the 
fragmentor voltage is to preferentially maximise the throughput of precursor ions into 
the MS.  As shown in Figure 3-10 optimisation of FV is achieved by monitoring the 
individual dasatinib precursor ion in selected ion monitor (SIM) mode, and increasing 
the fragmentor voltage sequentially at time segments, SIM only collects data for a 
preselected ion.  To increase accuracy duplicate injections were performed at each 
condition. 
 
By comparing the integrated peak area each set of peaks, it is possible to determine the 
optimum fragmentor voltage, i.e. the voltage that allowed maximum transit of dasatinib 
precursor ion, see Table 3-3.  In the case of dasatinib, the fragmentor voltage from 120-
180 gave similar peak areas.  The reduction in peak area at higher fragmentor voltage is 
due to the precursor ion being broken down before entering the MS.  
 
The optimum fragmentor voltage was selected to be 120. 
Table 3-3: Peak Area of Integrated SIM 
RT Area Area % FV 
0.5 935219 85.34 100 
1.7 983835 89.78 100 
2.8 1088537 99.33 120 
3.9 1051526 95.96 120 
5 1079208 98.48 140 
6.1 1052601 96.05 140 
7.2 1095838 100 160 
8.4 1065522 97.23 160 
9.5 1085210 99.03 180 
10.6 1060277 96.75 180 
11.7 1084343 98.95 200 
RT Area Area % FV 
12.8 1063929 97.09 200 
13.9 1047160 95.56 220 
15 1035890 94.53 220 
16.2 958307 87.45 240 
17.3 953548 87.02 240 
12.8 1063929 97.09 200 
13.9 1047160 95.56 220 
The correlation between peak area 
and fragmentor voltage as assessed 
by SIM ion scan 
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Figure 3-10: Fragmentor voltage optimisation 
 
The TIC for 488.1m/z. in selected ion monitoring (SIM) mode with increasing fragmentor voltage 
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3.3.3. Product ion determination 
The product ions are the ions detected by the detector in the third quad of the mass spec, 
as a result of the fragmentation of preselected precursor ions in the collision cells.  By 
exposing the precursor ion to increasing collision energy, fragmentation occurs and the 
product ions can be determined as the MS2 detector scans from 100m/z to 500m/z. 
 
By selected time segments, as highlighted in Figure 3-11 and extracting the MS 
spectrum we can analyse the breakdown of the precursor ion to its product ions, which 
gives a typical MS/MS fragmentation pattern, as shown in Figure 3-12.  
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Figure 3-11: TIC of Product Ion Scan 
 
 
The TIC for the product ion scan with increasing collision energies. The highlighted time segment shows where the MS spectra were extracted.  
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Figure 3-12: Extracted MS spectra for product ion scan 
 
Figure 3-12 shows the extracted MS spectrum of the TIC of the product ion scan, shown in Figure 3-11.  The details of spectrum A, B, C and D are 
detailed below.  
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Figure 3-12 shows the extracted MS spectrum of the TIC of the product ion scan.   
• Spectrum A was extracted between 0.49 and 0.59 minutes, and shows the 
precursor ion with no collision energy has been applied.   
• Spectrum B was extracted between 2.72 and 2.83 minutes, with a collision 
energy setting of 10keV.  The product ion 401.1m/z was seen.  A drop in the 
abundance of the precursor ion was also seen, indicating that 401m/z ion came 
from the 488m/z ion.   
• Spectrum C, extracted between 4.88 and 5.16 minutes showed that a collision 
energy of 20keV gave a second product ion and left little precursor ion.   
• Spectrum D, extracted between 7.14 and 7.32 minutes with a collision energy of 
30keV showed that a high collision energy completely broke down the precursor 
ion so that was it no longer detectable 
 
3.3.4. MRM transition optimisation 
MRM (multi-reaction monitoring) can track many precursor ions and their multiple 
product ions through the MS to provide spectra that are quantifiable.  
 
Each transition from precursor ion to product ion can have different collision energies. 
By optimising the MRM transition, the collision energy for each transition was 
optimised.  
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Figure 3-13: TIC and EIC for dasatinib 
 
 
The TIC and the EIC for dasatinib with increasing collision energies.  
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Through flow injection analysis it was possible to determine the optimum collision 
energy for each transition.  Figure 3-13 shows duplicate 5μL injections in each time 
segment.  Collision energies were increased step-wise in units of 10 from a starting 
value of zero to 50keV.  The optimum collision energy for transition 488 – 401m/z was 
determined to be 30keV while the optimum collision energy for transition 488-231m/z 
was determined to be 50keV.  
 
While Figure 3-8 through to Figure 3-13 showed the determination of the optimum 
MRM transition setting for dasatinib, this is representative of the work carried out for 
each compound.  
 
Table 3-4 summarises the findings of these experiments.  
 
Table 3-4: Summary of MRM transition conditions 
Name 
Precursor 
Ion 
Optimum 
Fragmentor 
Voltage 
Product 
Ion 
Optimum 
Collision Energy 
Dasatinib 488 120 
401* 
231 
30 
50 
Lapatinib 581 200 365* 40 
Gefitinib 447.2 160 128* 30 
Erlotinib 393.9 160 
278* 
336 
35 
25 
Imatinib 494.2 120 
394* 
217 
99 
25 
25 
30 
Sorafenib 399.1 100 
252* 
326 
35 
20 
The optimal fragmentor voltages and collision energy settings for the determination of 
the TKI drugs employed in this study, * indicates quantifier ion.  
 
Quantification was based on the integrated peak area as determined by the Masshunter 
Quantification Analysis (Version B.01.04) software which quantifies the peak areas of 
the MRM transitions of each analyte.  
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3.4. Ion suppression  
Ion suppression or ion enhancement can be one of the disadvantages of mass 
spectrometry analysis, particularly of bio-analytical samples.  First identified by 
Buhrman et al.[298], ion suppression/enhancement effects are caused by co-eluting 
matrix artefacts.  These co-eluting matrix components cause quantification issues; ion 
suppression leads to reduced detection of the signal of the desired analyte whereas ion 
enhancement leads to amplification of the signal of the desired analyte.  Either case 
leads to problems in accurately quantifying the analyte of interest. 
 
3.4.1. Ion suppression issues – extraction vessel contamination 
The impact of ion suppression on the quantification of lapatinib and dasatinib was 
initially observed in experiments carried out to determine the optimum extraction 
conditions.  Extracted samples run in MRM mode showed unaccountably low recovery 
when compared to the standard sample, which was calculated to equal 100% recovery.  
Ion suppression can frequently be due to biological component in the analysis, however, 
LLE is known to give good recovery and this level of poor recovery was dramatic.  
Figure 3-14 shows the effects of ion suppression on the determination of dasatinib 
recovery.  The signal for the extracted dasatinib was suppressed by interfering 
background ions.  The peak area the “dasatinib calculated” sample was representative of 
100% and the peak area of the extracted dasatinib sampled was expressed as a 
percentage of the “dasatinib calculated” samples. 
 
Similarly for lapatinib Figure 3-15, the peak area of the extracted sample is expressed as 
a percentage of the peak area of the “calculated” sample, which is equivalent to 100% 
extraction. 
 
The contaminating ions were determined to have leached from standard laboratory 
polyethylene (PE) tubes. Drug standards prepared in plastic extraction tubes and 
extracted immediately gave good recovery while the same drug standards stored at 4°C 
over the weekend prior to extraction gave the appearance of low recovery since the 
detector was saturated with contaminating ions. When the samples were injected in 
duplicate, one for MRM analysis and one for MS2Scan analysis, samples with low 
quantifiable MRM signal had a corresponding high background in MS2Scan mode.  
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Figure 3-14: Example of poor dasatinib signal detection due to ion suppression 
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The effect of ion suppression on the detected dasatinib signal following extraction, 
expressed as a percentage of the expected signal. Results shown are the average of a 
minimum of triplicate samples.   
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Figure 3-15: Example of poor lapatinib signal detection due to ion suppression 
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The effect of ion suppression on the detected lapatinib signal following extraction, 
expressed as a percentage of the expected signal.  Results shown are the average of a 
minimum of triplicate samples.   
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The high level of background noise (from plasticisers leached from PE tubes) was seen 
to increase through the analyses of a batch of samples, increasing with the number of 
extracted samples injected. 
Figure 3-16 shows the TIC in MS2Scan mode of three injections of a system standard 
(mixture of lapatinib and dasatinib in pure acetonitrile) injected at different points 
during running of a worklist of extracted samples. System standards are routinely 
injected throughout the worklist run, frequently bracketing batches of samples.  
 
Here we see that the level of background acquired in the sample increased. This is 
attributed to carryover of plasticiser in the system from the extracted samples. 
 
Following the isolation of the ion suppression issue, all drug standards were prepared in 
10mL glass tubes. 
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Figure 3-16: Example of ion suppression from plasticiser leaching  
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Shown here is the TIC in MS2Scan trace of three injections from the same vial (mobile 
phase blank). The black trace (A) shows all ions detected the start of the run, the red 
trace (B) shows the MS2Scan after the injection of 10 extracted samples and the green 
trace (C) shows the MS2Scan after the injection of an additional 10 samples.  
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3.4.2. Ion suppression assessment of lapatinib and dasatinib extraction 
Having elucidated the problem of ion suppression it was then necessary to examine the 
impact of extraction and LC conditions on ion suppression  
 
Ion suppression can be analysed by either post-column infusion method or by 
reconstituting standard dilutions of each agent in extracted samples, as detailed by 
Zirolli et al[234]. 
 
The level of ion suppression on lapatinib and dasatinib was initially examined by post 
column infusion with isocratic elution at 60% (v/v) acetonitrile: 10mM ammonium 
formate pH4.  The analyte (2μg/mL) was introduced through a T-piece, by an infusion 
pump at a flow of 50μL/min, after the analytical column into the flow path, as 
illustrated in Figure 3-17.  
 
Samples of mobile phase and extracted blank samples were injected from the 
autosampler through the analytical column into the MS, while the MS monitored, in 
MRM mode, the constant signal of the analyte from the infusion pump.  Any ion 
suppression or enhancement effects would be seen as a drop or rise, respectively, in the 
constant signal for the analyte of interest.  
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Figure 3-17: Schematic of post-column infusion 
 
Figure 3-17 demonstrates the instrument configuration for the determination of ion 
suppression by post column infusion.  
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Figure 3-18 shows the investigation by direct post-column infusion of the effect of ion 
suppression on dasatinib. 
• Spectrum A showed the retention time for dasatinib on column. This illustrated 
the time range of importance for signs of ion suppression/enhancement effects.  
• Spectrum B is the MRM of dasatinib with 20μL injection of extraction blank 
cell sample and where ion suppression effects might be anticipated.  
• Spectrum C is the MRM of dasatinib infusion with a 20μL injection of mobile 
phase.  
 
The ion suppression effect of the extracted cell blank sample on dasatinib was 
determined to be approximately 40%.  This was determined by assessing the difference 
between response for dasatinib pre-injection and at the expected retention time, as 
indicated by the dashed lines in spectrum B, Figure3-18.  The injection of mobile phase, 
spectrum C, shows that the drop in the detection level of the infused dasatinib is from 
the injection of the extracted blank sample alone. 
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Figure 3-18 Dasatinib 2μg/mL infusion at 50μL/min 
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Figure 3-19 shows the investigation by direct infusion of the effect of ion suppression 
on lapatinib. 
• Spectrum A is the analysis of lapatinib in MRM with on-column separation 
which identifies the retention time of lapatinib and illustrates the time range of 
importance.  
• Spectrum B shows the injection of an extracted cell/matrix blank sample by the 
autosampler.  The red trace shows the detected levels of lapatinib as introduced 
through the T-piece, post-column, into the detector.  
• Spectrum C is the injection of 20μL injection mobile phase A 
(60%ACN/40%10mM ammonium formate pH4), again the detected trace is of 
lapatinib introduced through constant infusions.  
 
Injecting mobile phase identifies that any interfering artefacts seen in spectrum B are 
the result of the cell blank. 
 
The ion suppression effect of the extracted cell blank sample on lapatinib was 
determined to be approximately 10%.  This was assessed by determining the difference 
between the responses for lapatinib prior to injection (e.g. time point 0.5-1min) and the 
response for lapatinib at the retention time (4.4mins). 
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Figure 3-19: Infusion of 2μg/mL lapatinib at a constant rate of 50μL/min 
3x10
1
2
3
4
5
6
+ MRM (581.00000 -> 365.00000) IS_0003.d 
1
4x10
1
2
3
4
5
6
7
8
+ TIC MRM (** -> **) IS_0004.d  
1
4x10
3
4
5
6
7
+ TIC MRM (** -> **) IS_0006.d  
1 1
Counts vs. Acquisition T
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
A
B
C
 
Lapatinib ion suppression investigation by direct infusion of 2μg/mL  
 121
We can see from the infusion profile of dasatinib that a small shift in retention time of 
dasatinib would move it out of a region where ion suppression might be anticipated.  
The effect of altering the ratio of the mobile phase components on the retention time of 
lapatinib and dasatinib was assessed. 
 
The optimum isocratic mobile phase was found to be 54% acetonitrile: 10mM 
ammonium formate pH4.  By accurately measuring the 460mL of mobile phase A 
(10mM ammonium formate pH4) and 540mL of mobile phase B (acetonitrile) and 
injecting both analytes, retention times of 2.39mins (dasatinib) and 5.39mins (lapatinib) 
were seen.  This gives enough of a shift in retention time to avoid the worst area of ion 
suppression while still giving rapid and high efficiency separation and reasonably 
narrow peaks.  Figure 3-20 shows a representative chromatogram of lapatinib and 
dasatinib separation at 54% acetonitrile. 
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Figure 3-20: Representative spectrum of dasatinib and lapatinib 
 
Representative spectrum of dasatinib and lapatinib separation following mobile phase optimisation 
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To accurately assess the level of ion suppression from the cell pellet due to the 
extraction process, the method outlined by Zirrolli et al., was used[234].  
Standard dilutions of each drug in acetonitrile were prepared.  These solvent standards 
were added (40μL) to dry extracted cell blanks samples (post extraction samples) to 
clean LC vials (40μL). A volume of 20μL of each concentration was injected from each 
vial.  The post extraction standard was normalised to the solvent standard and expressed 
as a percentage. 
 
Figure 3-21 and Figure 3-22 show that under the tested conditions the ion suppression 
effects on the detection and quantification of lapatinib and dasatinib were found to be 
minimal. 
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Figure 3-21: Effect of Ion Suppression of Lapatinib 
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Figure 3-22: Effect of Ion Suppression on Dasatinib 
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Ion suppression was calculated as peak area of the analyte of interest in the post-extraction standard compared to the solvent standard. Data is 
expressed as a function of the initial mass of drug in the tube, n=3. 
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3.5. Assay validation 
The overall LC-MS method was validated for the following performance parameters- 
linearity and range, intra-day precision (repeatability) and inter-day precision 
(intermediate precision), accuracy, sensitivity (LOD and LOQ), recovery and sample 
stability according to the guidelines described by Ermer[299].  MRM allowed 
individual determination of each drug necessary with the use of internal standard-based 
quantification. 
 
3.5.1. Linearity and range 
Regression analysis was used to assess the linearity between the peak area ratios 
(analyte/internal standard) and the analyte concentration.  
The calibration curves for dasatinib and lapatinib were linear over the range of 0.1ng to 
200ng in tube and recovery was linear. Since the TKIs resolved well from each other 
and were extracted with high efficiency one TKI was used as the internal analytical 
standard for the other agent to reduce error. Internal standard (IS) of 50ng (100μL of a 
500ng/mL stock) was added to each tube.  Whilst the calibration curves were linear, 
over such a broad range, the bias of the regression line tends to make the determination 
of lower drug concentration values much less accurate; hence it was decided to use a 
LOG10-LOG10 plot of the peak area ratio versus the mass of drug in all calculations. The 
LOG10-LOG10 plot gave typical correlation coefficients (R2) values of 0.99, see Figure 
3-23 and Figure 3-24 for dasatinib and lapatinib. 
 
3.5.2. Precision and accuracy 
Intra-day precision and accuracy was assessed over the mass range (0.1ng - 200ng) by 
extraction and analysis of triplicate spiked samples on the same day. (Table 3-5) 
Inter-day precision and accuracy was assessed over the mass range (0.1ng - 200ng) by 
extraction and analysis of triplicate spiked samples over four days. (Table 3-6) 
The percentage relative standard deviation (%R.S.D.) was employed as a measure of 
precision. The percentage accuracy was determined by dividing the average calculated 
drug concentration by that of the spiked known concentration.  In all cases, the R.S.D. 
values were less than 13%, the majority were less than 10% and the average percentage 
accuracy was 102%.  
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Figure 3-23: Representative example of calibration curve for dasatinib 
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Representative standard curve for dasatinib extracted from spiked cell pellet matrix 
 
Figure 3-24: Representative example of calibration curve for lapatinib 
Lapatinib Standard Curvey = 1.0105x + 1.6564
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Representative standard curve for lapatinib extracted from spiked cell pellet matrix 
 
Both Figure 3-23 and Figure 3-24 are LOG10 /LOG10 plots of the spiked mass versus the 
peak area ratio of the analyte to the internal standard.  In line with ICH guidelines, more 
than five concentrations were used, and each concentration was examined in triplicate.  
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Table 3-5: Intra-day analysis for precision and accuracy (n=3) for lapatinib and dasatinib. 
Spiked Mass (ng)
Lapatinib Dasatinib 
Mean Mass Observed (ng) % Accuracy % R.S.D. Mean Mass Observed (ng) % Accuracy % R.S.D.
0.10 0.12 120.5 5.4 0.10 104.6 9.1 
0.25 0.24 95.5 8.1 0.26 102.3 12.6 
0.50 0.55 110.8 7.9 0.49 97.9 12.9 
10.0 9.1 91.0 2.7 9.1 90.7 11.4 
50.0 55.4 110.8 1.9 53.7 107.4 10.3 
200.0 209.7 104.8 2.8 200.9 100.4 9.2 
The accuracy and precision of lapatinib and dasatinib from triplicate intra-day analysis  
 
Table 3-6: Inter-Day analysis for accuracy and precision for lapatinib and dasatinib. 
Spiked Mass (ng)
Lapatinib Dasatinib 
Mean Mass Observed (ng) % Accuracy % R.S.D. Mean Mass Observed (ng) % Accuracy % R.S.D.
0.10 0.11* 110.9 7.5 0.10* 97.9 9.6 
0.25 0.25 99.0 6.1 0.25 100.9 2.5 
0.50 0.56 111.6 7.6 0.49 98.3 2.8 
10.0 8.7 87.0 8.9 10.3 102.8 6.8 
50.0 53.0 105.9 8.0 54.8 109.7 6.0 
200.0 199.8* 99.9 7.6 181.2 90.6 10.7 
The accuracy and precision of lapatinib and dasatinib from analysis on four* independent day (*indicated 3 days) 
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3.5.3. Selectivity and sensitivity 
The limit of detection (LOD) was defined as the mass of drug which gave a signal to 
noise ratio of 3:1.  The signal-to-noise ratio was calculated by the Masshunter 
Quantification Analysis Software (Version B.01.04). Calculations were based on the 
peak area of each drug individually not on the peak area ratio.  The limit of 
quantification (LOQ) was defined as the mass of drug which gave a signal to noise ratio 
of 5:1[300]. The limit of detection and limit of quantification are assessed on the peak 
area generated by the absolute mass of dasatinib or lapatinib spiked into the extraction 
tube and by the signal to noise ratio of the peak.  
 
During validation spiked samples were prepared (as outlined in Section 2.2.5.2) by 
spiking 50μL cell suspension with the analytes of interest.  This approximately equated 
to 2.5 x 105 cells, approximately the number of cells used for cell accumulation and 
efflux assays.  
 
Given these criteria, the LOD for dasatinib detection was determined to be 10pg, which 
equated to 3pg on column with an R.S.D. of 15%. The LOQ for dasatinib was 
determined to be 50pg which equates to 15pg on column with an R.S.D. of 8%. These 
values for LOD and LOQ enable pharmacokinetic monitoring of both drugs in cell 
samples.  
 
The LOD for lapatinib was determined to be 50pg of lapatinib in the extraction tube 
which equated to 15pg on column with a R.S.D. of 19%. The LOQ for lapatinib was 
100pg which equates to 31pg on column with an R.S.D. of 13%. 
 
However, Table 3-7 gives the absolute mass spiked into the extraction tube which was 
determined to be the LOD and LOQ as well as normalising the absolute mass to a cell 
number and an approximate volume. 
 
The selectivity of the assay is increased through the use of MRM transitions for 
quantification.  Assessed through in monitoring of the MRM transition in extracted cell 
samples there was no detected endogenous interaction for either dasatinib or lapatinib, 
see Section 9 Appendices II and III.  
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Table 3-7: Dasatinib and lapatinib limit of detection 
 
Dasatinib Lapatinib 
LOD LOQ LOD LOQ 
Absolute Mass 10pg 50pg 50pg 100pg 
Normalised to 
cell number 
40pg/million 
cells 
200pg/million 
cells 
200pg/million 
cells 
400pg/million 
cells 
 
The LC-MS method easily resolved both TKIs from each other. Excellent selectivity 
and the very low LOD and Loss were achieved due the low background when 
quantifying based on the molecular transitions of the ions in the collision cell (MRM).  
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3.5.4. Recovery/extraction efficiency 
The extraction efficiency of the procedure was determined by comparing the peak areas 
of the extracted analytes with those from non-extracted samples.  Non-extracted 
samples were prepared by calculating the mass of drug on column at 100% extraction.  
Recoveries at low, medium and high concentrations were evaluated.  Recoveries for 
both drugs at the concentrations used were good and ranged from 86%-112%. Results 
are shown in Table 3-8.  
 
Table 3-8: Lapatinib and dasatinib intra assay recovery 
 Lapatinib Dasatinib 
Mass (ng) 
Mean % 
Recovery %R.S.D. 
Mean % 
Recovery %R.S.D. 
0.1 112.4 21.8 99.2 16.1 
10 98.6 15.6 90.7 5.4 
100 85.8* 14.2 104.4 14.6 
The recovery of lapatinib and dasatinib from triplicate* intra-day (*indicated n=2) 
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3.5.5. Stability-through freeze/thaw 
The stability of lapatinib and dasatinib in the presence of cells was determined over four 
freeze-thaw cycle at in tube mass of 0.1, 0.5, 50 and 200ng, as shown in Table 3-9 and 
Table 3-10.  On day one, triplicate standards were extracted and the remaining samples 
were frozen at -20oC.  The samples were then thawed and extracted and refrozen each 
day for a further three days.  
 
The data generally indicate that both agents were stable over the course of the 
experiment. However, it was noted that the amount of lapatinib recovered on Day 4 of 
the freeze-thaw assay was decreased, suggesting that this agent is slightly less stable 
under these conditions.  
 
Table 3-9: Dasatinib Freeze/Thaw 
Mass 
(ng) 
First Freeze 
Thaw Cycle 
% Recovery 
Second Freeze 
Thaw Cycle 
% Recovery 
Third Freeze 
Thaw Cycle 
% Recovery 
Fourth Freeze 
Thaw Cycle 
% Recovery 
0.1 100 98.3 105.7 101.7 
0.5 100 104.1 91.1 100.5 
50 100 120.4 107.7 111.2 
200 100 84.9 94.8 90.3 
The recovery of dasatinib from four freeze/thaw cycles from triplicate intra-day 
analysis  
 
 
Table 3-10: Lapatinib Freeze/Thaw 
Mass 
(ng) 
First Freeze 
Thaw Cycle 
% Recovery 
Second Freeze 
Thaw Cycle 
% Recovery 
Third Freeze 
Thaw Cycle 
% Recovery 
Fourth Freeze 
Thaw Cycle 
% Recovery 
0.1 100 98.2 97.8 84.8 
0.5 100 102.1 101.3 89.8 
50 100 109.2 102.1 81.4 
200 100 92.5 98.1 88.5 
The recovery of lapatinib from four freeze/thaw cycles from triplicate intra-day 
analysis 
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3.6. Multiple tyrosine kinase inhibitor analysis 
The similarities in the physicochemical properties (such as lipophilicity) of many TKI 
inhibitors indicated that this newly developed LC-MS method might have a broader 
analytical applicability for this class of agents.  This method was therefore applied to 
the detection of four other TKIs (gefitinib, erlotinib, imatinib and sorafenib) in addition 
to lapatinib and dasatinib.  Sunitinib was also included in initial experiments but was 
excluded from multiple TKI extraction as sunitinib separation at these LC conditions 
was less than optimal.  
 
Shown in Figure 3-25 is the TIC and one extracted MRM for each of the six TKIs 
investigated. The figure illustrates that although the chromatographic separation did not 
resolve all the TKIs from each other, MRM determination enabled individual detection 
and resolution of each agent.  
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Figure 3-25: The analysis of multiple TKIs 
 
Total ion chromatogram and extracted MRM transitions of 6 tyrosine kinases inhibitors (lapatinib, dasatinib, erlotinib, gefitinib, imatinib and 
sorafenib), and one extracted transition for each analyte. 
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Preliminary examination of the other tyrosine kinase inhibitors investigated comprised 
of assessment of validation parameters, linearity and range, intra-day precision 
(repeatability) and inter-day precision (intermediate precision), accuracy, sensitivity 
(LOD and LOQ) and recovery at the extraction conditions already optimised for 
dasatinib and lapatinib. The results for the partial validation of erlotinib, imatinib and 
gefitinib are outlined here.  
 
3.6.1. Linearity and range 
Regression analysis was used to assess the linearity between the peak area ratios 
(analyte/IS) and the analyte concentration. Given the retention characteristics of 
erlotinib, imatinib and gefitinib the TKI lapatinib was used as the internal standard for 
all three TKI validations, findings summarised in Table 3-11.  
 
3.6.1.1. Erlotinib 
The calibration curves for erlotinib, using lapatinib as an internal standard were linear 
over the range of 0.05ng to 200ng in tube. The LOG10-LOG10 plot gave typical 
correlation coefficients (R2) values of 0.99, see Figure 3-26. 
3.6.1.2. Imatinib 
The calibration curves for imatinib, using lapatinib as an internal standard were linear 
over the range of 0.1ng to 200ng in tube. The LOG10-LOG10 plot gave typical 
correlation coefficients (R2) values of 0.99, see Figure 3-27.  
 
3.6.1.3. Gefitinib 
The calibration curves for gefitinib, using lapatinib as an internal standard, were linear 
over the range of 0.1ng to 200ng in tube. The LOG10-LOG10 plot gave typical 
correlation coefficients (R2) values of 0.99, see Figure 3-28. 
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Figure 3-26: Representative example of calibration curve for erlotinib 
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Figure 3-27: Representative example of calibration curve for imatinib 
Imatinib Standard Curve
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Figure 3-28: Representative example of calibration curve for gefitinib 
Gefitinib Standard Curve
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Representative standard curves for erlotinib, imatinib and 
gefitinib extracted from spiked cell pellet matrix 
 
Table 3-11: Summary of linearity and range 
Agent Range R2 Figure 
Erlotinib 0.05ng-200ng 0.99 Figure 3-26 
Imatinib 0.1ng -200ng 0.99 Figure 3-27 
Gefitinib 0.05ng-200ng 0.99 Figure 3-28 
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3.6.2. Precision and accuracy 
Intra-day precision and accuracy was assessed over the mass range by extraction and 
analysis of triplicate spiked samples on the same day.  Inter-day precision and accuracy 
was assessed over the mass range by extraction and analysis of triplicate spiked samples 
over independent days, indicated in the table for each TKI.  The percentage relative 
standard deviation (%R.S.D.) was employed as a measure of precision.  The % accuracy 
was determined by dividing the average calculated drug concentration by that of the 
spiked known concentration. 
 
The mass range employed for erlotinib was 0.05ng -200ng in tube. The mass range 
employed for imatinib and gefitinib was 0.1ng - 200ng.  
 
The precision and accuracy of the three TKIs examined here are generally good, though 
erlotinib does show a higher level of imprecision at the lower mass range. This is due to 
the slight peak broadening at these conditions. However, inter-day assay precision and 
accuracy is good and within range.  
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Table 3-12: Intra-day analysis for precision and accuracy for 
erlotinib. 
Spiked 
Mass (ng) 
Erlotinib 
Mean Mass 
Observed (ng) 
% 
Accuracy 
% 
R.S.D. 
0.05 0.06 118.1 12.1 
0.10 0.10 103.1 16.7 
0.50 0.42 83.8 13.8 
1.0 0.95 94.8 1.7 
5 4.7 93.6 9.7 
10 10.5 105.4 4.0 
50 53.4 106.9 0.5 
100 104.7 104.7 8.3 
200 192.6 96.3 1.5 
The accuracy and precision of erlotinib from triplicate intra-day  
analysis. 
Table 3-13: Inter-day analysis for accuracy and precision for 
erlotinib. 
Spiked 
Mass (ng) 
Erlotinib 
Mean Mass 
Observed (ng) 
% 
Accuracy 
% 
R.S.D. 
0.05 0.06 110.6 4.1 
0.10 0.10 95.2 6.1 
0.50 0.48 96.2 7.9 
1.0 1.0 98.7 7.7 
5 5.0 100.5 4.9 
10 10.1* 100.9 4.7 
50 51.9 103.8 5.1 
100 102.4 102.4 5.9 
200 194.1* 92.7 8.8 
The accuracy and precision of erlotinib from analysis on five 
Independent days (* indicated n=4) 
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Table 3-14: Intra-day analysis for precision and accuracy for 
imatinib. 
Spiked 
Mass (ng) 
Imatinib 
Mean Mass 
Observed (ng) 
% 
Accuracy 
% 
R.S.D.
0.10 0.10 98.0 9.3 
0.50 0.47 93.8 2.8 
1.0 1.0 100.7 5.3 
5.0 5.2 103.7 9.1 
10.0 10.5 104.9 9.3 
50.0 52.3 104.5 3.3 
100.0 102.6 102.6 1.3 
200.0 181.6 90.8 4.0 
The accuracy and precision of imatinib from triplicate intra-day 
analysis 
 
 
 
 
 
 
Table 3-15: Inter-Day analysis for accuracy and precision for 
imatinib. 
Spiked 
Mass (ng) 
Imatinib 
Mean Mass 
Observed (ng) 
% 
Accuracy 
% 
R.S.D.
0.10 0.10 100.7 14.0 
0.50 0.46 92.4 8.2 
1.0 1.0 102.7 4.8 
5.0 5.5 110.7 10.0 
10.0 10.6 106.5 4.7 
50.0 50.1 100.2 3.2 
100.0 95.3 95.3 5.6 
200.0 193.5 96.8 9.5 
The accuracy and precision of imatinib from analysis on five 
independent days 
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Table 3-16: Intra-day analysis for precision and accuracy for 
gefitinib. 
Spiked 
Mass (ng) 
Gefitinib 
Mean Mass 
Observed (ng) 
% 
Accuracy % R.S.D. 
0.10 0.09 89.4 2.6 
0.50 0.57 113.6 7.1 
1.0 1.1 105.6 13.3 
5.0 5.2 104.6 9.1 
10.0 10.0 99.8 8.2 
50.0 48.6 97.2 9.5 
100.0 102.1 102.1 8.1 
200.0 185.5 92.7 6.1 
The accuracy and precision of gefitinib from triplicate intra-
day analysis 
 
 
 
 
Table 3-17: Inter-Day analysis for accuracy and precision for 
gefitinib. 
Spiked 
Mass (ng) 
Gefitinib 
Mean Mass 
Observed (ng) 
% 
Accuracy % R.S.D. 
0.1 0.08 84.9 23.6 
0.5 0.45 90.6 20.0 
1.0 0.9 93.3 12.6 
5.0 4.9 97.8 10.0 
10.0 10.4 103.7 2.8 
50.0 56.2 112.3 9.9 
100.0 111.6 111.6 9.8 
200.0 195.0 97.5 15.8 
The accuracy and precision of gefitinib from analysis on four 
independent days  
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3.6.3. Selectivity and sensitivity 
The limit of detection (LOD) was defined as the mass of drug which gave a signal to 
noise ratio of 3:1. The limit of quantification (LOQ) was defined as the mass of drug 
which gave a signal to noise ratio of 5:1[300].  The signal-to-noise ratio was calculated 
by the Masshunter Quantification Analysis Software (Version B.01.04). Calculations 
were based on the peak area of each drug individually not on the peak area ratio. 
 
During validation spiked samples were prepared (as outlined in Section 2.2.5.2) by 
spiking 50μL cell suspension with the analyte of interest.  This approximately equated 
to 2.5 x 105 cells in the tube. This is approximately the cell number used for cell 
accumulation and efflux assays.  
 
3.6.3.1. Erlotinib 
Given these criteria, the LOD for erlotinib detection was determined to be 10pg, which 
equated to 3pg on column with an R.S.D. of 12% on the quantified mass.  The LOQ for 
erlotinib was determined to be 50pg which equates to 15pg on column with an R.S.D. of 
8%.  These values for LOD and LOQ enable pharmacokinetic monitoring of erlotinib in 
cell samples.  
 
3.6.3.2. Imatinib 
Given these criteria, the LOD for imatinib detection was determined to be between 50pg 
spiked mass which equated to 15pg on column with an R.S.D. of 13% on the quantified 
mass.  The LOQ for imatinib was determined to be 10pg which equates to 3pg on 
column with an R.S.D. of 7%.  These values for LOD and LOQ enable pharmacokinetic 
monitoring of both drugs in cell samples.  
 
3.6.3.3. Gefitinib  
Given the criteria previously outlined, the LOD for gefitinib detection was determined 
to be 10pg spiked mass which equated to 3pg on column with an R.S.D. of 3% on the 
quantified mass (n=2). The LOQ for gefitinib was determined to be 100pg which 
equates to 30pg on column with an R.S.D. of 2%.  
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3.6.4. Recovery/extraction efficiency 
The extraction efficiency of the procedure was determined by comparing the peak areas 
of the extracted analytes with those from non-extracted samples.  Differing from the 
validation for dasatinib and lapatinib the recovery for erlotinib was assessed on two 
types of recovery samples.  Non-extracted samples were prepared by calculating the 
mass of drug on column at 100% extraction.  The recovery was also assessed on the 
extraction of the analytes without a biological matrix.  The extraction efficiency of 
gefitinib was assessed by comparing the extracted samples with the samples with no 
matrix.  The extraction efficiency of imatinib remains to be assessed.  
 
3.6.4.1. Erlotinib 
Recovery across the concentration range was assessed.  Recoveries for erlotinib at the 
concentrations used were good, with an average recovery of 97% when assessed 
compared to the no matrix standard and 108% when compared to the calculated 
standard, results are shown in Table 3-18.  
 
Table 3-18: Erlotinib intra assay recovery 
 Erlotinib No Matrix Erlotinib Calculated 
Mass (ng) 
Mean % 
Recovery %R.S.D. 
Mean % 
Recovery %R.S.D. 
0.05 97.4 12.5 110.4 6.6 
0.10 97.9 2.4 86.2 22.5 
0.50 97.8 3.5 94.9 4.7 
1 103.1 2.8 89.5 16.4 
5. 99.5 10.9 111.3 4.2 
10. 93.3 17.8 138.5 12.7 
50 99.3 1.2 107.8 10.5 
100 88.2 1.0 114.8 2.4 
200 100.2 2.1 122.0 6.9 
The recovery of erlotinib was from triplicate intra-day assays.  
Extraction recovery by calculation and extraction recovery compared to the no matrix 
samples were carried out on separate days.  
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3.6.4.2. Gefitinib recovery/extraction efficiency 
The extraction efficiency of the procedure was determined by comparing the peak areas 
of the extracted analytes with those from non-extracted samples.  The recovery was 
assessed on the extraction of the analytes without a biological matrix (no matrix) 
compared to the extraction of the standard curve, with cell pellet. Recovery across the 
concentration range was assessed. Recoveries for both drugs at the concentrations used 
were good with and average recovery of 102% across the concentration range, results 
are shown in Table 3-19. 
 
Table 3-19: Gefitinib intra-assay recovery 
 Gefitinib No Matrix 
Mass (ng) 
Mean % 
Recovery %R.S.D. 
0.05 98.4 3.1 
0.1 97.8 0.8 
0.5 103.4 0.4 
1.0 104.6 3.2 
5.0 108.8 8.2 
10 115.0 9.9 
50 111.3 13.1 
100 88.4 19.0 
200. 90.0 6.9 
The recovery of gefitinib was from triplicate intra-day assays 
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3.7.  Method application 
The analytical method developed and validated for the quantification for lapatinib and 
dasatinib was applied to  
1) The quantification of intra-cellular levels of lapatinib and dasatinib to 
investigate the relationship between multi-drug resistance protein and tyrosine 
kinase inhibitors, as detailed in Section 4.   
2) The quantification of dasatinib in parental and resistant cell-lines models, 
Section 3.7.1 
3) The quantification of low level dasatinib in cardiac cells, Section 3.7.2 
4) The analysis of additional TKIs (erlotinib, imatinib and gefitinib) as detailed in 
Section 3.6 
5) The quantification of erlotinib imatinib and gefitinib in primary glioma cell 
cultures Section 3.8 
 
3.7.1. Dasatinib quantification in resistant cell-line models 
MDA-MB-231 is a triple negative breast cancer cell-line model.  Triple negative breast 
cancer is a particularly difficult cancer to treat as the cells lack the oestrogen receptor, 
progesterone receptor and HER2 receptor, which are used as targets for treatment in 
other breast cancer types.  A dasatinib-resistant variant of the dasatinib sensitive triple 
negative breast cancer cell-line MDA-MB-231 was developed by Dr Brendan 
Corkery[301, 302].  To determine if the mechanism of acquired resistance to dasatinib 
was due to alterations in the uptake and accumulation of the agent in the cells, an 
accumulation assay was performed to measure the difference in drug levels in the 
resistant and parental cell-lines.  
 
The data indicated that transmembrane proteins were not responsible for the level of 
resistance seen in the MDA-MB231-Das cell-line.  As there is no significant difference 
in the mass of dasatinib accumulated in the resistant cell-line when compared to the 
parental cell-line we can conclude that active transport of dasatinib out of the cell is not 
the mechanism of resistance, Figure 3-29. 
 144
Figure 3-29: Accumulation of 2μM dasatinib in triple negative breast cancer cell-lines 
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Figure 3-29 shows the effect on seeding density on the quantification of dasatinib in 
triple negative MDA-MB-231 cell-line model. Data indicates the average and standard 
deviation of triplicate estimates. The mass of drug accumulated is expressed as mass in 
nanograms per million cells.  
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3.7.2. Dasatinib accumulation in cardiac cells 
In collaboration with the Dr Sundaravadivel Balasubramanian[303] of the Gazes 
Cardiac Research Institute at the Medical University of South Carolina we have 
undertaken to study the accumulation of dasatinib in two different cardiac cell types.  
 
The major cellular components of the heart are cardiomyocytes, cardiac fibroblasts and 
vascular cells (smooth muscle, endothelium). Cardiomyocytes and cardiac fibroblasts 
together account for 90% of the cells in the myocardium. The myocardium is the 
muscular middle layer of the wall of the heart. Together these cells regulate the normal 
cardiac function[304].  
 
Given the difference of size between the cardiomyocytes and the cardiac fibroblasts the 
mass of dasatinib accumulated in the cells was normalised to mass of protein, as 
quantified by the collaborating laboratory, Figure 3-30.   
 
These results show that at low exposure concentrations, 100nM, and low exposure time, 
30 minutes, is easily detectable using the developed method.  At the earliest time point, 
30 minutes, there is a difference in the accumulated levels of dasatinib. This many be 
due to differences in uptake and efflux of the agent from the cells.  
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Figure 3-30: Accumulation of dasatinib in cardiac cells 
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Figure 3-30 shows the accumulation of 100nM dasatinib in cardiomyocytes and 
cardiac fibroblasts.  
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3.8. Application of quantification methods to primary glioma 
cell cultures 
In collaboration with Dr Paula Kinsella & Dr Verena Amberger-Murphy, NICB, 
investigations were undertaken to examine the accumulation of tyrosine kinase 
inhibitors in glioma primary cultures.  Glioma are the most aggressive form of brain 
tumours, they arise from glial cells.  Gliomas are categorised by histopathology, grade21 
and location into glioblastomas (GBM), astrocytomas, oligodendrogliomas, 
oligoastrocytomas, and ependymomas [305].  Malignant gliomas comprise WHO grade 
IV glioblastomas and WHO grade III astrocytoma, oligodendroglioma, and 
oligoastrocytoma. The prognosis for patients diagnosed with GBMs is grave with only 
17-30% survival at year 1 and 3-5% survival at year 2[306].  
 
The treatment of gliomas is hampered by the blood-brain barrier (BBB) which prevents 
the transport of chemotherapeutics from the blood stream to the required site of action 
in the brain.  The invasiveness of these tumours within the brain makes curative surgical 
resection impossible as infiltration of the tumour cells may extend up to 2cm away from 
the radiographically visible contrast mass[307].  Additionally, molecularly malignant 
gliomas are heterogeneous with several different signalling pathways activated[308].  
 
There is an interest in the use of tyrosine kinase inhibitors in gliomas because 
expression of epidermal growth factor receptor (EGFR), vascular endothelial growth 
factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) are 
know to be up-regulated in malignant gliomas and contribute to their malignancy [309].  
Erlotinib and gefitinib are TKIs which specifically target EGFR, and the TKI imatinib 
targets PDGFR. 
 
Through collaboration with Beaumont Hospital, a bio-bank of glioma cell cultures were 
established and characterised[310].  Using the newly developed methods for the 
quantification of erlotinib, imatinib and gefitinib in cells, the accumulation of these 
agents in primary cell cultures was investigated. 
 
                                                 
21 World Health Organisation classification 
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Figure 3-31, Figure 3-32 and Figure 3-33 all detail the accumulation of TKIs in primary 
glioma cell cultures. The primary cell cultures along the x-axis of the graphs are aligned 
the same order.  
 
Table 3-19 is a summary of the findings of the characteristics of the primary glioma cell 
culture as detailed in the PhD thesis of Dr Paula Kinsella[310]. Three of the primary 
cell cultures used in this study were grade IV GBM and one was a grade III 
oligoastrocytoma.  
 
The level of MDR transporter expression as determined by Western blot analysis is 
indicated in Table 3-20, represented by symbols “-” to “+++”, where – indicates no 
detectable level of protein found, + indicates low level of protein expression, ++ 
indicates moderate level of protein expression and +++ indicates high level of protein 
expression. 
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Table 3-20: Summary of characteristics of primary cell cultures and quantified TKI intra-cellular mass 
Primary 
Culture Tumour Grade 
Transporter 
Expression  
Quantified TKI Mass  
(ng/million cells) 
P-gp BCRP Gefitinib Erlotinib Imatinib 
N070055 
Oligoastrocytoma 
Grade III + +++ 
1125.1 
+/- 230 
22.1 
+/- 9.7 
351.52 
+/- 94 
N070152 
GBM 
Grade IV - +++ 
291.5 
+/- 57.6 
7.6 
+/- 1 
86.7 
+/-5.3 
N08923 
GBM 
Grade IV +++ +++ 
257.5 
+/- 52.4 
5.5 
+/- 1.1 
35.8 
+/-3.3 
N08943 
GBM 
Grade IV - + 
136.2 
+/- 14.7 
4.4 
+/- 0.3 
136.9 
+/-14.4 
Summary findings of the characteristics of the cells investigated. Transporter status was determined by Western blot analysis and response 
status was determined by monolayer in vitro proliferation assay[310]. TKI was quantified by LC-MS. 
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Figure 3-31 shows the accumulation of 2μM gefitinib in four primary cultures after two 
hour incubation.  
 
The greatest mass of gefitinib per cell number was accumulated in the Grade III 
Oligoastrocytoma, N070055, and the least was accumulated in the Grade IV GBM, 
N08943.  
 
Figure 3-31: Gefitinib accumulation (2μM) in glioma primary cell cultures 
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Shown is the quantified mass of gefitinib in four glioma primary cell cultures following 
two hours exposure to 2μM gefitinib. Data is shown as the average and SD of triplicate 
determinations. 
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Figure 3-32 shows the accumulation of 2μM erlotinib in four primary cultures following 
a two hour incubation. The greatest mass of erlotinib per cell number was accumulated 
in the Grade III Oligoastrocytoma, N070055, and the least was accumulated in the 
Grade IV GBM, N08943.  
 
 
Figure 3-32: Erlotinib accumulation (2μM) in glioma primary cell cultures 
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Shown is the quantified mass of erlotinib in four glioma primary cell cultures 
following two hours exposure to 2μM erlotinib. Data is shown as the average and 
standard deviation of triplicate determinations. 
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Figure 3-33 shows the accumulation of 2μM imatinib in four primary cultures after two 
hour incubation.  
The greatest mass of imatinib per cell number was accumulated in the Grade III 
Oligoastrocytoma, N070055, and the least was accumulated in the Grade IV GBM, 
N08923. 
 
Figure 3-33: Imatinib accumulation (2μM) in glioma primary cell cultures 
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Shown is the quantified mass of imatinib in four glioma primary cell cultures 
following two hours exposure to 2μM imatinib. Data is shown as the average and 
standard deviation of triplicate determinations. 
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Overall, more gefitinib accumulated in the cells than imatinib or erlotinib, with erlotinib 
having the least overall mass accumulated.  In all three TKIs examined the grade III 
oligoastrocytoma, N07005, had the greatest level of accumulation, while grade IV GBM, 
N08943, had the lowest level for gefitinib and erlotinib and grade IV GBM, N08923, 
had the lowest level for imatinib.  As these primary cell cultures are heterogeneous it is 
unlikely that the differences in the levels of TKI accumulated are due to cell size as the 
none of the cultures were uniform in size, differences in cell size should average out 
between the four cell cultures. 
 
The lower grade N07005 significantly over-expresses BCRP and expresses low levels 
of P-gp and showed the greatest level of accumulation of all TKIs  
 
In the Grade IV GBM, N070152, high levels of BCRP expression was detected and no 
P-gp was detected by Western blot, N08923 had high levels of BCRP and P-gp and 
N08943 showed high levels of BCRP and no detectable P-gp.  
 
N08943 had the lowest accumulated mass of gefitinib and erlotinib though N08923 had 
the lowest level of imatinib detected.  
 
For the three grade IV GBMs tested N070152 had a higher level of intracellular 
gefitinib accumulated when compared to the other two glioma cultures of the same 
grade.  
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3.9. Discussion 
3.9.1. Separation conditions and internal standard identification 
The development of an LC-MS method for the quantification of TKIs was dependent on 
the optimisation of separation conditions including column selection, mobile phase 
optimisation, and selection of an appropriate internal standard. 
 
The optimisation of the mobile phase and stationary phase (column selection) is an 
intrinsically intertwined process.  However, certain considerations are made at the 
outset of the optimisation process.  For the aqueous component of the mobile phase 
10mM ammonium formate was selected due to its compatibility with LC-MS.  
Phosphate buffers were the aqueous phase of choice for traditional HPLC; however, for 
hyphenated techniques such as LC-MS simple acids such as formic acids are frequently 
used.  For our application, where the pH control of the mobile phase gives optimal 
separation, the ammonium salt of formic acid, ammonium formate, was used as the 
aqueous phase, as formate and acetate are volatile and therefore MS compatible[311].  
Acetonitrile was selected as the organic modifier of the mobile phase as it is a stronger 
solvent than methanol, with more resolving power to separate analytes with similar 
retention chemistry.  Reverse phase (RP) chromatography was selected due to its 
breadth of applications including pesticide analysis[312], forensic analysis[313], and the 
analysis of food-stuffs[314].   
 
A selection of reverse phase (RP) columns were evaluated as outlined in Table 3-1.  
Column #1 the SynergSi-Hydro column was determined to be unsuitable for the 
application due to shifting retention times and instability of the retention profile. 
Column #2, Hyperclone C18 (100mm x 4.6mm 3μm particle size) gave perfectly 
acceptable separation of lapatinib and gefitinib (the internal standard used for column 
assessment).  However, by using the narrower column (column #3), Hyperclone C18 
(150mm x 2.0mm 3μm particle size), it was possible to scale down the mobile phase 
flow rate from 0.4mL/min to 0.2mL/min and still maintain adequate separation.  
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This was chosen as the most suitable column for the application as it gave suitable 
separation and the reduced mobile phase flow rate results in lower usage of solvent and 
lower volumes of waste for disposal and thereby reducing costs.  
 
Previous methods for the analysis of lapatinib have used its deuterated analogue as an 
internal standard[200].  This is often, though not always, considered the best option in 
terms of internal standards [315, 316].  However, deuterated analogues were not 
available to us and as the agents are recently released, routinely available structural 
analogues could not be identified for use as internal standards.  Also several articles 
reported that isotopically labelled internal standards failed to compensate for ion 
suppression effects[317, 318].  Several of the TKIs have broadly similar physiochemical 
properties and are more widely available to researchers hence we chose to investigate 
alternative TKIs as a potential internal standard for lapatinib.   
 
Gefitinib, dasatinib and erlotinib were assessed as potential internal standards for 
lapatinib with the view to developing a method for the simultaneous analysis and 
quantification of two tyrosine kinase inhibitors.  Table 3-2 outlines the results of the 
comparisons of the three potential internal standards with respect to peak shape, 
resolution with lapatinib and limit of detection on the LC-MS.  
 
Generally, quantification is based on the peak area, peak height, or the ratio of the peak 
areas of the analyte of interest against the internal standard.  Measuring the area 
included under the chromatographic peak, or the area under the curve, is called 
integration.  Chromatographic peaks are integrated by adding the voltage measurements 
made at equal time intervals from the beginning to the end of the peak, then subtracting 
a "correction trapezoid" to correct for the offset of the chromatographic baseline from 
true zero as well as baseline drift[319].  The key to accurately determining the peak area 
is the ability to:  
• ignore random fluctuations in baseline noise  
• identify the beginning and end of the peak 
• to identify the retention time (peak maximum) 
Figure 3-3 illustrates the asymmetry factor.  The asymmetry factor of a peak is in 
simple terms, a factor given to describe the peak shape.  During a chromatographic 
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separation individual solutes develop a symmetrical or Gaussian concentration profile in 
the direction of the mobile phase[195].  The perfect peak should be symmetrical/ 
Gaussian.  With continued migration through the stationary phase peaks gradually 
broaden and often become asymmetrical.  A peak may be asymmetrical due to peak 
tailing or peak fronting.  Peak fronting is usually a result of over-loading the column, 
such that some of the solute elutes early as it has been unable to interact with the 
column[320].  Peak tailing is caused by too much interaction between the column and 
solute.  In a gradient elution this can be rectified by increasing the organic component in 
the mobile phase composition.  However, in isocratic elution this is not straight-forward 
as increasing the organic composition will affect the resolution between the analytes of 
interest.  
 
Peak asymmetry affects the ability to accurately identify the beginning and end of a 
peak, and therefore affects the peak area calculation, which in turn affects the analyst’s 
ability to accurately quantify the analyte.  Figure 3-34 illustrates peak fronting and peak 
tailing. 
 
Figure 3-34: Illustration of peak fronting and tailing[295].  
 
 
As identified by LC-UV, dasatinib and erlotinib had better peak shape with less tailing 
and a lower asymmetry factor than gefitinib, making them both applicable as internal 
standards for lapatinib.  However, analysis of the LC-MS findings with dasatinib and 
erlotinib showed that dasatinib has a lower limit of detection than erlotinib, thus making 
dasatinib more suitable to our application.  
 
LC-MS compatible 10mM ammonium formate buffer was chosen as the aqueous 
mobile phase.  Even though the pKa of dasatinib is 5.8 and the pKa of lapatinib is 
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6.61[321], the pH 4 was chosen as the optimum mobile phase pH as pH 3 gave poorer 
lapatinib peak shape with a greater asymmetry factor than evident with a pH4 aqueous 
mobile phase.  
 
Optimal resolution of dasatinib and lapatinib peaks from each other and from the void 
volume was achieved with 54% ACN in the mobile phase when run isocratically at 
0.2mL/minute.  
 
3.9.2. Optimisation of MRM transitions 
The MRM transition was optimised for each agent in the same manner as detailed for 
dasatinib in Section 3.3.  Detection and quantification by multi reaction mode is 
undoubtedly the optimum in bio-analytical methods, as the incoming ion stream is 
filtered for the specific ion of interest.  The specific ion undergoes fragmentation in the 
collision cell, in the presence of an inert gas, in this case pure nitrogen, to yield product 
ions.  The most abundant product ion is used for quantification, while any additional 
product ions detected are used as qualifier ions.  Qualifier ions increase the specificity 
of the analysis.  Frequently in small molecule analysis e.g. pesticide analysis, 
compounds which differ in structure may have indistinguishable molecular weights, 
however, product ion(s) increase the selectivity of the analysis.  A schematic diagram 
for MRM mode has been included in Section 1.8.3.4.  
 
3.9.3. Optimisation of extraction  
Extraction, in terms of bio-analytical chemistry, is the process of removing the analytes 
of interest from other potentially confounding substances.  Bio-analytical quantification 
methods are generally desired for the quantification of analytes in patient samples or 
cell-lines models.  From an analytical point of view biological matrices are an 
additional complication.  Biological matrices such as serum, blood, saliva or cells 
contain lipids, proteins, salts and sugars which would, if not removed, interfere with 
detection and damage the analytical equipment.  The extraction process is based on 
exploiting the chemical differences between the analyte and the predominantly protein 
biological sample.  
In terms of general bio-analytical extraction procedures, e.g. from serum, it is possible 
to extract using either on-line or off-line methods.  On-line methods are increasingly 
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advantageous in terms of speed and throughput but do require additional investment in 
terms of equipment such as robotic liquid handling systems.  Off-line extraction 
methods such as solid phase extraction (SPE), liquid-liquid extraction (LLE) and 
protein precipitation (PPT) are widely used in quantification of analytes in complex 
mixtures.  
 
Solid phase extraction is probably the most prolific extraction method used in 
bioanalysis, with a cursory search yielding 1000s of articles directly related to SPE and 
LC-MS, ranging from the determination of brostallicin levels in human plasma[322] to 
pesticides in waste water[323].  Liquid-liquid extraction is similarly prolific and has 
been used to extract analytes from plant material[324], from plasma[325] and from 
tissue[326] for quantitative analysis. Protein precipitation (PPT), is preferred for its 
simplicity, however the extracts obtained are not as clean as those from SPE or LLE and 
may give rise to matrix effects[327]. PPT is predominantly used for the extraction of 
agents from plasma[213, 328], though can also be used for blood samples[329].  
 
Due to the high binding affinity of TKI agents to intracellular targets, and the complex 
nature of cell culture samples, liquid-liquid extraction (LLE) was chosen in preference 
to other forms of drug extraction as it yields cleaner samples with less matrix 
effects[327]. LLE physically takes the drug from the high affinity compartment of the 
cells into the extraction solvent for easier separation.  
 
Based on work by Oostendorp et al.[330], for the liquid-liquid extraction of gefitinib, 
the extraction efficiencies for dasatinib and lapatinib in various solvents alone and in 
combination with ACN were tested, with the summary findings presented in Figure 3-6.  
A combination of acetonitrile and tert-butyl methyl ether (tBME) was determined to be 
the optimum solvent system for both dasatinib and lapatinib in combination with 
extraction buffer pH 3.5. The combination of tBME with acetonitrile gave the optimal 
compromise of separating the drugs of interest from their intracellular binding sites 
while keeping extraction of potential interfering substances from cells to a minimum; 
use of the tBME  solvent with ACN also gave the best drug recovery across a number of 
different pH values, Figure 3-7.  
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3.9.4. Optimisation of extraction buffer pH  
To determine the optimum extraction system for the extraction of lapatinib and 
dasatinib it was also necessary to examine the effect of varying the pH of the aqueous 
extraction buffer. Due to its compatibility with mass spectrometry, 1M ammonium 
formate was selected as the aqueous buffer. The aqueous phase was tested across a pH 
range to determine an optimum in combination with tBME/ACN (3:1v/v) extraction 
solvent.  
As shown in Figure 3-7 the optimum extraction buffer pH was determined to be pH 3.5 
as this gave greater recovery than pH 4 but also gave lower standard deviations and 
noise in the recovery estimates than were evident at pH 3.  
 
3.9.5. Ion suppression study and effects 
3.9.5.1. Ion Suppression 
Ion suppression occurs in situations such as illustrated in Figure 3-35.  The red crosses 
indicate the analytes of interest and the black triangles indicate background ions.  Only 
a finite number of ions can be processed by the MS.  In cases of high level of 
background ions, greater numbers of background ions than analyte ions enter the MS 
system leading to lower detection, whereas, as illustrated in the second scenario, with 
lower levels of background “noise” greater numbers of analyte ions can enter the system 
resulting in an improved signal and better detection.  
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Figure 3-35 Schematic representation of ion suppression 
 
Representation of ion suppression from confounding matrix and background ions, which can saturate the detector preventing maximum ions of 
interest into the MS  
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Initially ion suppression was shown to have a dramatic effect on the results. A limitation 
of the QQQ system is that the MS only searches for the ions and transitions 
programmed for in MRM mode.  While this improves specificity for quantification of 
known analytes, in the development stage this led to unforeseen issues.  
 
Dramatically lower signals were detected with both analytes persistently in the initial 
stages of development than would have been expected with liquid-liquid extraction.  As 
shown in Figure 3-14 and Figure 3-15, the quantified mass of the detected analyte for 
both lapatinib and dasatinib was initially seen to be less than 10% of the expected signal 
intensity.  Good levels of recovery are generally seen from liquid-liquid extractions, 
therefore these unusual findings indicated an additional problem in the method. 
 
The MRM mode function, (multi-reaction monitoring), illustrated in Figure 1-10, is a 
setting that employs the three quadrupoles to function precisely at optimised conditions, 
to quantify a known transition of precursor and product ion.  The fragmentor voltage 
setting acts as a filter allowing the maximum number of precursor ions to enter the 
system in quadrupole one.  The collision cell, considered the second quadrupole, 
contains pure nitrogen gas.  In the collision cell a voltage is applied and the precursor 
ions are split into their products ions.  This explosion occurs as the products ions smash 
in to the nitrogen ions with the energy from the voltage applied.  These product ions 
continue to travel onwards (in the x direction) to the final quadrant, the third 
quadrupole.  In the third quadrupole the accurate masses of the product ions are 
detected. 
 
MS2Scan mode is where the first quadrupole allows all ions unfiltered into the collision 
cell. The collision cell directs the ions to pass unchanged through the octopole and enter 
into the third sector where all ions are detected.  
 
By monitoring duplicate sample injections in MS2Scan mode, as well as in MRM 
mode, substantial levels of background ions were detected.   
 
Figure 3-16 shows that the high level of background ions seen in the extracted samples 
was not from biological matrix.  In Figure 3-16 we see three TIC spectrums, injected 
from the same vial and difference points during the worklist run.  This sample was a 
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mobile phase blank.  The black trace, barely visible at the bottom of the image, was 
injected at the start of the run, the red trace, with high abundance, was injected after 10 
extracted samples and the green trace was injected after an additional 10 samples.  This 
indicated that something in the extracted samples was carrying over and sticking to the 
analytical column and causing high level of ion suppression, as seen with the extremely 
low analyte signal, Figure 3-14 and Figure 3-15. 
 
The high level of background detected in MS2Scan mode was attributed to the 
preparation and storage of stock standards in polypropylene (PE) tubes.  These tubes 
showed no detectable level of contamination in extractions over a short storage period 
(1 day) but over longer periods (2-3 days) significant contamination was detected which 
caused the suppression of the ion signal.  The contaminating ions were possibly 
plasticiser which leached from the plastics over a prolonged period of time in the 
presence of a strong solvent, acetonitrile.  While it is also possible that artefacts from 
the biological matrix caused the background, this was eliminated as samples prepared 
from freshly prepared stock standards showed good recovery and low background, 
while samples prepared from stock standards that were stored for 3 days showed poor 
recovery and high background.  As the biological matrix was the same in each sample 
set analysed the only difference was the length of time the stock standards were stored.  
As a result of this, stock standards were prepared fresh in glass 10mL tubes, with 
working calibration curves being used within an hour of being prepared.  
 
Having identified the issue leading to poor extraction, it was then necessary to quantify 
the normal level of ion suppression from the biological matrix in the assay.  Two 
methods were used to identify the level of ion suppression from the biological matrix.  
 
Post-column infusion is frequently used for the determination of ion suppression.  Post 
column infusion, as illustrated in Figure 3-17, involves the infusion of a concentration 
of the analyte, in this case 2μg/mL, using an infusion pump to provide a constant steady 
flow, in this case 50μL/min.  This was “T”-pieced into the flow-path before the ion 
source but after the analytical column.  Using the LC method, extracted blank samples 
were injected from the autosampler.  The flow of analyte into the MS gives a constant 
signal, and as the flow was steady and controlled the signal was level.  This made it 
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possible to determine any disturbances in the signal that may have been ion suppression 
or ion enhancement.  By injecting the extracted cell blank sample through the analytical 
column it was possible to determine when any potentially confounding substances may 
elute and to what level these substances had an effect.  The main source of commonly 
observed matrix effects in bio-analytical LC-MS is thought to be endogenous 
phospholipids and proteins[327].  Post-column infusion was initially used to determine 
the ion suppression of lapatinib and dasatinib as shown in Figure 3-18 and Figure 3-19.   
 
In Figure 3-18, the ion suppression of dasatinib was assessed.  The injection of an 
extracted blank cell sample showed dasatinib to suffer approximately 40% loss in signal 
due to ion suppression (spectrum B).  This was identified to have been due to the 
extracted cell blank as an injection of mobile phase through the system showed no effect 
on the dasatinib signal. 
 
Similarly in Figure 3-19 we see that the ion suppression of lapatinib at the retention 
time for lapatinib is approximately 10% when extracted cell blanks were injected 
(spectrum B).  The drop in signal was due to the extraneous elements of the cells which 
were extracted in the LLE process.  The stability of the signal when mobile phase is 
injected indicates that the suppressing ions were coming from the extracted cell sample. 
 
Dasatinib suffered a much greater level of ion suppression as it elutes earlier than 
lapatinib and elutes closer to the column dead time. Column dead time is the time for 
elution of the earliest possible band, or mobile phase molecules[295].  
 
Small changes in the ratio of organic to aqueous in the mobile phase composition have a 
substantial effect on the retention time of the analytes. Increasing the ratio of organic 
decreases the solute’s interaction with the column and decreases the retention time. The 
optimum mobile phase for isocratic elution was found to be ACN: 10mM ammonium 
formate pH4, 54/46, (v/v). This was verified by premixing the solutions for mobile 
phase and injecting the sample. The retention time of dasatinib has shifted to 2.39 
minutes and lapatinib has shifted to 5.39 minutes.   
 
Using these conditions the new level of ion suppression was assessed using a post 
extraction spike method detailed in Zirrolli et al.[234],but developed by Matuszewski et 
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al., in 2003 [331].  Over the mass range of 1 to 100ng the percentage of signal intensity 
affected by the ion suppression/enhancement was minimal, Figure 3-21and Figure 3-22.  
This would indicate that a small shift in retention time was sufficient to alleviate the 
issue.  
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3.9.6. Assay validation  
The validation of an analytical method should be designed to test the suitability of the 
method for its intended purpose[332].  The overall LC-MS method was validated for the 
following performance parameters- linearity and range, intra-day precision 
(repeatability) and inter-day precision (intermediate precision), accuracy, sensitivity, 
(LOD and LOQ), recovery and sample stability according to the guidelines described by 
Ermer[299].  MRM allows for the individual determination of each drug, with the use of 
internal standard-based quantification. 
 
Figure 3-25 shows the extraction and detection of multiple TKIs using the method 
validated for lapatinib and dasatinib, without any changes.  While the method is 
currently not completely validated for the analysis of additional TKIs, this demonstrates 
the broader applicability of this method to extract other TKIs and quantify by LC-
MS/MS.  The TKIs used in this study, erlotinib, imatinib, gefitinib and sorafenib are all 
clinically relevant agents.   
 
Preliminary partial validation of erlotinib, imatinib and gefitinib has been carried out 
using the same exact conditions as optimised for dasatinib and lapatinib.  
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3.9.6.1. Linearity and Range 
Dasatinib and lapatinib 
For dasatinib and lapatinib analysis the standard curves were linear across the 
concentration range investigated. In a phase II study of dasatinib treatment in head and 
neck squamous cell carcinoma the maximum plasma concentration was 168.2 
ng/mL[333]. In 50μL, the estimated volume of the cell pellet, this would equate to 8ng. 
This is comfortably within the assayed range.  The mean peak plasma concentration of 
lapatinib in a Phase I study of lapatinib in combination with Herceptin was 1.5μg/mL, 
which equates approximately to 75ng in a 50μL sample[334].  These levels are within 
the range examined.  
 
Erlotinib, Imatinib, Gefitinib 
All three agents, erlotinib imatinib and gefitinib were linear across the concentration 
range employed.  The upper level spiked mass was 200ng/tube.  Masses greater than 
this were not investigated as our experience with lapatinib and dasatinib as well as with 
erlotinib, imatinib and gefitinib in glioma cells showed that higher mass ranges are not 
necessary to encompass the samples.  An in tube mass of 200ng equates approximately 
to 4μg/mL when the volume of the cell pellet is approximated to 50μL.  The maximum 
plasma concentration of erlotinib was found to be 2.6μg/mL for a patient receiving 
150mg [220].  The maximum plasma concentration of imatinib was found to be 
1.5μg/mL for a patient receiving 600mg/day[335].  The maximum plasma concentration 
of gefitinib was found to be 212ng/mL following a single dose of 250mg[221].  These 
levels are well within the range examined.  
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3.9.6.2. Precision and accuracy 
Precision is a measure of how close to each other a group of results are.  Accuracy is a 
measure of how close to the expected values a group of results are.  It is possible for 
analysis to be precise but not accurate and for an assay to be accurate but not precise.  
Both precision and accuracy are important in quantitative analysis for an assay to be 
reliable.  The precision and accuracy was assessed both inter-day and intra-day.  The 
intra-day precision and accuracy is the evaluation of triplicate samples analysed on the 
same day, whereas inter-day precision and accuracy is the evaluation of triplicate 
samples on independent days.  
 
Dasatinib and lapatinib 
The average inter-day accuracy across the concentration ranged examined was 100% 
and 102% for dasatinib and lapatinib respectively.  The average precision (%R.S.D.) 
across the concentration range was 6.4% and 7.6% for dasatinib and lapatinib 
respectively.  With an average inter-day precision of less than 10% the reproducibility 
of the method was deemed acceptable.  
 
Erlotinib, Imatinib, Gefitinib 
The precision and accuracy for erlotinib, imatinib and gefitinib was assessed both intra-
day (repeatability) and inter-day (reproducibility).  The average inter-day accuracy 
across the concentration range was 100.1%, 100.7% and 99% respectively for erlotinib, 
imatinib and gefitinib.  The average inter-day precision was 6.1% 7.5% and 13.1% 
respectively.  
 
The developed extraction and separation procedure was deemed acceptable for the 
extraction and separation of each agent individually from the internal standard.  The 
method had good repeatability and good reproducibility as well as a high level of 
accuracy. 
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3.9.6.3. Selectivity  
Selectivity and specificity are terms that are often used interchangeably. Vessman et 
al.[336], discusses, in detail the definitions of these terms as defined by various 
interested organisations. The Western European Laboratory Accreditation Cooperation 
(WELAC) definitions of selectivity and specificity are:  
• Selectivity of a method refers to the extent to which it can determine particular 
analyte(s) in a complex mixture without interference from other components in 
the mixture 
• A method which is perfectly selective for an analyte or group of analytes is said 
to be specific 
 
The International Conference on Harmonisation (ICH) defines specificity as 
• Specificity is the ability to assess unequivocally the analyte in the presence of the 
components which may be expected to be present. Typically these might include 
impurities, degradants, matrix etc.  
 
However, in its most basic format, according to G.D Christian [337] a method is 
specific when the analyte alone is responsible for the signal that is measured. 
 
The necessity for method selectivity and specificity and the intense focus that has come 
to bear on this requirement is a remnant of validation guidelines developed for the 
application of HPLC-UV methods.  In terms of MS and in particular tandem MS, 
selectivity and specificity are more clear-cut and apparent.  Both the selectivity and 
specificity are inherently linked to the mode of action of the triple quadrupole mass 
spectrometry.  As shown in Figure 1-12, a triple quadrupole consists of three chambers, 
MS1, the collision cell and MS2.  The triple quadrupole system allows for multiple 
reaction monitoring (MRM), and the ability to track ions of specific mass to charge ratio 
(m/z) though the system and monitor the break down from precursor to product ions.  
This is the specificity of tandem mass spectrometry (MS/MS).  The ability to monitor 
more than one product ion gives increased selectivity.  
 
Of the six TKIs investigated four, imatinib, dasatinib, erlotinib and sorafenib had 
multiple transitions from precursor to product ions.  The ability to monitor additional 
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product ions increases the specificity of the analysis.  While lapatinib and gefitinib had 
only one product ion the incorporation of both the retention characteristics and mass 
transitions make this assay specific for all analytes selected.  
 
3.9.6.4. Sensitivity 
LC-MS is inherently more sensitive than LC-UV detection because LC-MS can monitor 
individual ions whereas; LC-UV is reliant on an entirely different detection system. 
There are three types of UV detectors, which are single wavelength detectors, variable 
wavelength detectors and fast scan or diode-array detectors[338]. However, MS 
detectors combine specificity, selectivity and sensitivity[339]. 
 
The increased sensitivity of the LC-MS gave the ability to quantify in the picogram 
range.  Quantification was based on the mass transitions from precursor to product ion.  
The increased sensitivity of the Agilent Triple Quadrupole MS is in part due to the 
orientation of the ionisation.  The orthogonal orientation of the nebuliser spray to the 
sample capillary reduces the background noise from the samples allowing lower LOD 
and LOQ.  This is because any ions that are uncharged in the source do not make it into 
the MS system.  The MS is capable of being saturated i.e. it can only “count” a finite 
number of ions, it is imperative for high sensitivity to increase the number of analyte 
ions entering the system at a cost to the number of eluent ions and potentially 
confounding ions that would otherwise “dilute” the signal and result in reduced 
sensitivity.  
 
For the determination of the limit of quantification (LOQ) and limit of detection (LOD), 
guidelines by Shah et al.[300], were followed, whereby the LOQ was defined as the 
mass of drug which gave a signal to noise ratio of 5:1 and the LOD was defined as the 
mass of drug which gave a signal to noise ratio of 3:1.  Noise is the width of the 
baseline created by background fluctuations such as the detector electronics, pump 
oscillations and/or a dirty column or the baseline signal in the absence of the 
analyte[340].  Practically speaking the LOD is the minimum level at which we can 
identify the presence of the analyte of interest in the spectrum, whereas the LOQ is the 
level whereby we can, with confidence, quantify the mass of analyte present against the 
background of matrix ions.  
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Dasatinib and lapatinib 
The method developed here showed sensitivity comparable to if not better than recently 
published methods, with an LOQ of 200pg/million cells and 400pg/million cells for 
dasatinib and lapatinib respectively. If the cell pellet volume is estimated to be 
approximately 50μL, this gives an LOQ of 1ng/mL and 2ng/mL for dasatinib and 
lapatinib respectively.  Other published methods for the quantification of dasatinib and 
LOQ of 78.1ng/mL[212]. The method by Haouala et al.[213], reported a similar LOQ 
for dasatinib, 1ng/mL but is a longer more complex method.  
 
Previously reported LOQs for lapatinib were 5ng/mL[213] and 15ng/mL[200], 
indicating that the method developed here is more sensitive than those currently in the 
literature.  
 
Erlotinib, Imatinib, Gefitinib 
The developed method has shown good sensitivity for the three additional TKIs 
assessed.  The LOQ was found to be 50pg, 50pg and 100pg spiked mass for erlotinib 
imatinib and gefitinib respectively.  If the approximate volume of the cell pellet is 
estimated to be 50μL then the LOQ is determined to be 1ng/mL for erlotinib and 
imatinib and 2ng/mL for gefitinib. This compares favourable with recently published 
LC-MS methods.   
An LOQ of 10ng/mL[219] and 6.2ng/mL (reported as 12.7nM)[218] for erlotinib has 
been reported previously. The method developed here is more sensitive for erlotinib 
than these LC-MS methods.  An LOQ of 1ng/mL[213] as been previously reported for 
imatinib, though, as already described this gradient method is more complex and has a 
longer retention time than the method developed here.  An LOQ of 1ng/mL[221] 
0.5ng/mL[223] and 0.1ng/mL[222] have been reported for the analysis of gefitinib. The 
most recent publication also reported an LOQ of 4.9ng/mL (reported as11.2nM)[218].  
Quantified in this method is an LOQ of 2ng/mL.  The method validated here is more 
sensitive for erlotinib than previously reported methods, similar sensitivity for imatinib 
as previously reported and not quite as sensitive as the current published methods for 
gefitinib.  However, the sensitivity of this method for gefitinib is suitable for the 
requirement of the quantification of gefitinib in cells.  
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3.9.6.5. Recovery/extraction efficiency 
The percentage recovery and the extraction efficiency of the method were established 
by direct comparison of the peak areas of the extracted sample compared to that of a 
pure solvent standard. The peak area of the pure solvent standard was normalised to 
100% extraction.  
 
We have seen that both ion suppression and the extraction system employed play 
equally important roles in the measurement, the detection and hence the extraction 
recovery.  Figure 3-14 and Figure 3-15 show the detected analyte signal in a suppressed 
detection system.  Through the identification of the source of the contaminant and 
sensitivity dramatically improved, allowing for a calculation of extraction efficiency 
using LC-MS, Table 3-9. 
 
Dasatinib and lapatinib 
For validation studies the recovery was assessed at three concentrations 100, 10, 0.1ng 
for both lapatinib and dasatinib.  We determined the recoveries for both drugs ranged 
from 86-112%.  The recovery associated with the liquid-liquid extraction method 
developed here is compared, in Table 1-6 with validated published methods available to 
date in the literature.  It is clear that our method compares favourably to those outlined 
here, with some methods showing no evidence of recovery determination in the 
validation [205, 217], existing lapatinib methodology showing significantly lower 
recovery (75%)[200] and recently published dasatinib methodologies showed similar 
recovery ranges[212, 213].  
 
Erlotinib, Gefitinib 
The recovery for erlotinib was determined to be 97% when compared to the “no matrix” 
recovery sample and 108% when compared to the calculated recovery sample. This is 
inline with published methods such as Honeywell et al.[218], 96-109%, and Leper et 
al.[220], (~100%) and superior to the method published by Masters et al., 79-87%[219].  
For gefitinib the average recovery was determined to 101.9%, ranging from 88%-114% 
across the concentration range when compared to the “no matrix” recovery sample.  
This is similar to previously published methods detailing recoveries of 81-103 %[221] 
and more accurate than 111-124% as published by Jones et al.[223]. 
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3.9.6.6. Stability through freeze/thaw 
Sample stability is important in the development of bio-analytical methods though most 
validation advice and literature is geared towards the validation of serum as the 
biological matrix.  However, our study is based on the quantification of TKIs in cells 
with the cell pellet as our biological matrix.  For our study we chose freeze/thaw cycles 
of these cell samples as an indication of sample stability.  As described by Dadgar et 
al.[341], there are many types of stability validation for biological matrices and sample 
stability there within, including (i) long term stability of analytes (ii) stability of the 
reference standard (iii) short term stability of analytes (iv) in-process stability (v) 
processed sample stability (vi) freeze-thaw stability.  
Long term stability is more relevant for the validation of an analytical method for the 
analysis of serum as samples from a clinical study are potentially stored for long periods 
of time until the clinical study is complete and all samples can be analysed together.  
Concurrently with the validation for long term stability is the stability of the matrix 
itself and whether matrix degradation can lead to interferences.  Also of interest is that 
Dadgar states that the long term stability of a matrix should be evaluated for each 
applicable matrix and that inter-species extrapolation is invalid.  This is predominantly 
relevant to the validation of serum as the biological matrix.  
 
More relevant for the intended purpose of this method is a freeze thaw stability analysis, 
predominantly as the cell samples are stored for short periods before extraction and post 
extraction samples are directly injected with minimal lag time.  Potential instability 
would most likely come from samples being moved thus inducing a freeze thaw cycle.  
 
As pointed out by Karnes[342] there is very little FDA guidance on the issue of stability 
testing, though generally accepted principles were set down by Trissel [343] in 1983.  
 
Table 3-9 and Table 3-10 show stability of dasatinib and lapatinib, respectively.  As can 
been seen from the results, dasatinib is very stable over the tested conditions.  Lapatinib 
is acceptably stable though some deterioration in stability is seen on the fourth 
freeze/thaw cycle.  This would indicate that either the analyte is breaking down under 
the test conditions or that additional components are interfering with the detection of the 
analyte.  Additional analysis to determine the cause of the instability is unnecessary as 
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this level of instability is acceptable and indicates that no more than three freezer/thaw 
cycles should be allowed prior to extraction and analysis.  Realistically samples rarely, 
if ever, undergo freeze/thaw cycles.  
 
The stability of erlotinib, gefitinib and imatinib remains to be tested.  
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3.9.7. Summary of method validation 
Overall the use of a liquid–liquid extraction clean-up stage gives the simplicity of 
application making the method accessible to other researchers undertaking large 
numbers of analyses without the need for extra equipment or expensive clean-up 
columns, while an isocratic elution scheme gives a simple, robust and reproducible 
chromatographic method. 
 
In summary the method outlined and validated here compares excellently with other 
methods published in the literature, detailed in Table 1-6.   
 
• The method developed here for dasatinib is more sensitive than De Francia et 
al.[212], 1ng/mL compared to 78ng/mL. The sensitivity for our method is 
equivalent to Haouala et al.[213], however, our method is more straight-
forward, with a isocratic separation compared to a step-wise gradient elution and 
faster with a 8 minute run time in comparison to a 20 minute run time.  
 
• This method is more sensitive for lapatinib than the method of Bai et al.[200], 
for the quantification of lapatinib - 2ng/mL compared to 15ng/mL. 
 
• Our experimental approach has yielded superior levels of sensitivity and the 
specificity of the analytical method may also allow for broader applicability to 
the determination of a number of other TKI agents and from other biological 
matrices, e.g. patient serum. 
 
• The partial validation of this method for erlotinib indicated that the range is 
suitable for the investigation of cell and patient samples. The sensitivity is 
superior to previously published method and the recovery is excellent.  
 
• The partial validation of this method for imatinib indicated it is suitable for the 
analysis of imatinib across a broad concentration range, with sensitivity in line 
with work already published. 
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• Likewise this method is suitable for the analysis of gefitinib in cell and possibly 
patient samples with a good range a linear response range. The sensitivity of the 
assay is acceptable for the application and could possibly be improved with 
alternations to the analytical separations.  The recovery for gefitinib is also 
excellent.  
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3.9.8. Method applicability 
3.9.8.1. Analysis of dasatinib in resistant cell-line models 
The clear strength of this method is its applicability to determine useful information 
about the resistance of lapatinib and dasatinib in cell-line models.  The cellular 
mechanism of resistance can be attributed to many factors including a) the inducement 
of the over-expression of ABC multi drug transporters as a response to drug exposure b) 
modulations of the cell death pathways, where by the cell avoids apoptosis by switching 
on other cellular pathways.  
 
MDA-MD-231 is a triple negative breast cancer cell-line which is sensitive to dasatinib.  
Through continuous selection with dasatinib, a resistant variant was developed, by Dr 
Brendan Corkery[302].  To determine if resistance was due to changes in the membrane 
transport proteins, we investigated the level of dasatinib accumulation in the parental 
and resistant models.  The data indicated no significant difference between the mass of 
drug accumulated between the resistant and parental cell-lines.   
 
Figure 3-29 shows the mass of dasatinib accumulated in the resistant and parental cell-
lines and examines the effect of varying cell seeding density.  To eliminate and account 
of possible inaccuracies or errors/variations in the trypsinisation of one group of flasks 
compared to another, the mass of drug quantified in each flask is ultimately normalised 
to the number of cells in the flask, as determined through manual counting or counting 
by flow-cytometric methods e.g. Guava.  
 
The lowest seeding density examined gave results in a non-linear agreement to other 
investigations.  This low cell number may be more vulnerable to errors in counting and 
this more unreliable.  Also, in Figure 3-29 we can see that there is no significant 
difference across the range of seeding densities investigated in the mass of dasatinib 
accumulated in the parental compared to the resistant.  This would indicate that the 
mechanism of resistance of dasatinib in MDA-MB-231 cell-line is not through the over-
expression or ABC transporters.  
 
We can see from Figure 3-29 that the LLE-LC-MS/MS method developed for the 
quantification of lapatinib and dasatinib not only validated but is also “fit for purpose” 
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i.e. the quantification of the intracellular levels of dasatinib in cancer cell-line models 
and the utilisation of this information to determine the resistance status of a cancer cell-
line model.  
 
3.9.8.2. Dasatinib analysis in cardiac cells 
The technical challenges faced in the analysis of dasatinib in two types of cardiac cells 
involved both the low level of dasatinib exposed to the cells (100nM), the short time 
frame for exposure (30 minutes) and unknown uptake properties of dasatinib in cardiac 
cells.  
 
The high level of sensitivity of the method allowed for easy quantification of dasatinib 
in both cell types. The difference in cell size, with the cardiomyocytes being noticeably 
larger than the cardiac fibroblast, does lead to a bias in the evaluation of the data as the 
quantified mass is generally normalised to cell number. However, the normalisation of 
the quantified mass to the mass of total protein in the pellet reduced the effect of cell 
volume on the analysis.  
 
It is clear that the method developed here is very sensitive and highly applicable to 
alternative cell types in addition to cancer cell-line models. The ability to accurately 
quantify the mass within these cells enables the researcher determine if differences in 
response are due to differences in accumulated mass of the agent.  
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3.9.9.  Analysis of TKIs in glioma 
Malignant gliomas are inherently difficult to treat with chemotherapeutics due to their 
location (inside the blood brain barrier) and their heterogeneous nature.  The use of 
TKIs in the treatment of malignant glioma are currently being investigated[309].  
Detailed in Section 3.8 is the accumulation of TKIs erlotinib, imatinib and gefitinib in 
primary glioma cell cultures, which were established in-house[310].  
 
Erlotinib, a targeted therapy approved for the treatment of non small cell lung cancer 
(NSCLC), targets the EGFR receptor.  It has been shown in vitro that erlotinib is a 
substrate of P-gp and BCRP[344].  Animal studies with knock-out mice showed that P-
gp appeared to be the most effective factor in limiting brain penetration of erlotinib, 
though BCRP also reduced brain penetration[185]. 
 
Our results indicate that the lower grade III primary cell culture, N070055, accumulated 
more erlotinib than the other higher grade IV primary cell cultures.  While N070055 
does express low levels of P-gp and high levels of BCRP it also showed a response to 
erlotinib.  
 
Imatinib, an approved therapy for the treatment of CML, is a multi-kinase inhibitor 
targeting PDGFR, Abl kinase, cKit.  Imatinib has been shown to inhibit glioma invasion 
in combination with docetaxel in vitro[345].  In a Phase II study imatinib was detected 
in glioblastoma tissue however, it was suggested that imatinib does not substantially 
reduce proliferation and survival mechanisms[346].  In our study imatinib only showed 
a response in the lower grade III N070055, which also showed the greater level of 
accumulation than the other cell cultures.  N08923 which strongly over-expresses both 
P-gp and BCRP had the lowest level of accumulation of imatinib, indicating that the 
level of imatinib is affected by ABC transporter expression.  
 
Levels of TKI accumulated in glioma cells analysed showed that quantified mass of in 
the order of gefitinib> imatinib>erlotinib, however three out of four cell-lines showed 
response to erlotinib, two out of four were classed as responders to gefitinib and only 
one of the four cell-cultures responded to imatinib.  
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Gefitinib is an EGFR inhibitor, approved for treatment in NSCLC. It is thought that 
gefitinib may be of particular benefit to patients who express particular mutations of 
EGFR[156]. Gefitinib increases brain accumulation of topotecan [347].  However, the 
expression of P-gp and BCRP has been shown to limit the accumulation of gefitinib in 
the brain of knock-out mice.[348] 
 
Our studies have shown that a greater mass of gefitinib accumulated in the primary cell 
cultures than either of the other two TKIs.  Also the lower grade III, N070055, showed 
the greatest accumulation of gefitinib of the four cell cultures examined. However, 
gefitinib showed no toxic response in this cell culture.   
 
Interestingly, considering the weight given to the expression of efflux pumps in the 
BBB and gliomas, this non-responsive grade IV did not have any detectable expression 
of P-gp and only low level expression for BCRP.  N08943 also had the lowest level of 
accumulation of erlotinib and gefitinib, though not imatinib.  This indicates that while 
the role of ABC transporters is important in elucidating functional logical for the 
response or lack of response of an agent it is not the complete picture.  
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3.9.10. Summary of method application discussion 
Here we have shown the multiple applications of our novel method for the 
quantification of TKIs.  
• Our developed method has been shown to be straight-forward, sensitive and 
suitable for the quantification of intra-cellular levels of dasatinib. 
 
• Using the dasatinib quantification method developed, we determined that 
resistance in a newly developed dasatinib-resistant cell-line model, MDA-MD-
231-Das, was not due to the efflux of dasatinib.  
 
• The superior level of sensitivity in our developed method was capable of 
quantifying low level dasatinib accumulation in cardiac cells.  
 
• The extraction and separation criteria have been shown to be applicable for the 
analysis of multiple TKIs.  
 
• The multiple applicability of the TKI method developed has been partially 
validated for erlotinib, gefitinib and imatinib in cells. 
 
• This quantification technique has been applied to the novel quantification of 
erlotinib, imatinib and gefitinib in primary glioma cell-cultures, and shown the 
differences in the uptake of TKIs in glioma cell-cultures.  
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4. Investigation of dasatinib and lapatinib interaction 
with MDR over-expressing cell-lines 
Introduction 
Having developed a method for the quantification of lapatinib and dasatinib in the 
biological matrix of cells, this was brought forward and applied to the investigation of 
the kinetics of uptake and efflux of lapatinib and dasatinib in cancer cell-line models.  
This section examined the uptake and efflux of dasatinib and lapatinib in ABC transport 
protein over-expressing cell-line models.  
For clarity, through the course of the results and discussion ABCB1, also called MDR-1 
and P-glycoprotein will be referred to as P-gp, ABCC1 also called MRP or MRP-1 will 
be referred to as MRP-1 and ABCG2 also called MXR, ABCP and BCRP will be 
referred to as BCRP. 
 
4.1. Cell-line models 
The cell line models used have been extensively characterised both in-house and in the 
literature.  Each model selected was chosen on the basis of its MDR status. Table 4-1 
gives the MDR status of each cell-line in addition to the level of protein expression. 
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Table 4-1: Cell-line models used and the MDR expressed 
Cell-line 
MDR  
protein 
expressed 
Level of 
expression Western Figure # Ref. 
DLKP - - Y 
Figure 4-1 to 
Figure 4-6 [283, 349] 
DLKP-A P-gp high Y 
Figure 4-1 & 
Figure 4-4 [284] 
DLKP-Sq - - Y 
Figure 4-8 & 
Figure 4-9 
Helena 
Joyce 
DLKP-
Sq/Mitox-
BCRP BCRP high Y 
Figure 4-8 & 
Figure 4-9 
Helena 
Joyce 
DLKP-
Sq/Mitox-
MDR P-gp high Y 
Figure 4-8 & 
Figure 4-9 
Helena 
Joyce 
A549 MRP-1 moderate Y 
Figure 4-4 to 
Figure 4-6  
A549-tax P-gp low Y 
Figure 4-4 to 
Figure 4-6 [5, 286] 
2008/MRP-1 MRP-1 moderate Y Figure 4-2  
HL60/S - - Y 
Figure 4-1 to 
Figure 4-3 [287, 288] 
HL60/Adr MRP-1 moderate Y Figure 4-2 [288] 
HL60/Mdr1 P-gp high Y Figure 4-1 [123] 
HL60/Mxr BCRP high Y Figure 4-3 [123] 
RPMI-
2650/Tax P-gp High Y (from lit) 
Figure 4-10 & 
Figure 4-11 [289] 
KB-3-1 - - Y (from lit) Figure 4-12 [350] 
KB-8-5-11 P-gp High Y (from lit) Figure 4-12 [350] 
IGROV-
1CDDP P-gp High Y Figure 4-7 [351] 
Table 4-1 details the cell-line models used through-out this section of the thesis and the 
status of the MDR protein, as determined by Western blot analysis.  
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The DLKP cell-line was established in the NICB from the biopsy of lung 
carcinoma[285, 352].  DLKP-A is a resistant variant, which was selected by exposure to 
adriamycin, over-expresses P-gp[109]. Figure 4-1 and Figure 4-4 shows the P-gp 
overexpression in DLKP-A 
 
HL-60/S, HL-60/Adr, HL-60/Mdr1 and HL-6-/Mxr are a panel of leukemic cell-lines.  
In this panel of cell-lines, the parental cell-line HL-60/S does not over-express any of 
the three main ABC transporters, P-gp, BCRP or MRP-1.  HL-60/Mdr1 is a P-gp over-
expressing cell-model.  The P-gp over-expression was developed by transfection with 
the MDR1 gene.  HL-60/Adr is an MRP-1 over-expressing variant, selected by exposure 
to adriamycin.  HL-60/Mxr is a BCRP over-expressing variant which has retrovirally 
transduced to over-express BCRP[123].  Figures 4-1, Figure 4-2 and Figure 4-3 show 
the ABC transporter expression for these cell-lines.  
 
2008/MRP-1 is a human ovarian carcinoma transfected to over-express MRP-1 which is 
predominantly localized in the plasma membrane[290].  The MRP-1 expression is 
shown is Figure 4-2.  
 
Table 4-2: Lane designations for Western blot analysis [6] 
 P-gp MRP-1 BCRP 
1 HL60/S (40µg) HL60/S (40µg) HL60/S (40µg) 
2 DLKP (40µg) DLKP (40µg) DLKP (40µg) 
3 2008/MRP-1 (10µg) 2008/MRP-1 (10µg) 2008/MRP-1 (40µg) 
4 HL-60/Adr (40µg) HL-60/Adr (40µg) HL-60/Adr (40µg) 
5 DLKP-A (10µg) DLKP-A (10µg) DLKP-A (40µg) 
6 H1299-Taxol (40µg) H1299-Taxol (40µg) H1299-Taxol (40µg) 
7 HL-60/Mdr (20µg) HL-60/Mdr1 (20µg) HL-60/Mdr1 (40µg) 
8 M14 (40µg) M14 (40µg) DLKP-Sq/Mitox-BCRP (10µg) 
9 DLKP-Sq/Mitox-BCRP (40µg) DLKP-Sq/Mitox-BCRP (40µg) M14 (50µg) 
10 HL-60/Mxr (40µg) HL-60/Mxr (40µg) HL-60/Mmxr (10µg) 
11 
Positive control: DLKP-A 
(10µg) 
Positive control: 2008/MRP-1 
(10µg) 
Positive control: DLKP-
SQ/Mitox-BCRP (5µg) 
Table 4-2 shows the lane designations for Western blotting for P-gp, MRP-1 and 
BCRP blots in figures 4-1, figures 4-2 and figure 4-3.  Cell-lines which have been 
greyed out were not used in this thesis.  
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Figure 4-1: Western blot analysis of P-gp[6] 
 
Lane 2 shows P-gp expression for DLKP, lane 5 for DLKP-A, lane 
7 for HL-60/Mdr1.  Lane 11 is DLKP-A, which was used as a 
positive control.  
 
Figure 4-2: Western blot analysis of MRP-1[6]  
 
Lane 3 shows MRP-1 expression for 2008/MRP-1 and lane 4 for 
HL-60/Adr.  Lane 11 shows the expression of MRP-1 in 
2008/MRP-1 cell-line which was used as a positive control.  
 
 
 
 
Figure 4-3: Western blot analysis of BCRP[6]  
 
Lane 8 shows the expression of BCRP in DLKP-Sq /Mitox-BCRP 
and of HL-60/Mxr in lane 10.  
 
 
 
 
BCRP 
β-Actin 
MRP1 
β-Actin 
P-glycoprotein
β-Actin
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Likewise, the MDR status of A549 and A549-tax has been established previously. 
A549, a lung adenocarcinoma cell-line model and A549-tax, the resistant variant, which 
was selected in-house by Dr Laura Breen, [286] were used as one P-gp model for 
transport assay. A549-tax has been shown to express P-gp[179], while the parental cell-
line does not show any P-gp expression 
 
Figure 4-4, Figure 4-5 and Figure 4-6 were taken from the work of Gráinne Dunne, 
2009 (MSc Thesis, 2009)[7]  
 
Figure 4-4: P-gp Western blot for A549 
and A549-tax[7] 
P-gp
β-Actin
A549   A549-T  DLKP DLKP-A
 
Figure 4-4 shows the P-gp expression 
A549, A549-tax, DLKP and DLKP-A.  
 
Figure 4-5: MRP-1 Western blot for A549 
and A549-tax[7] 
MRP1
β-Actin
A549   A549-T  DLKP DLKP-A
 
Figure 4-5 shows the MRP-1 
expression A549, A549-tax, DLKP and 
DLKP-A.  
Figure 4-6: BCRP Western blot for A549 
and A549-tax[7] 
β-Actin
A549   A549-T  DLKP DLKP-A
BCRP
 
Figure 4-6 shows the BCRP expression 
A549, A549-tax, DLKP and DLKP-A.  
 
 
 
 
 
 
 
No P-gp was detected in the parental cell-lines, while DLKP-A significantly over-
expressed P-gp while A549-tax show minor expression of P-gp.  MRP-1 was detected 
in the parental cell-line, A549, while lower expression was seen in the resistant A549-
tax, neither DLKP nor the resistant DLKP-A showed any expression of MRP-1.  Low 
levels of BCRP were detected in the resistant A549-tax cell-line 
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P-glycoprotein 
β-Actin 
The cell-line IGROV-1 is an ovarian cell-line and IGROV-1CDDP is a resistant variant 
selected with cisplatin.  The cell-line was originally developed in the Netherlands 
Cancer Institute [292].  This cell-line is used in collaboration with Dr Britta Stordal, 
NICB[351]. 
 
Figure 4-7: Western blot analysis of P-gp in IGROV-1CDDP cell-line[351] 
 
 
 
 
 
 
 
 
Lane Cell-line 
1 IGROV-1 
2 IGROV-1CDDP 
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The DLKP cell-line has been characterised to contain three morphologically distinct 
populations.  The three clones corresponding to these populations were established from 
the parental DLKP cells.  The clones were designated M (mesenchymal-like), I 
(intermediate) and SQ (squamous)[285]. 
 
Within the NICB, a drug resistant variety of DLKP-Sq was established by pulsed 
exposure to mitoxantrone, by Helena Joyce.  Uniquely, two separate mechanisms of 
resistance were established, resulting in “sister” resistant models, one which over-
expressed BCRP (DLKP-Sq/Mitox-BCRP) and one which over-expressed P-gp (DLKP-
Sq/Mitox-MDR).  This work was carried out by Helena Joyce, and these images were 
kindly reproduced with her permission. This work is currently unpublished.  
 
 
Figure 4-8: BCRP expression in DLKP-
Sq/Mitox-BCRP 
 
Figure 4-8 shows the BCRP expression 
of DLKP-Sq/Mitox-BCRP 
Figure 4-9:  P-gp expression in DLKP-
Sq/Mitox-MDR 
 
Figure 4-9 shows the P-gp expression 
for DLKP-Sq/Mitox-MDR. DLKP-A 
was included as a positive control. 
 
 
DLKP-
Sq 
DLKP-Sq/ 
Mitox-BCRP 
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The cell-line RPMI-2650Tx is a drug resistant variant of RPMI-2650 which was 
selected by continuous exposure to paclitaxel[289].  RPMI-2650 was originally derived 
from a malignant tumour of the nasal septum.  Figure 4-10 and Figure 4-11 show the P-
gp over-expression in RPMI-2650Tx compared to the parent, RPMI-2650, both at the 
protein and RNA level, by Western blot analysis and RT-PCR. Reproduced from Liang 
et al[289]. 
 
Figure 4-10: P-gp Western for RPMI-
2650Tx[289] 
 
The expression of P-gp in RPMI-
2650Tx by Western blot analysis, 
DLKP-A was included as a positive P-
gp control, reproduced from Liang et 
al.[289] 
Figure 4-11: RT-PCR for RPMI-
2650Tx[289] 
 
The RT-PCR analysis confirmed up-
regulation of the mdr-1 gene 
expression, which encoded for P-gp 
expression, reproduced from Liang et 
al.[289] 
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The cell-line KB -3-1 is a subclone of KB cells, which is a HeLa derivative[291] KB-8-
5-11 is a resistant variant of KB-3-1 developed by selection with colchicine[291]. The 
P-gp overexpression of KB-8-5-11 has previously been reported [350, 353-355] as well 
as having been confirmed in-house, data not shown.  
 
Figure 4-12: Western blot analysis of KB-3-1 and KB-8-5-11 cell-lines[350] 
 
 
 
Lane Cell-line 
1 KB 3–1 
2 KB 8–5 
3 KB 8–5-11 
 191
4.2. Dasatinib  
At the commencement of this body of work there had been little reported on the 
relationship between dasatinib and the ABC protein pumps.  An article published by 
Kamath et al.[173], stated that dasatinib was not a P-gp substrate.  However, work 
published in 2008 [174] and 2009 [175] identified that dasatinib was a substrate for P-
gp and BCRP.  
 
In this section the role of P-gp, MRP-1 and BRCP in the transport of dasatinib is 
examined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Throughout this section, accumulation/efflux graphs in two different colours 
represent two different cell-lines, whereas two shades of the same colour represent the 
same cell-line treated with and without an inhibitor.  
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4.2.1. The interaction of dasatinib with P-glycoprotein 
P-glycoprotein is responsible for the resistance of many forms of cancer to a multitude 
of chemotherapeutics, including the TKI imatinib.  Here, using a range of P-gp over-
expressing cell-line models, the transport of dasatinib by P-gp was examined.   
 
4.2.1.1. DLKP and DLKP-A cell-line models 
Figure 4-13 shows the accumulation of increasing concentrations of dasatinib in DLKP 
and DLKP-A cell-lines over two hours.  Even though the overall level of drug 
accumulation was low, the difference between the level of dasatinib accumulated in 
DLKP and the P-gp over-expressing-DLKP-A was significant.  Significantly more 
dasatinib was accumulated in the parental cell-line compared to the P-gp over-
expressing cell-line.  Evaluation of significance at the lowest concentration (0.1μM) 
resulted in a p value of 0.000072.   
 
Elacridar is a P-gp inhibitor which completely inhibits the action of P-gp at 0.25μM[7, 
356].  Elacridar was added to the cell culture media to investigate the effect of 
preventing P-gp action from the point exposure to dasatinib. Figure 4-14 and Figure 
4-15 shows this accumulation profile over time in DLKP-A.  The difference between 
the level of dasatinib accumulated in the experimental arm with the inhibitor and the 
arm without inhibitor was significant, with an average of 90% less accumulated in the 
inhibitor free experiment.   
 
Interestingly the inhibition of P-gp from the point of exposure shows that the level of 
dasatinib accumulation in the resistant DLKP-A is almost equivalent to the parental 
levels of accumulation, Figure 4-19. 
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Figure 4-13: Dasatinib Accumulation in DLKP and DLKP-A 
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Figure 4-13 shows the accumulation of dasatinib across an increasing concentration 
range after two hours of drug exposure, in DLKP and DLKP-A. Analysis was carried 
out in technical triplicates on biological duplicates. The quantified mass was 
normalised to mass per million cells.  Statistical significance was calculated used the 
paired student t-test of unequal variance, (see Section 2.3).  Statistical significance was 
calculated between the parental (DLKP) and resistant (DLKP-A) model at each 
concentration. 
 
 
 
 
 
 
 
*** 
*** 
*** 
** 
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Figure 4-14: Accumulation of 1μM dasatinib in DLKP-A 
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Figure 4-14 shows the accumulation of 1μM dasatinib in DLKP-A 
cell-line model.  Accumulation levels are illustrated in the presence 
and absence of P-gp inhibitor, elacridar. The quantified mass was 
normalised to mass per million cells. 
 
 
 
 
 
Figure 4-15: Accumulation of 2μM dasatinib in DLKP-A 
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Figure 4-15 shows the accumulation of 2μM dasatinib in DLKP-A 
cell model.  Accumulation levels are illustrated in the presence and 
absence of P-gp inhibitor, elacridar. The quantified mass was 
normalised to mass per million cells. 
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To further investigate the transport of dasatinib in P-gp expressing cell-lines a series of 
efflux assays were performed.  Figure 4-16, Figure 4-17 and Figure 4-18 show the 
efflux of dasatinib in DLKP and DLKP-A with and without elacridar.   
 
In DLKP, the parental cell-line, there was no difference in the intracellular level of 
dasatinib at the efflux time points with and without the inhibitor.  However, in DLKP-
A, the P-gp over-expressing cell-line, dasatinib was retained inside the cell in the 
presence of the inhibitor. 
 
The difference in the quantified intracellular mass of dasatinib in the presence and 
absence of elacridar was significant in DLKP-A at all time points and at both 1μM and 
2μM concentrations of dasatinib.  However, when the accumulated mass of dasatinib in 
DLKP with and without elacridar was compared there was no significant difference in 
intracellular dasatinib.   
 
Figure 4-19 shows an interesting trend where there appears to be an increased 
intracellular concentration at 90 minutes compared to 60 minutes.  This is possibly due 
to an experimentally error in the assay timing, that possible the flasks at 60 minutes 
were exposed to dasatinib for a shorter time period than the other time points.  As the 
same trend is not seen in the assay at 2μM, which was carried out on biological 
duplicates this is not believe to be a true biological trend.  However the effect of 
comparing the samples treated with elacridar to the samples without is significant.  
 
Given the complexity of efflux assays and higher level of error associated them efflux 
assays, further analysis to test the effect of P-gp on an agent were carried out as 
accumulation assays in the presence of an inhibitor.  
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Figure 4-16: Efflux of 2μM dasatinib in DLKP 
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Figure 4-16 shows the efflux of 2μM dasatinib in parental cell-line DLKP over 90 
minutes.  Results shown are the average of technical triplicates. The quantified mass 
was normalised to mass per million cells 
 
Table 4-3: Statistical significance 
Time 
(mins) p-value 
30 0.289191 
60 0.63928 
90 0.011066 
p-values determined by paired student’s t-test of unequal variance.  Comparison was 
made between samples with and without elacridar samples at each time point.  
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Figure 4-17: Efflux of 2μM dasatinib in DLKP-A 
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Figure 4-17 shows the efflux of 2μM dasatinib in resistance cell-line DLKP-A over 90 
minutes.  Results shown are the average of technical triplicates, on biological 
duplicates. The quantified mass was normalised to mass per million cells. Statistical 
significance was calculated used the paired student t-test of unequal variance, (see 
Section 2.3). 
 
 
 
Table 4-4: Statistical significance 
Time 
(mins) p-value 
30 0.001457 
60 0.002337 
90 0.000249 
p-values determined by paired student’s t-test of unequal variance. Comparison was 
made between samples with and without elacridar at each time point.  
 
 
 
 
 
*** 
*** *** 
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Figure 4-18: Efflux of dasatinib 1μM in DLKP-A 
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Figure 4-18 shows the efflux of 1μM dasatinib in the P-gp over-expressing cell-line 
DLKP-A over 90 minutes.  Results shown are the average of technical triplicates 
(technical repeats). The quantified mass was normalised to mass per million cells. 
Statistical significance was calculated used the paired student t-test of unequal 
variance, (see Section 2.3). 
 
 
 
Table 4-5: Statistical significance 
Time 
(mins) p-value 
30 0.0145447 
60 0.0259020 
90 0.0000156 
p-values determined by paired student’s t-test of unequal variance. Comparison was 
made between samples with and without elacridar at each time point.  
 
 
 
* 
* 
*** 
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Figure 4-19: Overall effect of elacridar on dasatinib accumulation 
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Figure 4-20 shows the effect of elacridar on dasatinib accumulation. The green bar 
represents 2μM accumulation in DLKP after 2 hours, the blue bar represents the 
accumulation of 2μM dasatinib in DLKP-A after 2 hours with elacridar present. The 
purple bar shows the mass of dasatinib accumulated in DLKP-A after two hours with 
no elacridar present. The green and the purple bars are the average and SD of 
biological duplicates. The blue bar is the average and SD of technical triplicates.  
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To examine the effect of dasatinib transport by P-gp, on resistance in the cell lines the 
cytotoxicity of dasatinib was analysed using an in vitro proliferation assay in 
combination with P-gp inhibitor elacridar.  The setup of the assay was such that the 
plate was split horizontally so that the exact same concentration of dasatinib was 
applied to the cells with and without elacridar.  Dasatinib was assessed across a 
concentration range while a fixed concentration of elacridar was added, 0.25μM.  
 
The inclusion of elacridar had no impact on the sensitivity of DLKP to dasatinib, Figure 
4-20.  However, the inclusion of elacridar in the proliferation assay for DLKP-A had a 
significant impact on dasatinib toxicity, Figure 4-21. A p-value of 0.000158 was 
determined for the lowest concentration (0.1μM) of dasatinib examined.  The IC50, 
toxicity at which 50% cell kill is achieved, was determined to be 0.47μM dasatinib in 
combination with elacridar while the IC50 of dasatinib alone was 3.65μM.  This 
represents a 7-fold resistance to dasatinib associated solely with P-gp expression.  
 
It should also be noted that the parental cell-line, DLKP, is still more sensitive to 
dasatinib than the resistant DLKP-A after the protecting effect of P-gp has been 
neutralised. At 100nM dasatinib, the parental cell-line experienced 75% cell kill, while 
in the resistant cell-line, DLKP-A, experienced only a 25% cell kill in combination with 
elacridar. This would indicate that other mechanisms of resistance are present in DLKP-
A, though P-gp over-expression does play a significant role in cell protection.  
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Figure 4-20: In vitro proliferation assay of dasatinib plus elacridar in DLKP 
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The % cell survival DLKP was determined by acid phosphatase assay in response to a 
six day treatment of dasatinib in combination with elacridar. Data are mean and 
standard deviation of biological triplicates. 
 
Figure 4-21: In vitro proliferation assay of dasatinib plus elacridar in DLKP -A 
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The % cell survival was determined by acid phosphatase assay in response to a six day 
treatment of dasatinib in combination with elacridar.  Data are mean and standard 
deviation of biological triplicates. 
***
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To examine the effect of dasatinib on P-gp function, rather than the effect of P-gp 
function on dasatinib, the accumulation of a known P-gp substrate was assessed.  
Epirubicin is a known P-gp substrate[10].  By comparing the accumulation profile of 
epirubicin in P-gp over-expressing DLKP-A to epirubicin accumulation inhibited by 
elacridar and epirubicin accumulation in the presence of dasatinib it is possible to 
determine the effect of dasatinib on the function of P-gp. Epirubicin was quantified by 
LC-MS/MS[293] (Section 2.2.7). 
 
This effect was also examined toxicologically in DLKP and DLKP-A.  The effect of 
dasatinib in combination with epirubicin or taxol was assessed by in vitro proliferation 
assays, Figure 4-23 to Figure 4-26.  The addition of dasatinib to either epirubicin or 
taxol in either DLKP or DLKP-A cell line model did not increase the effect of either 
chemotherapeutic agent. 
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Figure 4-22: Epirubicin accumulation in DLKP-A 
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The accumulated mass of epirubicin in DLKP-A alone and in the presence of dasatinib 
or elacridar.  Results shown are the average of technical triplicates and standard 
deviations. The quantified mass was normalised to mass per million cells 
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Figure 4-23: Combination of epirubicin and dasatinib in DLKP-A cell-line 
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Figure 4-31 shows the % cell survival in DLKP-A as determined by 
acid phosphatase assay in response to a seven day treatment of fixed 
concentration epirubicin (500nM) in combination with increasing 
concentrations of dasatinib. Data shown are mean +/- SD of triplicate 
determination. 
 
 
 
 
Figure 4-24: Combination of taxol and dasatinib in DLKP-A cell-line 
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Figure 4-32 shows the % cell survival in DLKP-A as determined 
by acid phosphatase assay in response to a seven day treatment of 
fixed concentration taxol (100nM) in combination with increasing 
concentrations of dasatinib. Data shown are mean +/- SD of 
triplicate determination. 
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Figure 4-25: Combination of epirubicin and dasatinib in DLKP 
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Figure 4-33 shows the % cell survival in DLKP as determined by acid 
phosphatase assay in response to a seven day treatment of fixed 
concentration epirubicin (3nM) in combination with increasing 
concentrations of dasatinib. Data shown are mean +/- SD of triplicate 
determination. 
 
 
 
 
 
Figure 4-26: Combination of taxol and dasatinib in DLKP 
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Figure 4-34 shows the % cell survival in DLKP as determined by acid 
phosphatase assay in response to a seven day treatment of fixed 
concentration taxol (0.5nM) in combination with increasing 
concentrations of dasatinib. Data shown are mean +/- SD of triplicate 
determination. 
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4.2.1.2. DLKP-SQ and DLKP-Sq/Mitox-MDR cell-line models 
The DLKP-Sq/Mitox-MDR cell-line model, which was recently developed by Helena 
Joyce in our laboratory, highly over-expresses P-gp, as described in Section 4.1.  The 
resistant model was developed by pulsed selection with mitoxantrone.  
 
Figure 4-27 shows the accumulation of dasatinib in the P-gp over-expression model 
compared to the parental cell-line.  Significantly less intracellular dasatinib was 
quantified in the resistant cell-model compared to the parental model.   
 
When the effect of elacridar on the accumulation was examined, Figure 4-28, we can 
see that there was significantly more intracellular dasatinib present when the P-gp 
inhibitor elacridar was added to the cell culture media. When Figure 4-28 and Figure 4-
29 are compared we see that the level of dasatinib accumulated after two hours in 
DLKP-Sq/Mitox-MDR with elacridar present was similar to levels accumulated in 
DLKP-Sq after two hours.  
 
The cytotoxic effect of dasatinib and the effect of P-gp on the resistance of dasatinib 
were examined using in vitro proliferation assays.  Figure 4-30 and Figure 4-30 shows 
the effect of P-gp inhibition on the cytotoxic resistance of known P-gp substrates, taxol 
and epirubicin. This demonstrated the dramatic effect of functional P-gp in protecting 
the cell and the effect on toxicity of P-gp inhibition.  Figure 4-32 shows that effect of 
elacridar on dasatinib cytotoxicity.  While there was a clear significant difference in the 
accumulation of dasatinib in DLKP-Sq/Mitox-MDR with and without elacridar,  the 
difference in the cytotoxic effect of dasatinib on DLKP-Sq/Mitox-MDR with and 
without elacridar was not significant.  There was a visible trend that the inhibition of P-
gp by elacridar increased the cytotoxicity of dasatinib but standard deviations in the 
assay meant that the difference was not clearly significant.  
 
Figure 4-32 and Figure 4-33 show the effect of dasatinib in combination with P-gp 
substrates epirubicin and taxol. The addition of dasatinib did not increase the cytotoxic 
effect of either chemotherapeutic.  
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Figure 4-27: Accumulation of dasatinib in DLKP-Sq and DLKP-Sq/Mitox-MDR 
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The comparison between the accumulation of 1μM dasatinib at 30 minute intervals 
over a two hour period, in DLKP-Sq and DLKP-Sq/Mitox-MDR. Analysis was carried 
out in technical triplicates. The quantified mass was normalised to mass per million 
cells. 
 
 
Table 4-6: Statistical significance 
Time 
(mins) p-value 
30 0.017 
60 0.004 
90 0.009 
120 0.006 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between samples with and without elacridar at each time point.  
 
 
* *** ** ** 
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Figure 4-28: Dasatinib accumulation in DLKP-Sq/Mitox-MDR with and without elacridar 
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Figure 4-28 shows the accumulation of 1μM dasatinib at 30 minute intervals over a 
two hour period, DLKP-Sq/Mitox-MDR with and without elacridar. Analysis was 
carried out in technical triplicates. The quantified mass was normalised to mass per 
million cells. 
 
 
Table 4-7: Statistical significance 
Time 
(mins) p-value 
30 0.021 
60 0.002 
90 0.021 
120 0.036 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between samples with and without elacridar at each time point.  
 
 
 
* ** * * 
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Figure 4-29: In vitro proliferation assay of taxol plus elacridar in DLKP-Sq/Mitox-MDR 
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Figure 4-30 shows the % cell survival in DLKP-Sq/Mitox-MDR which was determined 
by acid phosphatase assay in response to a six day treatment of taxol in combination 
with elacridar.  Data are mean and standard deviation of biological triplicates. 
 
Figure 4-30: In vitro proliferation assay of epirubicin + elacridar in DLKP-Sq/Mitox-MDR 
Epirubicin in Combination with Elacridar in DLKP-Sq/Mitox-MDR
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Figure 4-30 shows the % cell survival in DLKP-Sq/Mitox-MDR which was determined 
by acid phosphatase assay in response to a six day treatment of taxol in combination 
with elacridar.  Data are mean and standard deviation of biological triplicates. 
 210
Figure 4-31: In vitro proliferation assay of dasatinib + elacridar in DLKP-Sq/Mitox-MDR 
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Figure 4-32 shows the % cell survival in DLKP-Sq/Mitox-MDR which was determined 
by acid phosphatase assay in response to a six day treatment of taxol in combination 
with elacridar.  Data are mean and standard deviation of biological triplicates.  
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Figure 4-32: Combination of epirubicin and dasatinib in DLKP-Sq/Mitox-MDR  
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The % cell survival in DLKP-Sq/Mitox-MDR as determined by acid phosphatase 
assay in response to a seven day treatment of fixed concentration epirubicin (1.5μM) in 
combination with increasing concentrations of dasatinib. Data shown are mean +/- SD 
of triplicate days. 
 
Figure 4-33: Combination of taxol and dasatinib in DLKP-Sq/Mitox-MDR 
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The % cell survival in DLKP-Sq/Mitox-MDR as determined by acid phosphatase 
assay in response to a seven day treatment of fixed concentration taxol (234μM) in 
combination with increasing concentrations of dasatinib. Data shown are mean +/- SD 
of triplicate days. 
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4.2.1.3. IGROV-1 and IGROV-1CDDP cell-line model 
The cell-line models IGROV-1CDDP is a resistant variant for the ovarian model 
IGROV-1.  The mechanism of resistance is mediated through P-gp over-expression as a 
result of pulse selection with cisplatin, an agent commonly used in the treatment of 
ovarian cancer.  TLDA data showed the up-regulation of P-gp at RNA level and the lack 
of over-expression of other ABC transporters.  The lack of BCRP and MRP-1 
expression has been confirmed by Western blot[357].  Work carried out by Stordal et 
al., showed P-gp mediated resistance in IGROV-1CDDP[357]. 
 
The accumulation of dasatinib, 1μM, was examined in the IGROV-1CDDP cell-line 
model.  The addition of elacridar increased the intracellular concentration of dasatinib 
across the time course examined.  The average fold increase of intracellular dasatinib 
was 16.8 (+/-1.4) across all time points, ranging from 15 to 18.  The difference in 
accumulated mass was in all cases significant.  
 
Inhibition of P-gp by elacridar was shown to have an effect on the cytotoxicity of 
dasatinib in IGROV-1CDDP, Figure 4-35, through the incorporation of elacridar had no 
effect on dasatinib in the parental cell-line IGROV-1, Figure 4-36. 
 
The functionality of P-gp resistance mechanism in IGROV-1CDDP was demonstrated 
by the in vitro cytotoxicity assays carried out in IGROV-1CCDP and the parental 
IGROV-1 cell-line with and without elacridar, Table 4-9.  This analytical technique can 
therefore also be used to investigate further mechanisms for cross-resistance.   
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Figure 4-34: Dasatinib accumulation in IGROV-1CDDP 
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Figure 4-34 shows the accumulation of 1μM dasatinib in resistance cell-line IGROV-
1CDDP over 120 minutes.  Results shown are the average of technical triplicates. The 
quantified mass was normalised to mass per million cells. Statistical significance was 
calculated used the paired student t-test of unequal variance, (see Section 2.3). 
 
 
Table 4-8: Statistical significance 
Time 
(mins) p-value 
30 0.00002 
60 0.00113 
90 0.02060 
120 0.00035 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between samples with and without elacridar at each time point.  
 
 
*** *** * *** 
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Figure 4-35 In vitro proliferation assay of dasatinib plus elacridar in IGROV-1CDDP[357] 
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Figure 4-35 shows the % cell survival of IGROV-1CDDP determined by acid phosphatase 
assay in response to a six day treatment of taxol in combination with elacridar.  Data are 
mean and standard deviation of biological triplicates. 
 
Figure 4-36: In vitro proliferation assay of dasatinib plus elacridar in IGROV-1[357] 
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Figure 4-36 shows the % cell survival of IGROV-1 determined by acid phosphatase assay 
in response to a six day treatment of taxol in combination with elacridar.  Data are mean 
and standard deviation of biological triplicates. 
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Table 4-9: IC50 results for selected P-gp substrates in IGROV-1 and IGROV-1CDDP[357] 
Drug 
(Units) 
IGROV-1 IGROV-1CDDP Resistant vs Sensitive
IGROV-1 
+/- Elacridar
IGROV-1CDDP
+/- Elacridar 
Mean ± SD Mean ± SD Fold p-value p-value p-value 
Cisplatin 
(ng/ml) 43.2 ± 16.8 809.3 ± 344.8 18.7 0.000003   
+Elacridar 
0.25μM 41.3 ± 28.6 575.1 ± 366.1 13.9 0.0271 0.8792 0.3020 
       
Taxol 
(ng/ml) 0.99 ± 1.1 127.9 ± 64.8 128.9 0.007807   
+ Elacridar 
0.25μM 0.6 ± 0.4 0.3 ± 0.6 0.5 0.8692 0.0318 0.0021 
       
Epirubicin 
(ng/ml) 6.8 ± 4.3 363.4 ± 218.5 53.2 0.047517   
+ Elacridar 
0.25μM 2.6 ± 2.8 1.9 ± 2.3 0.7 0.9201 0.1967 0.0460 
IC50 values determined from proliferation assays. Results are expressed as IC50 +/- SD.  Fold difference in resistance was calculated between the 
parental and resistant cell-line.  
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4.2.1.4. KB-8-5-11 cell-line model 
The KB-8-5-11 cell-line was established in 1985 from the parental cell-line KB-3-1 
which was cloned from the KB human cell-line.  The KB human cell-line is a HeLa- 
derived cell-line[291]. KB-8-5-11 was selected by exposure to colchicine[291].  This 
model was selected for examination as it highly over-expressed P-gp and was well 
reported in the literature.  
 
A brief examination of the accumulation of dasatinib in the resistant model was 
investigated at two separate drug concentration, 1μM and 0.1μM dasatinib, Figure 4-37 
and Figure 4-38.  The peak plasma concentration of dasatinib has been found to be 
approximately 1μM[358].  At both concentrations examined the addition of elacridar 
increased the intracellular mass of dasatinib.  The method can clearly distinguish a 
significant difference in accumulation, even at a low exposure concentration.  
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Figure 4-37: Accumulation of 1μM dasatinib in KB-8-5-11 
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Figure 4-37: shows the accumulation of 1μM dasatinib in KB-8-5-11 over 120 minutes.  
Results shown are the average of technical triplicates. The quantified mass was 
normalised to mass per million cells. Statistical significance was calculated used the 
paired student t-test of unequal variance, (see Section 2.3). 
 
Table 4-10: Statistical significance 
Time 
(mins) p-value 
30 0.0002 
60 0.0185 
90 0.0226 
120 0.0067 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between with and without elacridar samples at each time point.  
 
 
* ** * *** 
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Figure 4-38: Accumulation of 0.1μM dasatinib in KB-8-5-11 
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Figure 4-38 shows the accumulation of 0.1μM dasatinib KB-8-5-11 over 120 minutes.  
Results shown are the average of technical triplicates. The quantified mass was 
normalised to mass per million cells. Statistical significance was calculated used the 
paired student t-test of unequal variance, (see Section 2.3). 
 
Table 4-11: Statistical significance 
Time 
(mins) p-value 
30 0.0115 
60 0.0054 
90 0.0037 
120 0.0004 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between samples with and without elacridar at each time point.  
 
 
** *** *** * 
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4.2.1.5. A549 and A549-tax cell-line models 
A549 is a lung adenocarcinoma cell-line. A549-tax is a P-gp expressing resistant variant 
developed through exposure to taxol[286].  The A549 and A549-tax cell-line model was 
also investigated as the A549-tax cell-line model expresses a low level of P-gp and is 
mildly resistant (5-fold) to taxol[286].  
 
There was little or no difference in the level of dasatinib accumulated in the P-gp 
expressing cell line (A549-tax) compared to the P-gp non expressing cell-line (A549), 
Figure 4-39.  Also, more dasatinib was accumulated in the A549 and A549-tax cell 
models, Figure 4-39 compared to the DLKP and DLKP-A cell models, Figure 4-13.   
 
Figure 4-40 and Figure 4-41 shows the efflux of dasatinib in A549 cell-line and A549-
tax over time in the presence and absence of P-gp inhibitor, elacridar.  However, in the 
A549 and A549-tax model there was no significant difference in the intracellular level 
of dasatinib in the P-gp expressing cell-line between the experiment with and without 
inhibitor.  
 
The efflux of 1μM dasatinib was assessed over 120 minutes in A549 and A549-tax, 
Figure 4-40 and Figure 4-41.  While there was a difference in the quantified 
intracellular mass of dasatinib in A549-tax with and without the inhibitor, there was 
also a difference in the intracellular mass of A549 with and without elacridar.  The data 
suggests that while there is a mechanism for dasatinib exclusion from A549-tax, it is not 
P-gp mediated. Also there appears to be no active efflux of dasatinib from A549, as the 
intracellular mass was sustain over the 120 minute assay.  
 
The effect of elacridar on dasatinib toxicity was assessed by in vitro proliferation 
assays, Figure 4-42 and Figure 4-43.  The addition of elacridar had no effect on 
dasatinib potency in A549 and had a small but insignificant effect in A549-tax.  
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Figure 4-39: Dasatinib Accumulation in A549 and A549-tax 
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Figure 4-39 shows the accumulation of dasatinib in A549 and P-gp expressing A549-
tax cell-lines after 2 hours with varying concentrations. Analysis was performed on 
technical triplicates. The quantified mass was normalised to mass per million cells. 
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Figure 4-40: Efflux of 1μM dasatinib in A549-tax 
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Analysis was performed on technical triplicates. The quantified 
mass was normalised to mass per million cells. 
 
 
 
 
 
 
 
 
Figure 4-41: Efflux of 1μM dasatinib in A549 
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Analysis was performed on technical triplicates. The quantified 
mass was normalised to mass per million cells. 
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Figure 4-42: In vitro proliferation assay of dasatinib plus elacridar in A549-tax 
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Figure 4-43 shows the % cell survival in A549-tax as determined by acid phosphatase 
assay in response to a six day treatment of increasing concentrations of dasatinib in 
combination with a fixed concentration of elacridar (0.25μM). Data shown are mean 
and standard deviation of triplicate determinations. 
 
Figure 4-43: In vitro proliferation assay of dasatinib plus elacridar in A549 
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Figure 4-44 shows the % cell survival in A549 as determined by acid phosphatase assay in 
response to a six day treatment of increasing concentrations of dasatinib in combination 
with a fixed concentration of elacridar (0.25μM). Data shown are mean +/- SD of triplicate 
days. 
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4.2.1.6. RPMI-2650/Tx cell-line model 
RPMI-2650/Tx is the taxol derived, P-gp expressing resistant variant of RPMI-2650. 
Given that the taxol resistant variant of A549, A549-tax, showed no difference in the 
levels of dasatinib accumulation, an additional model was selected.  This model had 
also been induced by taxol selection.   
 
The mass of dasatinib accumulated in the presence of the P-gp inhibitor was 
significantly greater than without an inhibitor present, Figure 4-44.  
 
The presence of an inhibitor also had a significant impact on the cytotoxicity of 
dasatinib in RPMI-2650/Tx at concentrations below 2.5μM, Figure 4-45.  
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Figure 4-44: Dasatinib accumulation in RPMI-2650/Tx 
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Figure 4-44 shows the accumulation of 1μM dasatinib in RPMI-2650/Tx over 120 
minutes.  Results shown are the average of technical triplicates. The quantified mass 
was normalised to mass per million cells.  Statistical significance was calculated used 
the paired student t-test of unequal variance, (see Section 2.3) 
 
Table 4-12: Statistical significance 
Time 
(mins) p-value 
30 0.0286 
60 0.0010 
90 0.0080 
120 0.0134 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between samples with and without elacridar at each time point.  
 
 
*** 
*** *** 
*
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Figure 4-45: In vitro proliferation assay of dasatinib plus elacridar in RPMI-2650Tx 
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Figure 4-45 shows the % cell survival in RPMI-2650/Tx as determined by acid 
phosphatase assay in response to a six day treatment of increasing concentrations of 
dasatinib in combination with a fixed concentration of elacridar (0.25μM). Data shown are 
mean +/- SD of triplicate determinations.  The impact of elacridar was significant at 
concentrations below 2.5μM 
 
*** 
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4.2.1.7. Summary of results for the effect of P-gp on dasatinib 
A range of P-gp over-expressing cell-line models were used for this investigation.  
 
A significant difference was seen in the accumulation of dasatinib in DLKP and P-gp 
over-expressing DLKP-A.  That P-gp was significantly involved in the causation of this 
difference was verified by both accumulation and efflux assay which incorporated P-gp 
inhibitor elacridar in the assay.   
 
As the observation of dasatinib being as a substrate of P-gp was further validated in 
subsequent cell-line models including DLKP-Sq and DLKP-Sq/Mitox-MDR.  Again a 
significant difference was quantified in the intracellular mass of dasatinib accumulated 
in the parental and the P-gp over-expressing resistant model was quantified.  While the 
resistance phenotype is predominantly P-gp driven, the analysis of the cytotoxicity 
assays showed that epirubicin and taxol resistance was solely P-gp related while 
dasatinib resistance was partially P-gp mediated. This is shown by the incomplete 
reversal of resistance to dasatinib in the P-gp over-expressing model.  
 
The accumulation of dasatinib in the resistant ovarian cell model IGROV-1CDDP was 
examined in combination with elacridar. A significant difference was seen between the 
levels of dasatinib accumulated in the cell-line with and without elacridar. The 
inhibition of P-gp by elacridar substantially increased the mass of dasatinib in the cell.  
Cytotoxically the addition of elacridar to the dasatinib toxicity assay for the parental cell 
line had no effect however the addition of elacridar in IGROV-1CDDP increased the 
effectiveness of dasatinib.   
 
The effect of P-gp on dasatinib was further validated in the cell-lines KB-8-5-11 and 
RPMI-2650/Tx in combination with elacridar.  
 
Of the P-gp cell-line models studied only A549-tax did not show the same trend as the 
other cell-lines. This is possible a function of the low level of P-gp over-expression in 
this cell-line.  
 
 227
4.2.2. The interaction of dasatinib with BCRP 
Breast Cancer Resistant Protein, BCRP, is a half-transporter involved in the transport of 
mitoxantrone, while the mutant variant R482G is involved in the transport of 
anthracyclines and Rhodamine 123, (Section 1.3.4).  A study published at the end of 
2009 by Lagas et al., demonstrated that dasatinib is a substrate of BCRP[175].  This 
study by Lagas et al., focussed on the limited concentration of dasatinib in the central 
nervous system (CNS) and the implications in primary and metastatic brain 
tumours[175]. 
 
Using DLKP-Sq/Mitox-BCRP, the BCRP over-expressing “sister” cell-line of DLKP-
Sq/Mitox-MDR, the accumulation of 1μM dasatinib was assessed in comparison to the 
parental cell-line, DLKP-Sq.  At all time points examined, significantly more dasatinib 
was accumulated in the parental cell-line, Figure 4-46. 
 
As well as being a P-gp inhibitor, elacridar also inhibits the action of BCRP[359]. When 
the accumulation of dasatinib in the presence and absence of elacridar was examined (in 
the BCRP-overexpressing cell line model), significantly more intracellular dasatinib 
was detected in the flasks with elacridar present, Figure 4-47.  Also it was seen that the 
mass of dasatinib did not change significantly between the first and last time points.  
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Figure 4-46: Dasatinib accumulation in DLKP-Sq and DLKP-Sq/Mitox-BCRP 
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Figure 4-46 shows the accumulation of 1μM dasatinib in DLKP-Sq and BCRP over-
expressing DLKP-Sq/Mitox-BCRP cell-lines over two hours with samples taken every 
30 minutes. Analysis was performed on technical triplicates.  The quantified mass was 
normalised to mass per million cells. Statistical significance was calculated used the 
paired student t-test of unequal variance, (see Section 2.3). 
 
Table 4-13: Statistical significance 
Time 
(mins) p-value 
30 0.0176 
60 0.0082 
90 0.0052 
120 0.0059 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between the dasatinib accumulated in the parental and BCRP resistant 
model at each time point. 
 
 
 
*** ** ** **
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Figure 4-47: Dasatinib accumulation in DLKP-Sq/Mitox-BCRP 
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Figure 4-48 shows the accumulation of 1μM dasatinib, with and without elacridar, in 
BCRP over-expressing DLKP-Sq/Mitox-BCRP cell-lines over two hours with samples 
taken every 30 minutes. Analysis was performed on technical triplicates.  The 
quantified mass was normalised to mass per million cells. Statistical significance was 
calculated used the paired student t-test of unequal variance, (see Section 2.3). 
 
Table 4-14: Statistical significance 
Time 
(mins) p-value 
30 0.0300 
60 0.0278 
90 0.0005 
120 0.0100 
p-values were determined by paired student’s t-test of unequal variance. Comparison 
was made between samples with and without elacridar at each time point. 
* * *** **
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The cytotoxic effect of dasatinib on BCRP over-expressing cell-line DLKP-Sq/Mitox-
BCRP was examined in a 7 day in vitro proliferation assay, Figure 4-48.  The inhibition 
of BCRP by elacridar increased the potency of dasatinib, resulting in increased cell kill.  
The IC50 for dasatinib in DLKP-Sq/Mitox-BCRP was 174nM, the IC50 for dasatinib 
with a fixed dose of elacridar (0.25μM) was 60nM, representing a fold change of 2.9 
due to the addition of elacridar, Figure 4-48.  
 
As expected, due to the lack of detectable levels of P-gp and BCRP, in the parental cell-
line the addition of elacridar had no effect on dasatinib potency, Figure 4-49.  
Interestingly though the potency of dasatinib in the parental and resistant (without 
elacridar) were similar, Figure 4-50.  The increase in BCRP expression did not itself 
lead to increased resistance to dasatinib, however in the BCRP resistant cell-line model 
the potency of dasatinib was increased with the addition of a BCRP inhibitor, elacridar.   
 231
Figure 4-48: In vitro proliferation assay of dasatinib plus elacridar in DLKP-Sq/Mitox-
BCRP 
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Figure 4-49 shows the % cell survival in DLKP-Sq/Mitox-BCRP, determined by acid 
phosphatase assay in response to a six day treatment of increasing concentrations of 
dasatinib in combination with a fixed concentration of elacridar (0.25μM). Data shown 
are mean and standard deviations of triplicate determinations.  The asterisk indicates 
significance as determined by paired student’s t-test of unequal variance between the 
cell survival determined with and without elacridar at 100nM.  
 
 
*** 
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Figure 4-49: In vitro proliferation assay of dasatinib plus elacridar in 
DLKP-Sq 
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Figure 4-49 shows the % cell survival in DLKP-Sq, determined by 
acid phosphatase assay in response to a six day treatment of 
increasing concentrations of dasatinib in combination with a fixed 
concentration of elacridar (0.25μM). Data shown are mean and 
standard deviations of triplicate determinations.   
 
Figure 4-50: Comparison of dasatinib in DLKP-Sq and DLKP-
Sq/Mitox-BCRP 
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Figure 4-50 shows the comparison of DLKP-Sq and DLKP-Sq/Mitox 
cell survival after exposure to dasatinib. Data shown are mean and 
standard deviations of triplicate determinations.   
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The efflux protein BCRP has a more selective transport profile than P-gp. BCRP does 
not transport taxol, vincristine or verapamil.  However, irinotecan and its active 
metabolite SN-38 are substrates of BCRP[90].  BCRP can have functional variants, 
where by a mutation in the sequence leads to an amino acid substitution. The wild-type 
BCRP has an arginine (R) at position 482.  Two know variants exist; variant R482T 
which has threonine (T) at position 482 and variant R482G where position 482 is the 
amino acid glycine (G).  These variations can lead to functional changes.  The wild type 
BCRP does not transport the anthracycline, epirubicin, where as the R482G variant does 
transport anthracyclines, (Section 1.3.4)[93].  
 
The effect of epirubicin on DLKP-Sq/Mitox-BCRP was examined by in vitro 
proliferation assays in combination with elacridar to test if the BCRP over-expressed 
was variant or wild-type.  The addition of elacridar increased the toxicity of epirubicin, 
Figure 4-51.  The IC50 of epirubicin alone was 40nM and in combination with elacridar, 
28nM.  This suggests that DLKP-Sq/Mitox-BCRP expresses a variant of BCRP rather 
than the wild type of the transporter (which does not pump epirubicin).  
 
To show conclusively that the resistance mechanism in this cell-line was mediated 
through the over-expression of ABC transporter BCRP not P-gp, an in vitro 
proliferation assay of taxol in combination with elacridar was performed.  As expected, 
as taxol is not a substrate of BCRP, no alteration in toxicity was seen with the addition 
of elacridar, Figure 4-52.  The irinotecan metabolite SN-38 is a known substrate of 
BCRP.  Elacridar potentiates the toxicity of SN-38 in DLKP-Sq/Mitox-BCRP, Figure 
4-53.   
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Figure 4-51: In vitro proliferation assay of epirubicin/elacridar in DLKP-Sq/Mitox-BCRP 
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Figure 4-51 shows the % cell survival in DLKP-Sq/Mitox-BCRP, determined by acid 
phosphatase assay in response to a six day treatment of increasing concentrations of 
epirubicin in combination with a fixed concentration of elacridar (0.25μM). Data 
shown are mean and standard deviations on triplicate determinations.   
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Figure 4-52: In vitro proliferation assay of taxol plus elacridar in DLKP-Sq/Mitox-BCRP 
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Shown is the % cell survival following exposure to a concentration range to taxol alone 
and in combination with a fixed concentration of elacridar (0.25μM).  Data shown is 
the average and standard deviations of biological triplicates.  
 
Figure 4-53: In vitro proliferation assay of SN-38 plus elacridar in DLKP-Sq/Mitox-BCRP 
SN-38 in combination with elacridar in DLKP-Sq/Mitox-BCRP
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Shown is the % cell survival following exposure to a concentration range to taxol alone 
and in combination with a fixed concentration of elacridar (0.25μM).  Data shown is 
the average and standard deviations of biological triplicates. 
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To examine if dasatinib potentiates or inhibits the activity of BCRP, the effect of 
dasatinib in combination with epirubicin and SN-38 was examined by in vitro 
proliferation assays.  No effect was seen with the addition of dasatinib to epirubicin or 
to SN-38, Figure 4-54 and Figure 4-55.   
 
To examine if the dynamic accumulation of epirubicin was affected by dasatinib, the 
accumulated mass epirubicin was quantified over 90 minutes at 30 minute intervals, 
Figure 4-56.  Technical triplicates were quantified at each condition and each time 
point.  One batch of flasks contained epirubicin only, to monitor the natural 
accumulation pattern.  One batch of flasks contained epirubicin and elacridar, as a 
positive control for the inhibition of BCRP and one batch contained epirubicin and 
dasatinib.   
 
The addition of elacridar had a small but significant effect on the accumulation of 
epirubicin.  The mass of intracellular epirubicin was increased at each time-point.  The 
addition of dasatinib to the accumulation of epirubicin had no discernible effect at 30 
and 60 minutes, however, at 90 minutes a small but significant decrease in the 
intracellular mass of dasatinib was calculated, Figure 4-56.  
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Figure 4-54: Epirubicin in combination with dasatinib in DLKP-Sq/Mitox-BCRP 
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Figure 4-54 shows the % cell survival in DLKP-Sq/Mitox-BCRP as determined by acid 
phosphatase assay in response to a six day treatment of fixed concentration epirubicin 
(12.5nM) in combination with increasing concentrations of dasatinib. Data shown are 
mean +/- SD of triplicate determinations. 
 
Figure 4-55: SN-38 in combination with dasatinib in DLKP-Sq/Mitox-BCRP 
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Figure 4-55 shows the % cell survival in DLKP-Sq/Mitox-BCRP as determined by acid 
phosphatase assay in response to a six day treatment of fixed concentration SN-38 
(3.1nM) in combination with increasing concentrations of dasatinib. Data shown are 
mean +/- SD of triplicate determinations. 
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Figure 4-56: Epirubicin accumulation in DLKP-Sq/Mitox-BCRP 
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Figure 4-56 shows the accumulated intracellular mass of epirubicin over 90 minutes, alone and in combination with dasatinib or in combination 
with elacridar. Data represents the average and standard deviation of technical triplicates, (+ indicates n=2).  Statistical significance was 
calculated using the paired two-tailed student t-test with unequal variance.  Statistical significance was tested by comparing the epirubicin 
samples with dasatinib to the control samples at individual time points and the epirubicin samples with elacridar to the control samples at each 
individual time point.  
 
+ 
*
*** ** 
*
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4.2.3. The interaction of dasatinib with MRP-1  
To further study the profile of dasatinib with the three main ABC transport proteins 
the kinetics of dasatinib uptake and efflux was examined in the MRP-1 over-
expressing cell-lines, HL-60/Adr and 2008/MRP-1.  The relationship between 
dasatinib and MRP-1 is so far unreported. 
 
HL-60/Adr is a drug-resistant leukemic cell-line which was selected with adriamycin 
to over-express MRP-1[360].  The parental HL-60/S cell-line does not express any of 
the ABC transporters.  Figure 4-57 shows the accumulation of dasatinib in HL-60/Adr 
in comparison to the parental cell-line HL-60/S.  There was no predominant trend or 
difference between the MRP-1 expressing cell-line and the parental cell-line when 
assessed over biological duplicates.   
 
Sulindac sulphide is the active form of sulindac.  At non toxic levels, this non-
steroidal anti-inflammatory drug (NSAID) has been shown to significantly increase 
the cytotoxicity of anthracyclines in MRP-1 expressing cell models as sulindac 
sulphide inhibits the action of MRP-1[109].  
 
Figure 4-58 shows the efflux of 1μM dasatinib in HL-60/Adr in the presence and 
absence of sulindac sulphide (5μM).  The addition of the inhibitor did not reduce the 
rate of efflux of dasatinib from the cells. 
 
In a second MRP-1 over-expressing cell-line, 2008/MRP-1, the accumulation of 
dasatinib in the presence and absence of an inhibitory concentration of sulindac 
sulphide was quantified.  Though a slight increase in the dasatinib intracellular 
concentration was seen in the inhibited flasks, this was not significant, Figure 4-60.   
 
These results suggest that dasatinib is not a substrate of MRP-1.  
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Figure 4-57: Dasatinib accumulation in HL-60/Adr 
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Figure 4-58 shows the accumulation of dasatinib in HL-60/Adr in comparison to the 
parental cell-line HL-60/S, across a concentration range. Data represents the 
average and standard deviation, n=6.  The quantified mass was normalised to mass 
per million cells. 
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Figure 4-58:  Efflux of 1μM dasatinib in HL-60/Adr 
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Figure 4-59 shows the efflux of dasatinib in HL-60/Adr cell line with and without the 
MRP-1 inhibitor sulindac sulphide.  The quantified mass was normalised to mass 
per million cells. Data represents the average and standard deviation of technical 
triplicates 
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Figure 4-59: Dasatinib accumulation in 2008/MRP-1 with and without sulindac sulphide 
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Figure 4-60 shows the efflux of dasatinib in 2008/MRP1 cell line with and without 
the MRP-1 inhibitor sulindac sulphide. Analysis was preformed in triplicate. The 
quantified mass was normalised to mass per million cells 
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4.3. Lapatinib 
4.3.1. The interaction of lapatinib with P-glycoprotein 
To investigate lapatinib as a substrate for transport proteins, P-gp, MRP-1 and BCRP, 
accumulation assays were carried out in various cell-lines.  Through work carried out 
by Collins et al.[179], it was previously demonstrated that lapatinib inhibits the action 
of P-gp.  Lapatinib has also been shown to alter the expression level of P-gp[7, 180].  
To identify if competitive inhibition plays a role in this inhibition of lapatinib, 
lapatinib transport was examined in cell-line models which over-express P-
glycoprotein.   
 
4.3.1.1. A549 and A549-Tax 
A549, a lung adenocarcinoma cell-line model and A549-tax, the resistant variant, 
which was selected in-house by Dr Laura Breen, [286] were used as one P-
glycoprotein model for transport assay. A549-tax has been shown to express low but 
measurable levels of P-gp[179], while the parental cell-line does not show any P-gp 
expression.  
 
To determine if P-gp plays a role in the level of cellular accumulation of lapatinib, 
A549 and A549-tax were exposed to increasing concentrations of lapatinib in media.  
The cells were exposed to the drug for 2 hours.  Assays were carried out in technical 
triplicates.  At the lower concentrations (0.1μM and 0.5μM) there was slightly but not 
significantly less intracellular lapatinib quantified. At 1μM and 2μM there was equal 
and slightly more lapatinib accumulated in the P-gp resistant cell-line than the parent.  
Overall, across the concentration range there was no difference between the parent 
and resistant models, Figure 4-61. 
 
The in vitro toxicity of lapatinib in combination with elacridar in A549 and A549-tax 
showed that elacridar did not increase the toxicity of lapatinib in either the parental of 
the resistant cell-line, Figure 4-61 and Figure 4-62.   
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Figure 4-60: Lapatinib accumulation in A549 and A549-tax after 2 hours. 
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Figure 4-61 shows the mass of lapatinib accumulated after exposed of A549 and 
A549-tax to increasing concentrations of drug. Mass of drug detected has been 
normalised to cell number and the results expressed the average and standard 
deviation as mass per million cells in nanograms. Analysis was preformed in 
technical triplicates.  
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Figure 4-61: In vitro toxicity assay of lapatinib plus elacridar in A549-tax 
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Figure 4-62 shows the % cell survival in A549-tax as determined by acid 
phosphatase assay in response to a six day treatment of increasing concentrations of 
lapatinib in combination with a fixed concentration of elacridar (0.25μM). Data 
shown are mean +/- SD of triplicate determinations. 
 
Figure 4-62: In vitro toxicity assay of lapatinib plus elacridar in A549 
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Figure 4-63 shows the % cell survival in A549 as determined by acid phosphatase 
assay in response to a six day treatment of increasing concentrations of lapatinib in 
combination with a fixed concentration of elacridar (0.25μM). Data shown are mean 
+/- SD of triplicate determinations.   
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4.3.1.2. HL-60/Mdr-1 
The leukemic cell-line model HL-60/Mdr-1 has been transduced to over-express P-gp.  
HL-60/S, the parental cell-line does not over-express any multi-drug resistant proteins 
and therefore was used as a control.  By exposing HL-60/s and HL-60/Mdr-1 to 
increasing concentrations of lapatinib in media we can examine the role of P-gp in the 
transport of lapatinib.  
The level of intracellular accumulation of lapatinib was comparable between the cell-
lines across a concentration range (0.1μM-2μM).  No significant difference in 
lapatinib accumulation was detected between the resistant and the parental cell-line, 
Figure 4-63.  
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Figure 4-63: Lapatinib accumulation in HL-60/S and HL-60/Mdr-1 
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Figure 4-64 shows the accumulation in mass per million cells of lapatinib across a 
concentration range in the leukemic suspension cell-line HL-60/Mdr-1 and HL-60/S 
cell-line.  Data represents the average and standard deviation of technical triplicates.  
The quantified mass was normalised to mass per million cells 
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4.3.1.3. DLKP and DLKP-A 
DLKP[285], a lung cell-line, and the drug resistant variant DLKP-A[109], were 
selected as a model for drug transport assay as DLKP-A has be shown to significantly 
over-express P-gp, while the parental cell-line does not express P-gp.  
 
The level of lapatinib accumulated in DLKP-A in comparison to the parental cell-line 
was examined across a concentration range for two hours to determine if P-gp is 
exerting an effect on the kinetics of lapatinib uptake and accumulation in the cell-line 
model.  
 
Across the concentration range there was no significant difference between the levels 
of lapatinib accumulated in the P-gp over-expressing DLKP-A, and the parental 
DLKP, Figure 4-64.  
 
To examine the efflux profile of lapatinib in DLKP and DLKP-A the intercellular 
level of lapatinib was quantified after the cells were allowed to efflux in media with 
and without inhibitor present.  Examination of the efflux profile of lapatinib in DLKP-
A and DLKP showed that the addition of P-gp inhibitor elacridar had no effect on the 
efflux profile of lapatinib.   
 
Figure 4-65 gives the timed efflux profile of lapatinib in the presence and absence of 
P-gp inhibitor, elacridar, in DLKP-A cell-line model after a two hours exposure to 
2μM lapatinib.  The rate of efflux for both arms of the study shows an equivalent 
trend and similar quantitative levels of lapatinib present.  
 
Similar to Figure 4-65, Figure 4-66 showed the efflux profile of lapatinib in DLKP in 
the presence and absence of elacridar in the cell culture media following accumulation 
for two hours.   
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Figure 4-64: Lapatinib accumulation in DLKP and DLKP-A 
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Figure 4-64 shows the accumulation in mass per million cells of lapatinib in DLKP 
and in the resistant variant DLKP-A across increasing concentrations range, after 
two hours exposure. Data represents the average and standard deviation, n=6.  The 
quantified mass was normalised to mass per million cells 
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Figure 4-65: Efflux profile of lapatinib in DLKP-A with and without elacridar 
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Efflux profile of 2μM lapatinib in DLKP-A, with 0.25μM elacridar.  Data represents 
the average and standard deviation of technical triplicates.  The quantified mass was 
normalised to mass per million cells. 
 
Figure 4-66: Efflux profile of lapatinib in DLKP with and without elacridar 
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Efflux profile of 2μM lapatinib in DLKP, with 0.25μM elacridar Data represents the 
average and standard deviation of technical triplicates.  The quantified mass was 
normalised to mass per million cells. 
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The effect of inhibition of P-gp on the cytotoxicity of lapatinib was investigated.  In 
both the P-gp over-expressing model (DLKP-A) and the parental model (DLKP) no 
significant effect was seen from the addition of elacridar to a range of lapatinib 
concentrations, Figure 4-67 and Figure 4-68. 
 
The effect of lapatinib in combination with other chemotherapeutics, epirubicin, 
paclitaxel, 5- fluorouracil, vinblastine, docetaxel, has been extensively researched. 
Synergistic toxicity was observed with lapatinib when combined with P-gp substrates 
epirubicin, paclitaxel, docetaxel and vinblastine in DLKP-A and A549-T. However, 
no synergy was observed in when lapatinib was combined with 5- fluorouracil[7]. 
 
To demonstrate kinetically the effect of lapatinib on a P-gp substrate, the accumulated 
mass of epirubicin was monitored.  Elacridar was included as a positive control to 
demonstrate the effect complete inhibition of P-gp would have on the quantified mass.  
 
Lapatinib inhibits the accumulation of epirubicin to an equal if not greater extent than 
elacridar, Figure 4-69.  
 
Overall this data indicates that lapatinib is not a substrate of P-gp but does inhibit the 
transporter.  
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Figure 4-67: In vitro toxicity assay of lapatinib plus elacridar in DLKP 
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Figure 4-67 shows the % cell survival in DLKP as determined by acid phosphatase 
assay in response to a seven day treatment of increasing concentrations of lapatinib 
in combination with a fixed concentration of elacridar (0.25μM). Data shown are 
mean +/- SD of triplicate determinations. 
 
Figure 4-68: In vitro toxicity assay of lapatinib plus elacridar in DLKP-A 
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Figure 4-68 shows the % cell survival in DLKP as determined by acid phosphatase 
assay in response to a seven day treatment of increasing concentrations of lapatinib 
in combination with a fixed concentration of elacridar (0.25μM). Data shown are 
mean +/- SD of triplicate determinations. 
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Figure 4-69: Epirubicin accumulation in DLKP-A 
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Shown is the accumulated intracellular mass of epirubicin over 90 minutes, alone and in 
combination with 2μM lapatinib or 0.25μM elacridar. Data represents the average and 
standard deviation of technical triplicates.  Statistical significance was calculated used the 
paired student t-test with equal variance. Statistical significance was tested by comparing the 
epirubicin samples with lapatinib to the control samples at individual time points and 
epirubicin samples with elacridar to the control samples at each individual time point.  
Table 4-15: Statistical Significance 
Time 
(mins) 
Lapatinib 
vs Control 
Elacridar 
vs Control 
30 0.00051 0.01812 
60 0.00064 0.00008 
90 0.00043 0.02026 
p-values determined by paired 
student’s t-test of equal variance.  
Comparisons were made between 
epirubicin accumulation and 
epirubicin accumulation with 
lapatinib or epirubicin accumulation 
and epirubicin accumulation with 
elacridar. 
 
 
 
*** *
***
***
*** *
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4.3.2. The interaction of lapatinib with BCRP 
Breast Cancer Resistant Protein, BCRP, is a half-transporter involved in the transport 
of mitoxantrone.  HL-60/Mxr is a leukemic cell-line, transfected with the MXR gene 
to over-express the BCRP transporter protein.  In this assay HL-60/S was used as the 
control as it does not over-express any ABC transporter. 
 
The accumulated mass of lapatinib in the cell-line models examined in Figure 4-70 
showed that the transporter BCRP had little of no effect on the intracellular mass of 
lapatinib.   
 
 
Figure 4-71 further expands on the relationship between lapatinib and BCRP efflux 
protein.  An inhibitory concentration of 0.25μM elacridar was added and the efflux 
pattern was observed.  
 
There was no significant difference between the mass of drug in the cell in the flasks 
treated with the inhibitor when compared to the flasks efflux in cell culture media 
alone.  The addition of elacridar did not appear to maintain the intracellular 
concentration of lapatinib.  
 
A brief examination on the influence of lapatinib on BCRP modulation was examined 
in the DLKP-Sq/Mitox-BCRP cell-line.  Accumulation in the presence of lapatinib 
and elacridar showed that, over prolonged exposure, lapatinib may have an effect on 
the accumulation of epirubicin.  However, at the lower time-points the addition of 
lapatinib to the cell-culture media appeared ineffectual. 
 
Overall, lapatinib is not a substrate of BCRP but does have a modulatory effect on the 
action of BCRP.  
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Figure 4-70: Lapatinib accumulation in HL-60/Mxr 
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Figure 4-71 quantifies the mass of lapatinib accumulated in HL-60/Mxr and HL-
60/S cell-lines after two hours exposure over increasing lapatinib concentration. 
Analysis was performed on technical triplicates. The quantified mass was 
normalised to mass per million cells. 
 
Figure 4-71: Lapatinib efflux in HL-60/Mxr 
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Figure 4-72 shows the efflux profile of 1μM lapatinib in HL-60/Mxr in the presence 
and absence of 0.25μM elacridar.  Analysis was performed on technical triplicates.  
The quantified mass was normalised to mass per million cells. 
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Figure 4-72: Epirubicin accumulation in DLKP-Sq/Mitox-BCRP 
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Shown is the accumulated intracellular mass of epirubicin over 90 minutes, alone 
and in combination with lapatinib or elacridar. Data represents the average and 
standard deviation of technical triplicates, (+ indicates n=2).  Statistical significance 
was calculated used the student t-test with equal variance. Statistical significance 
was tested by comparing the epirubicin samples with lapatinib to the control 
samples at individual time points and epirubicin samples with elacridar to the 
control samples at each individual time point.  
 
 
 
* 
+ 
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4.3.3. The interaction of lapatinib with MRP-1 
MRP-1, an ABC transport protein, is responsible for the transport of anthracyclines, 
vinca alkaloids, epipodophyllotoxins and methotrexates.  To date the relationship 
between lapatinib and MRP-1 is unreported.  Using the MRP-1 over-expressing cell-
line model, HL-60/Adr as an in vitro model, the connection between lapatinib 
transport and MRP-1 was investigated.  
 
Figure 4-73 shows the accumulation of lapatinib over a two hour period across an 
increasing lapatinib concentration range in the HL-60/Adr cell-line with HL-60/S 
used as a control.  There was no significant difference in the levels of lapatinib 
accumulated in the MDR negative cell-line HL-60/S and the MRP-1 over-expressing 
cell-line HL-60/Adr. 
 
Sulindac sulphide, the active form of sulindac is an MRP-1 inhibitor was used to 
inhibit the action of MRP-1.  In the analysis, the intracellular level of lapatinib in HL-
60/Adr was quantified following the efflux in the presence and absence of sulindac 
sulphide.  The intracellular mass of lapatinib present was equivalent in both the 
inhibitor positive and control samples, Figure 4-74. 
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Figure 4-73: Lapatinib accumulation in HL-60/Adr 
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Figure 4-74 shows an accumulation across a concentration range of lapatinib in HL-
60-Adr cell-line, and HL-60/S cell-line. Data represents the average and standard 
deviation, n=3. The quantified mass was normalised to mass per million cells. 
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Figure 4-74: Lapatinib Efflux in HL-60/Adr 
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Figure 4-75 shows the efflux profile of 1μM Lapatinib in HL-60/Adr in the presence 
and absence of 5μM sulindac sulphide over a two hour time frame.  Data represents 
the average and standard deviation, n=3.  The quantified mass was normalised to 
mass per million cells. 
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4.4. Discussion 
The conventional chemotherapy drugs, used in the treatment of many forms of 
advanced cancer, attack proliferating healthy and cancerous cells leading to 
potentially serious side effects including myelosuppression, hair loss and 
gastrointestinal problems. The emerging goal of cancer pharmacology research is the 
development and optimal application of targeted therapies. Targeted therapies include 
drugs which are specifically active in cancer cells thereby giving increased activity 
while having reduced toxicity and side effects.  
 
Resistance to the therapeutic actions of cancer drugs is a significant clinical challenge 
[3].  In particular, the over expression of cellular drug efflux pumps, such as P-gp, in 
tumour cells is thought to play a significant role in the resistance phenotype[361].  
Research now indicates that many TKIs may interact with drug efflux pumps and in 
some cases these pumps may play a role in resistance to these newer anti-cancer 
agents[362]. 
 
Using a panel of MDR over-expressing cell-lines, which were chosen based on their 
MDR status, the role of MDR proteins in the transport of lapatinib and dasatinib was 
examined. 
 
LC-MS/MS was chosen as the analytical methodological approach most applicable to 
this study for a variety of reasons.  Accumulation and efflux studies can be preformed 
using radio-labelled agents and detection by scintillation counter giving a reading of 
counts per million.  Drug accumulation and transport in animal models can also be 
detected PET imaging and radiotracers.  However, LC-MS is fast becoming a 
standard tool in any bio-analytical laboratory.  The technique is sensitive, accurate 
and generally straight-forward.  Techniques can also be transferred with relative ease 
from laboratory to laboratory, assisting inter-agency collaboration.  LC-MS also 
avoids the use of radio-labelled agents and radiotracers and avoids the requirement of 
specialist licences required to work with radio-active material.  Also analytical 
methodologies developed for the quantification of intracellular levels of TKIs could 
be translated into the analysis of pharmacokinetics of TKIs in patient serum, which is 
not possible with other techniques.  
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The cell-lines selected in this study, both new and established, have been previously 
well characterised both in the literature [179, 283, 284, 286-289, 350, 351, 363] and 
internally[6, 7], to express the multi-drug resistant proteins of interest.  
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4.4.1. Dasatinib  
Dasatinib is approved for use clinically in imatinib-resistant and imatinib tolerant 
CML (chronic myelogenous leukaemia). Imatinib resistance is typically due to 
mutation is the kinase domain, in the drug-kinase interaction region[162, 364]. 
However, additional mechanisms for acquired resistance have been proposed which 
links of the over-expression of ABC transporters with imatinib resistance[123, 169, 
170].  
Therefore, determination of the relationship between dasatinib and the ABC multi-
drug resistance proteins is of critically clinical important. If dasatinib resistance is as a 
result of ABC transporter over-expression, then its position as a treatment for 
imatinib-resistant CML could be compromised.  
 
4.4.1.1. Interaction of dasatinib with P-glycoprotein 
Dasatinib as a P-glycoprotein substrate 
In 2008, Kamath et al.[173], showed in a Caco-2 cells permeability assay a BA/AB 
efflux ratio of 2.2, suggesting that dasatinib may be a substrate of an intestinal efflux 
transporter such as P-gp. However, to confirm these findings the authors tested the 
levels of unabsorbed dasatinib in the gastrointestinal tract of wild type and P-gp 
knock-out mice.  From this, the authors concluded that as there was no differences the 
levels of unabsorbed dasatinib in the wild type and P-gp knock-out mice that dasatinib 
was not a P-gp substrate and P-gp did not limit the oral absorption of dasatinib 
 
Using the lung squamous carcinoma, DLKP and its P-gp over-expressing variant 
DLKP-A, a preliminary examination of the effect of P-gp on dasatinib was performed 
by carrying out a two-hour accumulation assay, with increasing the concentrations of 
dasatinib.  Figure 4-13 shows the comparison between the parental cell-line and the P-
gp over-expressing cell-line.  Significantly more dasatinib was accumulated in the 
experimental time frame in DLKP compared to DLKP-A.  This suggests that P-gp 
plays a role in decreasing the accumulated mass of dasatinib.  
 
To identify the specific effect of P-gp on the intracellular mass of dasatinib in DLKP-
A, two specific concentrations (2μM and 1μM) were selected and examined in 
accumulation assays over 120 minutes, at 30 minutes intervals.  Experimentally, 
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dasatinib and elacridar, a P-gp inhibitor were added to flasks while other flasks 
(dasatinib only) were allowed accumulate over time without any inhibitor present.  
 
Figure 4-14 and Figure 4-15 showed that there was a significant difference in the 
mass of dasatinib accumulated in the uninhibited arm of the experiment when 
compared to the experimental arm, where P-gp was inhibited. The inhibition of P-gp 
led to a substantial increase in the mass of dasatinib accumulated. The inhibition of P-
gp in the accumulation of 2μM and 1μM dasatinib in DLKP-A yielded intracellular 
masses of dasatinib similar (though not equal) to the mass of dasatinib accumulated in 
DLKP, Figure 4-19.  
 
Figure 4-16, Figure 4-17 and Figure 4-18 showed the efflux profile of dasatinib in 
DLKP and DLKP-A in the presence and absence of elacridar.  The parental cell-line, 
DLKP, showed no difference in the efflux profile when the inhibitor was added.  
However, in DLKP-A, the P-gp over-expressing model, the inhibition of P-gp 
sustained the intracellular mass of dasatinib, as quantified by LC-MS/MS, whereas 
the inhibitor-free arm showed approximately a 75% reduction in the intracellular mass 
of dasatinib after 30 minutes.  This was confirmed by the subsequent analysis of the 
efflux of 1μM dasatinib, Figure 4-18.  Again the inhibition of P-gp by elacridar 
sustains the intracellular mass of dasatinib.  This showed that inhibiting P-gp 
prevented dasatinib from being pumped from the cell, which sustained the 
intracellular mass of dasatinib.  This would support the evidence that dasatinib is a 
substrate of P-gp.   
 
The DLKP-Sq/Mitox-MDR cell-line model was generated by pulsed exposure to 
mitoxantrone (Helena Joyce, data unpublished).  Western blot analysis and 
cytotoxicity analysis from characterisation experiments showed that P-gp was highly 
over-expressed in this model.  The accumulation of 1μM dasatinib, over two hours, 
showed very low levels of dasatinib accumulated when compared to the parental 
DLKP-Sq cell-line, Figure 4-27.  Examination of the accumulation profile in the 
presence or absence of elacridar shows that the inhibition of P-gp from the moment of 
exposure to dasatinib significantly increases the intracellular mass of dasatinib by an 
average of 20 fold.   
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The IGROV-1CDDP has been characterised as an P-gp over-expressing model of 
ovarian cancer[357].  Accumulation of 1μM dasatinib over 120 minutes in the 
presence and absence of elacridar showed remarkable differences in the accumulated 
mass of dasatinib.  The inhibition of P-gp increased the intracellular mass of dasatinib 
on average 16 fold, Figure 4-35.   
 
The cell-line model KB-8-5-11 again confirmed these findings, Figure 4-38 and 
Figure 4-39.  The inhibition of elacridar increased the intracellular mass of dasatinib.  
The inhibition was also insignificant at very low concentrations of dasatinib, 0.1μM, 
Figure 4-39.  In the KB-8-5-11 P-gp model the fold change in dasatinib accumulated 
was not as vast, with a more moderate average fold change of 2.5 for both 
concentrations examined.  
 
The lung adenocarcinoma cell-line A549-tax had previously been used as a P-gp 
model[179].  Across a concentration range (0.1 -2μM) after two hour exposure no 
difference was seen in the accumulated mass of dasatinib between the parental and the 
resistant model, Figure 4-40.  Likewise the inhibition of P-gp and the examination of 
intracellular dasatinib by efflux assay led to no increased intracellular dasatinib in the 
inhibited P-gp, Figure 4-41.  
 
As the body of evidence so far determined that dasatinib was in fact a P-gp substrate, 
the lack of effect in A549-tax was unusual.  To determine if P-gp derived from 
exposure to taxol selection showed a difference in selectivity for dasatinib another 
taxol derived resistant model was examined.  RPMI-2650Tx cell-line which over-
expresses P-gp was selected with taxol.  This over-expression of P-gp reduced the 
accumulation of dasatinib at 1μM by approximately 20 fold.  
 
The difference in the accumulation profile of dasatinib in A549-tax and other P-gp 
over-expressing models may be attributed to the difference in levels of P-gp over-
expression.  Given the low levels of P-gp expression in A549-tax, this may not be the 
best cell-line model for the examination of transport function due to P-gp expression.  
When examining the accumulation profile of radiolabelled docetaxel (14C) in A549 
and A549-tax cell-line models, Dr Denis Collins noted that the accumulation of 
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docetaxel was very similar for both the parental (A549)and resistant cell-lines (A549-
tax)[5].  Also the cross-resistance of A549-tax to epirubicin was negligible when 
compared to parental A549[7]. 
 
These results showed that dasatinib is a substrate of P-gp and that P-gp modulates the 
uptake and efflux of dasatinib. This is consistent with recently published literature 
evidence that identifies dasatinib as a P-gp substrate[174, 175].  Hiwase et al.[174], 
demonstrated using two over-expressing cell-line models in which the addition of the 
P-gp inhibitor PSC833 increased the intracellular uptake and retention of dasatinib. 
Using in vivo transport assays in polarised canine kidney cell-line MDCK-II, Lagas et 
al.[175], suggested that endogenous P-gp was responsible for the transport of 
dasatinib. Hegedus et al.[365], recently demonstrated that dasatinib was a high 
affinity substrate for P-gp and BCRP in cell-lines models.  Cell-lines K562/ACBB1 
and K562/ABCG2 had been selected and stably transduced from the parental K562 to 
over express the MDR protein of interest.  This is not only seen in stably transduced 
cell-lines, Chen et al.[366], showed in vitro and in vivo that P-gp limited the brain 
concentration of dasatinib.  As this study (Chen et al,[366]) was conducted in wild 
type and P-gp knock-down mice it is unclear why initial reports by Kamath et 
al.[173], did not find dasatinib to be a P-gp substrate.  
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The effect of P-glycoprotein on dasatinib resistance  
The effect of P-gp over-expression on dasatinib resistance was examined by in vitro 
toxicity assays.  In P-gp models DLKP-A (Figure 4-22), DLKP-Sq/Mitox-MDR 
(Figure 4-32) and IGROV-1CCDP (Figure 4-36) resistance to dasatinib was reversed 
by the addition of P-gp inhibitor, elacridar. In the parental cell-line models, DLKP 
(Figure 4-21), DLKP-Sq (Figure 4-54) and IGROV-1(Figure 4-37) the addition of 
elacridar had no effect on the chemo-toxicity of dasatinib, as expected.   
 
The effect of elacridar on known P-gp substrate chemotherapy agents, epirubicin and 
taxol, was examined in DLKP-Sq/Mitox-MDR and IGROV-1CDDP.  Similar to the 
profile for dasatinib, the addition of elacridar increased the toxicity of the 
chemotherapy agents.   
 
This indicated that a) the predominant mechanism of resistant in these cell-lines is 
through the over-expression of ABC transport P-gp, b) cross-resistance to dasatinib is 
modulated through the over-expression of P-gp and c) the addition of a P-gp inhibitor 
such as elacridar increases the toxicity of dasatinib.   
 
However, dasatinib-induced resistance is not necessarily P-gp-mediated, as shown in 
Section 3.7.1, where a dasatinib resistant cell-line model was generated by continuous 
exposure of dasatinib to a dasatinib-sensitive triple-negative breast cancer cell-line, 
MDA-MB-231. 
 
Our findings are in accordance with current finding where the expression of P-gp 
increased a dasatinib resistant phenotype [174, 365]. Both groups demonstrated in 
cell-line models (K562 and variants) that IC50 of dasatinib was increased in resistant 
models compared to the parent models and could be reversed with a specific P-gp 
inhibitor (PSC833). 
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Dasatinib as a P-glycoprotein inhibitor 
To examine if dasatinib modulated the function and activity of P-gp the accumulation 
of a highly efficient P-gp substrate (epirubicin) was examined by LC-MS/MS.  
Elacridar was included as a positive control for P-gp inhibition.  Dasatinib did not 
alter the accumulation profile of epirubicin in DLKP-A, (Figure 4-22).  In vitro 
toxicity assays on the combination of P-gp substrates epirubicin and taxol also 
showed no effect on the addition of dasatinib in with either DLKP-A and DLKP-
Sq/Mitox-MDR, (Figure 4-23, Figure 4-24, Figure 4-33, Figure 4-33).  In our studies, 
dasatinib did not inhibit the action of P-gp.  
 
Hegedus et al.[365], suggested that at high micromolar (>2μM) concentrations 
dasatinib may have an inhibitory effect on P-gp. This was shown by fluorescent dye 
extrusion studies monitoring the dye calcein-AM in P-gp over-expressing cell-line. 
Verapamil was used a P-gp inhibitor.  A more recent publication by Dohse et al.[367], 
showed that dasatinib inhibited rhodamine 123 efflux but to a lesser extent than 
nilotinib and imatinib and at higher concentrations.  Interestingly, this group also 
examined also the capability of dasatinib (and nilotinib and imatinib) to compete for 
P-gp binding sites.  Dasatinib was shown to interact at the prazosin binding site of P-
gp, though very weakly, even at high concentrations (20μM).   
 
Drug binding sites in P-gp which are involved in transport are the H site and the R 
site. The H site is selective for Hoeschst 33342 and colchicine[368] and the R site is 
selective for rhodamine 123 and anthracycline[369].  Substrate binding at one site 
stimulates transport at the other site.  Binding at prazosin site is suggested to stimulate 
transport at both the H and R site though is not directly implicated in transport 
itself[370]. 
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Summary 
• In summary dasatinib is a substrate of P-gp and increased cellular expression 
of P-gp increased resistance to dasatinib.   
 
• The addition of elacridar, a P-gp inhibitor, increased the intracellular mass of 
dasatinib accumulated and prevented the active efflux of dasatinib (in efflux 
assays).   
 
• The addition of elacridar was also shown to increase the sensitivity of resistant 
cell-line models to dasatinib, indicating that P-gp and decreased intracellular 
mass has a direct link in resistance to dasatinib.   
 
• Dasatinib does not appear to be a P-gp inhibitor at clinically relevant 
concentrations.  An inhibition of the action of P-gp by dasatinib in the 
literature has only been seen at high dasatinib concentrations.  
 
• Also, the cell-line models used here, with the exception of A549-tax were 
excellent P-gp cell-line models, for the examination of (dasatinib) substrate 
specificity and transport.  
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4.4.1.2. Interaction of dasatinib with BCRP  
As dasatinib is typically employed once there is evidence of imatinib resistance in a 
patient and given that it is known that imatinib resistance can occur through BCRP 
over-expression[170], the determination of the relationship between dasatinib and 
BCRP is of interest and clinically relevant.  
 
Using the resistant BCRP cell-line model DLKP-Sq/Mitox-BCRP, developed through 
exposure of DLKP-Sq cells with mitoxantrone, the effect of BCRP on dasatinib 
transport was examined.  The mass of dasatinib accumulated in the transporter naïve 
DLKP-Sq parental model was substantially more than in the resistant model, Figure 
4-46.  Examination of the mass of dasatinib accumulated over two hours showed a 
fold increase of 10-20 times dasatinib accumulated in the presence of elacridar 
compared to dasatinib alone across the experimental time frame.  The difference in 
accumulated mass in the resistant and parental model (Figure 4-46), as well as 
between the inhibited and non-inhibited resistant cell-line (Figure 4-47) suggest that 
dasatinib is a substrate of BCRP.  From the literature it has been recently shown that 
dasatinib is transported by BCRP[174, 175, 366]. These studies have included in vivo 
studies, as well directional flux assays and over-expressing cell-line models with 
inhibitor. 
 
Also of note is that the increase in accumulated mass from 30 minutes to 120 minutes 
was not significantly different from the first to the last time-point.  While the 
accumulated mass was different in both the inhibited and uninhibited samples this 
trend was the same.  One group has reported that maximum dasatinib uptake occurs 
within 5 minutes[174], whereas other TKIs like imatinib accumulate over two hours.  
Our experiments with dasatinib accumulation would agree with these earlier findings.  
 
In vitro proliferation toxicity assays of DLKP-Sq and DLKP-Sq/Mitox-BCRP for 
dasatinib show similar sensitivities for both cell-lines to the agent, Figure 4-50.  
However, the addition of elacridar (BCRP inhibitor) decreased the IC50 of dasatinib in 
DLKP-Sq/Mitox-BCRP, Figure 4-48.  This indicated that BCRP mediated decrease of 
the intracellular concentration of dasatinib, decreased the effectiveness of the 
dasatinib.  This would indicate that even though the resistant cell-line DLKP-
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Sq/Mitox-BCRP has increased ABC transport protein expression this is not seen in 
the resistance profile.  However, the inhibition of BCRP increased the sensitivity to 
the resistant cell-line to beyond the sensitivity of the parental cell-line.  The DLKP-
Sq/Mitox-BCRP was ultimately more modulatable, as inhibition of the BCRP 
increased the toxicity of dasatinib in DLKP-Sq/Mitox-BCRP, Figure 4-48, beyond 
that of the parental cell-line.  As expected, the addition of a fixed inhibitory 
concentration of elacridar had no effect on the parental cell-line Figure 4-49.  This 
would suggest that up-regulation of ABC transport BCRP is not the only molecular 
change in this cell-line DLKP-Sq/Mitox-BCRP compared to the parental cell-line.   
 
One hypothesis to explain this modulation comes for the agent used to develop 
resistance.  Mitoxantrone is a DNA damaging agent. Previously treatment with DNA 
damaging agents such as cisplatin and temozolomide has been shown to increase the 
levels of phospho-src (p-src)[371, 372]. Src kinase, one of the targets for dasatinib, is 
upstream of the Raf-MEK pathway.  Also, the differential regulation of BCRP by way 
of the MEK-ERK pathway as reported Imai et al.[373]. This group purposed that 
BCRP is transcriptionally up-regulated by inhibition of MEK-ERK-RSK pathway and 
post-transcriptionally down-regulated through an undetermined MEK-ERK-non-RSK 
pathway[373], see Figure 1-5. It is therefore possible, through our results are 
preliminary, to suggest that up-regulation of BCRP as a response to mitoxantrone also 
up- regulated p-src, a target of dasatinib, thus making the resistant BCRP expressing 
DLKP-Sq/Mitox more sensitive to dasatinib when the protecting effect of BCRP was 
negated.  
 
BCRP does not transport taxol, vincristine or verapamil.  However, irinotecan and its 
active metabolite SN-38 are substrates of BCRP[90].  BCRP can have functional 
variants, where by a mutation in the sequence leads to an amino acid substitution. The 
wild-type BCRP has an arginine (R) at position 482.  Two known variants exist; 
variant R482T which has threonine (T) at position 482 and variant R482G where 
position 482 is the amino acid glycine (G).  These variations can lead to functional 
changes.  The wild type BCRP does not transport the anthracycline, epirubicin, where 
as the R482G variant does transport anthracyclines, (Section 1.3.4)[93].  
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Figure 4-51 shows the increase in toxicity of epirubicin in DLKP-Sq/Mitox-BCRP, 
when modulated by the addition of elacridar.  Taxol toxicity was not modulated by 
the inhibition of BCRP (Figure 4-52), while SN-38 toxicity was modulated by 
elacridar addition (Figure 4-53). This suggests that the BCRP over-expressed in this 
cell-line is R482G variant (or other epirubicin transporting variant) not wild type 
BCRP.  
 
The accumulation of epirubicin in the DLKP-Sq/Mitox-BCRP alone or in the 
presence of dasatinib or elacridar showed that elacridar increases the intracellular 
mass of epirubicin, again suggesting that a variant form of BCRP rather than wild 
type.  Dasatinib modulated a small, but significant, decrease in intracellular epirubicin 
at 90 minutes.  The results of in vitro toxicity assays of combinations of epirubicin 
plus dasatinib and SN-38 plus dasatinib showed no additive effective from dasatinib 
in combination with these agents, Figure 4-54 and Figure 4-55.  Hegedus et al., 
showed that dasatinib inhibited BCRP[365].  However, results from that study 
showed that BCRP inhibition by dasatinib occurred at 10μM dasatinib. This was 
above our test range.  Dohse et al.[367], showed that dasatinib exposure (12 hours) 
decreased BCRP surface expression. The authors affirm that 12 hours was selected for 
optimised results but do not state how soon after exposure to dasatinib does 
expression being to decrease, though 1nM dasatinib was potent enough to decrease 
BCRP.  The effect of dasatinib in BCRP may be linked to the decrease in epirubicin 
accumulated after 90 minutes in the presence of 2μM.  
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Summary 
• In summary, dasatinib is a substrate of the ABC transport protein BCRP.   
 
• The inhibition of BCRP by elacridar increased the accumulated intracellular 
mass of dasatinib in BCRP over-expressing cell-line model.  Inhibition of 
BCRP over-expression also modulated the potency of dasatinib, indicating that 
decreased intracellular accumulation results in decreased efficacy of dasatinib.  
 
• In the cell model DLKP-Sq/Mitox-BCRP there does appear to be a change, 
additional to the over-expression of BCRP, through the MEK pathway, though 
this is undefined.  
 
 273
4.4.1.3. Interaction of dasatinib with MRP-1 
To date there has been no connection made in the literature between MRP-1 and 
dasatinib. Here we examined whether dasatinib is a substrate of MRP-1.  Through the 
accumulation of dasatinib in the leukemic cell-line HL-60/S, the parental cell-line, 
and the MRP-1 over-expressing cell-line Hl-60/Adr we looked for any potential 
relationship between dasatinib and MRP-1.  
 
The accumulation assay, Figure 4-57 and the efflux assay, Figure 4-58 showed no 
change in the intracellular mass of dasatinib either as a result of MRP-1 over 
expression or the presence of an inhibitor.  This would indicate that dasatinib is not a 
substrate for MRP-1.   
 
Additionally the accumulation of dasatinib in the presence and absence of the sulindac 
sulphide in the MRP-1 expressing cell-line 2008/MRP-1 was analysed.  This cell-line 
model highly over-expresses MRP-1.  At all concentrations examined (0.1-2μM) the 
accumulation of dasatinib does not appear to be modulated by the expression of MRP-
1 as the inhibition of MRP-1 did not increase the intracellular mass.  
 
This would indicate that dasatinib is not an MRP-1 substrate.   
 
Imatinib was the first generation TKI used in the treatment of CML. Imatinib has 
been showed to be a substrate on MRP-1[167]. Dasatinib is used a second-line 
therapy for treatment of imatinib resistant and imatinib intolerant patients.  In addition 
to its primary use in Acute Myeloid Leukaemia, imatinib is used as a treatment for 
gastrointestinal stromal tumours (GIST). A study by Théou et al.[374], assessed the 
MDR protein expression in GIST.  This study showed that 62% of GIST were 
positive for MRP-1, making the interaction of between dasatinib and MRP-1 
incredibly relevant to treatment options.  
Since dasatinib is not an MRP-1 substrate, dasatinib as a therapy is not likely to be 
affected by the expression of MRP-1 meaning no reduction in therapeutic efficacy 
would be anticipated as a result of active MRP-1 efflux, a common resistance protein 
in GIST.  Dasatinib is also not a substrate for OCT1 (organic cation transporter-1) 
which has been shown to lower the intracellular level of imatinib[176]. 
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Summary 
• In summary dasatinib is not a substrate of MRP-1 ABC transporter.  
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4.4.2. Lapatinib 
4.4.2.1. Interaction of lapatinib with P-glycoprotein 
A549-tax is known to express low levels of P-gp, HL-60/Mdr expresses moderate 
levels of P-gp and DLKP-A highly over expresses this transporter.  Previously work 
by Collins et al.[179], has shown that lapatinib inhibits the action of P-glycoprotein 
and suggests that lapatinib has a high affinity for a binding site affecting transport in 
the protein. Molina et al.[178], have also shown that lapatinib increases the 
accumulation of topotecan, a P-gp and BCRP substrate, in P-gp and BCRP-expressing 
cells.   
 
The levels of lapatinib accumulated can be examined in a multi-dimensional 
approach. That is, the level of accumulation can be examined with respect to exposure 
time or with respect to drug concentration. Here we have chosen a preliminary 
examination of the effect across a concentration range over a period of two hours. 
This fixed time point was chosen to allow sufficient time for any efflux action to be 
seen. Varying the concentration range to the nanomolar exposure range allowed the 
determination of the effect of clinically and sub-clinically relevant concentrations on 
the cell-line models.  
 
The levels of lapatinib accumulated in each P-gp-expressing model were examined 
with reference to its parental, non P-gp expressing, cell-line.  The LC-MS/MS method 
developed in Section 3 was used to quantify the intracellular mass of lapatinib.  
 
In a study carried out by Polli et al.[177], the authors state that lapatinib is substrate 
for the efflux protein P-gp and BCRP, however, the study did not identify the 
concentration of lapatinib used in the substrate assay.  Figure 4-60, Figure 4-63 and 
Figure 4-64 show the level of lapatinib accumulation in A549 compared to A549-tax, 
DLKP compared to DLKP-A and HL-60/S compared to HL-60/Mdr, respectively. 
When examining Figure 4-60, the accumulation profile of lapatinib in A549 vs A549-
tax (non-expressing vs lowly expressing) no significant difference was seen in the 
level of drug accumulated indicating that low levels of P-gp do not affect the 
disposition of lapatinib in vitro.  
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When comparing DLKP and DLKP-A cell-lines in, Figure 4-63, there was also no 
significant difference in the level of lapatinib accumulated between the parental, non-
P-gp-expressing cell-line and the highly over-expressing DLKP-A variant.  Figure 
4-65 showed the efflux profile of lapatinib in P-gp over-expressing DLKP-A. With 
the addition of 0.25μM elacridar, a P-gp inhibitor, it was possible to clearly define if 
lapatinib is a P-gp substrate. Over a two hour incubation period all samples where 
exposed to 2μM lapatinib. Following this exposure step, the lapatinib-containing 
media was removed. The control samples were given fresh media and efflux profile 
was examined over time while the test samples were given media contained the P-gp 
inhibitor (elacridar). The rational behind the experimental design was that by 
inhibiting the pump at a point where the agent was inside the cell one could determine 
the rate and the level of effect the pump has on the transport of the agent out of the 
cell.  By examining the efflux profile of lapatinib in the DLKP-A cell model we can 
see that the inclusion of an inhibitory concentration of elacridar, a specific P-gp 
inhibitor, did not change the efflux profile, Figure 4-65.  This would indicate that 
lapatinib is not a substrate of P-gp. As the efflux profile was examined in the presence 
and absence of elacridar it is possible to say with some level of certainty that the 
presence of a P-gp inhibitor does not prevent the efflux of lapatinib from the cell 
model, therefore lapatinib is not being extruded from the cell by P-gp.  
For completeness, the cell model DLKP was also examined using similar 
methodology, by taking samples at time points to quantify the drug level in the cells, 
Figure 4-66.  Similar to the DLKP-A model, the DLKP cell line showed no difference 
in the level of drug maintained in the cell in the presence or absence of elacridar.  
 
In third cell model Figure 4-63, the leukemic cell-line model HL-60/S, and HL-
60/Mdr-1 no difference was seen in the accumulation of lapatinib in the P-gp over 
expressing HL-60/Mdr-1 model in comparison to the HL-60/S model which does not 
over-express any of the ABC transporters.  
 
The accumulation profiles, the efflux profile and the toxicity assays indicate that 
lapatinib is not a substrate for P-gp.  
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The in vitro toxicity studies showed, in Figure 4-61 and Figure 4-62, the profile of 
lapatinib in combination with elacridar in A549 and A549-tax. The addition of P-gp 
inhibitor elacridar had no effect on the toxicity of lapatinib. This additionally 
indicated that P-gp is not responsible of lapatinib resistance as the inhibition of P-gp 
was ineffective in reducing the resistance to lapatinib. 
 
Figure 4-67 and Figure 4-68 show the effect of the addition of P-gp inhibitor elacridar 
on the toxicity profile of DLKP and DLKP-A. There was no significant difference in 
the percentage cell survival between lapatinib alone and lapatinib in combination with 
elacridar in DLKP. In DLKP-A there was also no significant difference in the 
percentage cell survival between the lapatinib and lapatinib with elacridar. However, 
it still remains clear that, at clinically relevant, concentrations lapatinib is not a P-gp 
substrate. 
 
Several authors have shown that lapatinib inhibits the function of P-gp [178, 179, 375, 
376].  Exposure to lapatinib is also seen to potentiate the expression level of P-gp 
[180].  An accumulation of classic P-gp substrate epirubicin was carried out in Figure 
4-69.  The addition of lapatinib increased the accumulation of epirubicin in the P-gp 
over-expressing cell-line.  The effect of level of inhibition of P-gp can be deduced to 
be similar to the level of inhibition of elacridar similar intracellular masses of 
epirubicin was quantified when either elacridar or lapatinib were used as inhibitors. 
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Summary 
• In summary, it has been shown that lapatinib is not a substrate of the ABC 
transporter, P-gp.   
 
• The cellular expression of P-gp does not increase resistance to lapatinib. We 
have confirmed previous finding that lapatinib inhibits the function of P-gp. 
Therefore, over-expression of the MDR transporter P-gp is unlikely to 
contribute to resistance to lapatinib, though lapatinib did modulate the activity 
of P-gp.  
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4.4.2.2. Interaction of lapatinib with BCRP 
BCRP, breast cancer resistant protein, described in 1998 by Doyle et al.[60], has been 
found in many tissues and cells including the blood brain barrier, intestine and various 
tumours [377].  
 
It addition to its interaction with P-gp, lapatinib has been shown to be a BRCP 
inhibitor [178]. Polli et al.[177], similarly indicated that lapatinib decreased the 
BCRP-mediated transport of cimetidine. However, there is little literature evidence 
clarifying the status of lapatinib as a BCRP substrate. 
 
The leukemic cell-line HL-60-Mxr was used as a BCRP over-expressing model. 
Accumulation assays were carried out across a concentration range, with samples 
taken after a two-hour exposure period. Figure 4-70 shows the accumulation of 
lapatinib in HL-60/S and HL-60/Mxr. A small and insignificant reduction in 
intracellular lapatinib quantified was noted the BCRP over-expressing cell-line 
compared to the parental cell-line.  
 
To examine further the relationship between lapatinib and BCRP, an efflux profile of 
HL-60/Mxr in the presence and absence of elacridar, a BCRP inhibitor, was 
performed,  
Figure 4-71. The similarity of the profile with and without elacridar present suggests 
that lapatinib is not being pumped by BCRP. Also, the lack of maintenance of the 
level of intercellular accumulation in the presence of elacridar suggests that BCRP is 
not responsible for the efflux of lapatinib from the cell.  These results suggest that 
lapatinib is not a substrate of BCRP. 
 
The analysis of the epirubicin accumulation in DLKP-Sq/Mitox-BCRP cell-line 
showed an increased mass of epirubicin as a result of lapatinib inhibition of BCRP at 
90 minutes, Figure 4-72. This indicates that lapatinib may inhibit the BCRP protein. A 
recent publication identifies lapatinib as a BCRP inhibitor, however, 10μM lapatinib 
was required to inhibit BCRP efflux[378].  
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Summary 
• In summary lapatinib is not a substrate of BCRP ABC transporter. 
 
• However, lapatinib does inhibit the action of BCRP after some exposure time.  
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4.4.2.3. Interaction of lapatinib with MRP-1 
The third of the ABC transporters that we focussed on was MRP-1. Also called 
ABCC1, this is the most prominent member of the C branch of the ABC superfamily 
of drug transporters.  Unlike P-gp and BRCP, little has been reported on the 
relationship between MRP-1 and lapatinib.  
 
The leukemic cell-line HL-60-Adr was used as an MRP-1 over-expressing model. 
Accumulation assays were carried out across a concentration range, with samples 
taken after a two-hour exposure period.  Figure 4-74 shows the accumulation of 
lapatinib in HL-60/S and HL-60/Adr. A slightly greater, though not significantly 
greater, mass of lapatinib was accumulated in the MRP-1 over-expressing cell-line 
model, when compared to the parental cell-line.  
 
To examine this further, an efflux profile of HL-60-Adr in the presence and absence 
of sulindac sulphide, a MRP-1 inhibitor was performed. The similarity of the efflux 
profile with and without the inhibitor present suggests that MRP-1 does not play a 
role in the efflux of lapatinib. As such, lapatinib is not a substrate of MRP-1.  
 
Summary 
• In summary, lapatinib was not shown to be a substrate of MRP-1 
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4.5. Overall findings 
• Overall, the LC-MS/MS method developed in Section 3 was used to determine 
the status of dasatinib and lapatinib as substrates of the main ABC transporter 
P-gp, BCRP and MRP-1.   
 
• The analytical method developed was sensitive, robust and reproducible for 
the analysis of clinically relevant concentrations of dasatinib and lapatinib in 
cancer cell-line models.    
 
• The use of a liquid-liquid extraction gave clean extracts, permitted the 
extraction of large batches of samples and amalgamated well with the 
experimental requirements of cell accumulation and efflux assays 
 
• It was possible to use the method developed here to answer questions about 
the pharmacokinetics of these tyrosine kinase inhibitors in vitro.   
 
• Through the quantification of intracellular dasatinib by LC-MS/MS it was 
deduced that dasatinib is a substrate of P-gp and BCRP but not a substrate of 
MRP-1.   
 
• Through the quantification of intracellular lapatinib by LC-MS/MS it was 
deduced that lapatinib is not substrate of P-gp, BCRP or MRP-1, though 
lapatinib does inhibit P-gp and at increased exposure times does have an effect 
on the activity of BCRP 
 
While the work here has been carried out in vitro the clinical implications of this 
study are  
• that as dasatinib is a substrate of P-gp and BCRP its efficacy is more 
susceptible to expression of high levels of these ABC transport proteins. 
Tumoural P-gp overexpression may therefore impact on therapeutic efficacy 
 
• Lapatinib is an inhibitor of P-gp and BCRP.  The incorporation of lapatinib 
into a chemotherapy regime which included a P-gp substrate cytotoxic may 
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alter both anti-tumour efficacy and systemic toxicity (since P-gp plays a 
significant role in the elimination of P-gp substrate agents from the body. 
Careful study may therefore be required to characterise the net effect 
(increased efficacy or increased systemic toxicity) which may result from 
lapatinib-containing regimens.  
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The development and validation of a method for the 
quantification of thalidomide 
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5. The development and validation of a method for 
the quantification of thalidomide 
Introduction 
Thalidomide (α-N-phthalimido –glutarimide), was originally developed and marketed 
as an anti-morning sickness medication in the 1960 but was withdrawn following the 
reported associations with birth defects[249-251].  Decades later, thalidomide 
approved as treatment for multiple myeloma, based on a randomized clinical trial 
conducted by the Eastern Oncology Group[379].   
 
Many cancer drugs are administered in a patient-normalised manner by dosing as a 
mass per unit body surface (BSA), mg/m2 or mg/kg to reduce side effects and to 
increase efficacy.  For example carboplatin is administered based on an area under the 
curve (AUC) calculation[380].  Epirubicin and other chemotherapy drugs are 
administered as mg/m2[70]. 
 
However, thalidomide is administered to patients as a fixed dose (mg/day) rather than 
as a function of the patient specific criteria.  
 
One of the side effects reported by patients receiving thalidomide is a sensation of 
tingling in the fingers and toes, which, if left untreated this can deteriorate into a 
serious condition called peripheral neuropathy.  Peripheral neuropathy is characterised 
by paraesthesia in the hands and feet.  Treatment of peripheral neuropathy is dose 
reduction, with some research suggesting that thalidomide therapy should be limited 
to less than 6 months.  This however, is likely to significantly impact response[268].  
 
While dose reduction has been shown to improve peripheral neuropathy, no 
correlations have been made between patient serum levels, patient doses and 
neuropathy experienced.  
 
The aim of this body of work is to develop a method for the accurate quantification of 
thalidomide in the serum of multiple myeloma patients as prelude to attempts to 
investigate potential correlations between circulating levels and toxicity.   
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5.1. LC separation optimisation 
Designing an LC method for the chromatographic separation of thalidomide involved 
examining a variety of components, columns, internal standard and mobile phase 
considerations.  The results are detailed in this section.   
 
5.1.1. Thalidomide lenalidomide separation 
5.1.1.1. Internal standard selection 
Tohnya et al.[381], detailed an LC-MS method for the quantification of lenalidomide, 
(CC-5013) an analogue of thalidomide, by reverse phase separation with tandem mass 
spectrometry.  The authors used umbelliferone as an internal standard for 
lenalidomide.  However, within the paper the authors mention their attempts to use 
thalidomide as an internal standard were unsuccessful due to poor peak shape.  
 
With lenalidomide being used in a similar manner to thalidomide, and in some cases 
replacing the older drug, a dual method for the quantification of both thalidomide and 
lenalidomide would be highly advantageous and the method development initially 
focussed on this goal. 
 
5.1.1.2. Separation optimisation 
Methods by both Teo et al.[273], and Meyring et al.[382], detailed LC methods for 
thalidomide analysis, using 0.1% (v/v) acetic acid as mobile phase A, the aqueous 
component of the mobile phase.  During the optimisation of thalidomide ionisation by 
flow injection analysis (detailed in Section 5.3) it was seen that acetic acid gave a 
high background in the Total Ion Count. 
 
Given the compatibility of formic acid with mass spectrometry, mobile phase A was 
changed to 0.1% (v/v) formic acid/water and mobile phase B to 0.1% (v/v) formic 
acid/ACN.  
 
Using a small reverse phase column (YMC-UltraHT Pro C18, 50 x 2.0mm I.D. 2μm 
particle size), a gift from Apex Scientific Ltd, the separation of thalidomide and 
lenalidomide was investigated.  Given the similar nature of the agents and the 
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properties of the column used, a gradient elution approach was explored.  Gradient 
elution generally involves increasing of the organic modifier in the mobile phase 
dynamically over time.  One of the disadvantages of gradient elution is the time 
required to re-equilibrate the column to the starting conditions after the run, necessary 
to ensure a reproducible quantification in subsequent runs.  Both the time required to 
re-equilibrate the column after injection and the injection volume were found to have 
an important impact on the development procedure.  The re-equilibration time is the 
time required for the column to return to the starting conditions.  Incomplete re-
equilibration affects the partitioning of the analyte between the stationary and mobile 
phase and thus affects the separation, Figure 5-2.  
 
Peak fronting and peak tailing are the distortion of what should normally be a 
Gaussian peak shape of the analyte in its path through the column.  Peak fronting is 
predominantly the result incomplete interaction of the solute with the stationary phase 
resulting in the solute eluting slightly before to the main peak.  The column may 
become over-loaded by injecting sample too large to be accommodated by the 
column, as shown in Figure 5-1, in the peak at 5.8 minutes.  The solute begins to elute 
from the column at approximately 4.8 minutes, in comparison to the peak at 6.8 
minutes which has a baseline peak width of approximately 0.2 minutes. 
 
Figure 5-2 and Figure 5-4 are examples of the optimisation of a gradient elution 
method for the separation of thalidomide and lenalidomide. Given with each 
chromatogram are the specific pump settings for the run.  
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Figure 5-1: Representation chromatogram of thalidomide and lenalidomide demonstrating of column overloading 
 
Figure 5-1 is a representative TIC trace of lenalidomide and thalidomide separation showing column overloading, peak at 5.8 minutes.  A sample 
volume of 10μL was injected. 
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Figure 5-2 shows the separation of lenalidomide and thalidomide by gradient elution 
as described in Table 5-1.  Sample A and B were exactly the same sample, run 
sequentially.  The compound which eluted first in both chromatograms, A and B, was 
lenalidomide.  
As seen in Figure 5-2 the column does not re-equilibrate before the beginning of the 
second injection (B) and the separation and peak shapes are completely distorted.  The 
inability of the column to re-equilibrate in the time frame distorted the separation of 
the two analytes.  Lenalidomide is more severely affected by this lack of re-
equilibration. 
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Figure 5-2: Illustration of the effect of the failure to achieve column equilibration 
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Figure 5-2 illustrates the effect of poor column equilibration on separation.  These samples were run 
sequentially from the same vial.  Trace A shows the retention time of lenalidomide to be 4.28mins and 
thalidomide to be 5.69 minutes.  Trace B was run immediately after sample A. 
 
 
Table 5-1: Pump profile for 
gradient elution 
Time 
(mins) % B
0 0 
1 0 
7 60 
7.1 100 
8.0 100 
8.1 0 
Table 5-1 shows gradient 
profile of the method.  The 
stop time was set to 9 
minutes. 
B 
A 
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By reducing the injection volume and adjusting the gradient profile a stable repeatable 
separation method was achieved.  Figure 5-3 shows an optimised gradient elution of 
lenalidomide and thalidomide separation on a reverse phase column.  Table 5-2 
details the pump setting to control the creation of the gradient profile.  The injection 
volume was reduced to 5μL and this was seen to have a significant effect on the peak 
shape.  
 
The resolution of lenalidomide and thalidomide was calculated to be 2.2.  The 
resolution, a unit-less factor, was calculated based on the peak width at baseline as 
described in the equation in Figure 5-3, where Rs is the resolution, t2 is the retention 
time of peak 2 (thalidomide), t1 is the retention time of peak 1 (lenalidomide), W1 
and W2 it the width of lenalidomide and thalidomide respectively, measure at the 
baseline, as described previously Figure 3-5, Section 3.1.2. 
 
Figure 5-3: Resolution equation 
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The symmetry factor for lenalidomide was determined to be 1.6 while the symmetry 
factor for thalidomide was determined to be 1.13.  The symmetry factors were 
determined by the Masshunter Quantification Analysis Software (Version B.01.04), 
whereby the symmetry of the peak was computed as the ratio between the front half-
width and the back half-width.    
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Figure 5-4: Representation trace of the separation of thalidomide and lenalidomide     Table 5-2: Pump profile for 
gradient elution 
Time 
(mins) % B 
0 0 
0.5 0 
4.5 60 
5 100 
5.5 100 
6 0 
Table 5-2 shows gradient profile of 
the method.  The pump flow was 
0.5mL/min.  The stop time was set 
to 9 minutes. 
 
 
 
 
Figure 5-4 shows the separation of lenalidomide and thalidomide by gradient elution on YMC 50 x 2.0mm, 2μm particle size C18 column. Flow 
was 0.5mL/min and the gradient was as described in Table 5-2.  Injection volume was 5μL. 
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However, despite good separation, good resolution, and acceptable asymmetry 
factors, the requirement of such a low injection volume was considered to be an 
unacceptable limitation of the method. 
 
Also given the ambition to use thalidomide as an internal standard for lenalidomide, 
and vice versa, the use of an isocratic separation makes the validation more 
straightforward.  In an isocratic elution scenario the column is in a state of constant 
equilibration and as such the ionisation of the analytes is consistent.  Therefore, it is 
acceptable to quantify by the peak area ratio of the analyte of interest to the internal 
standard, providing validation was successful.  
 
The separation of lenalidomide and thalidomide was investigated on a C18 Prodigy 
4.6 x 150mm 5μm particle size column from Phenomenex (Pangbourne, UK) under 
isocratic flow at 0.5mL/min. 
 
The aqueous phase, mobile phase A, was 0.1% (v/v) formic acid in water, and mobile 
phase B was 0.1% (v/v) formic acid in ACN.  In Figure 5-5, the effect of altering the 
mobile phase composition was seen.  Lenalidomide elutes before thalidomide in all 
cases.  The peak shape of lenalidomide was affected by the mobile phase composition, 
where as the retention time of thalidomide in addition to the peak shape was 
significantly affected by the mobile phase composition.  
 
All samples in Figure 5-5 were 10μL injections.  Given the experience of the effect of 
injection volume on peak shape on the YMC 50mm x 2.0mm column it was important 
to explore the effect of injection volume on the peak shape on the larger Prodigy 
150mm x 4.6mm column from Phenomenex.  
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Figure 5-5: Effect of mobile phase composition on retention time 
 
Figure 5-5 shows the overlaid chromatograms of three injections of lenalidomide 
thalidomide mix at different mobile phase compositions.  
 
 
Table 5-3: Mobile phase composition 
Label MP composition 
A 50% B 
B 40% B 
C 30% B 
Table 5-3 shows the mobile phase composition of figure 5-5.  Mobile phase A was 
0.1% (v/v) formic acid/water.  Mobile phase B was 0.1% (v/v) formic 
acid/acetonitrile. 
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In Figure 5-6 the effect of the injection volume on the peak shape of lenalidomide and 
thalidomide is examined.  All injections were performed at isocratic elution at 50% 
(v/v) ACN/water, 0.1% formic acid.  
 
While the 10μL injection gives the chromatographically optimum separation, this is 
not the most practical option.  The injection volume of 20μL was selected as the peak 
characteristics were acceptable and the large injection volume allows for more 
accurate reconstitution of samples in LC vials and a reduction in sample loss.  
 
Thalidomide and lenalidomide separation was achieved on Prodigy C18 150mm x 
4.6mm 5μm particle size column with isocratic elution at 50% (v/v)ACN/water, 0.1% 
formic acid, with a 20μL injection volume.  
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Figure 5-6:  Effect of injection volume on peak shape 
 
Figure 5-6 shows three TIC traces for lenalidomide and thalidomide separation on a 
Prodigy 4.6 x 150mm, 5μm particle size, column at 50% B.  All injection conditions 
are identical except the injection volume.  
 
 
Table 5-4: Effect of injection volume on peak symmetry 
# Inj. Vol. Peak RT Area Width Symmetry 
A 10μL 
1 - Lenalidomide 3.20 120232 0.12 1.21 
2 - Thalidomide 4.78 10882 0.16 0.51 
B 20μL 
1 - Lenalidomide 3.21 242187 0.13 1.11 
2 - Thalidomide 4.76 21999 0.21 1.38 
C 30μL 
1 - Lenalidomide 3.23 361149 0.12 1.45 
2 - Thalidomide 4.77 31979 0.24 1.13 
Table 5-4 gives the details of the peak characteristics as determined by the 
Masshunter Qualitative Analysis Software, (Version B.01.03).  
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5.1.2. Thalidomide umbelliferone separation optimisation 
Chromatographically, lenalidomide was a good internal standard for thalidomide and 
vice versa, however, examinations of the extraction properties of both analytes 
revealed differences in chemical properties.  Lenalidomide had significantly different 
extraction properties compared to thalidomide.  This made it unusable as an internal 
standard for thalidomide.  
 
5.1.2.1. Internal standard selection 
Umbelliferone has been used as the internal standard for lenalidomide quantification 
and was evaluated as an internal standard for thalidomide[381]. 
 
5.1.2.2. Separation optimisation 
Five columns were evaluated for the separation of umbelliferone and thalidomide.  
• Agilent XBD C18, 50mm x 4.6mm, 1.8μm particle size 
• Agilent C18 Eclipse, 150mm x 4.6mm, 5μm particle size 
• ZORBAX SB-Phenyl, 150mm x 2.1mm, 5μm particle size 
• Phenomenex Prodigy C18, 150mm x 2mm, 5μm particle size 
• Phenomenex Prodigy C18, 150mm x 4.6mm, 5μm particle size 
 
 
NOTE: For all separation optimisations detailed for each column, mobile phase A was 
0.1% (v/v) formic acid/water and mobile phase B was 0.1% (v/v) formic acid/ACN.  
A mixture of thalidomide umbelliferone was prepared at 250ng/mL of each agent.  
The ratio of mobile phase A/B was altered in the optimisation as specified in each 
section.  Mobile phase flow rate is also specified for each column investigated. 
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Column 1 - Agilent XBD C18 4.6 x 50, 1.8μm 
The Agilent XBD C18 4.6 x50mm column is a small wide column with small particle 
size (1.8μm), capable of sustaining backpressure of up to 400bar.  Figure 5-7 shows 
the separation of umbelliferone and thalidomide and the effect of varying mobile 
phase composition.  The pump was run as 1mL/min with isocratic elution.  
 
Outlined in Table 5-5 are the details of the mobile phase composition and the 
injection volume for each injection in Figure 5-7. 
 
Figure 5-7: Umbelliferone thalidomide separation 
 
Figure 5-7 shows the separation of umbelliferone and thalidomide on the Agilent 
XBD 4.6 x 50mm column.  
 
Table 5-5: Details of samples in figure 5-7 
 % B Inj. Vol. ( μL)   % B Inj. Vol. ( μL) 
A 20 10  D 28 10 
B 26 10  E 28 5 
C 26 5  F 30 10 
Table 5-5 shows the conditions for each injection in Figure 5-7 where A = 0.1% (v/v) 
formic acid/water and B =0.1% (v/v) formic acid/ACN 
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Column 2 – Agilent Eclipse 4.6 x150mm, 5μm 
The Eclipse 4.6mm x 150mm column is a standard length wide internal diameter C18 
reverse phase column.  
Figure 5-8 shows the separation of umbelliferone and thalidomide and the effect of 
varying mobile phase composition.  The pump was run as 0.5mL/min with isocratic 
elution.  
 
Figure 5-8: Umbelliferone thalidomide separation  
 
Figure 5-8 shows the difference in separation of umbelliferone and thalidomide in 
three injections of the same sample mix at different mobile phase mixtures.  
 
 
Table 5-6: Details of samples in Figure 5-8 
 % B Inj. Vol. ( μL) 
A 30 20 
B 40 20 
C 50 20 
Table 5-6 shows the conditions for each injection in Figure 5-8 where A = 0.1% (v/v) 
formic acid/water and B =0.1% (v/v) formic acid/ACN 
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Column 3 - ZORBAX SB-Phenyl 2.1 x 150mm, 5μm 
Given that both thalidomide and umbelliferone have ring components in their 
structures (see Appendix I), a column with a phenyl functional group was explored.  
Figure 5-9 shows the separation of umbelliferone and thalidomide on a Zorbax phenyl 
column.  Mobile phase composition was altered as detailed in Table 5-7. 
 
Figure 5-9: Umbelliferone thalidomide separation  
 
The effect of varying mobile phase composition on the retention and separation of 
umbelliferone and thalidomide 
 
Table 5-7: Details of run conditions in Figure 5-9 
 
 % B Inj. Vol. ( μL)   % B Inj. Vol. ( μL) 
A 20% 10  D 26% 10 
B 22% 10  E 26% 5 
C 24% 10  F 30% 10 
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Column 4- Phenomenex Prodigy C18 150 x 2mm, 5μm 
The Phenomenex Prodigy C18 is a standard length narrow reverse phase column. 
Shown in Figure 5-10 is the separation of umbelliferone and thalidomide on the 
prodigy 150 x 2.0mm column, with isocratic elution at 0.2mL/min. 
 
Figure 5-10: Umbelliferone thalidomide separation  
 
Figure 5-10 shows the separation of umbelliferone and thalidomide at mobile phase 
compositions ratio varying from 20% to 26%B. Alternation of injection volume was 
also seen to have an effect. 
 
Table 5-8: Details of run conditions in figure 5-10 
 % B Inj. Vol. ( μL)   % B Inj. Vol. ( μL) 
A 20% 10  E 24 20 
B 22% 10  F 26 10 
C 22% 20  G 26 20 
D 24 10     
Table 5-8 shows the conditions for each injection in Figure 5-10 where A = 0.1% 
(v/v) formic acid/water and B =0.1% (v/v) formic acid/ACN 
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Column 5 - Phenomenex Prodigy C18 150 x 4.6mm, 5μm 
Figure 5-11 shows the separation of umbelliferone and thalidomide and the effect of 
varying mobile phase composition. The pump was run as 0.5mL/min with isocratic 
elution.  
Only one peak (umbelliferone) appears in the sample A as the retention time of the 
second peak (thalidomide) was later than the run stop time of 20 minutes. 
 
A mobile phase mixture of between 20% and 30% B (A =0.1% (v/v) formic 
acid/water and B = 0.1% (v/v) formic acid/ACN) appears to be the area of interest and 
the optimum separation – with good baseline resolution, acceptable peak shape and 
appropriate injection volume for the application. 
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Figure 5-11: Umbelliferone-thalidomide separation  
 
Figure 5-11 shows the separation of umbelliferone and thalidomide at mobile phase 
composition ranging from 20% to 60% mobile phase B. 
 
 
Table 5-9: Details of run conditions in Figure 5-11 
 % B 
Inj. Vol. 
( μL) 
A 20% 10 
B 30% 10 
C 40% 10 
D 50% 10 
E 60% 10 
Table 5-9 shows the conditions for each injection in Figure 5-11 where A = 0.1% 
(v/v) formic acid/water and B =0.1% (v/v) formic acid/ACN 
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Figure 5-12 shows the separation at 24%/0.1% (v/v) ACN/FA/water and the effect of 
varying the injection volume on the peak shape. Table 5-10 details the peak 
characteristics of Figure 5-12. 
 
Sample A has good baseline separation and peak shape but a long retention time. 
Sample B has baseline separation but a deteriorating peak shape. Sample C is assessed 
a single peak by the software due to the lack of baseline separation.  
 
Figure 5-12: Umbelliferone thalidomide separation at 24% mobile phase B 
 
Figure 5-12 shows the retention time of umbelliferone and thalidomide at 24% 
mobile phase B and at 10μL, 20μL and 30μL injections.  
 
Table 5-10: Peak characteristics at 24% mobile phase B 
 
Inj. Vol. 
( μL) Peak RT Area Symmetry 
A 10 
1-Umbelliferone 11.85 11780 1.23 
2-Thalidomide 15.39 10406 0.67 
B 20 
1-Umbelliferone 11.81 21079 1.57 
2-Thalidomide 15.37 18402 1.45 
C 30 -no separation- 11.81 64025 1.25 
Table 5-10 gives the injection volume (μL) and the subsequent retention times, areas 
and peak symmetry for separation at 24% mobile phase B, was determined by the 
Masshunter Qualitative Analysis Software, (Version B.01.03). 
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Figure 5-13 shows the separation at 28%mobile phase B (A = 0.1% (v/v) formic 
acid/water mobile phase B = 0.1% (v/v) formic acid/ACN) and the effect of varying 
the injection volume on the peak shape.  Table 5-11 details the peak characteristics of 
Figure 5-13.  
 
Both samples A and B have good baseline separations and peak shapes.  Sample C is 
assessed a single peak by the software due to the lack of baseline separation.  
 
Figure 5-13: Umbelliferone thalidomide separation at 28% B 
 
Figure 5-13 shows the retention time of umbelliferone and thalidomide at 28%B and 
at 10μL, 20μL and 30μL injections.  
 
Table 5-11: Peak Characteristics at 28% B 
 Inj. Vol. ( μL) Peak RT Area Symmetry 
A 10 
1-Umbelliferone 8.98 15393 1.07 
2-Thalidomide 10.95 12772 1.64 
B 20 
1-Umbelliferone 8.96 22150 1.23 
2-Thalidomide 10.9 17846 1.28 
C 30 -no separation- 9.03 83964 0.87 
Table 5-11 gives the injection volume (μL) and the subsequent retention times, areas 
and peak symmetry for separation at 28%B, was determined by the Masshunter 
Qualitative Analysis Software, (Version B.01.03). 
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Figure 5-14 shows the separation at 30%B (A = 0.1% (v/v) formic acid/water mobile 
phase B = 0.1% (v/v) formic acid/ACN) and the effect of varying the injection 
volume on the peak shape.  Table 5-12 details the peak characteristics of Figure 5-14.  
 
Both samples A and B have good baseline separations and peak shapes. Sample C is 
assessed a single peak by the software due to the lack of baseline separation.  
 
Figure 5-14: Umbelliferone thalidomide separation at 30% B 
 
Figure 5-14 shows the retention time of umbelliferone and thalidomide at 30%B and 
at 10μL, 20μL and 30μL injections.  
 
Table 5-12: Peak Characteristics at 30% B 
 
Inj. Vol. 
( μL) Peak RT Area Symmetry 
A 10 
1-Umbelliferone 8.11 15615 0.96 
2-Thalidomide 9.62 12483 1.02 
B 20 
1-Umbelliferone 8.1 22984 1.29 
2-Thalidomide 9.53 19500 0.88 
C 30 -no separation- 8.1 87290 0.74 
Table 5-12 gives the injection volume (μL) and the subsequent retention times, areas 
and peak symmetry for separation at 30%B, was determined by the Masshunter 
Qualitative Analysis Software, (Version B.01.03). 
 
 
2x10
2.5
5
7.5
+ TIC MRM (** -> **) TU_06-r001.d  
8.11
9.62
1 1
2x10
5
+ TIC MRM (** -> **) TU_06-r003.d  
8.10
9.53
1 1
3x10
0.5
1
+ TIC MRM (** -> **) TU_06-r002.d  
8.101 1
Counts vs. Acquisition Time (min)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
B 
A 
C 
 307
Figure 5-15 shows the separation at 32%B (A = 0.1% (v/v) formic acid/water mobile 
phase B = 0.1% (v/v) formic acid/ACN) and the effect of varying the injection 
volume on the peak shape. Table 5-13 details the peak characteristics of Figure 5-15. 
 
Sample A has good symmetry but barely has baseline separation. Sample B does not 
achieve baseline separation and sample C is assessed a single peak by the software 
due to the lack of baseline separation.  
 
Figure 5-15: Umbelliferone thalidomide separation at 32% B 
 
Figure 5-15 shows the retention time of umbelliferone and thalidomide at 32%B and 
at 10μL, 20μL and 30μL injections.  
 
Table 5-13: Peak Characteristics at 30% B 
 
Inj. Vol. 
( μL) Peak RT Area Symmetry 
A 10 
1-Umbelliferone 7.4 12610 0.88 
2-Thalidomide 8.58 9291 0.81 
B 20 
1-Umbelliferone 7.39 24926 2.14 
2-Thalidomide 8.53 18036 1.7 
C 30 -no separation- 7.43 64440 0.82 
Table 5-13 gives the injection volume (μL) and the subsequent retention times, areas 
and peak symmetry for separation at 32%B, was determined by the Masshunter 
Qualitative Analysis Software, (Version B.01.03). 
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• Column 5 - Phenomenex Prodigy C18 150 x 4.6mm, 5μm particle size, with a 
mobile phase of 70% (v/v) water/ACN, 0.1%FA, with a 20μL injection 
volume was selected as the optimum separation criteria.(Figure 5-14, 
chromatogram B). 
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5.2. Extraction optimisation 
An extraction procedure is employed to remove analyte from the matrix containing 
the agent of interest, e.g. serum, prior to analysis by LC-MS. Removing the target 
analyte from the biological matrix gives cleaner samples, improved sensitivity and 
prolongs the life-time of the analytical equipment. 
 
Initial experiments varied many conditions including the samples volume, the 
extraction solvent, the extraction solvent volume and the aqueous component of the 
liquid-liquid extraction. The development process and the findings of the optimisation 
processes are outlined below.  
 
The primary focus of the extraction optimisation process is to remove biological 
materials (serum) prior to quantification by LC-MS to yield cleaner samples. Liquid-
liquid extraction was chosen to investigate due the suitability of this method for drug 
extraction from a wide variety of biological matrices.  Preliminary experiments 
examined the extraction potential of each solvent on 1mL of spiked serum sample.  
Samples were spiked with 20ng of thalidomide and 20ng of lenalidomide (serum 
concentration 20ng/mL). A volume of 2.5mL of solvent was used in the extraction.  
The recovery was calculated based on the peak area of the extracted sample compared 
to the peak area of a pure drug calculated to be equal to 100% recovery. 
 
Some of the extraction solvents examined were less suitable for the extraction 
process.  These are marked in Table 5-14.  The technical challenges generally 
involved the lack of formation of a distinct discrete solvent layer.  In the samples 
marked, either no discernible layer was formed or the solvent layer volume was less 
than expected.  
 
The startling poor recovery of lenalidomide highlighted the differences in the 
extraction profile of both analytes and the requirement of an alternative internal 
standard, as described in Section 5.1.2.  
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Table 5-14: Preliminary examination of a range of solvents 
Extraction 
Solvent 
Thalidomide Lenalidomide 
Comments
% 
Recovery SD 
% 
Recovery SD 
Control 100.0 2.7 2.7 100.0  
t-BME 70.9 1.9 2.6 4.4  
Chloroform* 81.2 3.3 4.0 9.9 unsuitable 
Dichloromethane* 87.4 1.5 1.7 7.1 unsuitable 
Ethyl Acetate 83.4 4.6 5.5 14.7  
Chloro-1-butane - -  - 
no layer 
formed 
t-BME/ACN (1:1) 69.4 4.7 6.8 13.8  
Chloroform/ ACN* 
(1:1) 97.6 7.8 7.9 17.1 unsuitable 
Dichloromethane/ 
ACN (1:1) - -   
no layer 
formed 
Chloro-1-butane/ 
ACN (1:1) 109.7 6.4 5.9 8.0  
Chloro-1-butane/ 
ACN (1:4) 98.6 7.8 8.0 17.3  
Ethyl Acetate/ ACN 
(1:1) 76.8 2.2 2.8 27.4  
Table 5-14 shows the effect of a range of solvents on the recovery of thalidomide and 
lenalidomide. The recovery was calculated based on the peak area of the extracted 
sample compared to the peak area of a pure drug calculated to be equal to 100% 
recovery. Data shown is the average of triplicate intra-day samples, unless indicated, 
* indicates n=2.  
Solvents highlighted in yellow were carried forward for further examination.  
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Combinations of ACN with ethyl acetate, chloro-1-butane and tBME were then 
examined further. Each solvent mixture was prepared first and mixed well before 
adding to the spiked sample. The sample volume was reduced to 0.5mL and 2.4mL of 
solvent was added to the samples. Samples were spiked with 10ng of thalidomide 
(20ng/mL).
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Figure 5-16: The effect of solvent ratios on thalidomide recovery 
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Figure 5-16 shows the effect of varying ratio of solvent with ACN. The recovery was calculated based on the peak area of the extracted sample 
compared to the peak area of a pure drug calculated to be equal to 100% recovery. The red bar (R) illustrates the recovery sample. Data shown 
is the average of triplicate intra-day samples. 
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Initial experiments were carried out with serum only.  However, all clinical samples 
were stored 1:1 (v/v) with citrate buffer (25mM sodium citrate, pH1.5).  Thalidomide 
is known to be unstable at physiological pH in aqueous conditions.  The acidification 
of the samples through the addition of a buffer has been shown to increase sample 
stability [282]. 
Therefore, the effect of citrate buffer on the recovery potential of thalidomide was 
assessed.  Figure 5-17 shows the effect of citrate buffer on extraction recovery.  A 
sample volume of 500μL of serum was used in the serum-only arm of the experiment, 
in the serum/water arm 500μL of serum and 500μL of water was used and in the 
citrate arm 500μL of serum and 500μL of citrate. The serum-only arm was included 
to maintain continuity with previous experiments. The serum/water arm was included 
to account for any differences attributed to additional volume. 
 
The extraction solvents of chloro-1-butane/ACN (4/1, v/v) and ethyl acetate/ACN 
(3/1, v/v) gave the best recovery of recovery when combined with the citrate buffer.  
 
These two solvent mixture and a mixture of tBME/ACN (3/1, v/v) was carried 
forward and the recovery was assessed over a thalidomide concentration range. All 
samples were prepared as serum/citrate (1/1, v/v) 
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Figure 5-17: The effect of citrate buffer on extraction efficiency  
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Figure 5-17 shows the effect of citrate on the extraction efficiency of each solvent. The data shown is the average and standard deviation, n=6.  
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The two solvent mixture, CB/ACN (4/1, v/v), EA/ACN (3/1, v/v) and the mixture of 
tBME/ACN (3/1, v/v) were carried forward and examined in more detail.  The 
recovery of thalidomide was assessed over a concentration range to verify that the 
recovery was dynamic across the range.  All samples were prepared in serum/citrate 
(1/1, v/v) 
 
The extraction solvent mixture of EA/ACN (3/1, v/v) was selected as the most 
appropriate solvent combination. The average recovery across the concentration range 
was 100.2% with a percent standard deviation of 3.2%. ACN/CB gave lower 
recoveries, especially at the lower concentrations examined. ACN/tBME also gave 
good recoveries, with an average recovery of 99% with a 5% deviation.  
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Figure 5-18: Recovery of thalidomide across a drug concentration range 
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Figure 5-18 shows extraction efficiency of thalidomide in three solvent mixes. The red bar indicates the recovery samples which were calculated 
to be equivalent to 100% extraction.  Data indicates average and standard deviation, n=3.  
 317
As discussed above (Section 5.1.2) umbelliferone was selected as an internal standard 
for thalidomide. The recovery of umbelliferone was assessed in the solvent mixtures 
above also. The samples were spiked with 10ng of umbelliferone in ACN (50μL of 
200ng/mL). Table 5-15 outlines the recovery of umbelliferone with the three solvent 
mixes examined.  
 
Table 5-15: The recovery of internal standard, umbelliferone 
Solvent 
% 
Recovery 
% 
Dev 
Recovery 100.0 2.3 
CB/ACN 4/1 120.4 2.9 
EA/ACN 3/1 114.2 5.6 
tBME/ACN 3/1 119.2 8.3 
Table 5-13 gives the recovery of umbelliferone Data is given as the percentage 
recovery assuming calculated recovery sample is 100%, n=12 for extracted samples. 
 
 
EA/ACN (3/1, v/v) gave the best recovery of the three solvents for thalidomide, 
however, the recovery for the internal standard umbelliferone was slightly high. The 
recovery of umbelliferone was examined across a concentration range. A volume of 
500μL of sample (serum/citrate 1/1, v/v) was spiked with 50μL of varying 
concentration of umbelliferone, Figure 5-19.  
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Figure 5-19: Umbelliferone recovery in EA/ACN (3/1, v/v) extraction  
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Figure 5-19 shows the extraction of umbelliferone at a range of concentrations of internal standard. Spike mass of 30ng, or 50μL of 600ng/mL 
was selected as the internal standard.  Data indicates average and standard deviation, n=3. 
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The recovery of thalidomide was also assessed across a wider concentration range. A 
sample volume of 500μL of sample, which is 250μL of serum, was spiked with 50μL 
of thalidomide in acetonitrile.  Figure 5-20 gives the recovery of thalidomide across a 
serum concentration range of 1000ng/mL to 1ng/mL.  The average recovery across 
the concentration range was 113% +/- 7%.  The extraction solvent was fixed as 
EA/ACN (3/1, v/v). 
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Figure 5-20: Thalidomide recovery  
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Figure 5-20 shows the recovery of thalidomide across a concentration range. Data shown is the average and standard deviations, of triplicate 
determinations.  
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5.3. MS detection conditions 
The optimum multi-reaction monitoring (MRM) settings were determined for 
thalidomide and umbelliferone, as well as for the additional multiple myeloma 
therapies. Table 5-17 gives the transitions from precursor to product ion as well as the 
optimum fragmentor voltage and optimum collision energy identified for each 
analyte.  All detected transitions were monitored for each agent as additional qualifier 
ions add specificity. The quantifier ions are indicated in the table with an asterisk. 
 
5.3.1. Precursor ion determination 
Initial precursor determination of thalidomide was more complicated than any of the 
other agents tested and as such the process for the determination of thalidomide MS 
detection conditions is outlined here. The other compounds mentioned were 
determined in a similar fashion to dasatinib, as described in Section 3.3.  
 
Routinely the precursor ion is determined by the flow injection analysis of a 
250ng/mL solution of the analyte of interest in acetonitrile. The precursor ion for 
thalidomide is 259m/z. This is the thalidomide ion in its protonated state [M+H+]. 
However, the determination of the thalidomide precursor ion proved consistently 
difficult to isolate in the MS2Scan by flow injection analysis. Therefore, it was 
decided to investigate and confirm the exact mass of the precursor ion by infusion of 
thalidomide directly into the source using a tee-pieced infusion pump. This is set up 
similarly to the assembly described in figure 3-17, however, only mobile phase 
flowed from the LC, the analytical column was by-passed and no injections were 
preformed by the autosampler.  Screenshots were taken of the real-time scans.  
 
Figure 5-21 shows the real-time MS scan of thalidomide infusion.  
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Figure 5-21: Real-time screenshot of infusion of thalidomide 
 
Figure 5-21 shows a real time screenshot of an infusion of thalidomide, 250ng/mL at 
a rate of 50μL/min. 
 
Owning to the significant level of interfering ions present in the scan (Figure 5-21), a 
scan of the background was taken, where nothing was infused through the pump and 
only mobile phase flowed through the LC system (Figure 5-22). 
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Figure 5-22: Real-time screenshot of background from mobile phase 
 
Figure 5-22 shows the background ion attributed to the mobile phase and system.  
 
Figure 5-22 indicated that the level of interfering ions seen in Figure 5-21were due to 
the thalidomide solution. By preparing fresh stocks of thalidomide, in acetonitrile 
from a newly opened bottle, in new glassware, the precursor ion was determined to be 
259.1m/z. 
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Figure 5-23: Real-time screenshot of fresh thalidomide infusion  
 
Figure 5-23 shows the MS2Scan from 200 – 280m/z. The thalidomide precursor ion 
was identified at 259.1m/z 
 
Figure 5-24: Real-time screenshot of fresh thalidomide infusion  
 
Figure 5-24 shows the MS2Scan scanning from 200-400m/z thalidomide precursor ion at 
259m/z. The ion at 282m/z is present in the background scan and can be disregarded as 
not from the sample.  
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Once the precursor ion had been confirmed the experiment was repeated using flow injection analysis and freshly prepared solutions.  
Figure 5-25: TIC of MS2Scan of thalidomide 
 
Figure 5-25 shows the TIC as detected in MS2Scan mode for six injections of thalidomide by Flow Injection Analysis (FIA) 
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Figure 5-26: Extracted MS Spectrum 
 
Figure 5-26 shows the MS spectrum of thalidomide extracted from the TIC (the greyed out section). The predominant ion, a protonated 
thalidomide ion, determined to be 259.1 m/z, is annotated (*). This is the precursor ion. 
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5.3.2. Fragmentor voltage optimisation 
As explained in Section 3.3.2, the fragmentor voltage is a setting of the MS which acts almost like a filter, the objective being to increase the 
number of precursor ions entering the first quadrupole. The thalidomide ion is monitored in SIM mode. The voltage setting with the maximum 
peak area for the precursor ion is the optimum. Each setting was analysed in duplicate. 
 
Figure 5-27: Fragmentor voltage optimisation 
 
Figure 5-27 shows the TIC for 259.1m/z. in selected ion monitoring (SIM) mode with increasing fragmentor voltage  
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Table 5-16: Peak Area of Integrated SIM 
Segment Peak # RT Area Area% FV 
1 
1 0.58 402916 25.76 0 
2 1.72 484422 30.97 0 
2 
3 2.85 802067 51.28 20 
4 3.98 792416 50.67 20 
3 
5 5.12 1010100 64.58 40 
6 6.25 994100 63.56 40 
4 
7 7.38 1202869 76.91 60 
8 8.51 1181001 75.51 60 
5 
9 9.65 1382260 88.38 80 
10 10.78 1376603 88.02 80 
6 
11 11.91 1508782 96.47 100 
12 13.05 1512559 96.71 100 
7 
13 14.18 1535811 98.2 120 
14 15.31 1563994 100 120 
8 
15 16.44 1475110 94.32 140 
16 17.58 1493133 95.47 140 
9 
17 18.71 1279867 81.83 160 
18 19.84 1264999 80.88 160 
10 
19 20.98 866763 55.42 180 
20 22.11 874326 55.9 180 
Table 5-16 shows peak area for the integrated area and the percentage peak area for 
the SIM scan of thalidomide (259.1m/z) in figure 5-28.  
 
By comparing the integrated peak area each set of peaks it is possible to determine the 
optimum fragmentor voltage, i.e. the voltage that allowed maximum transit of 
dasatinib precursor ion. In the case of thalidomide, the fragmentor voltage from 100-
140 gave similar peak areas – ranging form 96% to 100%.  The drop in peak area at 
higher fragmentor voltage is due to the precursor ion being broken down before 
entering the MS.  
 
The optimum fragmentor voltage was selected to be 120.  
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5.3.3. Product ion determination 
Figure 5-28: TIC of Product Ion Scan 
 
Figure 5-28 shows the TIC from the product ion scan, with increasing collision energies. The highlighted time segment shows where the MS 
spectra were extracted. Each segment represents an increase of 5 collision energy.  
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Figure 5-29: Extracted MS spectra for product ion scan 
 
Figure 5-29 shows the extracted MS spectrum of the TIC of the product ion scan, shown in figure 5-28. Spectrum A was extracted between 0.46 -
0.74mins, CE =5, spectrum B was extracted at 3.81-4.15mins CE=10, spectrum C was extracted at 6.18-6.33minutes, CE=15 and spectrum D was 
extracted between 8.46 and 8.66mins, CE=20. 
The correlation between the decline in abundance of 259.1m/z the increase in abundance of 84.1m/z and 186.0m/z indicating that these are the 
product ions for thalidomide. The ion at 231m/z does not appear to increase with the breakdown of the thalidomide precursor ion making it 
unacceptable as a product ion. 
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5.3.4. MRM optimisation 
Multi-reaction monitoring is used to quantify the abundance of a species by tracking 
precursor ions and their product ions though the MS to provide quantifiable spectra. 
Each transition from precursor ion to product ion can have different collision energies. 
By optimising the MRM transition we optimise the collision energy for each 
transition.  
 
Collision energies were increased step-wise in units of 5 from a starting value of zero 
to 40keV.The optimum collision energy for the transition 259.1 →84m/z was 
determined to be 15keV while the optimum collision energy for transition 259.1 
→186m/z was determined to be 25keV, Figure 5-30.   
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Figure 5-30: TIC and EIC for thalidomide MRM optimisation 
 
Figure 5-30 shows the TIC for the MRM for thalidomide and the extracted MRM for the transitions (259.1 →84) m/z (red trace) and the extracted 
MRM for (259.1 →186) m/z (green trace), * indicates optimum collision energy for each transitions. 
4x10
1
2
3
+ TIC MRM (** -> **) Thal-005.d  
1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9
4x10
1
2
+ MRM (259.10001 -> 84.00000) Thal-005.d 
5.12 6.252.85 3.99 8.527.39
10.799.65
1.71 11.92 13.06
0.59 14.19 15.33
16.46 17.60
1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9
4x10
1
2
+ MRM (259.10001 -> 186.00000) Thal-005.d 
9.65 10.80 13.0611.937.39 8.52
14.19 15.335.13 6.25
16.47 17.60
2.85 4.00
1.720.60
1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9
Counts vs. Acquisition Time (min)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
*
*
CE= 5   CE=10 CE=15    CE=20                  CE=25      CE=30     CE=35        CE=40
 333
This is representative of the work carried out for the detection condition optimisation 
of lenalidomide, umbelliferone and bortezomib.  Bortezomib, as a multiple myeloma 
medication was also examined at this time.  The optimised settings for each 
compound are detailed in Table 5-17. 
 
Table 5-17: Summary of MRM transition conditions of multiple myeloma agents 
Name 
Precursor 
Ion 
Optimum 
Fragmentor 
Voltage 
Product 
Ion 
Optimum 
Collision 
Energy 
Thalidomide 259.1 120 
84* 
186 
10 
25 
Umbelliferone 163.3 130 107.1 20 
Lenalidomide 260.1 90 
187.2 
148.8* 
106 
25 
15 
40 
Bortezomib 367.2 130 
226.3* 
208.1 
321.1 
15 
30 
20 
The optimal fragmentor voltages and collision energy settings for the determination 
of the multiple myeloma drugs employed in this study, * indicates quantifier ions. 
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5.4. Assay validation 
The overall LC-MS method was validated for the following performance parameters- 
linearity and range, intra-day precision (repeatability) and inter-day precision 
(intermediate precision), accuracy, sensitivity (LOD and LOQ), recovery and sample 
stability according to the guidelines described by Ermer [299].  An illustrative 
chromatogram is provided in Figure 5-31.  MRM allowed individual determination of 
each drug necessary with the use of internal standard-based quantification. Due to the 
sensitivity of the method for thalidomide, the method was validated in both a cancer 
cell line and serum.  
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Figure 5-31: Representative Chromatogram of Thalidomide and Umbelliferone 
 
Figure 5-31 shows a representative TIC of umbelliferone and thalidomide separation 
3x10
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
+ TIC MRM (** -> **) Sys Std1.d  
7.84
9.25
1 1
Counts vs. Acquisition Time (min)
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 10.5 11 11.5 12 12.5 13
 336
5.4.1. Assay validation in human serum 
5.4.1.1. Linearity and range 
Regression analysis was used to assess the linearity between the peak area ratios 
(analyte/IS) and the analyte concentration.  
 
The calibration curve for thalidomide was linear over the serum concentration range 
20μg/mL to 50ng/mL. Since thalidomide and umbelliferone resolved well from each 
other and were extracted with high efficiency umbelliferone was used as the internal 
analytical standard for thalidomide to reduce error. A volume of 50μL of a 600ng/mL 
stock of internal standard was spiked to each tube, sample and standards.  Whilst the 
calibration curves were linear, over such a broad range, the bias of the regression line 
tends to make the determination of lower drug concentration values much less 
accurate; hence it was decided to use a log-log plot of the peak area ratio versus the 
mass of drug in all calculations.  A weighted linear regression plot which ensures the 
accuracy at lower concentrations was also examined for the analysis of the standard 
curve and clinical patient samples.  This showed to be similarly appropriate for the 
lower ranges of thalidomide quantification.  However, the data in this thesis is 
presented as a calculated by LOG10-LOG10 plot.  The LOG10-LOG10 plot gave typical 
correlation coefficients (R2) values of 0.99. 
 
5.4.1.2. Precision and accuracy 
Intra-day precision and accuracy was assessed over the serum concentration range 
(20μg/mL-0.05μg/mL) by extraction and analysis of five spiked samples on the same 
day, Table 5-18. Inter-day precision and accuracy was assessed over the concentration 
range (20μg/mL-0.05μg/mL) by extraction and analysis of triplicate spiked samples 
over five days, Table 5-19. The percentage relative standard deviation (% R.S.D.) was 
employed as a measure of precision. The percentage accuracy was determined by 
dividing the average calculated drug concentration by that of the spiked known 
concentration.  The precision (% R.S.D.) in all cases was less that 5%, with the 
average intra-day % R.S.D. 3% and the average % R.S.D. for the inter-day analysis 
being 1.8%.  The accuracy ranges from 91% to 107%, with an average of 103% for 
the intra-day analysis and 100% average for the inter-day analysis.  
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Table 5-18: Intra-day analysis for precision and accuracy of thalidomide 
in serum  
Spiked 
Serum 
Conc. 
(μg/mL) 
Mean 
Observed  
Conc. 
(μg/mL) 
Mean 
Accuracy 
Observed 
(%) 
Precision 
(% R.S.D.) 
20 18.2 91.2 4.1 
10 10.1 100.9 2.3 
5 5.3 106.8 0.7 
1 1.03 103.3 4.5 
0.50 0.53 106.5 3.9 
0.10 0.10 98.6 4.2 
0.05 0.05 98.2 1.7 
The assessment of six samples over one day for intra-day precision 
and accuracy. 
 
 
 
 
 
 
Table 5-19: Inter-day analysis for accuracy and precision of thalidomide 
in serum 
Spiked 
Serum 
Conc. 
(μg/mL) 
Mean 
Observed 
Conc. 
(μg/mL) 
Mean 
Accuracy 
Observed 
(%) 
Precision 
(% R.S.D.) 
20 18.2 91.2 1.8 
10 9.9 99.2 2.2 
5 5.2 104.0 2.4 
1 1.1 106.3 1.6 
0.50 0.52 103.2 1.1 
0.10 0.10 99.1 2.0 
0.05 0.05 95.7 1.8 
The assessment of triplicate samples over five independent days. 
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5.4.1.3. Recovery/extraction efficiency 
The extraction efficiency of the procedure was determined by comparing the peak 
areas of the extracted analytes with those from non-extracted (calculated) samples and 
samples extracted without any matrix present.   Recoveries were evaluated across the 
concentration range.  “Sample/Calculated” recoveries were calculated by dividing the 
average quantified peak area of thalidomide from duplicate injections for five 
extracted samples by the average quantified peak area from duplicate injections for 
five “calculated” samples. "Sample/No matrix” recoveries were calculated by 
dividing the average quantified peak area of thalidomide from duplicate injections for 
five extracted samples by the average quantified peak area from duplicate injections 
for five samples extracted without matrix (serum/citrate) in the extraction tube. 
 
Recoveries for thalidomide drugs were generally good, with lower concentration 
levels showing a higher level of inaccuracy.  Results are given in Table 5-20. 
 
Table 5-20: Thalidomide intra assay recovery in serum  
Serum 
Conc. 
(μg/mL) 
Sample/Calculated Sample/No Matrix 
Mean % 
Recovery 
% 
R.S.D. 
Mean % 
Recovery 
% 
R.S.D. 
20 108.4 6.7 93.1 6.7 
10 119.3 4.1 99.2 4.1 
5 113.4 4.8 97.7 4.8 
1 109.5 4.5 98.8 4.5 
0.5 120.3 4.9 97.9 4.9 
0.1 120.0 5.1 93.5 5.1 
0.05 126.4 3.4 95.1 3.4 
(n=5)  
 
The average recovery across the concentration range when the extracted sample is 
compared to the calculated recovery sample was 117%. 
 
The average recovery across the concentration range when the extracted sample is 
compared to the no matrix recovery sample was 96%. 
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5.4.1.4. Stability 
The stability of thalidomide in serum has been described previously [247, 273, 278, 
282] highlighting the importance of prompt storage of acidified thalidomide below -
20°C. Upon arrival in the lab, all samples were processed promptly, acidified with 
25mM citrate buffer, pH 1.5 and stored at -80°C, as described in Section 2.2.6.1.   
 
The stability of thalidomide in serum was analysed over four freeze-thaw cycles at 
concentrations of 20, 5, 0.5, 0.05μg/mL of serum. On day 0, triplicate standards were 
extracted and the remaining samples were frozen at -20°C. The standards were then 
thawed and extracted and refrozen each day for a further four days. Samples were 
stored with and without citrate to examine the effect of citrate on sample stability. In 
samples without citrate, water was added to the serum for equate for equivalence in 
volumes.  
Samples were assessed on the thalidomide peak area and samples extracted on Day 0 
with citrate present were taken as 100%.  The results are given in Table 5-21and 
Table 5-22.  As expected, the samples without buffer degraded faster that the samples 
with buffer.  
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Table 5-21: Thalidomide stability in serum, stored with citrate  
Thalidomide Serum Stability – with citrate buffer 
Serum Conc. 
μg/mL 
Day 0 Day 1 Day 2 Day 3 Day 4 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
20 100 8.6 100 8.6 80 26.0 87 5.4 74+ 11.3 
5 100 5.9 102 10.1 101+ 14.7 90 12.4 73 10.5 
0.5 100 7.6 94+ 10.8 93 7.7 92 5.1 73+ 8.3 
0.05 100 9.0 92 19.5 94 7.3 92 7.2 68+ 15.2 
Table 5-21 details the recovery of thalidomide in serum samples following four freeze/thaw cycles. All spiked serum samples were stored 1/1 (v/v) 
with citrate buffer. The data is the average of duplicate injections of triplicate samples (n=3, +n= 2) 
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Table 5-22: Thalidomide stability in serum, stored without citrate 
Thalidomide Serum Stability – without citrate buffer 
Serum Conc. 
μg/mL 
Day 0 Day 1 Day 2 Day 3 Day 4 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
% 
Recovery 
% 
R.S.D. 
20 93 9.2 90 4.7 78+ 4.9 75+ 9.7 74 12.6 
5 93 6.7 86 10.6 74 9.8 72 5.9 91 8.8 
0.5 94 8.3 90 7.4 77 7.6 72+ 7.9 88 10.1 
0.05 89 8.5 90 10.3 70+ 9.3 73 7.2 92 11.6 
Table 5-22 details the recovery of thalidomide in serum samples following four freeze/thaw cycles. All serum samples were stored spiked with 
thalidomide with no citrate buffer added. The data shown is the average of duplicate injections of triplicate samples (n=3, +n= 2) 
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The effect of the sample storage conditions was also examined on patient samples.  
Patient serum was processed as described in Section 2.2.6.1.  In addition to storing 
samples with the 25mM citrate buffer at -80°C, a serum aliquot was stored with 
citrate at -20°C as well as without citrate buffer at -80°C and -20°C.  Samples were 
stored for 40 days prior to analysis.  Figure 5-32 graphically demonstrates the effect 
of storage conditions on thalidomide stability. The samples at -80°C and stored in 
citrate were more stable than those stored at -20°C. The citrate buffer clearly stabilises 
the agent. 
 
Table 5-23 shows the p-values, as calculated using student’s t-test, for the significance 
of loss of thalidomide between the standard storage conditions and the assayed 
conditions. 
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Figure 5-32: Effect of storage conditions on sample stability 
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The effect of altering the storage conditions on the stability of thalidomide, in two 
patient samples. The standard storage condition (with citrate @ -80°C) was assessed 
as 100% and the other samples were assessed as a function of the standard.  
 
 
Table 5-23: Effect of storage conditions on sample stability 
Storage 
Conditions 
Sample # 461 Sample # 462 
% 
Thalidomide 
% 
R.S.D. 
p- 
value 
% 
Thalidomide 
% 
R.S.D. 
p- 
value 
+ citrate, -80°C 100.0 1.3  100.0 4.3  
- citrate, -80°C 89.7 1.7 0.00004 87.1 0.3 0.00515 
+ citrate, -20°C 86.1 3.7 0.00054 86.1 0.9 0.00301 
- citrate, -20°C 89.4 4.7 0.00649 81.6 1.6 0.00104 
The standard storage condition (with citrate @ -80°C) was assessed as 100% and the 
other samples were assessed as a function of the standard. Significance was 
calculated using the paired student’s t-test, of unequal variance.  The p-values were 
calculated by comparison of each storage condition with “+ citrate -80°C”. 
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5.4.2. Assay validation in cells 
5.4.2.1. Linearity and range 
Regression analysis was used to assess the linearity between the peak area ratios 
(analyte/IS) and the analyte concentration.  
The calibration curve for thalidomide was linear over the cell mass range of 0.39ng – 
50ng in tube.  Based on the validation of thalidomide with umbelliferone as an 
internal standard and the similarities in extraction potential, umbelliferone at the same 
concentration was used at as an internal standard.  A volume of 50μL of a 600ng/mL 
stock of internal standard was spiked to each tube, sample and standards.  Whilst the 
calibration curves were linear, over such a broad range, the bias of the regression line 
tends to make the determination of lower drug concentration values much less 
accurate; hence it was decided to use a log-log plot of the peak area ratio versus the 
mass of drug in all calculations.  
The log-log plot gave typical correlation coefficients (R2) values of >0.99. 
 
5.4.2.2. Precision and accuracy 
Intra-day precision and accuracy was assessed over the mass range (0.39ng - 50ng) by 
extraction and analysis of six spiked samples on the same day, (Table 5-24).  Inter-
day precision and accuracy was assessed over the mass range (0.39ng - 50ng) by 
extraction and analysis of triplicate spiked samples over four days, (Table 5-25).  The 
percentage relative standard deviation (%R.S.D.) was employed as a measure of 
precision.  The % accuracy was determined by dividing the average calculated drug 
concentration by that of the spiked known concentration. 
 
For the intra-day analysis the average accuracy was 100% with an average % R.S.D. 
of 2.5%.  
For the inter-day analysis the average accuracy was 101% with an average % R.S.D. 
of 1.9% 
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Table 5-24: Intra-day analysis for precision and accuracy of thalidomide in cells 
Spiked Mass 
(ng) 
Mean Mass 
Observed (ng) 
Mean Accuracy 
Observed (%) 
Precision 
(% R.S.D.) 
0.39 0.39 99.9 4.1 
0.78 0.79 100.6 4.0 
1.56 1.58 100.8 3.3 
3.13 3.09 98.9 2.8 
6.25 6.24 99.9 1.6 
12.5 12.5 100.4 1.8 
25 25 100.5 1.2 
Intra-day analysis for precision and accuracy, n=6. 
 
Table 5-25: Inter-day analysis for precision and accuracy of thalidomide in cells 
Spiked Mass 
(ng) 
Mean Mass 
Observed (ng) 
Mean Accuracy 
Observed (%) 
Precision 
(% R.S.D.) 
0.39 0.40 102.94 4.19 
0.78 0.79 101.45 2.35 
1.56 1.57 100.61 2.46 
3.13 3.11 99.61 1.09 
6.25 6.28 100.47 0.69 
12.5 12.5 100.30 1.93 
25 25 100.76 0.86 
50 50 100.76 1.51 
Inter-day analysis for precision and accuracy, n=3. 
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5.4.2.3. Recovery/extraction efficiency 
The efficiency of the LLE method was assessed by comparing the peak areas of 
thalidomide in the extracted analytes with the peak area of thalidomide in non-
extracted (calculated) samples and samples extracted without any cells present, 
prepared as in Section 2.2.5.3.  Recoveries were evaluated across the concentration 
range.  “Sample/Calculated” recoveries were calculated by dividing the average 
quantified peak area of thalidomide of duplicate injections from triplicate extracted 
samples, by the average quantified peak area from duplicate injections for triplicate 
“calculated” samples. "Sample/No matrix” recoveries were calculated by dividing the 
average quantified peak area of thalidomide of duplicate injections for triplicate 
extracted samples by the average quantified peak area from duplicate injections for 
triplicate samples extracted without matrix (serum/citrate) in the extraction tube. 
 
Recoveries for thalidomide were generally good. Results are given in Table 5-26. 
 
 
Table 5-26: Intra-assay recovery of thalidomide in spiked cell samples (n=3) 
Spiked 
Mass (ng) 
Sample/Calculated Sample/No Matrix 
Mean % 
Recovery %R.S.D. 
Mean % 
Recovery %R.S.D. 
50 92.7 5.5 111.8 5.4 
5 90.7 3.6 115.1 3.6 
0.5 92.1 9.7 118.4 9.7 
 
 347
5.4.3. Selectivity & sensitivity 
The limit of detection (LOD) was defined as the mass of drug which gave a signal to 
noise ratio of 3:1. The limit of quantification (LOQ) was defined as the mass of drug 
which gave a signal to noise ratio of 5:1[300].  
 
The sensitivity of the assay was monitored against human serum as a matrix.  Given 
the criteria outlined, the LOD for thalidomide was determined to be approximately 
0.08ng spiked mass, and the LOQ for thalidomide was determined to be 
approximately less than 0.3ng and greater that 0.15ng, spiked mass. With a serum 
volume of 100μL, therefore, the LOQ for the method described here is between 
1.5ng/mL and 3ng/mL of serum. 
 
The signal-to-noise ratio was calculated by the Masshunter Quantification Analysis 
Software (Version B.01.04). Calculations were based on the peak area of thalidomide, 
not on the peak area ratio. 
 
Table 5-27: Thalidomide, LOD and LOQ 
Spiked 
Mass (ng) 
Mean Mass 
Observed (ng)
Mean 
Accuracy 
Observed (%) 
Precision 
(% R.S.D.) 
Mean 
Signal/ 
Noise 
0.313 0.324 104.79 1.99 6 
0.156 0.157 99.76 1.22 4 
0.078 0.076 96.91 2.78 2 
The limit of detection and limit of quantification of thalidomide as assessed in serum 
extracted samples (n=3). 
 
 
The selectivity of the assay is increased through the use of MRM transitions for 
quantification.  Assessed through in monitoring of the MRM transition in extracted 
cell samples there was no detected endogenous interaction for thalidomide, see 
Section 9 Appendices IV. 
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The LC-MS method easily resolved thalidomide from umbelliferone from each other 
and from any background from biological matrices.  Due to the high sensitivity of 
mass spectrometric detection, low background from the liquid-liquid extraction and 
the specificity imparted when quantifying based on the molecular transitions of the 
ions in the collision cell (MRM) the method is rapid, sensitive and specific.  
 
The ability to quantify a broad concentration range of thalidomide in two different 
biological matrices demonstrates the robust nature of LLE and the range of 
applications of the LC-MS. 
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5.5. Method application 
5.5.1. Quantification of thalidomide in patient serum 
This method was applied to the quantification of thalidomide levels in the serum of 
multiple myeloma patients  
 
Thalidomide is administered to multiple myeloma patients at a fixed dose irrespective 
of age, gender or body weight. Thalidomide dosage is adjusted in response to side 
effects or as function of patient response. Patients showing no signs of response 
received increased dosage of thalidomide and patients who show unmanageable side 
effects have a dose reduction.  
Thalidomide has been seen to cause multiple side effects including neuropathy, 
neutropenia, somnolence and constipation[268]. 
 
To examine the application of the developed thalidomide analysis method to the 
quantification of serum thalidomide levels, serum samples from multiple myeloma 
patients receiving thalidomide treatment were collected from patients of the Mater 
Misericordiae University Hospital, Eccles St, Dublin 7 under the care of Dr P 
O’Gorman by Dr R Rajpal under full ethical approval of the hospital Ethics 
committee. 
 
The patient cohort comprised ten patients, from whom 22 samples were collected. To 
combat the side effect of somnolence, patients are advised to take the thalidomide 
medication before bed. Samples were collected in clinic the following morning and 
processed as detailed in Section 2.2.6.1. 
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Table 5-28: Characteristics of the patient cohort 
Patient 
# of 
samples Age Gender
Serum 
Conc. 
(ng/mL) 
Dose 
(mg/day)
Response 
IMW22 
Neuropathy NCI 
criteria23 Other side effects 
A 3 79 Female 
164 100 
VGPR 
Grade 3 
constipation, tiredness and low energy, 
pins and needle sensation 
63 50 Grade 2 
low energy and tiredness marginally 
better 
27 50 Grade 2 
TIA24, constipation, tiredness and low 
energy 
B 3 64 Male 
1082 200 
VGPR 
Grade 1 
Pins and needle sensation, Tiredness 
and low energy 
25 200 Grade 0 
Pins and needle sensation improved, 
Tiredness and low energy 
1095 200 Grade 0 
mild Pins and needle sensation 
,Tiredness and low energy 
C 1 81 Male 209 100 PR Grade 2 
Neutropenic sepsis, Anaemia. 
Thrombocytopenia 
                                                 
22 IMW – Based on International Myeloma Workshop criteria  
23 NCI – Based on National Cancer Institute 
24 TIA - transient ischemic attack 
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Patient 
# of 
samples Age Gender
Serum 
Conc. 
(ng/mL) 
Dose 
(mg/day)
Response 
IMW22 
Neuropathy NCI 
criteria23 Other side effects 
D 2 68 Male 
ND 200 
PR Grade 3 (? Diabetic) 
DVT, constipation, low energy , 
Diabetic neuropathy 
755 300 
DVT, constipation, low energy , 
Diabetic neuropathy 
E 2 59 Male 
498 15025 
PD Grade 2 
Low energy, Constipation, Ankle 
oedema 
1407 200 
Severe low energy, constipation, Ankle 
oedema, skin rash 
F 1 77 Male 330 15026 PR Grade 2 – Grade 3 
Numbness in fingers, low energy and 
tiredness 
G 6 71 Male 
454 150 
VGPR Grade 2 
Skin rash, Peripheral Oedema, 
constipation 
781 200 
Skin rash improved , Peripheral Oedema 
improved 
573 150 Mild skin rash , Tiredness 
479 150 Tiredness and low energy 
                                                 
25 Patient switched from lenalidomide treatment to thalidomide 
26 Patient switched from thalidomide treatment to lenalidomide treatment 
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Patient 
# of 
samples Age Gender
Serum 
Conc. 
(ng/mL) 
Dose 
(mg/day)
Response 
IMW22 
Neuropathy NCI 
criteria23 Other side effects 
405 150 Tiredness and low energy 
634 100 Tiredness and low energy 
H 2 58 Male 
550 150 
PD Grade 1 
Low energy constipation 
198 100 Low energy constipation 
I 1 60 Female 182 100 PR Grade 1 Tiredness and low energy 
J 1 57 Male ND 50 VGPR Grade 1 Nil 
Table 5-28 details the patient cohort characteristics, including the detected serum concentrations, dose received, patient response and adverse 
effects experienced.  
 
Abbreviations: 
ND - non-detected 
TIA –transient ischaemic attack  
PR – partial response 
VGPR - very good partial response 
PD – progressive disease 
DVT – deep vein thrombosis 
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The adverse effects reported by the patients varied from day to day. Given here is a 
representation of the range of side effects experienced by the patient and reported by 
the patient/clinician.  
 
The International Myeloma Workshop established uniform criteria for the reporting of 
response in multiple myeloma[383].  CR is complete response, PR is partial response, 
VGPR is very good partial response, PD is progressive disease.  
 
Thalidomide-related neuropathy was evaluated by the clinician and classified based 
on National Cancer Institute Common Toxicity Criteria, version 2.0[384].  Grading is 
as follows: Grade 0 - Normal, Grade 1 - Loss of deep tendon reflexes or paraesthesia 
(including tingling and numbness) but not interfering with function, Grade 2 - 
objective sensory loss or paraesthesia (including tingling) interfering with function 
but not interfering with activities of daily living and activities.  Grade 3 - Sensory loss 
or paraesthesia interfering with activities of daily living, Grade 4 - Permanent sensory 
loss that interferes with function.  Assessment of neuropathy was evaluated by the 
clinician at point of care and correlated with time of blood sampling. 
 
The level of thalidomide quantified in all patients is shown in Figure 5-33.  Two 
patient samples “H” and “J” are excluded from this graph due to unclear information 
regarding the patient starting date.  
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Figure 5-33: Thalidomide levels in all patients 
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Figure 5-33 shows the thalidomide serum concentration of all patients as a function of duration of treatment 
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However, this does not take into account the dose of thalidomide which the patients 
were receiving, nor does it examine the neuropathy experienced by the patients.   
 
There is a general correlation between patient dose and detected serum concentration 
is examined.  Figure 5-34 shows this correlation ignoring any patient specific factors.  
There is a level of linearity between dose and detected serum concentration however; 
in general, the patients’ serum level of thalidomide is not predictable from the 
administered dose.  One sample, marked on the graph, clearly shows to be lying 
outside the trend.  This sample, from patient B, is suspected to have been taken after a 
missed dose. This is discussed later.  
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Figure 5-34: Thalidomide levels in all patients in comparison to dosage 
Profile of dose response
0
200
400
600
800
1000
1200
1400
1600
0 50 100 150 200 250 300 350
Thalidomide Dose (mg/day)
Pa
tie
nt
 S
er
um
 L
ev
el
s 
(n
g/
m
L)
 
Figure 5-34 shows the thalidomide serum concentration of all patients as a function 
dose received. 
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Figure 5-35 attempts to show the correlation between the neuropathy experienced, the 
serum levels detected and the patient dose per sample time-point.  The majority of 
patients cluster at Grade 2 neuropathy.   
 
However, as neuropathy is also dependant on the duration of treatment with 
thalidomide the data was re-plotted to examine any correlations between the duration 
of treatment, neuropathy grade evaluated and dose administered, Figure 5-36.  
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Figure 5-35: Thalidomide levels in all patients in comparison to dose and neuropathy 
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Figure 5-35 shows the relationship between neuropathy, serum levels and patient 
dose. 
 
Figure 5-36: Neuropathy levels in all patients in comparison to dose and duration of 
treatment 
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Figure 5-36 shows the relationship between neuropathy, duration of thalidomide 
treatment and patient dose. 
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Patient A is 79 year old female patient who initial dosage of 100mg/day was reduced 
to 50mg/day. The dose reduction showed a simultaneously serum level reduction. 
Figure 5-37 shows the comparison of the serum concentration in comparison to 
dosage level. 
 
A reduction in the thalidomide dosage was linked to an improvement in the 
neuropathy level, assessed under the NCI criteria, from Grade 3 neuropathy to Grade 
2 neuropathy. A marginal improvement was also noted in level of tiredness and low 
energy reported.  
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Figure 5-37: Profile of the serum levels in patient “A” 
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Figure 5-37 shows the comparison of serum levels over time with thalidomide prescribed dose over time. The pink line indicates the thalidomide 
dosage while the blue line is the quantified concentration of thalidomide in the patient serum. The neuropathy grade is indicated at each data 
point.  Serum level quantification was the average of two aliquots of sample and the standard deviations.  
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Grade 2 Grade 2 
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Three samples were collected for Patient “B”. Patient “B” is a 74 year old male, who 
was prescribed a consistent dosage of 200mg/day.  Figure 5-38 shows the serum 
levels for patient “B” in comparison to the prescribed thalidomide dose. 
 
The side effects suffered by patient “B” were tiredness and low energy and pins and 
needles sensation. The pins and needles sensation improved at the second time point 
and mild pins and needle sensation were reported at the third time point. Neuropathy 
levels of grade 1 to grade 0 were recorded at the time of consultation and blood 
sampling.   
 
The data point at 91 days, 25ng/mL, indicates that the patient may have missed one or 
more doses immediately prior to the blood sample being taken.  
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Figure 5-38: Profile of the serum levels in patient “B” 
Patient "B"
0
200
400
600
800
1000
1200
1400
40 50 60 70 80 90 100 110 120 130
Days of Treatment
T
h
a
l
 
s
e
r
u
m
 
c
o
n
c
.
 
(
n
g
/
m
L
)
0
50
100
150
200
250
T
h
a
l
i
d
o
m
i
d
e
 
D
o
s
e
 
(
m
g
/
d
a
y
)
Serum Levels Dose
 
Figure 5-38 shows the comparison of serum levels over time with thalidomide prescribed dose over time. Serum level quantification was the 
average of two aliquots of sample and the standard deviations.  The pink line indicates the thalidomide dosage while the blue line is the 
quantified concentration of thalidomide in the patient serum.  The neuropathy grade is indicated at each data point.  
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Two samples were collected from patient “E”. Patient “E” is a 59 year old male, who 
was prescribed a 150mg/day which was increased to 200mg/day 
 
Figure 5-39 shows the serum levels for patient “E” in comparison to the prescribed 
thalidomide dose. 
 
Patient E was switched from lenalidomide to thalidomide and was reported to be a 
non-responder to Velcade treatment. The side effects noted in the case of patient “E” 
were low energy, constipation and ankle oedema. The increased dosage of 
thalidomide prescribed corresponded with severe low energy. Neuropathy levels of 
were consistently recorded as grade 2. 
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Figure 5-39: Profile of the serum levels in patient “E” 
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Figure 5-39 shows the comparison of serum levels over time with thalidomide prescribed dose over time.  Serum level quantification was the 
average of two aliquots of sample and the standard deviations.  The pink line indicates the thalidomide dosage while the blue line is the 
quantified concentration of thalidomide in the patient serum. 
 
Grade 2 
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Six samples were collected from patient “G”. Patient “G” is a 71 year old male, who 
was prescribed a dosage of 150mg/day, which was increased to 200mg/day and then 
reduced to 150mg/day. The final recorded dose was 100mg/day.  
 
Figure 5-39 shows the serum levels for patient “G” in comparison to the prescribed 
thalidomide dose. 
 
Patient G suffered from skin rash, peripheral oedema, and constipation.  The skin rash 
improved to a mild rash, the peripheral oedema improved and tiredness and low 
energy were reported. Neuropathy levels of were consistently recorded as grade 2. 
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Figure 5-40: Profile of the serum levels in patient “G” 
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Figure 5-40 shows the comparison of serum levels over time with thalidomide prescribed dose over time.  Serum level quantification was the 
average of two aliquots of sample and the standard deviations.  The pink line indicates the thalidomide dosage while the blue line is the 
quantified concentration of thalidomide in the patient serum. 
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Two samples were collected from patient “H”. Patient “H” is a 58 year old male, who 
was prescribed a dosage of 150mg/day, which was decreased to 100mg/day.  Figure 
5-41 shows the serum levels for patient “H” in comparison to the prescribed 
thalidomide dose. 
 
Patient H suffered from side effects of low energy and constipation.  Neuropathy 
levels are assessed as Grade 1.  However, Patient H did not respond to thalidomide 
treatment with IMW criteria classified as PD, progressive disease.  
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Figure 5-41: Profile of the serum levels in patient “H” 
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Figure 5-41 shows the comparison of serum levels over time with thalidomide prescribed dose over time.  Serum level quantification was the 
average of two aliquots of sample and the standard deviations.  The pink line indicates the thalidomide dosage while the blue line is the 
quantified concentration of thalidomide in the patient serum. 
 
Grade 1 
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5.5.2. Quantification of thalidomide in cells 
The pharmacokinetic evaluation of thalidomide in cell culture models has not, to our 
knowledge, been reported previously. Zhou et al.[278], describes a method of the 
quantification of thalidomide in Hank’s balanced salt solution (HBSS), a transport 
buffer for the cell line, Caco-2. For this thesis, the accumulation and efflux of 2μM 
thalidomide in the cell-line models, DLKP and DLKP-A, was assessed over two 
hours, with samples taken at 15 minutes, 30 minutes, 1 hour and 2 hours. Each sample 
was assessed in triplicate flask.  
Eight samples (flasks) out 116 samples (flasks) had detectable levels of thalidomide. 
Of these estimates, none were repeatable within a triplicate set.  
 
Given the low and irreproducible levels of thalidomide found in the cell samples the 
stability of thalidomide in cell culture media was assessed. A solution of 2μM 
thalidomide was prepared in media and in HBSS and was incubated at 37°C for 24 
hours. Two stocks of thalidomide were assessed one (old) was stored for 47 days at 
4°C while the other (new) was prepared fresh on the day.  An aliquot (100μL) was 
removed and immediately mixed with citrate and stored at -20°C.  The results are 
given in Figure 5-42.  
 
The data indicates that thalidomide is reasonably stable in DMSO at 4°C as there is 
minimal difference in the mass detected in the old and the new thalidomide samples. 
The rate of breakdown of thalidomide is faster in HBSS than in cell culture media, 
however, 50% of the thalidomide had degraded within 4 hours in media at 37°C.  
Only thalidomide in media had any quantifiable drug remaining at the 20hr and 24hr 
sampling time-points.  
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Figure 5-42: The stability of thalidomide in cell culture media and HBSS 
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Figure 5-42 details the stability of thalidomide, fresh and 47 day old stock in HBSS and cell culture media. The data shown is the average of 
triplicate aliquots and their standard deviations normalised to the expected mass (50ng).  
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5.6. Discussion 
5.6.1. Method development  
The objective of this part of the research was to develop a separation and extraction 
method for the quantification of thalidomide in patient serum.  
5.6.1.1. Internal standard and column selection 
The initial obvious choice of internal standard for thalidomide analysis was 
lenalidomide.  Lenalidomide is a more recently developed analogue of thalidomide 
with similar chemistry and therefore should theoretically make a good internal 
standard[315].  The use of lenalidomide as an internal standard for thalidomide 
analysis was investigated as an efficient way of developing a method for 
determination of both multiple myeloma agents simultaneously.  A quantification 
method for the analysis of lenalidomide in serum which mentions within the article 
that thalidomide was unsuccessful as an internal standard for lenalidomide due to poor 
peak shapes alone[381].  Based on this the separation of thalidomide and lenalidomide 
was examined.  Teo et al.[273], used acetic acid as a mobile phase modifier, however, 
our initially analysis with acetic acid in the mobile phase demonstrated that this 
reagent was unusable due to high background in the MS detector.  Using formic acid 
to acidify the mobile phase simplified the mobile phase preparation, reducing the 
possibility for mobile phase contamination and gave consistent, clean 
chromatograms[311].   
 
The first column optimised for the separation of thalidomide and lenalidomide was a 
YMC 50mmx 2.0mm, 2μm particle size C18 column.  Separation was achieved with 
gradient elution as outlined in Table 5-2.  Baseline separation of both lenalidomide 
and thalidomide was achieved, with both peaks having good peak shape and the 
complete run-time, including re-equilibration time, was only 9 minutes.  However, a 
maximum injection volume of 5μL was possible as peak fronting was observed with 
increased injection volumes.  Peak fronting is usually the result of column 
overloading[320].   
 
The Prodigy (150mmx4.6mm, 5μm particle size) column was also investigated. The 
aim was to gain baseline separation of thalidomide and lenalidomide with isocratic 
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flow.  The use of isocratic flow is preferable when using compounds of a different 
chemical make-up as internal standards for each other as with isocratic flow 
conditions remain constant throughout the analysis. By keeping the mobile phase 
constant, the ionisation of each analyte remains constant and the peak area ratio of 
analyte to internal standard is robust.  A binary mobile phase of 50% (v/v) ACN/water 
0.1% formic acid gave good and repeatable separation, Figure 5-5.  An injection 
volume of 20μL gave an acceptable peak shape, Figure5-6.  An injection volume of 
10μL did show excellent peak shape, however, this is too small an injection volume 
for our purposes. During the liquid-liquid extraction process the analyte-containing 
organic solvent layer is removed and transferred to a 1.1mL conical LC vial.  The 
sample is evaporated in this vial and reconstituted for injection onto the LC in this 
vial. This reduces the error associated with transferring vials and increased level of 
sample handling. However, as the volume of the vial is 1.1mL a sufficient 
reconstitution volume is required to ensure complete reconstitution of the sample.  To 
avoid loss of sensitivity it is desirable to inject a maximum possible quotient of the 
reconstituted sample. 
 
Good separation of thalidomide and lenalidomide was achieved with isocratic elution 
and 20μL injection.  This is contradictory to the finding of Tohyna et al., who 
reported that thalidomide was unsuitable as an internal standard for lenalidomide due 
to poor separation[381].  However, examination of the extraction of lenalidomide and 
thalidomide showed that lenalidomide was not a suitable internal standard for 
thalidomide.  Lenalidomide showed poor recovery across all solvents ranges.  
Recoveries below 40% were consistently seen on inter-day analysis.  Whether this 
low recovery for lenalidomide resulted from extraction potential or poor solubility 
when samples were reconstituted has thus far been unconfirmed. An alternative 
internal standard was sought.  
 
Umbelliferone has previously been used as an internal standard for lenalidomide[381].  
Given that in this publication the authors also tried thalidomide as an internal standard 
for lenalidomide and reported no issues with the extraction potential, umbelliferone 
was investigated as an internal standard for thalidomide.  The most commonly used 
internal standard for the quantification of thalidomide in the literature is phenacetin. 
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Though deuterated standards are also commonly used in the quantification of analytes 
in bio-analytical chemistry, their cost frequently makes them prohibitively expensive.  
The use of deuterated internal standards are not always the best option for routine 
analysis[315].  
 
Umbelliferone is cheap, easily available compound which is less toxic than 
phenacetin, the most commonly used internal standard for thalidomide.  
 
Several separation columns were tested, four reverse-phase C18 and one phenyl 
column. Two of the columns investigated Agilent XBD C18 (4.6 x 50mm, 1.8μm 
particle size) and Phenomenex Prodigy C18 (150 x 4.6mm, 5μm particle size) gave 
good separation as shown in Figure 5-7 and Figure 5-11 respectively. The Prodigy 
(150 x 4.6mm, 5μm particle size) was selected as the most appropriate column for this 
method as the capability to inject the proportionally larger volume of 20μL, compared 
to 5μL was of particular importance.  As described above an injection volume is 
subject to the reconstitution volume.  An injection volume of 20μL was more suitable 
to the requirements of the method.  With the exception of methods where the focus 
has been to separate the enantiomers of thalidomide[272, 275] all published methods 
shows thalidomide separation from the internal standard on a reverse phase C18 
column.  All reverse phase columns reported to be used in the quantification of 
thalidomide (except one[273]) were developed using column 125mm long or 
greater[276-278], details given Table 1-8.  Additionally, it is interesting to note that 
most methods report and optimised mobile phase composition of low (<40%) organic 
modifier composition. This is similar to the optimised mobile phase composition 
described here.  
 
The Prodigy (150 x 4.6mm, 5μm particle size) was the bests of all the columns 
examined for the quantification of thalidomide.  It was able to separation thalidomide 
and umbelliferone easily from each other and from any confounding biological 
artefacts. Base-line separation was achieved with good resolution.  A suitable injected 
volume for the extraction procedure was accommodated.   
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5.6.1.2. MRM conditions optimisation 
The routine method for the determination of all the MRM conditions (precursor ion, 
fragmentation voltage, product ion and collision energy) is through the using of flow 
injection analysis (FIA).  However, the precursor ion for thalidomide initially proved 
difficult to identify. This led to the necessary utilisation of direct infusion to identify 
the precursor ion. The use of a direct infusion pump allows of an instantaneous 
response i.e. increasing the pressure of the infusion results in a chromatogram spike. 
The predominant molecular ions of a particular mass can then be with certainty 
concluded to be present in the infusion. This led the mass of precursor ion to be 
conclusive determination for thalidomide to be 259.1m/z which is the protonated 
molecular ion [M+H] +. The precursor ion was reconfirmed by FIA and the remaining 
criteria were identified by FIA. The MRM conditions for umbelliferone, lenalidomide 
and bortezomib were also characterised entirely by FIA.   
 
As previously discussed in Section 3.9.2 the use of MRM monitoring for the detection 
and quantification of analytes of interest gives increased specificity and selectivity 
compared to single reaction monitoring (SRM).  The ability to simultaneously 
monitor multiple ions means that the most abundant product ion can be used for 
quantification; any additional product ions detected are monitored as qualifier ions.  
For thalidomide the qualifier ion, the mass transition of 259.1mz/ →186m/z.  This has 
consistently ratio approximately 95%.  
 
5.6.1.3. Extraction conditions optimisation 
The requirement of the extraction process in the bio-analytical setting is to remove the 
analyte of interest from extraneous substances such as proteins, lipids and salts 
present in the sample which could interfere with the analysis.  Several sample clean-
up procedures have be used previously for the extraction of thalidomide from serum 
including solid phase extraction[273] and protein precipitation[274].  Three recent 
methods report the use of a liquid-liquid extraction method for sample clean up[275-
278], however both the methods by Yang et al.[277], and  Saccomani et al.[276], are 
adaptations of the modified LLE method developed by Zhou et al.[278].  Zhou et 
al.[278], details a sample clean-up procedure where the matrix is removed by the 
addition of two volumes (compared to the matrix volume) of ice-cold 
 375
acetonitrile/methanol (1:1, v/v) containing 2% (v/v) acetic acid to the sample and the 
supernatant is injected after centrifugation.  However, the solvents used here are not 
water immiscible, thus not a true liquid-liquid extraction.  
 
The liquid-liquid extraction method for the extraction of thalidomide described here 
was developed from first principles by identifying the optimum solvent extraction 
system.  The objective is to confine the sample matrix away from the immiscible 
analyte-containing organic solvent.  A variety of immiscible solvents and mixtures 
with acetonitrile were examined, Table 5-14.  The poor extraction recovery of 
lenalidomide made this agent unsuitable as an internal standard for thalidomide.  
Some of the solvents did not separate into discrete aqueous and organic layers.  Of the 
eleven solvent systems tested the two which had both the best extraction recovery and 
the lowest level of technical difficulty were carried forward and assessed further by 
varying the ratio of immiscible solvent to acetonitrile and examining the effect.  
Frequently an aqueous buffer is added to an extraction to aid the extraction. In this 
case the serum is already stored on processing in an aqueous citrate buffer, pH1.5.  
Ultimately ethyl acetate/acetonitrile (3/1., v/v) was selected as the most appropriate 
solvent as it gave the best recovery of thalidomide from a mixture of serum/citrate 
(1/1, v/v), Figure 5-17, and across a concentration range Figure 5-18.  While the 
mixture of choro-1-butane/ACN (4/1, v/v) gave good recovery at when extracting a 
spiked mass of 20ng, Figure 5-17, the recovery was variable across a concentration 
range, Figure 5-18.  Also the additional cost involved in the disposal of chlorinated 
solvents makes its use less desirable when alternative options are available.  
 
The extraction and recovery of umbelliferone was also acceptable using ethyl 
acetate/acetonitrile (3/1., v/v) as the extraction solvent. 
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5.6.2. Assay validation in serum and cells 
Given the sensitivity of the assay for the detection of thalidomide, it was decided to 
validate the method against two different biological matrices across two different 
concentration ranges. The details of assay validations are outlined in Section 5.4. 
According to Huber et al., the validation of an analytical method should be designed 
to test the suitability of the method for its intended purpose[332]. The intended 
purpose of this assay is to quantify the level of thalidomide in human serum and to 
quantify the mass of serum in cell pellets.  
 
The overall LC-MS method was validated for the following performance parameters- 
linearity and range, intra-day precision (repeatability) and inter-day precision 
(intermediate precision), accuracy, sensitivity, (LOD and LOQ), recovery and sample 
stability according to the guidelines described by Ermer[299].  
 
5.6.2.1. Selectivity  
As discussed in Section 3.9.6.2, the selectivity of the method is the ability to 
determine the analyte in a mixture whereas specificity is the ability to determine that 
the signal is solely the result of that analyte[336, 337].  Through the use of the MRM 
transition-based quantification it is possible to categorically identify the eluting peaks. 
The use of multiple transitions in MRM mode adds specificity to the method. All 
detected transitions for each analyte were monitored.  The quantifier ion was the mass 
transition of 259.1m/z → 84m/z. The qualifier ion was the mass transition of 
259.1m/z → 186m/z. The qualifier ratio is ratio of the peak area of the qualifier to the 
quantifier ion. This is set in quantification method and is one of the parameters 
analysed during the integration process of the software.  In the case of thalidomide, 
the qualifier ion is approximately 95% of the quantifier ion.   
 
 377
5.6.2.2. Sensitivity 
The sensitivity of the assay was monitored against human serum as a matrix.  Though 
the method was tested against both cells and serum as a biological matrix the volume 
of serum present in the method is far greater than the volume of cells.  Therefore, the 
sensitivity of the method using serum as a biological matrix should be far more 
challenging due to the presence of more interfering compounds.  
 
The increased sensitivity of the LC-MS, due to orthogonal positioning of the 
ionisation source employed by the Agilent 6410 MS system, gave the ability to 
quantify in the picogram range. Quantification was based on the mass transitions from 
precursor to the predominant product ion.  In the case of each agent the predominant 
product ion is marked, see Table 5-17.  Teo et al.[273], reported the only validated 
LC-MS/MS method for the quantification of thalidomide in the plasma and semen of 
HIV patients. The LOQ reported was 5ng/mL.  In our method a mass of 0.3ng was 
spiked into 200μL of sample matrix, which is 100μL of serum, resulted in a S/N ratio 
of 6, see Table 5-27.  Therefore the LOQ for the method described here is between 
>1.5ng/mL but <3ng/mL of serum.  The LOQ was defined as the mass of drug which 
gave a signal to noise ratio of 5:1[300].  Therefore the method developed here is more 
sensitive than any previously published method.   
 
The other major advancement in terms of sensitivity of this method compared to those 
already published is that this method permits the accurate analysis of small sample 
size.  Only Yang et al.[277], report a similar sample size but the LOQ for that method 
was 51.6ng/mL.  The average blood sample collected for thalidomide quantification 
yielded approximately 2-3mL of serum. The requirement only 100μL of serum for 
accurate quantification of thalidomide serum levels means that either (a) less blood 
tubes need to be taken from the patients and (b) more information can be gathered 
from the sample.  The ability to minimise the number of blood tubes required from the 
patient is important in terms of minimising patient discomfort.  A blood sample is a 
snap-shot of a patient at a particular point in his/her treatment.  The ability to 
maximise the information gathered from one sample is to be encouraged.  Proteomic 
analysis of clinical serum samples can result in the determination of relevant bio-
markers which may be used as predictors for response or treatment.  Advances in 
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proteome analysis have made it possible to simultaneously identify multiple proteins 
and their expression changes[361].  
 
5.6.2.3. Precision and accuracy 
The precision and accuracy of the method is a mark of the inherent level of error 
within the method. Precision is a mark of the closeness of the results to each other, 
while accuracy in a mark of the closeness of the result to the expected value. The 
precision and accuracy were assessed both on intra-day and inter-day experiments.  
 
The average precision across the concentration range examined was 3% and 1.8% for 
the intra-day and inter-day analysis respectively in serum.  The average precision 
across the concentration range examined was 2.6% and 1.8% for the intra-day and 
inter-day analysis respectively in cells.  All samples were very close with all samples, 
intra and inter-day, serum and cells having a precision of <5%.  
 
The average accuracy across the concentration range examined was 103% and 100% 
for the intra-day and inter-day analysis respectively in serum.  The accuracy of the 
method was 100% and 101% for the intra and inter-day analysis respectively in cells.  
ICH guidelines for precision and accuracy in bioanalytical method state that the 
precision at each concentration should not exceed 15% with the exception of the 
LOQ, which should not exceed 20%[385].  The method described here is clearly 
significantly precise by these standards. 
 
5.6.2.4. Recovery/extraction efficiency 
The extraction efficiency was established by direct comparison of the peak areas of 
the extracted sample compared to the peak area of a) the pure, unextracted sample 
calculated to be equivalent to 100% extraction or b) the sample extracted with no 
matrix in the tube. Overall the average percentage recovery is 106% for serum and 
103% for cells. Results are given in more detail in Table 5-20 and Table 5-26.  The 
recoveries were consistent across the concentration ranges examined.  This indicates 
that the extraction method was repeatable and stable both for intra and inter day 
experiments.  This is a higher recovery that obtained by Teo et al.[386], who detailed 
a 69% and 78% recovery of thalidomide in plasma and semen respectively, using SPE 
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as a sample preparation method for analysis by LC-MS/MS.  The most recently 
published validated (LC-UV) method gave a recovery of >90%  within a 
concentration range of 0.05-50μg/mL[276].  This would indicate that the efficiency of 
this extraction method is superior to SPE and that while a protein precipitation method 
gives reasonable results the concentration range examined was somewhat limited.  
 
5.6.2.5.  Stability through freeze/thaw 
The stability of thalidomide in serum has been described previously [247, 273, 278, 
282] highlighting the importance of prompt storage of acidified thalidomide below -
20°C. All samples employed in this project were acidified with 25mM citrate buffer, 
pH 1.5 and stored at -80°C, as described in Section 2.2.6.1.  The assay was validated 
using human serum as a matrix. This is compliant with the recommendations of 
Dadgar et al.[341], for the validation criteria for stability studies.  This is discussed 
further in Section 3.9.6.5.  Table 5-21and Table 5-22 detail the results of freeze thaw 
stability assay over four days in the presence and absence of citrate buffer.  As was 
expected the freeze/thaw stability of thalidomide in citrate buffer is seen to be greater 
than in serum alone.  For the stability of serum in citrate the stability is greatly 
reduced with increasing freeze thaw cycles.  In “Day1”, where the sample has been 
frozen once and thawed and extracted we see an average of 98% across the 
concentration range but by Day 4 an average of 73% of the starting agent was present.  
 
Stability analysis was also carried out in patient samples, Figure 5-32. Two samples 
from different patients on subsequent days were processed and stored with and 
without buffer, at -80°C and -20°C. Storage of the samples at -20°C with buffer 
showed a loss of 14% when compared to storage at -80°C with buffer. There was a 
minimum of a 10% loss of thalidomide by storing the samples at -80°C without 
buffer.  This would indicate that our procedure for storing thalidomide serum samples 
at -80°C with buffer is the best option. Though other authors have detailed storage at -
20°C[277]. 
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5.6.3. Thalidomide quantification in patient serum 
Thalidomide, an immunomodulatory, was approved for use in patients of multiple 
myeloma in May 2006[387].  An initial report published in 1999 showed that 
thalidomide was an effective treatment in 30–40% of patients with multiple myeloma, 
both advanced and refractory[257].  In collaboration with Dr P O’ Gorman and Dr R 
Rajpal of the Mater Misericordiae University Hospital, Dublin 7, samples were 
obtained from patients of multiple myeloma undergoing thalidomide treatment. Table 
5-28 gives the details of the patient cohort. From ten patients, ranging in age from 57-
81 years, two female and eight male patients, twenty one samples were collected for 
thalidomide quantification.  Two patients were switched from thalidomide to 
lenalidomide during the course of their treatment.  Some patients underwent dose 
alterations and two samples were definitely from patients who were non-compliant 
and one sample was from a patient who was potentially non-compliant.  
 
5.6.3.1. Serum level and dose correlations 
The serum level was found to range from 27ng/mL to 1407ng/mL across the patient 
group with large variations seen between patients (Figure 5-33).  The dose range of 
the patients ranged from 50mg/day to 300mg/day.  The quantified serum level of 
thalidomide in patients was correlated with dose (Figure 5-34) and with dose and 
neuropathy (Figure 5-35).  
 
The data shows that the dose given broadly correlates with the serum levels and that 
increasing or decreasing of the patient dose increased or decreased the thalidomide 
serum levels (Figure 5-37, Figure 5-38, Figure 5-39, Figure 5-40, Figure 5-41).  This 
correlates with previous study which showed that patients on low dose thalidomide 
(200mg) had a lower Cmax than patients on higher dose (800mg)[388].  Cmax is the 
maximum concentration of the drug observed after administration, also sometimes 
called “peak” concentration.  To the best of our knowledge this in the only study 
which has shown such a dynamic intra-patient variability of serum concentration at a 
specific time point.  This could possibly be due to patient variability in dosing 
schedules. As the timing of medication is fully in the control of the patient it is 
impossible in a real clinic situation to account for this variation.  The advice given to 
patients is to take thalidomide before bed-time, however, for some patients this may 
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be 7pm while for others it may be 11pm.  The large inter-patient variability may in 
part be due to these timing variables.  Another factor determining patient 
pharmacokinetics is diet as a high fat-containing meal cause minor changes in the 
Cmax but increases the time to maximum dose from 3.5/4.3hours to 6 hours in healthy 
volunteers[389]. 
 
Figure 5-43, Figure 5-44 and Figure 5-45 are examples taken from the literature of 
thalidomide pharmacokinetics profiles.  Figure 5-43 from Figg et al.[388], shows a 
study of the pharmacokinetics of thalidomide in elderly prostate cancer patients.  The 
thalidomide level was monitored over a 30 hour period, with samples taken ever hour 
for the first eight hours.  Figure 5-44 from Eriksson et al.[247], shows the 
pharmacokinetic profile of R and S thalidomide enantiomers in two subjects.  Figure 
5-45 from Saccomanni et al.[276], shows the plasma concentration of thalidomide in 
12 male subjects affected by hepatocellular carcinoma following singular oral dose 
administration (200 mg/BW). 
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Figure 5-43: Plasma concentration versus time curve, from Figg et al.[388] 
 
Thalidomide plasma concentration versus time in elderly prostate cancer patients 
who were administered low (200mg) graph A and high dose (800mg) graph B  
 
Plasma concentration 
versus time curves.  
(A) Plasma concentration 
versus time curve (mean +/-
SD) for patients in the 
low-dose group after a 
single oral dose of 200 mg 
of thalidomide.  
 
 
 
 
 
 
 
(B) Plasma concentration 
versus time curve (mean +/-
SD) for patients in the 
high-dose group after a 
single oral dose of 800 mg 
of thalidomide. 
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Figure 5-44: Blood concentration curves of thalidomide, from Eriksson et al.[247] 
 
Blood concentration curves observed (R) thalidomide – filled symbols, (S) 
thalidomide – open symbols and fitted concentration curves after oral (1mg/kg) or 
intravenous (i.v.50mg of 60 min) administration of the indicated enantiomers to two 
subjects. 
 
Figure 5-45:  Plasma concentration profile of thalidomide, from Saccomanni et al.[276] 
 
Plasma concentration versus time of thalidomide following singular oral dose 
administration (200 mg/BW). 
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5.6.3.2. Patient non-compliance 
Non-compliance or non-adherence is described as when a patient had missed some 
doses, had taken extra doses or had taken doses at the wrong time or the wrong 
quantity[390].  Non-compliance in oral medication is growing more important with 
many oral antineoplastic medications approved for use in the US such as 
cyclophosphamide, capecitabine, temozolomide, as well as the many of the new TKIs 
agents[391].  Though there is mention of patient adherence with reference to 
thalidomide in literature published by way of guidelines for oncology nurses, no 
study, to the best of our knowledge, has study the level of compliance in multiple 
myeloma patients received oral thalidomide.  
 
Of ten people prescribed thalidomide, two were actually non-compliant and one 
patient was suspected of being temporarily non-compliant.  The two patients (D and J) 
admitted to having been non-compliant after the results of the analytical study were 
analysed.  One patient (B) is suspected of non compliance, this patient has not 
admitted or mentioned missing doses, so it quite possible that any lapse in medication 
was unintentional.  The serum level of a fourth patient (G) also raised questions.  
 
Patient B is suspected of being temporarily non-adherent.  Of the three blood samples 
obtained from this patient two showed thalidomide serum levels approx 1000ng/mL 
(1082 and1095ng/mL) and one samples had a quantifiable thalidomide serum level of 
25ng/mL. This is a factor of 40 in the difference. As is shown in Figure 5-38, the 
patient dose was constant.  It is possible that in the case of this patient that a dose may 
have been missed or the timing of the medication was earlier in the day than normal.  
The half life of thalidomide is quite rapid.  In a study of patients with prostate cancer 
the median Tmax was 3.32hrs and 4.40hrs in patients receiving 200mg and 800mg of 
thalidomide respectively[388].  Tmax is the time after administration when the 
maximum concentration of the drug is in the patient blood.  This same study evaluated 
the elimination half-life for thalidomide to be 6.52+/-3.81 and 18.25 +/- 14.08hrs in 
for 200mg and 800mg thalidomide doses[388]. In our study, monitoring of the 
elimination rate was not possible, as to do so would have impacted on patient well-
being. However, from the literature (Figure 5-43, Figure 5-44, Figure 5-45) that 
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approximately less than half the Cmax is present in the patient serum at the time of 
blood sampling from our study.   
 
Patient J was non-compliant, with no detected thalidomide in the serum sample.  In 
consultation with the clinician after the analysis of the clinical samples the patient 
admitted non-compliance.  
 
Patient D was initially non-compliant and the lack of disease response led the clinical 
team to increase the patient’s dosage of thalidomide and eventual regime change.  The 
patient dose was increased due to lack of disease response.  The patient admitted non-
compliance after the serum samples were analysed.   
 
The serum levels for Patient G largely follow the trend of the prescribed dosing 
regime with the exception of the final sampling point.  For the last sampling point 
assessed the prescribed dose was reduced to 100mg/day to counteract the Grade 2 
neuropathy experienced.  However the quantified serum concentration for thalidomide 
for the 6th sampling point is approximately equivalent to previous samples taken when 
the patient was receiving 200mg/day.  It is possible that this patient either took a 
double dose of thalidomide prior to blood sampling or took his medication closer to 
the time of blood sample.  This patient had not admitted non-compliance and is 
suspected of so called “over-adherence” to the medication rather than non-
compliance.  
 
It is startling that a minimum 3, possibly 4, out of 10 patients investigated had some 
level of non-compliance demonstrated.  Even more so as patients involved in clinical 
studies are usually more adherent than the normal patient population due to patient 
selection and increased attention from the clinical staff[390, 392].  
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5.6.3.3. Serum level/neuropathy correlations 
When dose, quantified serum level and neuropathy (graded according to NCI criteria) 
was correlated we can see that regardless of dose the majority of samples had with 
Grade 2 neuropathy, Figure 5-35 and Figure 5-36.  Neuropathy was evaluated on 
consultation with the clinician at the time of blood sampling.  Two samples were 
evaluated as Grade 3, one of these patients was receiving 300mg/day and one patient 
was receiving 100mg/day.  As the effect of thalidomide on neuropathy is cumulative 
over time, you would expect that the patient receiving 100mg/day with Grade 3 
neuropathy have been taking thalidomide for an extended period of time.  However, 
from the point of view of cumulative time exposure some samples with lower Grade 
neuropathy also align time-wise with this sample.  
 
Two samples align with Grade 0 neuropathy; both (from the same patient) were 
prescribed to receive 200mg/day.  However one sample, contained 1407ng/mL 
thalidomide and one sample had considerably less thalidomide 25ng/mL.  Samples 
were taken approximately one month apart. It was suspected that this patient (Patient 
B) was partially non-adherent due to the low thalidomide serum concentration, as 
discussed in Section 5.5.3.2. 
 
Peripheral neuropathy is one of the most serious adverse effects associated with 
thalidomide treatment.  The frequency of Grade 3 and Grade 4 peripheral neuropathy 
in patients ranges from 3% to 15%[242, 268, 393, 394].  Peripheral neuropathy is 
normally managed by dose reduction or cessation, depending on the grade of 
neuropathy.  Of the ten patients in our study three experienced Grade 3 neuropathy.  
However, the serum levels for these patients differed greatly (164ng/mL, 755ng/mL 
and 330ng/mL).  This would suggest that while reduction of dose improves 
neuropathy, and the neuropathy is dose dependent, there does not appear to be a clear 
correlation between serious (Grade 3) neuropathy and thalidomide serum level.  There 
is some indication of cumulative effect of thalidomide in that a patient receiving 
50mg/mL was evaluated with Grade 2 neuropathy and had been taking thalidomide 
for over a year.  Some authors have suggested a limit of six months should be used for 
treatment with thalidomide to prevent neuropathy, though this would potentially have 
a huge impact on treatment and response. 
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Overall the serum levels quantified here broadly correlate with previously reported 
studies determining patient serum levels, where for hepatocellular carcinoma patients 
receiving 200mg/BW had a serum level of approximately 1000ng/mL after 12 
hours[276].  Also in a study of the pharmacokinetics of thalidomide in multiple 
myeloma patients who received 200mg the thalidomide serum concentration was 
<10μM (2500ng/mL) at 12 hours[271].  This is much higher that results seen in this 
study.  It is possible that as this study was conducted to have minimum impact on the 
patient that dosing times and samples times may have varied more than anticipated. 
 
5.6.3.4. Serum levels and disease response 
Of the two patients in the cohort, eight patients showed partial or very good partial 
response to thalidomide treatment. Two patients had progressive disease, Table 5-28.  
In such a small patient group it is difficult to make any clear statements regarding 
serum level and disease response.  Patients A, B, G and J all had very good partial 
response, though had difference ranges of thalidomide serum levels, from ~160ng/mL 
-~1000ng/mL.  Of the patients who showed disease progression one had the 
maximum thalidomide serum concentration found in the study and the other had an 
average serum level of ~375ng/mL.  
 
One of the considerations when administering chemotherapeutics is the determination 
of the correct dose for the patient.  One of the obvious results of incorrect dose 
calculations is overdose and excessive toxicity.  The key aim of Phase I clinical trials 
are generally to determine the dose limiting toxicity.  To prevent unacceptable toxicity 
the mean dose is generally aimed to the low range to minimise severe toxicity. As a 
result of this many cancer patients are inadvertently under dosed[380].   
 
In some tyrosine kinase inhibitors patients who exhibit a skin rash are more likely to 
respond that those that have no rash.  Future studies in the patient pharmacokinetics in 
multiple myeloma should include increased adverse effect monitoring as well as 
proteomic studies to monitoring levels of excretion enzymes if possible. It may then 
be possible to individualise that patient dose to a factor which could avoid under-
dosing. 
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5.6.4. Thalidomide quantification in cells 
Given the sensitivity of the method developed, the ability to quantify thalidomide in 
cell-culture was an objective.  The method validated without issue against the 
biological matrix of cancer cells, Section 5.4.2.  DLKP and DLKP-A cell-line models 
were exposed to 2μM thalidomide and samples taken at 30 minutes internals, as 
described in Section 2.1.8.  The cell pellets were stored in 50μL of citrate buffer. The 
samples were extracted and data analysed as described, Section 2.2.6.3. Upon analysis 
of the data, no quantifiable levels of thalidomide were detected in the cell pellets. 
 
Some groups have shown thalidomide activity in vitro such as Sung  et al.[395], who 
reported that curcumin plus thalidomide increased apoptosis in U266 cells, greater 
than either agent alone.  Keller et al.[396], reported that thalidomide inhibited 
Caspase-1 activity in vivo but not in vitro.  Hideshima et al.[397]. examined the 
activity of thalidomide and three thalidomide analogues, from Celgene, in multiple 
myeloma cells to discover that high dose thalidomide (100μmol/L) resulted in less 
than 20% inhibition on DNA synthesis in vitro, but the analogues achieved 50% 
inhibition.  DNA synthesis inhibition assays were performed after 48hours incubation 
of the agent with the cells at 37°C.  Thalidomide is noticeably unresponsive in assays 
in vitro with researchers using unfeasibly concentration to achieve results.  In our 
group thalidomide was also determined to be “non-toxic” when examined in vitro 7 
day toxicity assay, (data not shown). 
 
Given that thalidomide is know to hydrolyse in aqueous conditions at physiological 
pH, and given that only 8 samples out of 116 samples (~7%) had any detectable level 
of thalidomide present, an investigation of thalidomide stability in cell-culture media 
was undertaken.  Zhou et al.[278], monitored the concentration of thalidomide in 
HBSS transport buffer for the determination of thalidomide transport in Caco-2 cell 
monolayers. The stability of thalidomide in HBSS was also monitored. For this reason 
HBSS was included in this experiment.  In cell culture media and HBSS 2μM 
thalidomide was incubated at 37°C for 24hrs. Two stocks of thalidomide in DMSO 
were assessed.   
Figure 5-32 shows the rate of thalidomide degradation in cell-culture media and 
HBSS.  There is minimal difference between the old and new thalidomide stocks in 
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either HBSS or cell culture media.  This indicates that thalidomide is stable in DMSO 
at 4°C for at least 7 weeks.   
 
More than 50% of the thalidomide was degraded in HBSS within one hour. In media 
the rate of degradation was somewhat slower but with only 50% of thalidomide 
remaining after three hours.  This would indicate that thalidomide hydrolysed rapidly 
in cell culture media and HBSS.  This means that thalidomide is not stable in normal 
cell-culture media and that in vitro analysis of the function or response of thalidomide 
is questionable.   
 
This is not the first time that the hydrolysis of thalidomide has been reported.  In 1965 
Schumacher et al.,[398, 399] described the products of thalidomide in hydrolysis in 
the urine, blood and tissues of various species. Despite this however, much data 
continues to be published on thalidomide in vitro, with no mention or reference to the 
hydrolysis of thalidomide over the course of the assay.  
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5.6.5. Summary 
• In summary an LC-MS/MS was developed and validated for the quantification 
of thalidomide in human serum from multiple myeloma patients and 
thalidomide in cells and cell-culture media.   
 
• A liquid-liquid extraction sample clean-up step was optimised.  This 
combination gave a sensitive, accurate, reproducible method which only 
required 100μL of patient serum.  LLE was also applicable for the analysis of 
thalidomide in cells 
 
• This method was applied to the analysis of thalidomide in multiple myeloma 
patient serum.   
 
• While no clear relationship between serum level and outcome was seen, it is 
clear that serum level and dose are directly linked.  Also dose reduction 
decreases peripheral neuropathy.   
 
• However the clearest result from the study was the issue of patient non 
compliance.  
 
• To the best of our knowledge, this is the only study to report patient non-
compliance is terms of thalidomide monitoring in multiple myeloma patients.  
 
• The sensitivity of the LC-MS/MS method also meant that the method could be 
employed for the quantification of thalidomide in cell-lines.   
 
• Inconsistent results for the quantification of thalidomide in accumulation and 
efflux assays were shown to be caused by thalidomide instability in media. 
Thalidomide rapidly breaks down in cell-culture media. 
 
• Even though this rapid break-down of thalidomide has been monitored in 
HBSS for cell-based transport assays of thalidomide once previously[278], 
this is the first time these finding have been confirmed in cell-culture media.  
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Also the attention of the clinical and laboratory based investigator of 
thalidomide in vitro does not seem to have registered the issues of thalidomide 
in cell-based assays and do not account for thalidomide hydrolysis in their 
assay.  
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SECTION 6.0 –Conclusions 
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6. Conclusions 
Over the course of this body of work, two separate sensitive analytical methods have 
been developed for the analysis of clinically important therapeutic agents. Two 
classes of anti-cancer agents were investigated; 1) tyrosine kinase inhibitors, 
specifically dasatinib and lapatinib, and 2) immunomodulatory agents, specifically 
thalidomide.  These methods have been designed to be sensitive, rapid techniques that 
are easily transferable from one laboratory to another.  Using LC-MS/MS as a 
quantification tool has provided a level of sensitivity which can accurately and 
precisely determine minute differences in samples both in vitro and in vivo.  The 
extraction procedure (LLE) employed for the sample clean-up is a low cost, low 
technology option for the purification of target agents in biological samples.  This 
straightforward approach is applicable to a many biological matrices and can therefore 
be applied to a variety of cell types, patient serum and other sample types where 
applicable.  
 
The analytical method for the quantification of tyrosine kinase inhibitors has been 
applied to in vitro cell-line models and used to better understand the resistance 
mechanisms of dasatinib and lapatinib.  Also in conjunction with cell toxicity assays 
this techniques assists in the teasing apart of complex cross-resistance mechanism.  
The application of this analytical method for the quantification of erlotinib, gefitinib 
and imatinib in glioma primary cultures sheds new light on the role of these TKIs in 
glioma.  The greater level of accumulation of these agents in lower grade glioma 
cultures requires further investigation as to whether this reaction is specific to this cell 
model or whether this trend is universal for lower grade gliomas.  
 
The application of the LC-MS/MS method for the quantification of thalidomide in 
patient samples is the result of a pilot study in collaboration with the Mater Hospital, 
Dublin.  This study endeavoured to examine if the collection, the processing and 
analyses of patient samples was possible with minimum intrusion upon the patient.  
Although the numbers enrolled were small, a high level of patient non-compliance 
was detected in this study.  Also, the application of this method for the analysis of 
thalidomide in vitro demonstrated the impact of the rapid hydrolysis of thalidomide 
on in vitro assays. 
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Both of the methods designed within this thesis have further clinical impact beyond 
the scope of the analysis already undertaken.   
The method for the quantification of lapatinib could be employed to quantity the 
levels of lapatinib in the biopsies tissues of breast cancer patients. By monitoring both 
the circulating serum levels and the level of lapatinib within the tumour it would be 
possible to determine the impact of physiological mechanisms of resistance, such as 
the drug delivery and tumour micro-environment, on patient outcome.  As the method 
developed here is the only method in the literature validated for the quantification of 
lapatinib in cells it is inherently applicable.  
 
The clinical application of this method for any of the TKIs could be employed to 
further inform the clinical team and researchers with respect to circulating drug levels 
and the levels of therapeutic agents at the site of action.  
 
The methods developed here are truly translational in their ability to investigate both 
in vivo and in vitro queries.  
 
Detailed below are the specific conclusions of each section investigated. 
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6.1. The development and validation of a method of the 
quantification of dasatinib and lapatinib 
• A novel and sensitive LC-MS/MS assay has been developed and validated for 
the determination of cellular levels of the tyrosine kinase inhibitors dasatinib 
and lapatinib  
 
• The method is as sensitive as those already in the literature but through the use 
of an isocratic elution this separation method is more straight-forward, lower 
cost and easier to use.  
 
• The use of one tyrosine kinase inhibitor as the internal standard for the other 
agent gives excellent results and dual applicability of the method.  This avoids 
the use of expensive deuterated analogues of the analyte of interest as an 
internal standard.  
 
• The use of a liquid-liquid extraction clean up stage gives simplicity of 
application making the method accessible to other researchers, as this method 
does not require the additional equipment or commercial clean-up systems. 
The extraction solvents and standard laboratory equipment used here are 
routinely available in most laboratories.  
 
• The LLE method is capable of processing large numbers of samples without 
the need for extra equipment.  Also, the samples obtained from an LLE 
method are clean, have a low background and generally have excellent 
recoveries. 
 
• An isocratic elution scheme gives a simple, robust and reproducible 
chromatographic method. 
 
• Our experimental approach has yielded superior levels of sensitivity and the 
specificity for the analytical method. 
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• This LC-MS/MS technique has been successfully employed for the 
quantification of low dose dasatinib over short time frame in cardiac cells and 
in cancer cell-line models. 
 
• This LC-MS/MS method has been used to assist the characterisation of 
dasatinib resistant cell-line model, in collaboration with Dr Brendan Corkery. 
 
• This basic analytical method was applied and partially validated for other TKI 
molecules, erlotinib, gefitinib, imatinib.  This simple method transfer from one 
TKI to another minimise the time required for method developed and results in 
a simple and efficient method. 
 
• Using LC-MS/MS quantification techniques, it was possible to quantify the 
intracellular mass of these TKIs (erlotinib, gefitinib and imatinib) in glioma 
cell cultures.  To the best of our knowledge is the in first time that the 
accumulation of these agents has been measure in human primary glioma 
cultures.  
 
• Low grade glioma accumulated more of each TKI compared to higher grade 
gliomas.  While in differences in the level of intracellular TKI accumulated 
did not directly correlate with the levels of ABC transporters detected in the 
models, this interesting results requires closer investigation. 
 
6.2. Investigation of dasatinib and lapatinib interaction with 
MDR over-expressing cell-lines 
 
• Through accumulation and efflux profile of dasatinib in P-gp over-expressing 
cell-lines, we can conclude that dasatinib is a P-gp substrate.  This is a 
clinically relevant finding as the drug is currently used in the treatment of 
imatinib-intolerant and imatinib-resistant CML patient.  Should an imatinib-
resistant patient receiving dasatinib relapse or not respond to treatment this 
maybe due to the reduced efficacy of dasatinib at the required site of action 
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due to a lower intracellular concentration associated with intratumoural 
overexpression of P-gp.  
 
• The efflux of dasatinib by P-gp decreases the intracellular mass, which was 
seen with decreased the efficacy of dasatinib in vitro in resistant cell-line 
models compared to the parental cell-line models.  This was reversible with 
the inclusion of a P-gp inhibitor, elacridar.  
 
• At pharmacokinetically relevant concentrations, dasatinib is not a P-gp 
inhibitor. 
 
• Dasatinib is a substrate of the ABC transport BCRP and hence intratumour 
expression of the transporter may impact efficacy 
•  
 
• The active transport of dasatinib by BCRP decreased the efficacy if dasatinib 
in vitro. 
 
• Dasatinib did not appear to inhibit the action of BCRP at clinically relevant 
concentrations 
 
• Dasatinib is not a substrate of MRP-1. 
 
• Lapatinib is not a substrate of P-gp.  The mechanism of P-gp inhibition is not 
through competitive binding to substrate binding sites. 
 
• In the cell-line model examined, lapatinib is not a substrate of BCRP, though 
may have some BCRP-inhibitory activity. 
• . 
 
• In the cell-line models examined, lapatinib is not substrate of MRP-1. 
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• The “sister” resistant cell-line models DLKP-Sq/Mitox-BCRP and DLKP-
Sq/Mitox-MDR are excellent models for the examination of therapeutic agent 
transport in vitro. 
 
6.3. The development and validation of a method to quantify 
thalidomide 
 
• A sensitive straight-forward method for the quantification of thalidomide by 
LC-MS/MS has been developed. 
 
• This method is more sensitive, (Section 5.4.3 and Section 5.6.2.2) than 
methods previously published and the use of an isocratic separation adds 
simplicity to the analytical method.  
 
• Umbelliferone is an easy, cheap and safe compound to use as an internal 
standard for the quantification of thalidomide. 
 
• A method has been developed for the chromatographic separation of 
thalidomide and lenalidomide. 
 
• However, lenalidomide has very different physiochemical properties 
compared to thalidomide and as such is not appropriate as an internal standard 
for thalidomide. 
 
• Given the sensitivity of the method developed and the use of a liquid-liquid 
extraction procedure, this method was validated for the quantification of 
thalidomide in cells 
 
• However, in cell culture experiments the rate of thalidomide hydrolyses was 
shown to be detrimental to the quantification of thalidomide in cell efflux and 
accumulation assay.  
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• Thalidomide was shown to hydrolyse in cell culture media rapidly, with 50% 
of thalidomide remaining after three hours at physiological temperature and 
pH.  
 
• In multiple myeloma patients, the dose administered was shown to be related 
empirically to the serum concentration levels.  
• Non-compliance or partial compliance to the medication protocol was seen to 
be an issue in 30%-40% of the patient cohort.  
 
• Future clinical trial studies should include more rigorous monitoring and 
recording of individual patient factors such as medication timings as the rapid 
pharmacokinetics of thalidomide could be a factor in inter-patient variability 
following equal doses.  
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SECTION 7.0 –Future plans 
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7. Future plans 
7.1. LC-MS/MS method for the analysis of TKIs 
 
•  To improve the existing separation method of the analysis of lapatinib and 
dasatinib the effect of reducing the organic component of the mobile phase 
and increasing the flow should be examined. Theoretically reducing the 
organic component further should increase the separation of dasatinib from the 
dead volume and increasing the flow should reduce the time between dasatinib 
and lapatinib separation 
 
• Rapid resolution LC columns could also be examined for the separation of 
dasatinib and lapatinib.  The decreased particle size (sub 2μm particle size) 
columns capable of operating at high flow allows for ultra fast separations.  
 
• Investigation into improved separation of multiple TKI mixtures could be used 
to improve the multiple TKI separation.  
 
• The validation of gefitinib, erlotinib and imatinib should be completed.  Also 
other TKIs such as sorafenib and neratinib could be examined using this 
extraction and separation method.  
 
• The quantification of dasatinib and lapatinib in serum could be investigated. 
This would require a partial re-validation in the appropriate matrix (human 
serum).  This could be used for the evaluation of patient samples 
 
• Given that the quantification of erlotinib, gefitinib and imatinib in glioma cell 
cultures gave such interesting and clear results that showed that the more 
sensitive and responsive cells had increased TKI accumulation and 
investigation into other low grade gliomas to further explore this finding 
would be interesting.  
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7.2. Investigation of TKIs in MDR expressing cell-lines 
 
• The procedures followed here has given clear information about the MDR 
status of dasatinib and lapatinib and defined their positions as substrates or 
inhibitors.  This procedure of accumulation/efflux assays, in vitro toxicity 
assay and combination in vitro assays could be used to define the MDR status 
of other TKI agents such as neratinib 
 
7.3. LC-MS/MS methods for the analysis of multiple 
myeloma drugs 
 
• Given the success of the analysis of serum concentration levels thalidomide in 
a small group of patient samples this study could be continued and expanded.  
 
• An analytical method for the quantification of lenalidomide could be 
developed.  A method published by Liu et al.[400], details the quantification 
of lenalidomide using a protein precipitation sample preparation stage.  This 
method could be explored and optimised for the analysis of lenalidomide in 
patient samples in our laboratory. 
 
• An analytical method for the quantification of bortezomib could be developed.  
Bortezomib is dipeptidyl boronic acid is used in the treatment of multiple 
myeloma.  The quantification of bortezomib both in vitro and in vivo would be 
of clinical interest. 
 
 
 403
 
 
 
 
 
SECTION 8.0 – References 
 
 
 404
8. References 
 
 
 
 
 
1. Tsuruo, T., M. Naito, A. Tomida, N. Fujita, T. Mashima, S. Hirosh, and 
N. Haga, Molecular targeting therapy of cancer: drug resistance, apoptosis 
and survival signal. Cancer Science, 2003. 94(1): p. 15-21. 
2. Rosa, D.D., G. Ismael, L.D. Lago, and A. Awada, Molecular-targeted 
therapies: Lessons from years of clinical development. Cancer Treatment 
Reviews, 2008. 34(1): p. 61-80. 
3. O'Connor, R., The pharmacology of cancer resistance. Anticancer Research, 
2007. 27(3A): p. 1267-1272. 
4. Lage, H., An overview of cancer multidrug resistance: a still unsolved 
problem. Cell Mol Life Sci, 2008. 65(20): p. 3145-67. 
5. Collins, D.M., Docetaxel uptake and modulation of P-gp mediated docetaxel 
efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines. 
National Institute for Cellular Biotechnology (NICB), 2008:  
6. Devery, A., Pharmacological modulation and manipulation of cancer drug 
resistance. NICB, 2010:  
7. Dunne, G., Characterisation and Modulation of Drug Resistance in Lung 
Cancer Cell Lines. NICB, 2009:  
8. O'Connor, R., A Review of Mechanisms of Circumvention and Modulation of 
Chemotherapeutic Drug Resistance Current Cancer Drug Targets, 2009. 9(3): 
p. 273-280. 
9. Seeger, M.A. and H.W. van Veen, Molecular basis of multidrug transport by 
ABC transporters. Biochimica et Biophysica Acta (BBA) - Proteins & 
Proteomics, 2009. 1794(5): p. 725-737. 
10. Ambudkar, S.V., S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and 
M.M. Gottesman, Biochemical, cellular, and pharmacological aspects of the 
multidrug transporter. Annu Rev Pharmacol Toxicol, 1999. 39: p. 361-98. 
11. Dean, M., A. Rzhetsky, and R. Allikmets, The human ATP-binding cassette 
(ABC) transporter superfamily. Genome Res, 2001. 11(7): p. 1156-66. 
12. Higgins, C.F., ABC transporters: from microorganisms to man. Annu Rev 
Cell Biol, 1992. 8: p. 67-113. 
13. Walker, J.E., M. Saraste, M.J. Runswick, and N.J. Gay, Distantly related 
sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases 
and other ATP-requiring enzymes and a common nucleotide binding fold. 
Embo J, 1982. 1(8): p. 945-51. 
14. Hyde, S.C., P. Emsley, M.J. Hartshorn, M.M. Mimmack, U. Gileadi, S.R. 
Pearce, M.P. Gallagher, D.R. Gill, R.E. Hubbard, and C.F. Higgins, 
Structural model of ATP-binding proteins associated with cystic fibrosis, 
multidrug resistance and bacterial transport. Nature, 1990. 346(6282): p. 362-
5. 
15. Rocchi, E., A. Khodjakov, E.L. Volk, C.H. Yang, T. Litman, S.E. Bates, 
and E. Schneider, The product of the ABC half-transporter gene ABCG2 
(BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys 
Res Commun, 2000. 271(1): p. 42-6. 
 405
16. Litman, T., T.E. Druley, W.D. Stein, and S.E. Bates, From MDR to MXR: 
new understanding of multidrug resistance systems, their properties and 
clinical significance. Cell Mol Life Sci, 2001. 58(7): p. 931-59. 
17. Loo, T.W. and D.M. Clarke, The packing of the transmembrane segments of 
human multidrug resistance P-glycoprotein is revealed by disulfide cross-
linking analysis. J Biol Chem, 2000. 275(8): p. 5253-6. 
18. Cragg, G.M. and D.J. Newman, Plants as a source of anti-cancer agents. 
Journal of Ethnopharmacology, 2005. 100(1-2): p. 72-79. 
19. Laing, N.M., M.G. Belinsky, G.D. Kruh, D.W. Bell, J.T. Boyd, L. Barone, 
J.R. Testa, and K.D. Tew, Amplification of the ATP-binding cassette 2 
transporter gene is functionally linked with enhanced efflux of estramustine in 
ovarian carcinoma cells. Cancer Res, 1998. 58(7): p. 1332-7. 
20. Vulevic, B., Z. Chen, J.T. Boyd, W. Davis, Jr., E.S. Walsh, M.G. Belinsky, 
and K.D. Tew, Cloning and characterization of human adenosine 5'-
triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer 
Res, 2001. 61(8): p. 3339-47. 
21. Mack, J.T., D.M. Townsend, V. Beljanski, and K.D. Tew, The ABCA2 
transporter: intracellular roles in trafficking and metabolism of LDL-derived 
cholesterol and sterol-related compounds. Curr Drug Metab, 2007. 8(1): p. 
47-57. 
22. Boonstra, R., H. Timmer-Bosscha, J. van Echten-Arends, D.M. van der 
Kolk, A. van den Berg, B. de Jong, K.D. Tew, S. Poppema, and E.G. de 
Vries, Mitoxantrone resistance in a small cell lung cancer cell line is 
associated with ABCA2 upregulation. Br J Cancer, 2004. 90(12): p. 2411-7. 
23. Steinbach, D., J.P. Gillet, A. Sauerbrey, B. Gruhn, K. Dawczynski, V. 
Bertholet, F. de Longueville, F. Zintl, J. Remacle, and T. Efferth, ABCA3 
as a possible cause of drug resistance in childhood acute myeloid leukemia. 
Clin Cancer Res, 2006. 12(14 Pt 1): p. 4357-63. 
24. Lage, H., ABC-transporters: implications on drug resistance from 
microorganisms to human cancers. Int J Antimicrob Agents, 2003. 22(3): p. 
188-99. 
25. Szakacs, G., J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. 
Gottesman, Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 
2006. 5(3): p. 219-34. 
26. Riordan, J.R. and V. Ling, Purification of P-glycoprotein from plasma 
membrane vesicles of Chinese hamster ovary cell mutants with reduced 
colchicine permeability. J Biol Chem, 1979. 254(24): p. 12701-5. 
27. Kartner, N., J.R. Riordan, and V. Ling, Cell surface P-glycoprotein 
associated with multidrug resistance in mammalian cell lines. Science, 1983. 
221(4617): p. 1285-8. 
28. Ueda, K., A. Yoshida, and T. Amachi, Recent progress in P-glycoprotein 
research. Anticancer Drug Des, 1999. 14(2): p. 115-21. 
29. Izquierdo, M.A., J.J. Neefjes, A.E. Mathari, M.J. Flens, G.L. Scheffer, 
and R.J. Scheper, Overexpression of the ABC transporter TAP in multidrug-
resistant human cancer cell lines. Br J Cancer, 1996. 74(12): p. 1961-7. 
30. Lage, H., C. Perlitz, R. Abele, R. Tampe, M. Dietel, D. Schadendorf, and 
P. Sinha, Enhanced expression of human ABC-transporter tap is associated 
with cellular resistance to mitoxantrone. FEBS Lett, 2001. 503(2-3): p. 179-
84. 
 406
31. Gottesman, M.M., T. Fojo, and S.E. Bates, Multidrug resistance in cancer: 
role of ATP-dependent transporters. Nat Rev Cancer, 2002. 2(1): p. 48-58. 
32. Ruetz, S. and P. Gros, Phosphatidylcholine translocase: a physiological role 
for the mdr2 gene. Cell, 1994. 77(7): p. 1071-81. 
33. Chen, K.G., G. Szakacs, J.P. Annereau, F. Rouzaud, X.J. Liang, J.C. 
Valencia, C.N. Nagineni, J.J. Hooks, V.J. Hearing, and M.M. Gottesman, 
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) 
of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and 
melanocytes. Pigment Cell Res, 2005. 18(2): p. 102-12. 
34. Frank, N.Y., A. Margaryan, Y. Huang, T. Schatton, A.M. Waaga-Gasser, 
M. Gasser, M.H. Sayegh, W. Sadee, and M.H. Frank, ABCB5-mediated 
doxorubicin transport and chemoresistance in human malignant melanoma. 
Cancer Res, 2005. 65(10): p. 4320-33. 
35. Huang, Y., P. Anderle, K.J. Bussey, C. Barbacioru, U. Shankavaram, Z. 
Dai, W.C. Reinhold, A. Papp, J.N. Weinstein, and W. Sadee, Membrane 
transporters and channels: role of the transportome in cancer 
chemosensitivity and chemoresistance. Cancer Res, 2004. 64(12): p. 4294-301. 
36. Yasui, K., S. Mihara, C. Zhao, H. Okamoto, F. Saito-Ohara, A. Tomida, 
T. Funato, A. Yokomizo, S. Naito, I. Imoto, T. Tsuruo, and J. Inazawa, 
Alteration in copy numbers of genes as a mechanism for acquired drug 
resistance. Cancer Res, 2004. 64(4): p. 1403-10. 
37. Paterson, J.K., S. Shukla, C.M. Black, T. Tachiwada, S. Garfield, S. 
Wincovitch, D.N. Ernst, A. Agadir, X. Li, S.V. Ambudkar, G. Szakacs, S. 
Akiyama, and M.M. Gottesman, Human ABCB6 localizes to both the outer 
mitochondrial membrane and the plasma membrane. Biochemistry, 2007. 
46(33): p. 9443-52. 
38. Childs, S., R.L. Yeh, D. Hui, and V. Ling, Taxol resistance mediated by 
transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res, 
1998. 58(18): p. 4160-7. 
39. Gerloff, T., B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, J. Roth, 
A.F. Hofmann, and P.J. Meier, The sister of P-glycoprotein represents the 
canalicular bile salt export pump of mammalian liver. J Biol Chem, 1998. 
273(16): p. 10046-50. 
40. Cole, S.P., G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. 
Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan, and R.G. Deeley, 
Overexpression of a transporter gene in a multidrug-resistant human lung 
cancer cell line. Science, 1992. 258(5088): p. 1650-4. 
41. Haimeur, A., G. Conseil, R.G. Deeley, and S.P. Cole, The MRP-related and 
BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity 
and regulation. Curr Drug Metab, 2004. 5(1): p. 21-53. 
42. Jedlitschky, G., I. Leier, U. Buchholz, K. Barnouin, G. Kurz, and D. 
Keppler, Transport of glutathione, glucuronate, and sulfate conjugates by the 
MRP gene-encoded conjugate export pump. Cancer Res, 1996. 56(5): p. 988-
94. 
43. Taniguchi, K., M. Wada, K. Kohno, T. Nakamura, T. Kawabe, M. 
Kawakami, K. Kagotani, K. Okumura, S. Akiyama, and M. Kuwano, A 
human canalicular multispecific organic anion transporter (cMOAT) gene is 
overexpressed in cisplatin-resistant human cancer cell lines with decreased 
drug accumulation. Cancer Res, 1996. 56(18): p. 4124-9. 
 407
44. Materna, V., B. Liedert, J. Thomale, and H. Lage, Protection of platinum-
DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 
hammerhead ribozymes in human cancer cells. Int J Cancer, 2005. 115(3): p. 
393-402. 
45. Cui, Y., J. Konig, J.K. Buchholz, H. Spring, I. Leier, and D. Keppler, 
Drug resistance and ATP-dependent conjugate transport mediated by the 
apical multidrug resistance protein, MRP2, permanently expressed in human 
and canine cells. Mol Pharmacol, 1999. 55(5): p. 929-37. 
46. Konig, J., A.T. Nies, Y. Cui, I. Leier, and D. Keppler, Conjugate export 
pumps of the multidrug resistance protein (MRP) family: localization, 
substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys 
Acta, 1999. 1461(2): p. 377-94. 
47. Borst, P., C. de Wolf, and K. van de Wetering, Multidrug resistance-
associated proteins 3, 4, and 5. Pflugers Arch, 2007. 453(5): p. 661-73. 
48. Kool, M., M. van der Linden, M. de Haas, G.L. Scheffer, J.M. de Vree, 
A.J. Smith, G. Jansen, G.J. Peters, N. Ponne, R.J. Scheper, R.P. Elferink, 
F. Baas, and P. Borst, MRP3, an organic anion transporter able to transport 
anti-cancer drugs. Proc Natl Acad Sci U S A, 1999. 96(12): p. 6914-9. 
49. de Jong, M.C., J.W. Slootstra, G.L. Scheffer, A.B. Schroeijers, W.C. 
Puijk, R. Dinkelberg, M. Kool, H.J. Broxterman, R.H. Meloen, and R.J. 
Scheper, Peptide transport by the multidrug resistance protein MRP1. Cancer 
Res, 2001. 61(6): p. 2552-7. 
50. Zeng, H., L.J. Bain, M.G. Belinsky, and G.D. Kruh, Expression of 
multidrug resistance protein-3 (multispecific organic anion transporter-D) in 
human embryonic kidney 293 cells confers resistance to anticancer agents. 
Cancer Res, 1999. 59(23): p. 5964-7. 
51. Schuetz, J.D., M.C. Connelly, D. Sun, S.G. Paibir, P.M. Flynn, R.V. 
Srinivas, A. Kumar, and A. Fridland, MRP4: A previously unidentified 
factor in resistance to nucleoside-based antiviral drugs. Nat Med, 1999. 5(9): 
p. 1048-51. 
52. Chen, Z.S., K. Lee, and G.D. Kruh, Transport of cyclic nucleotides and 
estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance 
to 6-mercaptopurine and 6-thioguanine. J Biol Chem, 2001. 276(36): p. 
33747-54. 
53. Chen, Z.S., K. Lee, S. Walther, R.B. Raftogianis, M. Kuwano, H. Zeng, 
and G.D. Kruh, Analysis of methotrexate and folate transport by multidrug 
resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate 
efflux system. Cancer Res, 2002. 62(11): p. 3144-50. 
54. Wijnholds, J., C.A. Mol, L. van Deemter, M. de Haas, G.L. Scheffer, F. 
Baas, J.H. Beijnen, R.J. Scheper, S. Hatse, E. De Clercq, J. Balzarini, and 
P. Borst, Multidrug-resistance protein 5 is a multispecific organic anion 
transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A, 
2000. 97(13): p. 7476-81. 
55. Jedlitschky, G., B. Burchell, and D. Keppler, The multidrug resistance 
protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J 
Biol Chem, 2000. 275(39): p. 30069-74. 
56. Belinsky, M.G., Z.S. Chen, I. Shchaveleva, H. Zeng, and G.D. Kruh, 
Characterization of the drug resistance and transport properties of multidrug 
resistance protein 6 (MRP6, ABCC6). Cancer Res, 2002. 62(21): p. 6172-7. 
 408
57. Kruh, G.D., Y. Guo, E. Hopper-Borge, M.G. Belinsky, and Z.S. Chen, 
ABCC10, ABCC11, and ABCC12. Pflugers Arch, 2007. 453(5): p. 675-84. 
58. Hopper-Borge, E., Z.S. Chen, I. Shchaveleva, M.G. Belinsky, and G.D. 
Kruh, Analysis of the drug resistance profile of multidrug resistance protein 7 
(ABCC10): resistance to docetaxel. Cancer Res, 2004. 64(14): p. 4927-30. 
59. Oguri, T., Y. Bessho, H. Achiwa, H. Ozasa, K. Maeno, H. Maeda, S. Sato, 
and R. Ueda, MRP8/ABCC11 directly confers resistance to 5-fluorouracil. 
Mol Cancer Ther, 2007. 6(1): p. 122-7. 
60. Doyle, L.A., W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, A.K. Rishi, 
and D.D. Ross, A multidrug resistance transporter from human MCF-7 breast 
cancer cells. Proc Natl Acad Sci U S A, 1998. 95(26): p. 15665-70. 
61. Allikmets, R., L.M. Schriml, A. Hutchinson, V. Romano-Spica, and M. 
Dean, A human placenta-specific ATP-binding cassette gene (ABCP) on 
chromosome 4q22 that is involved in multidrug resistance. Cancer Res, 1998. 
58(23): p. 5337-9. 
62. Miyake, K., L. Mickley, T. Litman, Z. Zhan, R. Robey, B. Cristensen, M. 
Brangi, L. Greenberger, M. Dean, T. Fojo, and S.E. Bates, Molecular 
cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant 
cells: demonstration of homology to ABC transport genes. Cancer Res, 1999. 
59(1): p. 8-13. 
63. Lage, H. and M. Dietel, Effect of the breast-cancer resistance protein on 
atypical multidrug resistance. Lancet Oncol, 2000. 1: p. 169-75. 
64. Doyle, L.A. and D.D. Ross, Multidrug resistance mediated by the breast 
cancer resistance protein BCRP (ABCG2). Oncogene, 2003. 22(47): p. 7340-
58. 
65. Biedler, J.L. and H. Riehm, Cellular resistance to actinomycin D in Chinese 
hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic 
studies. Cancer Res, 1970. 30(4): p. 1174-84. 
66. Juliano, R.L. and V. Ling, A surface glycoprotein modulating drug 
permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 
1976. 455(1): p. 152-62. 
67. Riehm, H. and J.L. Biedler, Cellular resistance to daunomycin in Chinese 
hamster cells in vitro. Cancer Res, 1971. 31(4): p. 409-12. 
68. Dano, K., Cross resistance between vinca alkaloids and anthracyclines in 
Ehrlich ascites tumor in vivo. Cancer Chemother Rep, 1972. 56(6): p. 701-8. 
69. Dano, K., Active outward transport of daunomycin in resistant Ehrlich ascites 
tumor cells. Biochim Biophys Acta, 1973. 323(3): p. 466-83. 
70. Gottesman, M.M. and I. Pastan, Biochemistry of multidrug resistance 
mediated by the multidrug transporter. Annu Rev Biochem, 1993. 62: p. 385-
427. 
71. Bellamy, W.T., P-glycoproteins and multidrug resistance. Annu Rev 
Pharmacol Toxicol, 1996. 36: p. 161-83. 
72. Garrigues, A., N. Loiseau, M. Delaforge, J. Ferte, M. Garrigos, F. Andre, 
and S. Orlowski, Characterization of two pharmacophores on the multidrug 
transporter P-glycoprotein. Mol Pharmacol, 2002. 62(6): p. 1288-98. 
73. Pleban, K., S. Kopp, E. Csaszar, M. Peer, T. Hrebicek, A. Rizzi, G.F. 
Ecker, and P. Chiba, P-glycoprotein substrate binding domains are located 
at the transmembrane domain/transmembrane domain interfaces: a combined 
photoaffinity labeling-protein homology modeling approach. Mol Pharmacol, 
2005. 67(2): p. 365-74. 
 409
74. Omote, H. and M.K. Al-Shawi, A novel electron paramagnetic resonance 
approach to determine the mechanism of drug transport by P-glycoprotein. J 
Biol Chem, 2002. 277(47): p. 45688-94. 
75. Sharom, F.J., M.R. Lugo, and P.D. Eckford, New insights into the drug 
binding, transport and lipid flippase activities of the p-glycoprotein multidrug 
transporter. J Bioenerg Biomembr, 2005. 37(6): p. 481-7. 
76. Sharom, F.J., R. Liu, Q. Qu, and Y. Romsicki, Exploring the structure and 
function of the P-glycoprotein multidrug transporter using fluorescence 
spectroscopic tools. Semin Cell Dev Biol, 2001. 12(3): p. 257-65. 
77. Loo, T.W. and D.M. Clarke, Recent progress in understanding the 
mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol, 2005. 
206(3): p. 173-85. 
78. Loo, T.W. and D.M. Clarke, Determining the dimensions of the drug-binding 
domain of human P-glycoprotein using thiol cross-linking compounds as 
molecular rulers. J Biol Chem, 2001. 276(40): p. 36877-80. 
79. Zaman, G.J., J. Lankelma, O. van Tellingen, J. Beijnen, H. Dekker, C. 
Paulusma, R.P. Oude Elferink, F. Baas, and P. Borst, Role of glutathione in 
the export of compounds from cells by the multidrug-resistance-associated 
protein. Proceedings of the National Academy of Sciences of the United States 
of America, 1995. 92(17): p. 7690-7694. 
80. Deeley, R.G., C. Westlake, and S.P.C. Cole, Transmembrane Transport of 
Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug 
Resistance Proteins. Physiol. Rev., 2006. 86(3): p. 849-899. 
81. Nooter, K., G. Brutel de la Riviere, M.P. Look, K.E. van Wingerden, S.C. 
Henzen-Logmans, R.J. Scheper, M.J. Flens, J.G. Klijn, G. Stoter, and J.A. 
Foekens, The prognostic significance of expression of the multidrug 
resistance-associated protein (MRP) in primary breast cancer. Br J Cancer, 
1997. 76(4): p. 486-93. 
82. Arts, H.J., D. Katsaros, E.G. de Vries, M. Massobrio, F. Genta, S. Danese, 
R. Arisio, R.J. Scheper, M. Kool, G.L. Scheffer, P.H. Willemse, A.G. van 
der Zee, and A.J. Suurmeijer, Drug resistance-associated markers P-
glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-
associated protein 2, and lung resistance protein as prognostic factors in 
ovarian carcinoma. Clin Cancer Res, 1999. 5(10): p. 2798-805. 
83. Walsh, N., A. Larkin, S. Kennedy, L. Connolly, J. Ballot, W. Ooi, G. 
Gullo, J. Crown, M. Clynes, and L. O'Driscoll, Expression of multidrug 
resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell 
carcinoma. BMC Urol, 2009. 9: p. 6. 
84. Walsh, N., S. Kennedy, A.M. Larkin, D. Tryfonopoulos, A.J. Eustace, T. 
Mahgoub, C. Conway, I. Oglesby, D. Collins, J. Ballot, W.S. Ooi, G. 
Gullo, M. Clynes, J. Crown, and L. O'Driscoll, Membrane transport 
proteins in human melanoma: associations with tumour aggressiveness and 
metastasis. Br J Cancer. 102(7): p. 1157-62. 
85. Borst, P., R. Evers, M. Kool, and J. Wijnholds, A Family of Drug 
Transporters: the Multidrug Resistance-Associated Proteins. Journal of the 
National Cancer Institute, 2000. 92(16): p. 1295-1302. 
86. Xu, J., Y. Liu, Y. Yang, S. Bates, and J.-T. Zhang, Characterization of 
Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2. Journal 
of Biological Chemistry, 2004. 279(19): p. 19781-19789. 
 410
87. Hegedús, C., C. Ozvegy-Laczka, G. Szakacs, and B. Sarkadi, Interaction of 
ABC multidrug transporters with anticancer protein kinase inhibitors: 
substrates and/or inhibitors? Curr Cancer Drug Targets, 2009. 9(3): p. 252-72. 
88. Jonker, J.W., M. Buitelaar, E. Wagenaar, M.A. Van Der Valk, G.L. 
Scheffer, R.J. Scheper, T. Plosch, F. Kuipers, R.P. Elferink, H. Rosing, 
J.H. Beijnen, and A.H. Schinkel, The breast cancer resistance protein 
protects against a major chlorophyll-derived dietary phototoxin and 
protoporphyria. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15649-54. 
89. Jonker, J.W., J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, 
J.H. Schellens, and A.H. Schinkel, Role of breast cancer resistance protein 
in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst, 
2000. 92(20): p. 1651-6. 
90. Polgar, O., R.W. Robey, and S.E. Bates, ABCG2: structure, function and 
role in drug response. Expert Opinion on Drug Metabolism & Toxicology, 
2008. 4(1): p. 1-15. 
91. Honjo, Y., C.A. Hrycyna, Q.W. Yan, W.Y. Medina-Perez, R.W. Robey, A. 
van de Laar, T. Litman, M. Dean, and S.E. Bates, Acquired mutations in 
the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-
overexpressing cells. Cancer Res, 2001. 61(18): p. 6635-9. 
92. Volk, E.L., K.M. Farley, Y. Wu, F. Li, R.W. Robey, and E. Schneider, 
Overexpression of wild-type breast cancer resistance protein mediates 
methotrexate resistance. Cancer Res, 2002. 62(17): p. 5035-40. 
93. Sarkadi, B., C. Özvegy-Laczka, K. Német, and A. Váradi, ABCG2 - a 
transporter for all seasons. FEBS Letters, 2004. 567(1): p. 116-120. 
94. Sharom, F.J., ABC multidrug transporters: structure, function and role in 
chemoresistance. Pharmacogenomics, 2008. 9(1): p. 105-127. 
95. Shtil, A.A., Signal Transduction Pathways and Transcriptional Mechanisms 
as Targets for Prevention of Emergence of Multidrug Resistance in Human 
Cancer Cells. Current Drug Targets, 2001. 2(1): p. 57. 
96. Tsuruo, T., H. Iida, S. Tsukagoshi, and Y. Sakurai, Overcoming of 
Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through 
Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil. Cancer 
Research, 1981. 41(5): p. 1967-1972. 
97. Twentyman, P.R., N.E. Fox, and D.J. White, Cyclosporin A and its 
analogues as modifiers of adriamycin and vincristine resistance in a multi-
drug resistant human lung cancer cell line. British  Journal of Cancer. 1987 
July; 56(1): 55–57., 1987. 56(1): p. 55–57. . 
98. Wu, C.-P., A.M. Calcagno, and S.V. Ambudkar, Reversal of ABC drug 
transporter-mediated multidrug resistance in cancer cells: Evaluation of 
current strategies. Current molecular pharmacology, 2008. 1(2): p. 93-105. 
99. Benson, A., D. Trump, J. Koeller, M. Egorin, E. Olman, R. Witte, T. 
Davis, and D. Tormey, Phase I study of vinblastine and verapamil given by 
concurrent iv infusion. Cancer Treat Reports, 1985. 69`: p. 795-9. 
100. Bartlett, N.L., B.L. Lum, G.A. Fisher, N.A. Brophy, M.N. Ehsan, J. 
Halsey, and B.I. Sikic, Phase I trial of doxorubicin with cyclosporine as a 
modulator of multidrug resistance. Journal of Clinical Oncology, 1994. 12(4): 
p. 835-842. 
101. Dhainaut, A., G. Regnier, G. Atassi, A. Pierre, S. Leonce, L. Kraus-
Berthier, and J.F. Prost, New triazine derivatives as potent modulators of 
 411
multidrug resistance. Journal of Medicinal Chemistry, 1992. 35(13): p. 2481-
2496. 
102. Twentyman, P.R. and N.M. Bleehen, Resistance modification by PSC-833, a 
novel non-immunosuppressive cyclosporin A. European Journal of Cancer and 
Clinical Oncology, 1991. 27(12): p. 1639-1642. 
103. Kuppens, I.E.L.M., E.O. Witteveen, R.C. Jewell, S.A. Radema, E.M. Paul, 
S.G. Mangum, J.H. Beijnen, E.E. Voest, and J.H.M. Schellens, A Phase I, 
Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar 
(GF120918) and Oral Topotecan in Cancer Patients. Clinical Cancer 
Research, 2007. 13(11): p. 3276-3285. 
104. Chi, K.N., S.K. Chia, R. Dixon, M.J. Newman, V.J. Wacher, B. Sikic, and 
K.A. Gelmon, A phase I pharmacokinetic study of the P-glycoprotein 
inhibitor, ONT-093, in combination with paclitaxel in patients with advanced 
cancer. Investigational New Drugs, 2005. 23(4): p. 311-315. 
105. Abraham, J., M. Edgerly, R. Wilson, C. Chen, A. Rutt, S. Bakke, R. 
Robey, A. Dwyer, B. Goldspiel, F. Balis, O. Van Tellingen, S.E. Bates, and 
T. Fojo, A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in 
Combination with Vinorelbine. Clinical Cancer Research, 2009. 15(10): p. 
3574-3582. 
106. Ruff, P., D. Vorobiof, J. Jordaan, G. Demetriou, S. Moodley, A. 
Nosworthy, I. Werner, J. Raats, and L. Burgess, A randomized, placebo-
controlled, double-blind phase 2 study of docetaxel compared to docetaxel 
plus zosuquidar (LY335979) in women with metastatic or locally recurrent 
breast cancer who have received one prior chemotherapy regimen. Cancer 
Chemotherapy and Pharmacology, 2009. 64(4): p. 763-768. 
107. Baumert, C. and A. Hilgeroth, Recent Advances in the Development of P-gp 
Inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 2009. 9(4): p. 415-
436. 
108. Gekeler, V., W. Ise, K.H. Sanders, W.R. Ulrich, and J. Beck, The 
Leukotriene LTD4 Receptor Antagonist Mk571 Specifically Modulates MRP 
Associated Multidrug Resistance. Biochemical and Biophysical Research 
Communications, 1995. 208(1): p. 345-352. 
109. Duffy, C.P., C.J. Elliott, R.A. O'Connor, M.M. Heenan, S. Coyle, I.M. 
Cleary, K. Kavanagh, S. Verhaegen, C.M. O'Loughlin, R. NicAmhlaoibh, 
and M. Clynes, Enhancement of chemotherapeutic drug toxicity to human 
tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs 
(NSAIDs). European Journal of Cancer, 1998. 34(8): p. 1250-1259. 
110. Rabindran, S.K., D.D. Ross, L.A. Doyle, W. Yang, and L.M. Greenberger, 
Fumitremorgin C Reverses Multidrug Resistance in Cells Transfected with the 
Breast Cancer Resistance Protein. Cancer Research, 2000. 60(1): p. 47-50. 
111. Allen, J.D., A. van Loevezijn, J.M. Lakhai, M. van der Valk, O. van 
Tellingen, G. Reid, J.H.M. Schellens, G.-J. Koomen, and A.H. Schinkel, 
Potent and Specific Inhibition of the Breast Cancer Resistance Protein 
Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of 
Fumitremorgin C Molecular Cancer Therapeutics, 2002. 1(6): p. 417-425. 
112. Schlessinger, J., Cell Signaling by Receptor Tyrosine Kinases. Cell, 2000. 
103(2): p. 211-225. 
113. Özvegy-Laczka, C., J. Cserepes, N.B. Elkind, and B. Sarkadi, Tyrosine 
kinase inhibitor resistance in cancer: role of ABC multidrug transporters. 
Drug Resistance Updates, 2005. 8(1-2): p. 15-26. 
 412
114. Steeghs, N., J.W. Nortier, and H. Gelderblom, Small molecule tyrosine 
kinase inhibitors in the treatment of solid tumors: an update of recent 
developments. Ann Surg Oncol, 2007. 14(2): p. 942-53. 
115. Arora, A. and E.M. Scholar, Role of tyrosine kinase inhibitors in cancer 
therapy. J Pharmacol Exp Ther, 2005. 315(3): p. 971-9. 
116. Krause, D.S. and R.A. Van Etten, Tyrosine kinases as targets for cancer 
therapy. N Engl J Med, 2005. 353(2): p. 172-87. 
117. Vlahovic, G. and J. Crawford, Activation of Tyrosine Kinases in Cancer. 
Oncologist, 2003. 8(6): p. 531-538. 
118. van Erp, N.P., H. Gelderblom, and H.-J. Guchelaar, Clinical 
pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews, 
2009. 35(8): p. 692-706. 
119. Bukowski, R.M., U. Yasothan, and P. Kirkpatrick, Pazopanib. Nat Rev 
Drug Discov. 9(1): p. 17-18. 
120. National Cancer Institute.   [cited; Available from: http://www.cancer.gov/. 
121. Druker, B.J., Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic 
strategy for CML. Oncogene, 2002. 21(56): p. 8541-6. 
122. Weisberg, E. and J.D. Griffin, Resistance to imatinib (Glivec): update on 
clinical mechanisms. Drug Resist Updat, 2003. 6(5): p. 231-8. 
123. Ozvegy-Laczka, C., T. Hegedús, G. Varady, O. Ujhelly, J.D. Schuetz, A. 
Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi, High-Affinity 
Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug 
Transporter. Mol Pharmacol, 2004. 65(6): p. 1485-1495. 
124. Nimmanapalli, R., E. O'Bryan, M. Huang, P. Bali, P.K. Burnette, T. 
Loughran, J. Tepperberg, R. Jove, and K. Bhalla, Molecular 
characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-
resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase 
inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer 
Res, 2002. 62(20): p. 5761-9. 
125. Campbell, L.J., C. Patsouris, K.C. Rayeroux, K. Somana, E.H. 
Januszewicz, and J. Szer, BCR/ABL amplification in chronic myelocytic 
leukemia blast crisis following imatinib mesylate administration. Cancer 
Genet Cytogenet, 2002. 139(1): p. 30-3. 
126. Morel, F., M.J. Bris, A. Herry, G.L. Calvez, V. Marion, J.F. Abgrall, C. 
Berthou, and M.D. Braekeleer, Double minutes containing amplified bcr-abl 
fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J 
Haematol, 2003. 70(4): p. 235-9. 
127. Mahon, F.X., F. Belloc, V. Lagarde, C. Chollet, F. Moreau-Gaudry, J. 
Reiffers, J.M. Goldman, and J.V. Melo, MDR1 gene overexpression confers 
resistance to imatinib mesylate in leukemia cell line models. Blood, 2003. 
101(6): p. 2368-73. 
128. Hamada, A., H. Miyano, H. Watanabe, and H. Saito, Interaction of 
imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther, 2003. 
307(2): p. 824-8. 
129. Houghton, P.J., G.S. Germain, F.C. Harwood, J.D. Schuetz, C.F. Stewart, 
E. Buchdunger, and P. Traxler, Imatinib mesylate is a potent inhibitor of the 
ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 
in vitro. Cancer Res, 2004. 64(7): p. 2333-7. 
 413
130. Gardner, E.R., N.F. Smith, W.D. Figg, and A. Sparreboom, Influence of 
the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral 
imatinib in mice. J Exp Clin Cancer Res, 2009. 28: p. 99. 
131. Gambacorti-Passerini, C., R. Barni, P. le Coutre, M. Zucchetti, G. 
Cabrita, L. Cleris, F. Rossi, E. Gianazza, J. Brueggen, R. Cozens, P. 
Pioltelli, E. Pogliani, G. Corneo, F. Formelli, and M. D'Incalci, Role of 
alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) 
leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst, 2000. 92(20): p. 
1641-50. 
132. Jorgensen, H.G., M.A. Elliott, E.K. Allan, C.E. Carr, T.L. Holyoake, and 
K.D. Smith, alpha 1-Acid glycoprotein expressed in the plasma of chronic 
myeloid leukemia patients does not mediate significant in vitro resistance to 
STI571. Blood, 2002. 99(2): p. 713-715. 
133. le Coutre, P., K.-A. Kreuzer, I.-K. Na, J. Lupberger, M. Holdhoff, C. 
Appelt, M. Schwarz, C. Müller, C. Gambacorti-Passerini, U. Platzbecker, 
R. Bonnet, G. Ehninger, and C.A. Schmidt, Determination of [alpha]-1 
Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the 
First 13 Weeks of Therapy with STI571. Blood Cells, Molecules, and Diseases, 
2002. 28(1): p. 75-85. 
134. Lombardo, L.J., F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, K. Behnia, S. 
Castaneda, L.A. Cornelius, J. Das, A.M. Doweyko, C. Fairchild, J.T. 
Hunt, I. Inigo, K. Johnston, A. Kamath, D. Kan, H. Klei, P. Marathe, S. 
Pang, R. Peterson, S. Pitt, G.L. Schieven, R.J. Schmidt, J. Tokarski, M.L. 
Wen, J. Wityak, and R.M. Borzilleri, Discovery of N-(2-chloro-6-methyl- 
phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- 
ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase 
inhibitor with potent antitumor activity in preclinical assays. J Med Chem, 
2004. 47(27): p. 6658-61. 
135. Ramirez, P. and J.F. DiPersio, Therapy options in imatinib failures. 
Oncologist, 2008. 13(4): p. 424-34. 
136. Shah, N.P., C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers, 
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 
2004. 305(5682): p. 399-401. 
137. Nam, S., D. Kim, J.Q. Cheng, S. Zhang, J.-H. Lee, R. Buettner, J. 
Mirosevich, F.Y. Lee, and R. Jove, Action of the Src Family Kinase 
Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells. Cancer 
Res, 2005. 65(20): p. 9185-9189. 
138. Martin, G.S., The hunting of the Src. Nat Rev Mol Cell Biol, 2001. 2(6): p. 
467-75. 
139. Manning, G., D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam, 
The protein kinase complement of the human genome. Science, 2002. 
298(5600): p. 1912-34. 
140. Frame, M.C., Src in cancer: deregulation and consequences for cell 
behaviour. Biochim Biophys Acta, 2002. 1602(2): p. 114-30. 
141. Fizazi, K., The role of Src in prostate cancer. Ann Oncol, 2007. 18(11): p. 
1765-73. 
142. Summy, J.M. and G.E. Gallick, Treatment for advanced tumors: SRC 
reclaims center stage. Clin Cancer Res, 2006. 12(5): p. 1398-401. 
143. Xia, W., R.J. Mullin, B.R. Keith, L.H. Liu, H. Ma, D.W. Rusnak, G. 
Owens, K.J. Alligood, and N.L. Spector, Anti-tumor activity of GW572016: 
 414
a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and 
downstream Erk1/2 and AKT pathways. Oncogene, 2002. 21(41): p. 6255-63. 
144. Geyer, C.E., J. Forster, D. Lindquist, S. Chan, C.G. Romieu, T. 
Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. 
Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S.D. Rubin, S. 
Stein, and D. Cameron, Lapatinib plus capecitabine for HER2-positive 
advanced breast cancer. N Engl J Med, 2006. 355(26): p. 2733-43. 
145. Hynes, N.E. and G. MacDonald, ErbB receptors and signaling pathways in 
cancer. Current Opinion in Cell Biology, 2009. 21(2): p. 177-184. 
146. Graus-Porta, D., R.R. Beerli, J.M. Daly, and N.E. Hynes, ErbB-2, the 
preferred heterodimerization partner of all ErbB receptors, is a mediator of 
lateral signaling. Embo J, 1997. 16(7): p. 1647-1655. 
147. Wada, T., X. Qian, and M.I. Greene, Intermolecular association of the 
p185neu protein and EGF receptor modulates EGF receptor function. Cell, 
1990. 61(7): p. 1339-1347. 
148. Slamon, D.J., G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. 
McGuire, Human Breast Cancer: Correlation of Relapse and Survival with 
Amplification of the HER-2/neu Oncogene. Science, 1987. 235(4785): p. 177-
182. 
149. Carter, C.A., R.J. Kelly, and G. Giaccone, Small-molecule inhibitors of the 
human epidermal receptor family. Expert Opinion on Investigational Drugs, 
2009. 18(12): p. 1829-1842. 
150. Spector, N.L., W. Xia, H. Burris, III, H. Hurwitz, E.C. Dees, A. Dowlati, 
B. O'Neil, B. Overmoyer, P.K. Marcom, K.L. Blackwell, D.A. Smith, 
K.M. Koch, A. Stead, S. Mangum, M.J. Ellis, L. Liu, A.K. Man, T.M. 
Bremer, J. Harris, and S. Bacus, Study of the Biologic Effects of Lapatinib, a 
Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth 
and Survival Pathways in Patients With Advanced Malignancies. J Clin Oncol, 
2005. 23(11): p. 2502-2512. 
151. Rusnak, D.W., K. Lackey, K. Affleck, E.R. Wood, K.J. Alligood, N. 
Rhodes, B.R. Keith, D.M. Murray, W.B. Knight, R.J. Mullin, and T.M. 
Gilmer, The Effects of the Novel, Reversible Epidermal Growth Factor 
Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of 
Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo. Molecular 
Cancer Therapeutics, 2001. 1(2): p. 85-94. 
152. Gazdar, A.F., Activating and resistance mutations of EGFR in non-small-cell 
lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. 
Oncogene. 28(S1): p. S24-S31. 
153. Thatcher, N., A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. 
von Pawel, S. Thongprasert, E.H. Tan, K. Pemberton, V. Archer, and K. 
Carroll, Gefitinib plus best supportive care in previously treated patients with 
refractory advanced non-small-cell lung cancer: results from a randomised, 
placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung 
Cancer). The Lancet, 2005. 366(9496): p. 1527-1537. 
154. Blackhall, F., M. Ranson, and N. Thatcher, Where next for gefitinib in 
patients with lung cancer? The Lancet Oncology, 2006. 7(6): p. 499-507. 
155. Paez, J.G., P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. 
Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. 
Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson, EGFR 
 415
Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib 
Therapy. Science, 2004. 304(5676): p. 1497-1500. 
156. Lynch, T.J., D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, 
B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, 
D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber, Activating 
Mutations in the Epidermal Growth Factor Receptor Underlying 
Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med, 
2004. 350(21): p. 2129-2139. 
157. Pao, W., V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, 
M.G. Kris, and H. Varmus, Acquired resistance of lung adenocarcinomas to 
gefitinib or erlotinib is associated with a second mutation in the EGFR kinase 
domain. PLoS Med, 2005. 2(3): p. e73. 
158. Bianco, R., T. Gelardi, V. Damiano, F. Ciardiello, and G. Tortora, 
Mechanisms of resistance to EGFR inhibitors. Targeted Oncology, 2007. 2(1): 
p. 31-37. 
159. Wilhelm, S.M., C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. 
Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao, J. Shujath, S. Gawlak, 
D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. 
Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L.E. Post, G. Bollag, and 
P.A. Trail, BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity 
and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases 
Involved in Tumor Progression and Angiogenesis. Cancer Res, 2004. 64(19): 
p. 7099-7109. 
160. Chen, F.L., W. Xia, and N.L. Spector, Acquired resistance to small molecule 
ErbB2 tyrosine kinase inhibitors. Clin Cancer Res, 2008. 14(21): p. 6730-4. 
161. Steegmann, J.L., M. Michallet, E. Morra, D. Marin, G.J. Ossenkoppele, 
G. Verhoef, T. Kuhr, M. Bjoreman, M. Sterckx, and K. Cerri, Imatinib use 
in chronic phase CML in clinical practice: the UNIC study. J Clin Oncol 
(Meeting Abstracts), 2008. 26(15_suppl): p. 7077-. 
162. Gorre, M.E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, 
and C.L. Sawyers, Clinical Resistance to STI-571 Cancer Therapy Caused by 
BCR-ABL Gene Mutation or Amplification. Science, 2001. 293(5531): p. 876-
880. 
163. Druker, B.J., Imatinib and chronic myeloid leukemia: validating the promise 
of molecularly targeted therapy. European Journal of Cancer, 2002. 38 Suppl 
5: p. S70-6. 
164. Schindler, C.G., T. Armbrust, B. Gunawan, C. Langer, L. Fuzesi, and G. 
Ramadori, Gastrointestinal stromal tumor (GIST) -- single center experience 
of prolonged treatment with imatinib. Z Gastroenterol, 2005. 43(3): p. 267-73. 
165. Mahon, F.X., M.W.N. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, 
J.M. Goldman, and J.V. Melo, Selection and characterization of BCR-ABL 
positive cell lines with differential sensitivity to the tyrosine kinase inhibitor 
STI571: diverse mechanisms of resistance. Blood, 2000. 96(3): p. 1070-1079. 
166. Hegedús, T., L. Orfi, A. Seprodi, A. Váradi, B. Sarkadi, and G. Kéri, 
Interaction of tyrosine kinase inhibitors with the human multidrug transporter 
proteins, MDR1 and MRP1. Biochimica et Biophysica Acta (BBA) - 
Molecular Basis of Disease, 2002. 1587(2-3): p. 318-325. 
167. Mukai, M., X.-F. Che, T. Furukawa, T. Sumizawa, S. Aoki, X.-Q. Ren, M. 
Haraguchi, Y. Sugimoto, M. Kobayashi, H. Takamatsu, and S.-i. 
 416
Akiyama, Reversal of the resistance to STI571 in human chronic 
myelogenous leukemia K562 cells. Cancer Science, 2003. 94(6): p. 557-563. 
168. Jordanides, N.E., H.G. Jorgensen, T.L. Holyoake, and J.C. Mountford, 
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is 
inhibited by imatinib mesylate. Blood, 2006. 108(4): p. 1370-1373. 
169. Houghton, P.J., G.S. Germain, F.C. Harwood, J.D. Schuetz, C.F. Stewart, 
E. Buchdunger, and P. Traxler, Imatinib Mesylate Is a Potent Inhibitor of 
the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and 
SN-38 in Vitro. Cancer Res, 2004. 64(7): p. 2333-2337. 
170. Burger, H., H. van Tol, A.W.M. Boersma, M. Brok, E.A.C. Wiemer, G. 
Stoter, and K. Nooter, Imatinib mesylate (STI571) is a substrate for the 
breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004. 
104(9): p. 2940-2942. 
171. Brendel, C., C. Scharenberg, M. Dohse, R.W. Robey, S.E. Bates, S. 
Shukla, S.V. Ambudkar, Y. Wang, G. Wennemuth, A. Burchert, U. 
Boudriot, and A. Neubauer, Imatinib mesylate and nilotinib (AMN107) 
exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem 
cells. Leukemia, 2007. 21(6): p. 1267-1275. 
172. Artursson, P., K. Palm, and K. Luthman, Caco-2 monolayers in 
experimental and theoretical predictions of drug transport. Advanced Drug 
Delivery Reviews, 2001. 46(1-3): p. 27-43. 
173. Kamath, A.V., J. Wang, F.Y. Lee, and P.H. Marathe, Preclinical 
pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a 
potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer 
Chemother Pharmacol, 2008. 61(3): p. 365-76. 
174. Hiwase, D.K., V. Saunders, D. Hewett, A. Frede, S. Zrim, P. Dang, L. 
Eadie, L.B. To, J. Melo, S. Kumar, T.P. Hughes, and D.L. White, 
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: 
therapeutic implications. Clin Cancer Res, 2008. 14(12): p. 3881-8. 
175. Lagas, J.S., R.A. van Waterschoot, V.A. van Tilburg, M.J. Hillebrand, N. 
Lankheet, H. Rosing, J.H. Beijnen, and A.H. Schinkel, Brain accumulation 
of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer 
resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin 
Cancer Res, 2009. 15(7): p. 2344-51. 
176. White, D.L., V.A. Saunders, P. Dang, J. Engler, A.C.W. Zannettino, A.C. 
Cambareri, S.R. Quinn, P.W. Manley, and T.P. Hughes, OCT-1-mediated 
influx is a key determinant of the intracellular uptake of imatinib but not 
nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro 
sensitivity to imatinib. Blood, 2006. 108(2): p. 697-704. 
177. Polli, J.W., J.E. Humphreys, K.A. Harmon, S. Castellino, M.J. O'Mara, 
K.L. Olson, L.S. John-Williams, K.M. Koch, and C.J. Serabjit-Singh, The 
role of efflux and uptake transporters in [N-{3-chloro-4-[(3-
fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-
furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug 
interactions. Drug Metab Dispos, 2008. 36(4): p. 695-701. 
178. Molina, J.R., S.H. Kaufmann, J.M. Reid, S.D. Rubin, M. GÃ¡lvez-Peralta, 
R. Friedman, K.S. Flatten, K.M. Koch, T.M. Gilmer, R.J. Mullin, R.C. 
Jewell, S.J. Felten, S. Mandrekar, A.A. Adjei, and C. Erlichman, 
Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, 
 417
Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research, 
2008. 14(23): p. 7900-7908. 
179. Collins, D.M., J. Crown, N. O'Donovan, A. Devery, F. O'Sullivan, L. 
O'Driscoll, M. Clynes, and R. O'Connor, Tyrosine kinase inhibitors 
potentiate the cytotoxicity of MDR-substrate anticancer agents independent of 
growth factor receptor status in lung cancer cell lines. Invest New Drugs, 
2009. 
180. Dunne, G., L. Breen, D. Collins, S. Roche, M. Clynes, and R. O’Connor, 
Modulation of P-gp expression by lapatinib. Investigational New Drugs, 2010: 
p. 1-10. 
181. Kuang, Y.-H., T. Shen, X. Chen, K. Sodani, E. Hopper-Borge, A.K. 
Tiwari, J.W.K.K. Lee, L.-W. Fu, and Z.-S. Chen, Lapatinib and erlotinib 
are potent reversal agents for MRP7 (ABCC10)-mediated multidrug 
resistance. Biochemical Pharmacology, 2010. 79(2): p. 154-161. 
182. Kitazaki, T., M. Oka, Y. Nakamura, J. Tsurutani, S. Doi, M. Yasunaga, 
M. Takemura, H. Yabuuchi, H. Soda, and S. Kohno, Gefitinib, an EGFR 
tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in 
multidrug resistant cancer cells. Lung Cancer, 2005. 49(3): p. 337-343. 
183. Nakamura, Y., M. Oka, H. Soda, K. Shiozawa, M. Yoshikawa, A. Itoh, Y. 
Ikegami, J. Tsurutani, K. Nakatomi, T. Kitazaki, S. Doi, H. Yoshida, and 
S. Kohno, Gefitinib ("Iressa", ZD1839), an Epidermal Growth Factor 
Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance 
Protein/ABCG2-Mediated Drug Resistance. Cancer Res, 2005. 65(4): p. 1541-
1546. 
184. Azzariti, A., L. Porcelli, G.M. Simone, A.E. Quatrale, N.A. Colabufo, F. 
Berardi, R. Perrone, M. Zucchetti, M. D'Incalci, J.M. Xu, and A. 
Paradiso, Tyrosine kinase inhibitors and multidrug resistance proteins: 
interactions and biological consequences. Cancer Chemother Pharmacol, 
2009. 
185. de Vries, N., T. Buckle, J. Zhao, J. Beijnen, J. Schellens, and O. van 
Tellingen, Restricted brain penetration of the tyrosine kinase inhibitor 
erlotinib due to the drug transporters P-gp and BCRP. Investigational New 
Drugs: p. 1-7. 
186. Li, J., G. Cusatis, J. Brahmer, A. Sparreboom, R.W. Robey, S.E. Bates, 
M. Hidalgo, and S. Baker, Association of variant ABCG2 and the 
pharmacokinetics of epidermal growth factor receptor tyrosine kinase 
inhibitors in cancer patients. Cancer and  Biology Therapy, 2007. 6(3). 
187. Shi, Z., X.-X. Peng, I.-W. Kim, S. Shukla, Q.-S. Si, R.W. Robey, S.E. 
Bates, T. Shen, C.R. Ashby, L.-W. Fu, S.V. Ambudkar, and Z.-S. Chen, 
Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B 
Member 1 and ATP-Binding Cassette Subfamily G Member 2â€“Mediated 
Drug Resistance. Cancer Research, 2007. 67(22): p. 11012-11020. 
188. Alnaim, L., Therapeutic drug monitoring of cancer chemotherapy. Journal of 
Oncology Pharmacy Practice, 2007. 13(4): p. 207-221. 
189. McLeod, H.L., Therapeutic drug monitoring opportunities in cancer therapy. 
Pharmacology & Therapeutics, 1997. 74(1): p. 39-54. 
190. Liu, Y., Y. Yang, X. Liu, and T. Jiang, Quantification of pegylated 
liposomal doxorubicin and doxorubicinol in rat plasma by liquid 
chromatography/electrospray tandem mass spectroscopy: Application to 
preclinical pharmacokinetic studies. Talanta, 2008. 74(4): p. 887-895. 
 418
191. Jain, K.K., Personalised medicine for cancer: from drug development into 
clinical practice. Expert Opinion on Pharmacotherapy, 2005. 6(9): p. 1463-
1476. 
192. Chatelut, E., X. Pivot, J. Otto, C. Chevreau, A. Thyss, N. Renée, G. 
Milano, and P. Canal, A limited sampling strategy for determining 
carboplatin AUC and monitoring drug dosage. European Journal of Cancer, 
2000. 36(2): p. 264-269. 
193. Rousseau, A. and P. Marquet, Application of pharmacokinetic modelling to 
the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin 
Pharmacol, 2002. 16(4): p. 253-62. 
194. McMahon, G., Analytical Instrumentation, A Guide to Laboratory, Portable 
and Miniaturized Instruments. First ed. 2007: John Wiley & Sons Ltd. 
195. Kealey, D. and P. Haines, Analytical Chemistry. Instant Notes, ed. B.D. 
Haines. 2002, Leeds, UK: BIOS Scientific Publishers Ltd. 
196. Ardrey, R.E., Liquid Chromatography –Mass Spectrometry: An Introduction, 
ed. D.J. Ando. 2003: John Wiley & Sons Ltd,. 
197. Gates, P. Mass Spectrometry Resource -Electrospray Ionisation 2004  [cited; 
Available from: http://www.chm.bris.ac.uk/ms/theory/esi-ionisation.html. 
198. Agilent. Agilent 6410 Triple Quadrupole LC/MS.   [cited; Available from: 
http://www.chem.agilent.com/Library/brochures/5989-4894EN_Lo.pdf. 
199. Shin, K.-H., B.-H. Kim, T.-E. Kim, J.W. Kim, S. Yi, S.-H. Yoon, J.-Y. 
Cho, S.-G. Shin, I.-J. Jang, and K.-S. Yu, The effects of ketoconazole and 
rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male 
volunteers: An open-label, one-sequence, three-period, three-treatment 
crossover study. Clinical Therapeutics, 2009. 31(12): p. 3009-3020. 
200. Bai, F., B.B. Freeman, 3rd, C.H. Fraga, M. Fouladi, and C.F. Stewart, 
Determination of lapatinib (GW572016) in human plasma by liquid 
chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J 
Chromatogr B Analyt Technol Biomed Life Sci, 2006. 831(1-2): p. 169-75. 
201. Owen, L.J., S. Haslam, J.E. Adaway, P. Wood, C. Glenn, and B.G. Keevil, 
A simplified liquid chromatography tandem mass spectrometry assay, using 
on-line solid-phase extraction, for the quantitation of cortisol in saliva and 
comparison with a routine DELFIA method. Ann Clin Biochem, 2010: p. 
acb.2009.009053. 
202. Phillip, A.S., D.S. Kelsie, and K. Sarah, Quantitative Analysis of Gamma-
Hydroxybutyrate at Endogenous Concentrations in Hair using Liquid 
Chromatography Tandem Mass Spectrometry. Journal of Forensic Sciences. 
9999(9999). 
203. de Bruijn, P., I.M.G. Moghaddam-Helmantel, M.J.A. de Jonge, T. Meyer, 
M.-H. Lam, J. Verweij, E.A.C. Wiemer, and W.J. Loos, Validated 
bioanalytical method for the quantification of RGB-286638, a novel multi-
targeted protein kinase inhibitor, in human plasma and urine by liquid 
chromatography/tandem triple-quadrupole mass spectrometry. Journal of 
Pharmaceutical and Biomedical Analysis, 2009. 50(5): p. 977-982. 
204. Chang, M.S., Q. Ji, J. Zhang, and T.A. El-Shourbagy, Historical review of 
sample preparation for chromatographic bioanalysis: pros and cons. Drug 
Development Research, 2007. 68(3): p. 107-133. 
205. Hsieh, S., T. Tobien, K. Koch, and J. Dunn, Increasing throughput of 
parallel on-line extraction liquid chromatography/electrospray ionization 
tandem mass spectrometry system for GLP quantitative bioanalysis in drug 
 419
development. Rapid Communications in Mass Spectrometry, 2004. 18(3): p. 
285-292. 
206. Scorrano, S., L. Longo, and G. Vasapollo, Molecularly imprinted polymers 
for solid-phase extraction of 1-methyladenosine from human urine. Analytica 
Chimica Acta. 659(1-2): p. 167-171. 
207. Pérez-Moral, N. and A.G. Mayes, Direct rapid synthesis of MIP beads in 
SPE cartridges. Biosensors and Bioelectronics, 2006. 21(9): p. 1798-1803. 
208. Anderson, R.A., M.M. Ariffin, P.A.G. Cormack, and E.I. Miller, 
Comparison of molecularly imprinted solid-phase extraction (MISPE) with 
classical solid-phase extraction (SPE) for the detection of benzodiazepines in 
post-mortem hair samples. Forensic Science International, 2008. 174(1): p. 40-
46. 
209. Little, J.L., M.F. Wempe, and C.M. Buchanan, Liquid chromatography-
mass spectrometry/mass spectrometry method development for drug 
metabolism studies: Examining lipid matrix ionization effects in plasma. 
Journal of Chromatography B, 2006. 833(2): p. 219-230. 
210. Jemal, M., High-throughput quantitative bioanalysis by LC/MS/MS. Biomed 
Chromatogr, 2000. 14(6): p. 422-9. 
211. Hopfgartner, G. and E. Bourgogne, Quantitative high-throughput analysis 
of drugs in biological matrices by mass spectrometry. Mass Spectrom Rev, 
2003. 22(3): p. 195-214. 
212. De Francia, S., A. D'Avolio, F. De Martino, E. Pirro, L. Baietto, M. 
Siccardi, M. Simiele, S. Racca, G. Saglio, F. Di Carlo, and G. Di Perri, 
New HPLC-MS method for the simultaneous quantification of the 
antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J 
Chromatogr B Analyt Technol Biomed Life Sci, 2009. 877(18-19): p. 1721-6. 
213. Haouala, A., B. Zanolari, B. Rochat, M. Montemurro, K. Zaman, M.A. 
Duchosal, H.B. Ris, S. Leyvraz, N. Widmer, and L.A. Decosterd, 
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, 
nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2009. 
214. dell'Adulto, G.I.M.E. Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational 
Study (LAL1408).  2010  [cited; Available from: 
http://clinicaltrials.gov/ct2/show/NCT01025505?term=TKI&rank=31. 
215. dell'Adulto, G.I.M.E., Nilotinib and Imatinib Mesylate in Treating Patients 
With Early Chronic Phase Chronic Myelogenous Leukemia. 
2009(NCT00769327). 
216. Roche, S., G. McMahon, M. Clynes, and R. O'Connor, Development of a 
high-performance liquid chromatographic-mass spectrometric method for the 
determination of cellular levels of the tyrosine kinase inhibitors lapatinib and 
dasatinib. J Chromatogr B Analyt Technol Biomed Life Sci, 2009. 877(31): p. 
3982-90. 
217. Hsieh, Y., G. Galviz, Q. Zhou, and C. Duncan, Hydrophilic interaction 
liquid chromatography/tandem mass spectrometry for the simultaneous 
determination of dasatinib, imatinib and nilotinib in mouse plasma. Rapid 
Commun Mass Spectrom, 2009. 23(9): p. 1364-70. 
218. Honeywell, R., K. Yarzadah, E. Giovannetti, N. Losekoot, E.F. Smit, M. 
Walraven, J.S.W. Lind, C. Tibaldi, H.M. Verheul, and G.J. Peters, Simple 
and selective method for the determination of various tyrosine kinase 
 420
inhibitors used in the clinical setting by liquid chromatography tandem mass 
spectrometry. Journal of Chromatography B, 2010. 878(15-16): p. 1059-1068. 
219. Masters, A.R., C.J. Sweeney, and D.R. Jones, The quantification of erlotinib 
(OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem 
mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2007. 
848(2): p. 379-83. 
220. Lepper, E.R., S.M. Swain, A.R. Tan, W.D. Figg, and A. Sparreboom, 
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal 
growth factor receptor tyrosine kinase inhibitor. Journal of Chromatography 
B, 2003. 796(1): p. 181-188. 
221. Zhao, M., C. Hartke, A. Jimeno, J. Li, P. He, Y. Zabelina, M. Hidalgo, 
and S.D. Baker, Specific method for determination of gefitinib in human 
plasma, mouse plasma and tissues using high performance liquid 
chromatography coupled to tandem mass spectrometry. J Chromatogr B 
Analyt Technol Biomed Life Sci, 2005. 819(1): p. 73-80. 
222. Guetens, G., H. Prenen, G. De Boeck, W. Van Dongen, E. Esmans, F. 
Lemiere, A.T. van Oosterom, P. Schoffski, and E.A. de Bruijn, Sensitive 
and specific quantification of the anticancer agent ZD1839 (Gefitinib) in 
plasma by on-column focusing capillary liquid chromatography-tandem mass 
spectrometry. J Chromatogr A, 2005. 1082(1): p. 2-5. 
223. Jones, H.K., L.E. Stafford, H.C. Swaisland, and R. Payne, A sensitive 
assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and 
high performance liquid chromatography with mass spectrometric detection: 
validation and use in Phase I clinical trials. J Pharm Biomed Anal, 2002. 
29(1-2): p. 221-8. 
224. Widmer, N., A. Béguin, B. Rochat, T. Buclin, T. Kovacsovics, M.A. 
Duchosal, S. Leyvraz, A. Rosselet, J. Biollaz, and L.A. Decosterd, 
Determination of imatinib (Gleevec®) in human plasma by solid-phase 
extraction-liquid chromatography-ultraviolet absorbance detection. Journal of 
Chromatography B, 2004. 803(2): p. 285-292. 
225. Micová, K., D. Friedecký, E. Faber, A. Polýnková, and T. Adam, Flow 
injection analysis vs. ultra high performance liquid chromatography coupled 
with tandem mass spectrometry for determination of imatinib in human 
plasma. Clinica Chimica Acta. 411(23-24): p. 1957-1962. 
226. Roth, O., O. Spreux-Varoquaux, S. Bouchet, P. Rousselot, S. Castaigne, S. 
Rigaudeau, V. Raggueneau, P. Therond, P. Devillier, M. Molimard, and 
B. Maneglier, Imatinib assay by HPLC with photodiode-array UV detection 
in plasma from patients with chronic myeloid leukemia: Comparison with LC-
MS/MS. Clinica Chimica Acta. 411(3-4): p. 140-146. 
227. Titier, K., S. Picard, D. Ducint, E. Teilhet, N. Moore, P. Berthaud, F.X. 
Mahon, and M. Molimard, Quantification of imatinib in human plasma by 
high-performance liquid chromatography-tandem mass spectrometry. Ther 
Drug Monit, 2005. 27(5): p. 634-40. 
228. Masatomo, M., T. Naoto, and S. Ken-ichi, High-performance liquid 
chromatography with solid-phase extraction for the quantitative determination 
of nilotinib in human plasma. Biomedical Chromatography, 2009. 
9999(9999): p. n/a. 
229. Davies, A., A.K. Hayes, K. Knight, S.J. Watmough, M. Pirmohamed, and 
R.E. Clark, Simultaneous determination of nilotinib, imatinib and its main 
 421
metabolite (CGP-74588) in human plasma by ultra-violet high performance 
liquid chromatography. Leukemia Research, 2010. 34(6): p. 702-707. 
230. Zhao, M., M.A. Rudek, P. He, F.T. Hafner, M. Radtke, J.J. Wright, B.D. 
Smith, W.A. Messersmith, M. Hidalgo, and S.D. Baker, A rapid and 
sensitive method for determination of sorafenib in human plasma using a 
liquid chromatography/tandem mass spectrometry assay. J Chromatogr B 
Analyt Technol Biomed Life Sci, 2007. 846(1-2): p. 1-7. 
231. Minkin, P., M. Zhao, Z. Chen, J. Ouwerkerk, H. Gelderblom, and S.D. 
Baker, Quantification of sunitinib in human plasma by high-performance 
liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci, 2008. 
232. Blanchet, B., C. Saboureau, A.S. Benichou, B. Billemont, F. Taieb, S. 
Ropert, A. Dauphin, F. Goldwasser, and M. Tod, Development and 
validation of an HPLC-UV-visible method for sunitinib quantification in 
human plasma. Clinica Chimica Acta, 2009. 404(2): p. 134-139. 
233. Barattè, S., S. Sarati, E. Frigerio, C.A. James, C. Ye, and Q. Zhang, 
Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and 
its metabolite in monkey tissues by liquid chromatograph with tandem mass 
spectrometry following semi-automated liquid-liquid extraction. Journal of 
Chromatography A, 2004. 1024(1-2): p. 87-94. 
234. Zirrolli, J.A., E.L. Bradshaw, M.E. Long, and D.L. Gustafson, Rapid and 
sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in 
mouse plasma and tissues. J Pharm Biomed Anal, 2005. 39(3-4): p. 705-11. 
235. Kyle, R.A. and S.V. Rajkumar, Multiple Myeloma. New England Journal of 
Medicine, 2004. 351(18): p. 1860-1873. 
236. Kumar, S. and S.V. Rajkumar, Thalidomide and lenalidomide in the 
treatment of multiple myeloma. European journal of cancer (Oxford, England : 
1990), 2006. 42(11): p. 1612-1622. 
237. Voet, D. and J.G. Voet, Biochemistry. 1990. 1099-1100. 
238. Kumar, S.K., S.V. Rajkumar, A. Dispenzieri, M.Q. Lacy, S.R. Hayman, 
F.K. Buadi, S.R. Zeldenrust, D. Dingli, S.J. Russell, J.A. Lust, P.R. 
Greipp, R.A. Kyle, and M.A. Gertz, Improved survival in multiple myeloma 
and the impact of novel therapies. Blood, 2008. 111(5): p. 2516-2520. 
239. Winslow, T. Hematopoietic Tree Plasma Cell.  2008  [cited; Available from: 
http://www.cancer.gov/Common/PopUps/popImage.aspx?imageName=/image
s/cdr/live/CDR596562-
750.jpg&caption=Blood%20cell%20development.%20A%20blood%20stem%
20cell%20goes%20through%20several%20steps%20to%20become%20a%20r
ed%20blood%20cell,%20platelet,%20or%20white%20blood%20cell. 
240. Kyle, R.A. and S.V. Rajkumar, Multiple myeloma. Blood, 2008. 111(6): p. 
2962-2972. 
241. Kumar, S., Multiple myeloma - current issues and controversies. Cancer 
Treatment Reviews, 2010. 36: p. S3-S11. 
242. Palumbo, A., S. Bringhen, T. Caravita, E. Merla, V. Capparella, V. 
Callea, C. Cangialosi, M. Grasso, F. Rossini, M. Galli, L. Catalano, E. 
Zamagni, M.T. Petrucci, V. De Stefano, M. Ceccarelli, M.T. Ambrosini, I. 
Avonto, P. Falco, G. Ciccone, A.M. Liberati, P. Musto, and M. Boccadoro, 
Oral melphalan and prednisone chemotherapy plus thalidomide compared 
with melphalan and prednisone alone in elderly patients with multiple 
 422
myeloma: randomised controlled trial. The Lancet, 2006. 367(9513): p. 825-
831. 
243. Facon, T., J.Y. Mary, C. Hulin, L. Benboubker, M. Attal, B. Pegourie, M. 
Renaud, J.L. Harousseau, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, 
H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, C. Martin, P. 
Casassus, J. Jaubert, H. Jardel, C. Doyen, B. Kolb, B. Anglaret, B. 
Grosbois, I. Yakoub-Agha, C. Mathiot, and H. Avet-Loiseau, Melphalan 
and prednisone plus thalidomide versus melphalan and prednisone alone or 
reduced-intensity autologous stem cell transplantation in elderly patients with 
multiple myeloma (IFM 99-06): a randomised trial. The Lancet, 2007. 
370(9594): p. 1209-1218. 
244. Hulin, C., T. Facon, P. Rodon, B. Pegourie, L. Benboubker, C. Doyen, M. 
Dib, G. Guillerm, B. Salles, J.-P. Eschard, P. Lenain, P. Casassus, I. 
AzaÃ¯s, O. Decaux, L. Garderet, C. Mathiot, J. Fontan, I. Lafon, J.M. 
Virion, and P. Moreau, Efficacy of Melphalan and Prednisone Plus 
Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple 
Myeloma: IFM 01/01 Trial. Journal of Clinical Oncology, 2009. 27(22): p. 
3664-3670. 
245. Mateos, M.-V., J.M. Hernandez, M.T. Hernandez, N.C. Gutierrez, L. 
Palomera, M. Fuertes, P. Garcia-Sanchez, J.J. Lahuerta, J. de la Rubia, 
M.-J. Terol, A. Sureda, J. Bargay, P. Ribas, A. Alegre, F. de Arriba, A. 
Oriol, D. Carrera, J. Garcia-Larana, R. Garcia-Sanz, J. Blade, F. 
Prosper, G. Mateo, D.-L. Esseltine, H. van de Velde, and J.F. San Miguel, 
Bortezomib plus melphalan and prednisone in elderly untreated patients with 
multiple myeloma: updated time-to-events results and prognostic factors for 
time to progression. Haematologica, 2008. 93(4): p. 560-565. 
246. Palumbo, A., P. Falco, P. Corradini, A. Falcone, F. Di Raimondo, N. 
Giuliani, C. Crippa, G. Ciccone, P. OmedÃ¨, M.T. Ambrosini, F. Gay, S. 
Bringhen, P. Musto, R. FoÃ , R. Knight, J.B. Zeldis, M. Boccadoro, and 
M.T. Petrucci, Melphalan, Prednisone, and Lenalidomide Treatment for 
Newly Diagnosed Myeloma: A Report From the GIMEMAâ€”Italian Multiple 
Myeloma Network. Journal of Clinical Oncology, 2007. 25(28): p. 4459-4465. 
247. Eriksson, T., S. Björkman, and P. Höglund, Clinical pharmacology of 
thalidomide. European Journal of Clinical Pharmacology, 2001. 57(5): p. 365-
376. 
248. Kunz, W., N-Phthalyl glutaminsäure-imid. Arzneimittelforschung, 1956( 6): 
p. 426-430. 
249. Bartlett, J.B., K. Dredge, and A.G. Dalgleish, The evolution of thalidomide 
and its IMiD derivatives as anticancer agents. Nat Rev Cancer, 2004. 4(4): p. 
314-22. 
250. Lenz, W., R.A. Pfeiffer, W. Kosenow, and D.J. Hayman, THALIDOMIDE 
AND CONGENITAL ABNORMALITIES. The Lancet, 1962. 279(7219): p. 45-
46. 
251. McBride, W.G., THALIDOMIDE AND CONGENITAL ABNORMALITIES. 
The Lancet, 1961. 278(7216): p. 1358-1358. 
252. Melchert, M. and A. List, The thalidomide saga. The International Journal of 
Biochemistry & Cell Biology, 2007. 39(7-8): p. 1489-1499. 
253. Sheskin, J., Thalidomide in the treatment of lepra reactions. Clinical 
Pharmacology and Theraputics, 1965(6): p. 303–306  
 423
254. Iyer, C.G.S., J. Languillon, K. Ramanujam, G. Tarabini-Castellani, 
J.T.d.l. Aguas, L.M. Bechelli, K. Uemura, V.M. Dominguez, and T. 
Sundaresan, WHO co-ordinated short-term double-blind trial with 
thalidomide in the treatment of acute lepra reactions in male lepromatous 
patients. Bull World Health Organ, 1971. 45. (6): p. 719–732. 
255. Olson, K., T. Hall, J. Horton, C. Khung, and H. Hosley, Thalidomide (N-
phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol 
Ther., 1965. 6: p. 292-7. 
256. Grabstald, H. and R. Golbey, Clinical experiences with thalidomide in 
patients with cancer. Clin Pharmacol Ther., 1965. 6: p. 298-302. 
257. Singhal, S., J. Mehta, R. Desikan, D. Ayers, P. Roberson, P. Eddlemon, N. 
Munshi, E. Anaissie, C. Wilson, M. Dhodapkar, J. Zeldis, D. Siegel, J. 
Crowley, and B. Barlogie, Antitumor Activity of Thalidomide in Refractory 
Multiple Myeloma. New England Journal of Medicine, 1999. 341(21): p. 
1565-1571. 
258. Rajkumar, S.V., E. Blood, D. Vesole, R. Fonseca, and P.R. Greipp, Phase 
III Clinical Trial of Thalidomide Plus Dexamethasone Compared With 
Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical 
Trial Coordinated by the Eastern Cooperative Oncology Group. Journal of 
Clinical Oncology, 2006. 24(3): p. 431-436. 
259. Eriksson, T., S. Bjöurkman, B. Roth, Å. Fyge, and P. Höuglund, 
Stereospecific determination, chiral inversion in vitro and pharmacokinetics in 
humans of the enantiomers of thalidomide. Chirality, 1995. 7(1): p. 44-52. 
260. Kenyon, B.M., F. Browne, and R.J. D'Amato, Effects of Thalidomide and 
Related Metabolites in a Mouse Corneal Model of Neovascularization. 
Experimental Eye Research, 1997. 64(6): p. 971-978. 
261. Reist, M., P.-A. Carrupt, E. Francotte, and B. Testa, Chiral Inversion and 
Hydrolysis of Thalidomide:Mechanisms and Catalysis by Bases and Serum 
Albumin, and Chiral Stability of Teratogenic Metabolites. Chemical Research 
in Toxicology, 1998. 11(12): p. 1521-1528. 
262. D'Amato, R.J., M.S. Loughnan, E. Flynn, and J. Folkman, Thalidomide is 
an inhibitor of angiogenesis. Proceedings of the National Academy of 
Sciences of the United States of America, 1994. 91(9): p. 4082-4085. 
263. Bellamy, W.T., L. Richter, D. Sirjani, C. Roxas, B. Glinsmann-Gibson, Y. 
Frutiger, T.M. Grogan, and A.F. List, Vascular endothelial cell growth 
factor is an autocrine promoter of abnormal localized immature myeloid 
precursors and leukemia progenitor formation in myelodysplastic syndromes. 
Blood, 2001. 97(5): p. 1427-1434. 
264. Gupta, D., S.P. Treon, Y. Shima, T. Hideshima, K. Podar, Y.T. Tai, B. 
Lin, S. Lentzsch, F.E. Davies, D. Chauhan, R.L. Schlossman, P. 
Richardson, P. Ralph, L. Wu, F. Payvandi, G. Muller, D.I. Stirling, and 
K.C. Anderson, Adherence of multiple myeloma cells to bone marrow 
stromal cells upregulates vascular endothelial growth factor secretion: 
Therapeutic applications. Leukemia, 2001. 15(12): p. 1950-1961. 
265. Haslett, P.A.J., L.G. Corral, M. Albert, and G. Kaplan, Thalidomide 
Costimulates Primary Human T Lymphocytes, Preferentially Inducing 
Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ 
Subset. The Journal of Experimental Medicine, 1998. 187(11): p. 1885-1892. 
266. Celgene (2010) System for Thalidomide Education and Prescribing Safety.   
 424
267. Zeldis, J.B., B.A. Williams, S.D. Thomas, and M.E. Elsayed, 
S.T.E.P.S.(TM): A comprehensive program for controlling and monitoring 
access to thalidomide. Clinical Therapeutics, 1999. 21(2): p. 319-330. 
268. Mateos, M.-V., Management of treatment-related adverse events in patients 
with multiple myeloma. Cancer Treatment Reviews, 2010. 36(Supplement 2): 
p. S24-S32. 
269. Teo, S.K., P.J. Sabourin, K. O'Brien, K.A. Kook, and S.D. Thomas, 
Metabolism of thalidomide in human microsomes, cloned human cytochrome 
P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol, 2000. 
14(3): p. 140-7. 
270. Lu, J., B.D. Palmer, P. Kestell, P. Browett, B.C. Baguley, G. Muller, and 
L.M. Ching, Thalidomide metabolites in mice and patients with multiple 
myeloma. Clin Cancer Res, 2003. 9(5): p. 1680-8. 
271. Chung, F., J. Lu, B.D. Palmer, P. Kestell, P. Browett, B.C. Baguley, M. 
Tingle, and L.M. Ching, Thalidomide pharmacokinetics and metabolite 
formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res, 
2004. 10(17): p. 5949-56. 
272. Haque, A. and J.T. Stewart, Determination of Racemic Thalidomide in 
Human Plasma by use of an Avidin Column and Solid Phase Extraction. 
Journal of Liquid Chromatography & Related Technologies, 1998. 21(14): p. 
2151 - 2163. 
273. Teo, S.K., R.S. Chandula, J.L. Harden, D.I. Stirling, and S.D. Thomas, 
Sensitive and rapid method for the determination of thalidomide in human 
plasma and semen using solid-phase extraction and liquid chromatography-
tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 
2002. 767(1): p. 145-51. 
274. Toraño, J.S., A. Verbon, and H.J. Guchelaar, Quantitative determination of 
thalidomide in human serum with high-performance liquid chromatography 
using protein precipitation with trichloroacetic acid and ultraviolet detection. 
J Chromatogr B Biomed Sci Appl, 1999. 734(2): p. 203-10. 
275. Murphy-Poulton, S.F., F. Boyle, X.Q. Gu, and L.E. Mather, Thalidomide 
enantiomers: Determination in biological samples by HPLC and vancomycin-
CSP. Journal of Chromatography B, 2006. 831(1-2): p. 48-56. 
276. Saccomanni, G., V. Turini, C. Manera, G. Placanica, E.O. Salè, C. Jemos, 
M. Giorgi, and M. Macchia, High performance liquid chromatographic 
determination of thalidomide in patients affected by hepatocellular carcinoma. 
Journal of Pharmaceutical and Biomedical Analysis, 2008. 48(2): p. 447-451. 
277. Yang, X., Z. Hu, S.Y. Chan, P.C. Ho, E. Chan, W. Duan, B.C. Goh, and S. 
Zhou, Determination of thalidomide by high performance liquid 
chromatography: Plasma pharmacokinetic studies in the rat. Journal of 
Pharmaceutical and Biomedical Analysis, 2005. 39(1-2): p. 299-304. 
278. Zhou, S., Y. Li, P. Kestell, and J.W. Paxton, Determination of thalidomide 
in transport buffer for Caco-2 cell monolayers by high-performance liquid 
chromatography with ultraviolet detection. Journal of Chromatography B, 
2003. 785(1): p. 165-173. 
279. Teo, S.K., W.A. Colburn, and S.D. Thomas, Single-dose oral 
pharmacokinetics of three formulations of thalidomide in healthy male 
volunteers. J Clin Pharmacol, 1999. 39(11): p. 1162-8. 
280. Simmons, B.R., R.M. Lush, and W.D. Figg, A reversed-phase high 
performance liquid chromatography method using solid phase extraction to 
 425
quantitate thalidomide in human serum. Analytica Chimica Acta, 1997. 339(1-
2): p. 91-97. 
281. Delon, A., S. Favreliere, W. Couet, P.H. Courtois, and S. Bouquet, Rapid 
and Sensitive Determination of Thalidomide in Human Plasma by High-
Performance Liquid-Chromatography. Journal of Liquid Chromatography, 
1995. 18(2): p. 297-309. 
282. Eriksson, T., S. Bjorkman, A. Fyge, and H. Ekberg, Determination of 
thalidomide in plasma and blood by high-performance liquid 
chromatography: avoiding hydrolytic degradation. J Chromatogr, 1992. 
582(1-2): p. 211-6. 
283. Law, E., U. Gilvarry, V. Lynch, B. Gregory, G. Grant, and M. Clynes, 
Cytogenetic comparison of two poorly differentiated human lung squamous 
cell carcinoma lines. Cancer Genet Cytogenet, 1992. 59(2): p. 111-8. 
284. Clynes, M., A. Redmond, E. Moran, and U. Gilvarry, Multiple drug-
resistance in variant of a human non-small cell lung carcinoma cell line, 
DLKP-A. Cytotechnology, 1992. 10(1): p. 75-89. 
285. McBride, S., P. Meleady, A. Baird, D. Dinsdale, and M. Clynes, Human 
lung carcinoma cell line DLKP contains 3 distinct subpopulations with 
different growth and attachment properties. Tumour Biol, 1998. 19(2): p. 88-
103. 
286. Breen, L., L. Murphy, J. Keenan, and M. Clynes, Development of taxane 
resistance in a panel of human lung cancer cell lines. Toxicol In Vitro, 2008. 
22(5): p. 1234-41. 
287. Collins, S.J., R.C. Gallo, and R.E. Gallagher, Continuous growth and 
differentiation of human myeloid leukaemic cells in suspension culture. 
Nature, 1977. 270(5635): p. 347-9. 
288. Marsh, W., D. Sicheri, and M.S. Center, Isolation and characterization of 
adriamycin-resistant HL-60 cells which are not defective in the initial 
intracellular accumulation of drug. Cancer Res, 1986. 46(8): p. 4053-7. 
289. Liang, Y., P. Meleady, I. Cleary, S. McDonnell, L. Connolly, and M. 
Clynes, Selection with melphalan or paclitaxel (Taxol) yields variants with 
different patterns of multidrug resistance, integrin expression and in vitro 
invasiveness. European Journal of Cancer, 2001. 37(8): p. 1041-52. 
290. Hooijberg, J.H., H.J. Broxterman, M. Kool, Y.G. Assaraf, G.J. Peters, P. 
Noordhuis, R.J. Scheper, P. Borst, H.M. Pinedo, and G. Jansen, Antifolate 
Resistance Mediated by the Multidrug Resistance Proteins MRP1 and MRP2. 
Cancer Research, 1999. 59(11): p. 2532-2535. 
291. Akiyama, S., A. Fojo, J. Hanover, I. Pastan, and M. Gottesman, Isolation 
and genetic characterization of human KB cell lines resistant to multiple 
drugs. Somatic Cell Molecular Genetics, 1985. 11: p. 117-126. 
292. Ma, J., M. Maliepaard, H.J. Kolker, J. Verweij, and J.H. Schellens, 
Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant 
subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother 
Pharmacol, 1998. 41(3): p. 186-92. 
293. Wall, R., G. McMahon, J. Crown, M. Clynes, and R. O'Connor, Rapid and 
sensitive liquid chromatography-tandem mass spectrometry for the 
quantitation of epirubicin and identification of metabolites in biological 
samples. Talanta, 2007. 72(1): p. 145-54. 
294. Chandler, B., M. Detsika, A. Owen, S. Evans, R.C. Hartkoorn, P.A. Cane, 
D.J. Back, and S.H. Khoo, Effect of transporter modulation on the 
 426
emergence of nelfinavir resistance in vitro. Antivir Ther, 2007. 12(5): p. 831-
4. 
295. Dolan, J.W. LC resources - definitions.   [cited; Available from: 
http://www.lcresources.com/resources/TSWiz/hs150.htm. 
296. Hendriks, G., D.R.A. Uges, and J.P. Franke, Reconsideration of sample pH 
adjustment in bioanalytical liquid-liquid extraction of ionisable compounds. 
Journal of Chromatography B, 2007. 853(1-2): p. 234-241. 
297. IUPAC, Compendium of Chemical Terminology. 2nd ed. 1997. 
298. Buhrman, D.L., P.I. Price, and P.J. Rudewicz, Quantitation of SR 27417 in 
Human Plasma Using Electrospray Liquid Chromatography-Tandem Mass 
Spectrometry: A Study of Ion Suppression. Journal of the American Society for 
Mass Spectrometry, 1996. 7(11): p. 1099-1105. 
299. Ermer, J., Validation in pharmaceutical analysis. Part I: an integrated 
approach. J Pharm Biomed Anal, 2001. 24(5-6): p. 755-67. 
300. Shah, V.P., K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly , A. 
Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, R.D. McDowall, K.A. 
Pittman, and S. Spector, Analytical methods validation: Bioavailability, 
bioequivalence, and pharmacokinetic studies. J Pharm Sci, 1992. 81(3): p. 
309-312. 
301. Corkery, B., J. Crown, S. Roche, R. O'Connor, D. Tryfanopoulos, M. 
Clynes, and N. O'Donovan. Constitutive Activation of Src Kinase as a 
Mechanism of Acquired Resistance to Dasatinib in Triple Negative Breast 
Cancer. in San Antonio Breast Cancer Symposium 2009. 2009. 
302. Corkery, B., Tyrosine kinase inhibitors in triple negative breast cancer. 
NICB, 2010:  
303. Balasubramanian, S., S.K. Mani, H. Kasiganesan, C.C. Baicu, and D. 
Kuppuswamy, Hypertrophic stimulation increases beta-actin dynamics in 
adult feline cardiomyocytes. PLoS One. 5(7): p. e11470. 
304. Porter, K.E. and N.A. Turner, Cardiac fibroblasts: at the heart of 
myocardial remodeling. Pharmacol Ther, 2009. 123(2): p. 255-78. 
305. Kleihues, P., Pathology and Genetics of tumours of the Nervous System. 1997. 
306. Adamson, C., O.O. Kanu, A.I. Mehta, C. Di, N. Lin, A.K. Mattox, and 
D.D. Bigner, Glioblastoma multiforme: a review of where we have been and 
where we are going. Expert Opinion on Investigational Drugs, 2009. 18(8): p. 
1061-1083. 
307. Bidros, D.S. and M.A. Vogelbaum, Novel Drug Delivery Strategies in 
Neuro-Oncology. Neurotherapeutics, 2009. 6(3): p. 539-546. 
308. Omuro, A.M.P., S. Faivre, and E. Raymond, Lessons learned in the 
development of targeted therapy for malignant gliomas. Molecular Cancer 
Therapeutics, 2007. 6(7): p. 1909-1919. 
309. Huang, T.T., S.M. Sarkaria, T.F. Cloughesy, and P.S. Mischel, Targeted 
Therapy for Malignant Glioma Patients: Lessons Learned and the Road 
Ahead. Neurotherapeutics : the journal of the American Society for 
Experimental NeuroTherapeutics, 2009. 6(3): p. 500-512. 
310. Kinsella, P., The investigation of targets for therapy in brain tumours. NICB, 
School of Biotechnology, 2010:  
311. HPLC Troubleshooting Guide: Waters. 55-56. 
312. Picó, Y., G. Font, M.J. Ruiz, and M. Fernández, Control of pesticide 
residues by liquid chromatography-mass spectrometry to ensure food safety. 
Mass Spectrometry Reviews, 2006. 25(6): p. 917-960. 
 427
313. Kraemer, T. and L.D. Paul, Bioanalytical procedures for determination of 
drugs of abuse in blood. Anal Bioanal Chem, 2007. 388(7): p. 1415-35. 
314. Shephard, G.S., Determination of mycotoxins in human foods. Chem Soc 
Rev, 2008. 37(11): p. 2468-77. 
315. Wieling, J., LC-MS-MS experiences with internal standards. 
Chromatographia, 2002. 55: p. S107-S113. 
316. Stokvis, E., H. Rosing, and J.H. Beijnen, Stable isotopically labeled internal 
standards in quantitative bioanalysis using liquid chromatography/mass 
spectrometry: necessity or not? Rapid Communications in Mass Spectrometry, 
2005. 19(3): p. 401-407. 
317. Brockman, A.H., P. Hatsis, M. Paton, and J.-T. Wu, Impact of Differential 
Recovery in Bioanalysis: The Example of Bortezomib in Whole Blood. 
Analytical Chemistry, 2006. 79(4): p. 1599-1603. 
318. Jemal, M., A. Schuster, and D.B. Whigan, Liquid chromatography/tandem 
mass spectrometry methods for quantitation of mevalonic acid in human 
plasma and urine: method validation, demonstration of using a surrogate 
analyte, and demonstration of unacceptable matrix effect in spite of use of a 
stable isotope analog internal standard. Rapid Communications in Mass 
Spectrometry, 2003. 17(15): p. 1723-1734. 
319. Dolan, J.W. Getting started in HPLC.   [cited; Available from: 
http://www.lcresources.com/resources/getstart/2f01.htm. 
320. Snyder, L.R. and J.J. Kirkland, Introduction to Modern Liquid 
Chromatogrpahy. 2nd ed. 1979: John Wiley & Sons, Inc. 
321. ACD/Labs), C.u.A.C.D.A.L.S.V.f.S.-.   [cited. 
322. Calderoli, S., E. Colombo, E. Frigerio, C.A. James, and M. Sibum, LC-
MS-MS determination of brostallicin in human plasma following automated 
on-line SPE. Journal of Pharmaceutical and Biomedical Analysis, 2003. 32(4-
5): p. 601-607. 
323. Amini, N., M. Shariatgorji, C. Crescenzi, and G. Thorsen, Screening and 
Quantification of Pesticides in Water Using a Dual-Function Graphitized 
Carbon Black Disk. Anal Chem, 2009. 
324. van Beek, T.A. and P. Montoro, Chemical analysis and quality control of 
Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A, 
2009. 1216(11): p. 2002-32. 
325. Zhou, Q. and J.M. Gallo, Quantification of sunitinib in mouse plasma, brain 
tumor and normal brain using liquid chromatography-electrospray ionization-
tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed 
Anal, 2009. 
326. Koichi, I., Y. Yukiko, H. Tomoaki, and O. Hisao, Simultaneous 
determination of avermectins in bovine tissues by LC-MS/MS. Journal of 
Separation Science, 2009. 9999(9999): p. NA. 
327. Jemal, M. and X. Yuan-Qing, LC-MS Development Strategies for 
Quantitative Bioanalysis. Current Drug Metabolism, 2006. 7(5): p. 491-502. 
328. Giuseppe, C., C. Bruno, S. Sara, V. Emanuela, and T. Giuseppe, Rapid 
and sensitive analysis of vincristine in human plasma using on-line extraction 
combined with liquid chromatography/tandem mass spectrometry. Rapid 
Communications in Mass Spectrometry, 2008. 22(4): p. 519-525. 
329. Brunen, S., R. Kruger, S. Finger, F. Korf, F. Kiefer, K. Wiedemann, K.J. 
Lackner, and C. Hiemke, Determination of naltrexone and 6beta-naltrexol in 
human blood: comparison of high-performance liquid chromatography with 
 428
spectrophotometric and tandem-mass-spectrometric detection. Anal Bioanal 
Chem, 2009. 
330. Oostendorp, R.L., J.H. Beijnen, J.H. Schellens, and O. Tellingen, 
Determination of imatinib mesylate and its main metabolite (CGP74588) in 
human plasma and murine specimens by ion-pairing reversed-phase high-
performance liquid chromatography. Biomed Chromatogr, 2007. 21(7): p. 
747-54. 
331. Matuszewski, B.K., M.L. Constanzer, and C.M. Chavez-Eng, Strategies 
for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods 
Based on HPLCâˆ’MS/MS. Analytical Chemistry, 2003. 75(13): p. 3019-3030. 
332. Huber, L., Validation of Analytical Methods:Review and Strategy. LC-GC 
International, 1998(Feb): p. 95-105. 
333. Brooks, H.D., B.S. Glisson, B.N. Bekele, L.E. Ginsberg, A. El- Naggar, 
K.S. Culotta, N. Takebe, J. Wright, H.T. Tran, and V.A. 
Papadimitrakopoulou, Phase 2 study of dasatinib in the treatment of head 
and neck squamous cell carcinoma. Cancer: p. n/a-n/a. 
334. Storniolo, A.M., M.D. Pegram, B. Overmoyer, P. Silverman, N.W. 
Peacock, S.F. Jones, J. Loftiss, N. Arya, K.M. Koch, E. Paul, L. Pandite, 
R.A. Fleming, P.F. Lebowitz, P.T.C. Ho, and H.A. Burris, Phase I Dose 
Escalation and Pharmacokinetic Study of Lapatinib in Combination With 
Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. 
Journal of Clinical Oncology, 2008. 26(20): p. 3317-3323. 
335. Kondo, T., T. Tasaka, F. Sano, K. Matsuda, Y. Kubo, Y. Matsuhashi, H. 
Nakanishi, Y. Sadahira, H. Wada, T. Sugihara, and K. Tohyama, 
Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) 
treated with imatinib mesylate (IM): A report with IM plasma concentration 
and bcr-abl transcripts. Leukemia Research, 2009. 33(9): p. e137-e138. 
336. Vessman, J., Selectivity or specificity? Validation of analytical methods from 
the perspective of an analytical chemist in the pharmaceutical industry. 
Journal of Pharmaceutical and Biomedical Analysis, 1996. 14(8-10): p. 867-
869. 
337. Christian, G.D., Analytical Chemistry. 5th ed. 1994, New York: John Wiley. 
338. Jinno, K., Encyclopedia of Chromatography. Detection Principles, ed. J. 
Cazes. 2004, New York: Marcel Dekker, Inc. 
339. Papadoyannis, I.N. and G.A. Theodoridis, Encyclopedia of 
Chromatogrpahy. Liquid Chromatography–Mass Spectrometry, ed. J. Cazes. 
2004, New York: Marcel Dekker, Inc. 
340. Snyder, L.R., J.J. Kirkland, and J.L. Glajch, Practical HPLC Method 
Development. 2nd ed. 1997: John Wiley & Sons. 
341. Dadgar, D. and P.E. Burnett, Issues in evaluation of bioanalytical method 
selectivity and drug stability. J Pharm Biomed Anal, 1995. 14(1-2): p. 23-31. 
342. Karnes, H., Validation and Control of Bioanalytical Methods. Handbook of 
Anti-Cancer Pharmacokinetics and Pharmacodynamics–Cancer Drug 
Discovery and Development ed. H.M. WD Figg 2004, New Jersey: Humana 
Press. 91-111. 
343. Trissel, L.A., Avoiding common flaws in stability and compatibility studies of 
injectable drugs. Am J Hosp Pharm, 1983. 40(7): p. 1159-60. 
344. Marchetti, S., N.A. de Vries, T. Buckle, M.J. Bolijn, M.A.J. van 
Eijndhoven, J.H. Beijnen, R. Mazzanti, O. van Tellingen, and J.H.M. 
Schellens, Effect of the ATP-binding cassette drug transporters ABCB1, 
 429
ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in 
vitro and in vivo pharmacokinetic studies employing 
Bcrp1âˆ’/âˆ’/Mdr1a/1bâˆ’/âˆ’ (triple-knockout) and wild-type mice. Molecular 
Cancer Therapeutics, 2008. 7(8): p. 2280-2287. 
345. Kinsella, P., M. Clynes, and V. Amberger-Murphy, Imatinib and docetaxel 
in combination can effectively inhibit glioma invasion in an in vitro 3D 
invasion assay. Journal of Neuro-Oncology, 2010: p. 1-10. 
346. Razis, E., P. Selviaridis, S. Labropoulos, J.L. Norris, M.-J. Zhu, D.D. 
Song, T. Kalebic, M. Torrens, A. Kalogera-Fountzila, G. Karkavelas, S. 
Karanastasi, J.A. Fletcher, and G. Fountzilas, Phase II Study of 
Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular 
Effects of the Treatment. Clinical Cancer Research, 2009. 15(19): p. 6258-
6266. 
347. Carcaboso, A.M., M.A. Elmeliegy, J. Shen, S.J. Juel, Z.M. Zhang, C. 
Calabrese, L. Tracey, C.M. Waters, and C.F. Stewart, Tyrosine Kinase 
Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. Cancer 
Research, 2010. 70(11): p. 4499-4508. 
348. Agarwal, S., R. Sane, J.L. Gallardo, J.R. Ohlfest, and W.F. Elmquist, 
Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) 
and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux. 
Journal of Pharmacology and Experimental Therapeutics, 2010. 334(1): p. 
147-155. 
349. Liang, Y., L. O'Driscoll, S. McDonnell, P. Doolan, I. Oglesby, K. Duffy, R. 
O'Connor, and M. Clynes, Enhanced in vitro invasiveness and drug 
resistance with altered gene expression patterns in a human lung carcinoma 
cell line after pulse selection with anticancer drugs. International Journal of 
Cancer, 2004. 111(4): p. 484-493. 
350. Chen, W.S., K.E. Luker, J.L. Dahlheimer, C.M. Pica, G.D. Luker, and D. 
Piwnica-Worms, Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and 
BCRP/MXR/ABCP on the transport of 99mTc-tetrofosmin. Biochemical 
Pharmacology, 2000. 60(3): p. 413-426. 
351. Stordal, B., M. Clynes, M. Gottesman, and J.-P. Gillet. Mechanisms of 
cross resistance between cisplatin and paclitaxel in IGROV-1CDDP ovarian 
cancer cells. in TP-Binding Cassette (ABC) Proteins: From Multidrug 
Resistance to Genetic Diseases, . 2010. Innsbruck, Austria. 
352. Law, E., U. Gilvarry, V. Lynch, B. Gregory, G. Grant, and M. Clynes, 
Cytogenetic comparison of two poorly differentiated human lung squamous 
cell carcinoma lines. Cancer Genetics and Cytogenetics, 1992. 59(2): p. 111-
118. 
353. Shen, D.W., C. Cardarelli, J. Hwang, M. Cornwell, N. Richert, S. Ishii, I. 
Pastan, and M.M. Gottesman, Multiple drug-resistant human KB carcinoma 
cells independently selected for high-level resistance to colchicine, 
adriamycin, or vinblastine show changes in expression of specific proteins. 
Journal of Biological Chemistry, 1986. 261(17): p. 7762-7770. 
354. Hiss, D., G. Gabriels, P. Jacobs, and P. Folb, Tunicamycin potentiates drug 
cytotoxicity and vincristine retention in multidrug resistant cell lines. 
European Journal of Cancer, 1996. 32(12): p. 2164-2172. 
355. Richert, N., S. Akiyama, D. Shen, M.M. Gottesman, and I. Pastan, 
Multiply drug-resistant human KB carcinoma cells have decreased amounts of 
 430
a 75-kDa and a 72-kDa glycoprotein. Proceedings of the National Academy of 
Sciences of the United States of America, 1985. 82(8): p. 2330-2333. 
356. Hyafil, F., C. Vergely, P. Du Vignaud, and T. Grand-Perret, In Vitro and 
In Vivo Reversal of Multidrug Resistance by GF120918, an 
Acridonecarboxamide Derivative. Cancer Res, 1993. 53(19): p. 4595-4602. 
357. Stordal, B., M. Hamon, J.-P. Gillet, S. Roche, M. Gottesman, and M. 
Clynes, Cross resistance to paclitaxel in a cisplatin resistant ovarian cell line 
IGROV-1CDDP-2 is mediated by P-glycoprotein. Manuscript in preparation, 
2011. 
358. Porkka, K., P. Koskenvesa, T. Lundan, J. Rimpilainen, S. Mustjoki, R. 
Smykla, R. Wild, R. Luo, M. Arnan, B. Brethon, L. Eccersley, H. Hjorth-
Hansen, M. Hoglund, H. Klamova, H. Knutsen, S. Parikh, E. Raffoux, F. 
Gruber, F. Brito-Babapulle, H. Dombret, R.F. Duarte, E. Elonen, R. 
Paquette, C.M. Zwaan, and F.Y.F. Lee, Dasatinib crosses the blood-brain 
barrier and is an efficient therapy for central nervous system Philadelphia 
chromosome-positive leukemia. Blood, 2008. 112(4): p. 1005-1012. 
359. Giri, N., S. Agarwal, N. Shaik, G. Pan, Y. Chen, and W.F. Elmquist, 
Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-
Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro 
Assay Design. Drug Metabolism and Disposition, 2009. 37(3): p. 560-570. 
360. Holló, Z., L. Homolya, T. Hegedüs, and B. Sarkadi, Transport properties of 
the multidrug resistance-associated protein (MRP) in human tumour cells. 
FEBS Letters, 1996. 383(1-2): p. 99-104. 
361. O'Connor, R., M. Clynes, P. Dowling, N. O'Donovan, and L. O'Driscoll, 
Drug resistance in cancer - searching for mechanisms, markers and 
therapeutic agents. Expert Opinion on Drug Metabolism & Toxicology, 2007. 
3(6): p. 805-817. 
362. Ozvegy-Laczka, C., J. Cserepes, N.B. Elkind, and B. Sarkadi, Tyrosine 
kinase inhibitor resistance in cancer: role of ABC multidrug transporters. 
Drug Resist Updat, 2005. 8(1-2): p. 15-26. 
363. Qiang, F., B.-J. Lee, I. Ha, K.W. Kang, E.-R. Woo, and H.-K. Han, Effect 
of maceligan on the systemic exposure of paclitaxel: In vitro and in vivo 
evaluation. European Journal of Pharmaceutical Sciences, 2010. 41(2): p. 226-
231. 
364. Shannon, K.M., Resistance in the land of molecular cancer therapeutics. 
Cancer Cell, 2002. 2(2): p. 99-102. 
365. Hegedus, C., C. Ozvegy-Laczka, A. Apáti, M. Magócsi, K. Német, L. Orfi, 
G. Kéri, M. Katona, Z. Takáts, A. Váradi, G. Szakács, and B. Sarkadi, 
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: 
implications for altered anti-cancer effects and pharmacological properties. 
Br J Pharmacol, 2009. 158(4): p. 1153-64. 
366. Chen, Y., S. Agarwal, N.M. Shaik, C. Chen, Z. Yang, and W.F. Elmquist, 
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain 
Distribution of Dasatinib. J Pharmacol Exp Ther, 2009. 330(3): p. 956-963. 
367. Dohse, M., C. Scharenberg, S. Shukla, R.W. Robey, T. Volkmann, J.F. 
Deeken, C. Brendel, S.V. Ambudkar, A. Neubauer, and S.E. Bates, 
Comparison of ATP-Binding Cassette Transporter Interactions with the 
Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib. Drug 
Metabolism and Disposition. 38(8): p. 1371-1380. 
 431
368. Shapiro, A.B. and V. Ling, Extraction of Hoechst 33342 from the 
Cytoplasmic Leaflet of the Plasma Membrane by P-Glycoprotein. European 
Journal of Biochemistry, 1997. 250(1): p. 122-129. 
369. Shapiro, A.B. and V. Ling, Transport of LDS-751 from the cytoplasmic 
leaflet of the plasma membrane by the rhodamine-123-selective site of P-
glycoprotein. European Journal of Biochemistry, 1998. 254(1): p. 181-188. 
370. Shapiro, A.B., K. Fox, P. Lam, and V. Ling, Stimulation of P-glycoprotein-
mediated drug transport by prazosin and progesterone. European Journal of 
Biochemistry, 1999. 259(3): p. 841-850. 
371. Ceppi, P., M. Papotti, V. Monica, M.L. Iacono, S. Saviozzi, M. Pautasso, 
S. Novello, S. Mussino, E. Bracco, M. Volante, and G.V. Scagliotti, Effects 
of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell 
lines treated with cisplatin. Molecular Cancer Therapeutics, 2009. 8(11): p. 
3066-3074. 
372. Eustace, A., Investigation of response and resistance to dasatinib in 
melanoma cells. NICB, 2010:  
373. Imai, Y., K. Ohmori, S.i. Yasuda, M. Wada, T. Suzuki, K. Fukuda, and Y. 
Ueda, Breast cancer resistance protein/ABCG2 is differentially regulated 
downstream of extracellular signal-regulated kinase. Cancer Science, 2009. 
100(6): p. 1118-1127. 
374. Théou, N., S. Gil, A. Devocelle, C. Julié, A. Lavergne-Slove, A. Beauchet, 
P. Callard, R. Farinotti, A. Le Cesne, A. Lemoine, L. Faivre-Bonhomme, 
and J.-F. Emile, Multidrug Resistance Proteins in Gastrointestinal Stromal 
Tumors: Site-Dependent Expression and Initial Response to Imatinib. Clinical 
Cancer Research, 2005. 11(21): p. 7593-7598. 
375. Medina, P.J. and S. Goodin, Lapatinib: A dual inhibitor of human epidermal 
growth factor receptor tyrosine kinases. Clinical Therapeutics, 2008. 30(8): p. 
1426-1447. 
376. Dai, C.-l., A.K. Tiwari, C.-P. Wu, X.-d. Su, S.-R. Wang, D.-g. Liu, C.R. 
Ashby, Jr., Y. Huang, R.W. Robey, Y.-j. Liang, L.-m. Chen, C.-J. Shi, 
S.V. Ambudkar, Z.-S. Chen, and L.-w. Fu, Lapatinib (Tykerb, GW572016) 
Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of 
ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Res, 
2008. 68(19): p. 7905-7914. 
377. Staud, F. and P. Pavek, Breast cancer resistance protein (BCRP/ABCG2). 
The International Journal of Biochemistry & Cell Biology, 2005. 37(4): p. 
720-725. 
378. Perry, J., E. Ghazaly, C. Kitromilidou, E. Nsubuga-McGrowder, S.P. 
Joel, and T. Powles, A synergistic interaction between lapatinib and 
chemotherapy agents in a panel of cell lines is due to inhibition of the efflux 
pump BCRP. Molecular Cancer Therapeutics. 
379. Cavo, M., E. Zamagni, P. Tosi, P. Tacchetti, C. Cellini, D. Cangini, A. de 
Vivo, N. Testoni, C. Nicci, C. Terragna, T. Grafone, G. Perrone, M. 
Ceccolini, S. Tura, and M. Baccarani, Superiority of thalidomide and 
dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as 
primary therapy in preparation for autologous transplantation for multiple 
myeloma. Blood, 2005. 106(1): p. 35-9. 
380. Gurney, H., Defining the starting dose. Handbook of Anticancer 
Pharmacokinetics and Pharmacodynamics, ed. W.D. Figg and M. H.L., 
Totowa, NJ: Humana Press Inc. 
 432
381. Tohnya, T.M., K. Hwang, E.R. Lepper, H.A. Fine, W.L. Dahut, J. Venitz, 
A. Sparreboom, and W.D. Figg, Determination of CC-5013, an analogue of 
thalidomide, in human plasma by liquid chromatography-mass spectrometry. J 
Chromatogr B Analyt Technol Biomed Life Sci, 2004. 811(2): p. 135-41. 
382. Meyring, M., D. Strickmann, B. Chankvetadze, G. Blaschke, C. Desiderio, 
and S. Fanali, Investigation of the in vitro biotransformation of R-(+)-
thalidomide by HPLC, nano-HPLC, CEC and HPLC--APCI-MS. J 
Chromatogr B Biomed Sci Appl, 1999. 723(1-2): p. 255-64. 
383. Durie, B.G.M., J.L. Harousseau, J.S. Miguel, J. Blade, B. Barlogie, K. 
Anderson, M. Gertz, M. Dimopoulos, J. Westin, P. Sonneveld, H. Ludwig, 
G. Gahrton, M. Beksac, J. Crowley, A. Belch, M. Boccadaro, I. Turesson, 
D. Joshua, D. Vesole, R. Kyle, R. Alexanian, G. Tricot, M. Attal, G. 
Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, G. Morgan, and 
S.V. Rajkumar, International uniform response criteria for multiple 
myeloma. Leukemia, 2006. 20(9): p. 1467-1473. 
384. (1999) National Cancer Insitute, Cancer Therapy Evaulation Program, 
Common Toxicity Criteria, Version 2.0.   
385. Swartz, M. and I. Krull, Validation of Bioanalytical Methods —Highlights of 
FDA’s Guidance. LCGC NORTH AMERICA, 2003. 21(2): p. 136. 
386. Teo, S.K., Properties of thalidomide and its analogues: implications for 
anticancer therapy. Aaps J, 2005. 7(1): p. E14-9. 
387. NCI. FDA Approval for Thalidomide.  2006  [cited; Available from: 
http://www.cancer.gov/cancertopics/druginfo/fda-thalidomide. 
388. Figg, W.D., S. Raje, K.S. Bauer, A. Tompkins, D. Venzon, R. Bergan, A. 
Chen, M. Hamilton, J. Pluda, and E. Reed, Pharmacokinetics of 
thalidomide in an elderly prostate cancer population. Journal of 
Pharmaceutical Sciences, 1999. 88(1): p. 121-125. 
389. Skirvin, J.A. and S.M. Lichtman, Pharmacokinetic Considerations of Oral 
Chemotherapy in Elderly Patients with Cancer. Drugs & Aging, 2002. 19(1): 
p. 25-42. 
390. Ruddy, K., E. Mayer, and A. Partridge, Patient adherence and persistence 
with oral anticancer treatment. CA Cancer J Clin, 2009. 59(1): p. 56-66. 
391. O'Neill, V.J. and C.J. Twelves, Oral cancer treatment: developments in 
chemotherapy and beyond. Br J Cancer, 2002. 87(9): p. 933-937. 
392. Partridge, A.H., J. Avorn, P.S. Wang, and E.P. Winer, Adherence to 
Therapy With Oral Antineoplastic Agents. Journal of the National Cancer 
Institute, 2002. 94(9): p. 652-661. 
393. Palumbo, A., S. Bringhen, A.M. Liberati, T. Caravita, A. Falcone, V. 
Callea, M. Montanaro, R. Ria, A. Capaldi, R. Zambello, G. Benevolo, D. 
Derudas, F. Dore, F. Cavallo, F. Gay, P. Falco, G. Ciccone, P. Musto, M. 
Cavo, and M. Boccadoro, Oral melphalan, prednisone, and thalidomide in 
elderly patients with multiple myeloma: updated results of a randomized 
controlled trial. Blood, 2008. 112(8): p. 3107-3114. 
394. Rajkumar, S.V., L. RosiÃ±ol, M. Hussein, J. Catalano, W. Jedrzejczak, L. 
Lucy, M. Olesnyckyj, Z. Yu, R. Knight, J.B. Zeldis, and J. BladÃ©, 
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of 
Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial 
Therapy for Newly Diagnosed Multiple Myeloma. Journal of Clinical 
Oncology, 2008. 26(13): p. 2171-2177. 
 433
395. Sung, B., A.B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, and B.B. 
Aggarwal, Curcumin circumvents chemoresistance in vitro and potentiates 
the effect of thalidomide and bortezomib against human multiple myeloma in 
nude mice model. Molecular Cancer Therapeutics, 2009. 8(4): p. 959-970. 
396. Keller, M., G. Sollberger, and H.-D. Beer, Thalidomide Inhibits Activation 
of Caspase-1. J Immunol, 2009. 183(9): p. 5593-5599. 
397. Hideshima, T., D. Chauhan, Y. Shima, N. Raje, F.E. Davies, Y.-T. Tai, 
S.P. Treon, B. Lin, R.L. Schlossman, P. Richardson, G. Muller, D.I. 
Stirling, and K.C. Anderson, Thalidomide and its analogs overcome drug 
resistance of human multiple myeloma cells to conventional therapy. Blood, 
2000. 96(9): p. 2943-2950. 
398. Schumacher, H., R.L. Smith, and R.T. Williams, The metabolism of 
thalidomide: the fate of thalidomide and some of its hydrolysis products in 
various species. British journal of pharmacology and chemotherapy, 1965. 
25(2): p. 338–351. 
399. Schumacher, H., R.L. Smith, and R.T. Williams, The metabolism of 
thalidomide: the spontaneous hydrolysis of thalidomide in solution. British 
journal of pharmacology and chemotherapy, 1965.  25: p. 324-337. 
400. Liu, Q., K.L. Farley, A.J. Johnson, N. Muthusamy, C.C. Hofmeister, K.A. 
Blum, L.J. Schaaf, M.R. Grever, J.C. Byrd, J.T. Dalton, and M.A. Phelps, 
Development and validation of a highly sensitive liquid chromatography/mass 
spectrometry method for simultaneous quantification of lenalidomide and 
flavopiridol in human plasma. Ther Drug Monit, 2008. 30(5): p. 620-7. 
 
 - 1 -
 
 
 
 
 
SECTION 9.0 – Appendices 
 
 
 
 
 - 2 - 
9. Appendices 
Appendix 1-Details of drugs 
This table contains a list of all drugs used in this project. All drugs were disposed of by incineration 
Drug 
Mr 
(g/mol) Structure Source Storage 
Bortezomib 384.24 
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
Dasatinib 506 
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
 - 3 - 
Drug 
Mr 
(g/mol) Structure Source Storage 
Daunorubicin 527.52  
St Vincent’s 
University Hospital 4oC 
Elacridar 
(GF120918) 600.1 Sigma-Aldrich -20oC 
Epirubicin* 543.52  
St Vincent’s 
University Hospital 4oC 
 - 4 - 
Drug 
Mr 
(g/mol) Structure Source Storage 
Erlotinib 
(HCl) 429.9  
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
Gefitinib 446.9 
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
Imatinib 
(Mesylate) 589.72 
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
 - 5 - 
Drug 
Mr 
(g/mol) Structure Source Storage 
Lapatinib 
(Ditosylate 
Monohydrate) 943.5 
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
Lenalidomide 259.3  
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
Paclitaxel 
(Taxol)* 853.9 
St Vincent’s 
University Hospital 
Room 
temperature in 
the dark 
 - 6 - 
Drug 
Mr 
(g/mol) Structure Source Storage 
Sorafenib 
(Tosylate) 464.825 
Sequoia Research 
Chemicals 
Room 
temperature in 
the dark 
Sulindac 
Sulfide 340.4  Sigma-Aldrich 4
oC 
Thalidomide 464.825  Sigma-Aldrich -20
oC 
Umbelliferone 162.14  Sigma-Aldrich -20
oC 
* Clinical formulation 
All structures were taken from http://www.chemblink.com/ 
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Appendix 2: Lapatinib matrix sample 
Figure 9-1: : Example of lapatinib in cell blank 
4x10
0.5
1
1.5
+ TIC MRM (** -> **) Sample_1704_25.d
1 1
4x10
0.5
1
1.5
+ MRM (581.00000 -> 365.00000) Sample_1704_25.d
1 1
3x10
5
+ TIC MRM (** -> **) Sample_1704_28.d
1 1
1x10
2
4
+ MRM (581.00000 -> 365.00000) Sample_1704_28.d
1 1
Counts vs. Acquisition Time (min)
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10
 
Figure 9-1 shows a quantification of lapatinib in an extracted cell sample in 
comparison to the quantification of lapatinib in a treated cell sample, where A 
indicates the TIC for the treated sample and B is the extracted MRM for lapatinib in 
the treated sample.  C shows the TIC for the untreated cell sample with dasatinib 
internal standard added, while D shows the extracted MRM of lapatinib in the 
untreated cell sample 
A 
B 
C 
D 
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Appendix 3: Dasatinib matrix sample 
Figure 9-2: Example of dasatinib in cell blank 
5x10
1
+ TIC MRM (** -> **) Sample_09.d
1 1
1x10
0
+ MRM (488.00000 -> 231.00000) Sample_09.d
1 1
3x10
0
+ MRM (488.00000 -> 401.00000) Sample_09.d
1 1
1x10 + TIC MRM (** -> **) Sample_44.d
1 1
0
2
+ MRM (488.00000 -> 231.00000) Sample_44.d
1 1
0
+ MRM (488.00000 -> 401.00000) Sample_44.d
1 1
Counts vs. Acquisition Time (min)
0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10
 
Figure 9-2 shows a quantification of dasatinib in an extracted cell sample in 
comparison to the quantification of dasatinib in a treated cell sample, where A 
indicates the TIC for the treated sample, B and C are the extracted MRM for 
dasatinib in the treated sample.  D shows the TIC for the untreated cell sample, E 
and F show the extracted MRM from the untreated cell sample.  
 
 
 
A 
B 
C 
D 
E 
F 
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Appendix 4- Thalidomide blank chromatogram 
Figure 9-3: Example of thalidomide blank in serum 
 
Figure 9-3 shows a quantification of thalidomide in a serum samples. 
The TIC A is shown for a patient sample with no thalidomide, though internal 
standard has been added and D is a patient receiving thalidomide.  B and C are the 
extracted MRM for thalidomide in a thalidomide negative patient while E and F 
show the extracted MRM transitions for thalidomide in the samples of patient 
receiving thalidomide.  
 
3x10
0
+ TIC MRM (** -> **) Sample_A_01-r001.d  
1 1
0
+ MRM (259.10001 -> 84.00000) Sample_A_01-r001.d 
1 1
0
+ MRM (259.10001 -> 186.00000) Sample_A_01-r001.d 
1 1
3x10
0
+ TIC MRM (** -> **) Sample_A_10-r001.d  
1 1
3x10
0
1
+ MRM (259.10001 -> 84.00000) Sample_A_10-r001.d 
1 1
2x10
0
+ MRM (259.10001 -> 186.00000) Sample_A_10-r001.d 
1 1
Counts vs. Acquisition Time (min)
1 2 3 4 5 6 7 8 9 10 11 12 13
A 
B 
C 
D 
E 
F 
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Figure 9-4: Expanded viewed of Figure 9-3 
2x10
0
1
2
3
4
5
6
7
8
9
+ MRM (259.10001 -> 186.00000) Sample_A_10-r001.d
Counts vs. Acquisition Time (min)
8.6 8.8 9 9.2 9.4 9.6 9.8 10 10.2
 
Shown here is a zoom of the overlay of the extracted MRM chromatograms C and F 
above, where the green trace is for the blank and the blue trace is the thalidomide 
measured in a patient sample.  
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Publications 
• Roche S., McMahon G., Clynes M., O’Connor R, Development of a high-
performance liquid chromatographic–mass spectrometric method for the 
determination of cellular levels of the tyrosine kinase inhibitors lapatinib and 
dasatinib, Journal of Chromatography B, Volume 877, Issue 31, 1 December 
2009, Pages 3982-3990 
 
• Dunne G., Breen L., Collins D.M., Roche S., Clynes M., O'Connor R., 
Modulation of P-gp expression by lapatinib. Investigational New Drugs, 2010 
Jul 6 
 
 
Oral Presentation 
• “LC-MS in the Analysis of Tyrosine Kinases Inhibitors in Cancer Cell-Lines” 
presented at The Irish Mass Spectrometry Society, Dublin, Ireland, May 2009 
 
 
Posters 
• Roche S., Clynes M., O’ Connor R., “The Uptake of Tyrosine Kinase 
Inhibitors in MDR Cell Lines” presented at the Irish Association for Cancer 
Research, Athlone, Ireland, March 2009 
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